CN101663028A - 托吡酯和昂丹司琼对酒精消费的联合效果 - Google Patents
托吡酯和昂丹司琼对酒精消费的联合效果 Download PDFInfo
- Publication number
- CN101663028A CN101663028A CN200780051498A CN200780051498A CN101663028A CN 101663028 A CN101663028 A CN 101663028A CN 200780051498 A CN200780051498 A CN 200780051498A CN 200780051498 A CN200780051498 A CN 200780051498A CN 101663028 A CN101663028 A CN 101663028A
- Authority
- CN
- China
- Prior art keywords
- given
- treatment
- topiramate
- kinds
- antagonist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 title claims abstract description 381
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 title claims description 86
- 229960005343 ondansetron Drugs 0.000 title claims description 86
- 229960004394 topiramate Drugs 0.000 title claims description 86
- FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 title claims description 85
- 230000002301 combined effect Effects 0.000 title description 5
- 239000003814 drug Substances 0.000 claims abstract description 156
- 238000011282 treatment Methods 0.000 claims abstract description 135
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 130
- 201000010099 disease Diseases 0.000 claims abstract description 105
- 229940079593 drug Drugs 0.000 claims abstract description 45
- 230000037396 body weight Effects 0.000 claims abstract description 19
- 150000001875 compounds Chemical class 0.000 claims description 235
- 238000000034 method Methods 0.000 claims description 185
- 239000000203 mixture Substances 0.000 claims description 114
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims description 73
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims description 67
- 230000000694 effects Effects 0.000 claims description 66
- -1 glutamine antagonist Substances 0.000 claims description 62
- 239000008194 pharmaceutical composition Substances 0.000 claims description 56
- 208000007848 Alcoholism Diseases 0.000 claims description 50
- 201000007930 alcohol dependence Diseases 0.000 claims description 43
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 claims description 43
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims description 42
- 229960003086 naltrexone Drugs 0.000 claims description 41
- 239000003795 chemical substances by application Substances 0.000 claims description 36
- 230000035622 drinking Effects 0.000 claims description 36
- 238000002560 therapeutic procedure Methods 0.000 claims description 36
- 229960003638 dopamine Drugs 0.000 claims description 35
- 150000003839 salts Chemical class 0.000 claims description 35
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 33
- 150000001413 amino acids Chemical class 0.000 claims description 29
- 229940024606 amino acid Drugs 0.000 claims description 28
- 235000001014 amino acid Nutrition 0.000 claims description 27
- 241001597008 Nomeidae Species 0.000 claims description 26
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 claims description 25
- 239000003420 antiserotonin agent Substances 0.000 claims description 25
- 208000030990 Impulse-control disease Diseases 0.000 claims description 24
- 230000006399 behavior Effects 0.000 claims description 24
- 229940025084 amphetamine Drugs 0.000 claims description 23
- 239000005557 antagonist Substances 0.000 claims description 23
- 229960003920 cocaine Drugs 0.000 claims description 23
- 239000000463 material Substances 0.000 claims description 23
- 206010036067 polydipsia Diseases 0.000 claims description 22
- 230000002265 prevention Effects 0.000 claims description 20
- 230000008569 process Effects 0.000 claims description 20
- 208000020016 psychiatric disease Diseases 0.000 claims description 20
- 230000001225 therapeutic effect Effects 0.000 claims description 20
- 239000000380 hallucinogen Substances 0.000 claims description 18
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 claims description 17
- 239000000556 agonist Substances 0.000 claims description 16
- 229940127239 5 Hydroxytryptamine receptor antagonist Drugs 0.000 claims description 14
- 239000003112 inhibitor Substances 0.000 claims description 14
- 230000005764 inhibitory process Effects 0.000 claims description 14
- 230000002829 reductive effect Effects 0.000 claims description 14
- 241000218236 Cannabis Species 0.000 claims description 13
- 230000036541 health Effects 0.000 claims description 13
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 claims description 13
- 206010012218 Delirium Diseases 0.000 claims description 12
- 235000005686 eating Nutrition 0.000 claims description 12
- 239000001961 anticonvulsive agent Substances 0.000 claims description 11
- 229960003965 antiepileptics Drugs 0.000 claims description 11
- 238000013459 approach Methods 0.000 claims description 11
- 230000003291 dopaminomimetic effect Effects 0.000 claims description 11
- 208000019901 Anxiety disease Diseases 0.000 claims description 10
- 229940122459 Glutamate antagonist Drugs 0.000 claims description 10
- AFCGFAGUEYAMAO-UHFFFAOYSA-N acamprosate Chemical compound CC(=O)NCCCS(O)(=O)=O AFCGFAGUEYAMAO-UHFFFAOYSA-N 0.000 claims description 10
- 229960004047 acamprosate Drugs 0.000 claims description 10
- 230000001773 anti-convulsant effect Effects 0.000 claims description 10
- 230000000975 bioactive effect Effects 0.000 claims description 10
- AUZONCFQVSMFAP-UHFFFAOYSA-N disulfiram Chemical group CCN(CC)C(=S)SSC(=S)N(CC)CC AUZONCFQVSMFAP-UHFFFAOYSA-N 0.000 claims description 10
- 239000003937 drug carrier Substances 0.000 claims description 10
- 239000003825 glutamate receptor antagonist Substances 0.000 claims description 10
- 229960002715 nicotine Drugs 0.000 claims description 10
- 239000003401 opiate antagonist Substances 0.000 claims description 10
- 239000003148 4 aminobutyric acid receptor blocking agent Substances 0.000 claims description 9
- 108091006146 Channels Proteins 0.000 claims description 9
- 229940123605 Dopamine release inhibitor Drugs 0.000 claims description 9
- 208000004547 Hallucinations Diseases 0.000 claims description 9
- 201000001880 Sexual dysfunction Diseases 0.000 claims description 9
- 229940049706 benzodiazepine Drugs 0.000 claims description 9
- 230000001149 cognitive effect Effects 0.000 claims description 9
- 239000003210 dopamine receptor blocking agent Substances 0.000 claims description 9
- 239000003823 glutamate receptor agonist Substances 0.000 claims description 9
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 claims description 9
- 231100000872 sexual dysfunction Toxicity 0.000 claims description 9
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims description 8
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 claims description 8
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 claims description 8
- 208000001613 Gambling Diseases 0.000 claims description 8
- 239000002671 adjuvant Substances 0.000 claims description 8
- 229960004372 aripiprazole Drugs 0.000 claims description 8
- 208000035475 disorder Diseases 0.000 claims description 8
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 claims description 8
- 210000004877 mucosa Anatomy 0.000 claims description 8
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims description 8
- 210000000664 rectum Anatomy 0.000 claims description 8
- 201000009032 substance abuse Diseases 0.000 claims description 8
- 208000028017 Psychotic disease Diseases 0.000 claims description 7
- 230000003276 anti-hypertensive effect Effects 0.000 claims description 7
- 239000000935 antidepressant agent Substances 0.000 claims description 7
- 229940005513 antidepressants Drugs 0.000 claims description 7
- 229940006133 antiglaucoma drug and miotics carbonic anhydrase inhibitors Drugs 0.000 claims description 7
- 235000019789 appetite Nutrition 0.000 claims description 7
- 230000036528 appetite Effects 0.000 claims description 7
- 239000003489 carbonate dehydratase inhibitor Substances 0.000 claims description 7
- 206010012601 diabetes mellitus Diseases 0.000 claims description 7
- 208000024732 dysthymic disease Diseases 0.000 claims description 7
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 claims description 7
- 229960002073 sertraline Drugs 0.000 claims description 7
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 claims description 6
- 238000001467 acupuncture Methods 0.000 claims description 6
- 238000007792 addition Methods 0.000 claims description 6
- 206010001584 alcohol abuse Diseases 0.000 claims description 6
- 208000025746 alcohol use disease Diseases 0.000 claims description 6
- 239000002269 analeptic agent Substances 0.000 claims description 6
- 230000003555 analeptic effect Effects 0.000 claims description 6
- 230000001430 anti-depressive effect Effects 0.000 claims description 6
- 230000000561 anti-psychotic effect Effects 0.000 claims description 6
- 239000002830 appetite depressant Substances 0.000 claims description 6
- 210000004369 blood Anatomy 0.000 claims description 6
- 239000008280 blood Substances 0.000 claims description 6
- 230000008451 emotion Effects 0.000 claims description 6
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 6
- 229940088597 hormone Drugs 0.000 claims description 6
- 239000005556 hormone Substances 0.000 claims description 6
- 230000000147 hypnotic effect Effects 0.000 claims description 6
- 238000007918 intramuscular administration Methods 0.000 claims description 6
- 230000003340 mental effect Effects 0.000 claims description 6
- 229960001534 risperidone Drugs 0.000 claims description 6
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 claims description 6
- 208000019116 sleep disease Diseases 0.000 claims description 6
- 208000020685 sleep-wake disease Diseases 0.000 claims description 6
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 claims description 5
- WJBLNOPPDWQMCH-MBPVOVBZSA-N Nalmefene Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=C)O)CC1)O)CC1CC1 WJBLNOPPDWQMCH-MBPVOVBZSA-N 0.000 claims description 5
- 239000008896 Opium Substances 0.000 claims description 5
- 229940125713 antianxiety drug Drugs 0.000 claims description 5
- 230000033228 biological regulation Effects 0.000 claims description 5
- 230000008450 motivation Effects 0.000 claims description 5
- 229960002748 norepinephrine Drugs 0.000 claims description 5
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 claims description 5
- 229960001027 opium Drugs 0.000 claims description 5
- 230000002688 persistence Effects 0.000 claims description 5
- JZCPYUJPEARBJL-UHFFFAOYSA-N rimonabant Chemical compound CC=1C(C(=O)NN2CCCCC2)=NN(C=2C(=CC(Cl)=CC=2)Cl)C=1C1=CC=C(Cl)C=C1 JZCPYUJPEARBJL-UHFFFAOYSA-N 0.000 claims description 5
- 229960003015 rimonabant Drugs 0.000 claims description 5
- 210000001685 thyroid gland Anatomy 0.000 claims description 5
- 229960003991 trazodone Drugs 0.000 claims description 5
- PHLBKPHSAVXXEF-UHFFFAOYSA-N trazodone Chemical compound ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 PHLBKPHSAVXXEF-UHFFFAOYSA-N 0.000 claims description 5
- 229940127291 Calcium channel antagonist Drugs 0.000 claims description 4
- 229940122697 Glutamine antagonist Drugs 0.000 claims description 4
- 230000000202 analgesic effect Effects 0.000 claims description 4
- 239000003472 antidiabetic agent Substances 0.000 claims description 4
- 239000003246 corticosteroid Substances 0.000 claims description 4
- 229960003980 galantamine Drugs 0.000 claims description 4
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 claims description 4
- 230000002045 lasting effect Effects 0.000 claims description 4
- 229960005297 nalmefene Drugs 0.000 claims description 4
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 claims description 4
- 229960004127 naloxone Drugs 0.000 claims description 4
- 230000000324 neuroprotective effect Effects 0.000 claims description 4
- 239000003488 releasing hormone Substances 0.000 claims description 4
- 230000004799 sedative–hypnotic effect Effects 0.000 claims description 4
- 230000001568 sexual effect Effects 0.000 claims description 4
- 208000017194 Affective disease Diseases 0.000 claims description 3
- 208000031091 Amnestic disease Diseases 0.000 claims description 3
- 201000006474 Brain Ischemia Diseases 0.000 claims description 3
- 206010008120 Cerebral ischaemia Diseases 0.000 claims description 3
- 206010012289 Dementia Diseases 0.000 claims description 3
- 108090000371 Esterases Proteins 0.000 claims description 3
- 208000019022 Mood disease Diseases 0.000 claims description 3
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 claims description 3
- 229960004373 acetylcholine Drugs 0.000 claims description 3
- 210000004404 adrenal cortex Anatomy 0.000 claims description 3
- 239000003470 adrenal cortex hormone Substances 0.000 claims description 3
- 239000000464 adrenergic agent Substances 0.000 claims description 3
- 229940083712 aldosterone antagonist Drugs 0.000 claims description 3
- 239000002170 aldosterone antagonist Substances 0.000 claims description 3
- 238000004458 analytical method Methods 0.000 claims description 3
- 239000002579 antinauseant Substances 0.000 claims description 3
- 230000003115 biocidal effect Effects 0.000 claims description 3
- 230000000747 cardiac effect Effects 0.000 claims description 3
- 206010008118 cerebral infarction Diseases 0.000 claims description 3
- 239000000731 choleretic agent Substances 0.000 claims description 3
- 230000001989 choleretic effect Effects 0.000 claims description 3
- 239000000064 cholinergic agonist Substances 0.000 claims description 3
- 239000003623 enhancer Substances 0.000 claims description 3
- 230000001976 improved effect Effects 0.000 claims description 3
- 238000001990 intravenous administration Methods 0.000 claims description 3
- 230000036651 mood Effects 0.000 claims description 3
- 230000001256 tonic effect Effects 0.000 claims description 3
- 239000005526 vasoconstrictor agent Substances 0.000 claims description 3
- 230000024883 vasodilation Effects 0.000 claims description 3
- WUFQLZTXIWKION-UHFFFAOYSA-N Deoxypeganine Chemical compound C1C2=CC=CC=C2N=C2N1CCC2 WUFQLZTXIWKION-UHFFFAOYSA-N 0.000 claims description 2
- 230000000578 anorexic effect Effects 0.000 claims description 2
- 239000002249 anxiolytic agent Substances 0.000 claims description 2
- 239000002327 cardiovascular agent Substances 0.000 claims description 2
- 229940125692 cardiovascular agent Drugs 0.000 claims description 2
- 230000000718 cholinopositive effect Effects 0.000 claims description 2
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 claims description 2
- 229940001470 psychoactive drug Drugs 0.000 claims description 2
- 239000004089 psychotropic agent Substances 0.000 claims description 2
- 229940088594 vitamin Drugs 0.000 claims description 2
- 239000011782 vitamin Substances 0.000 claims description 2
- 235000013343 vitamin Nutrition 0.000 claims description 2
- 229930003231 vitamin Natural products 0.000 claims description 2
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 2
- 208000002249 Diabetes Complications Diseases 0.000 claims 3
- 229940127003 anti-diabetic drug Drugs 0.000 claims 3
- 239000003524 antilipemic agent Substances 0.000 claims 3
- 102000017462 5-hydroxytryptamine 3 receptors Human genes 0.000 claims 2
- 108050005670 5-hydroxytryptamine 3 receptors Proteins 0.000 claims 2
- 102000014630 G protein-coupled serotonin receptor activity proteins Human genes 0.000 claims 2
- FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 claims 1
- 229960003089 pramipexole Drugs 0.000 claims 1
- 206010012335 Dependence Diseases 0.000 abstract description 41
- 208000008589 Obesity Diseases 0.000 abstract description 13
- 235000020824 obesity Nutrition 0.000 abstract description 13
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 137
- 238000002360 preparation method Methods 0.000 description 95
- 238000012360 testing method Methods 0.000 description 31
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 21
- 230000006870 function Effects 0.000 description 20
- 239000000243 solution Substances 0.000 description 20
- 239000003826 tablet Substances 0.000 description 20
- 230000001276 controlling effect Effects 0.000 description 19
- 238000011160 research Methods 0.000 description 19
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 18
- 239000000725 suspension Substances 0.000 description 18
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 18
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 17
- 241000700159 Rattus Species 0.000 description 17
- 239000002253 acid Substances 0.000 description 17
- 229940127240 opiate Drugs 0.000 description 17
- 150000001412 amines Chemical class 0.000 description 16
- 238000012856 packing Methods 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- 229940124597 therapeutic agent Drugs 0.000 description 15
- 239000007788 liquid Substances 0.000 description 14
- 239000000843 powder Substances 0.000 description 14
- 239000000126 substance Substances 0.000 description 14
- 235000019197 fats Nutrition 0.000 description 12
- 238000011262 co‐therapy Methods 0.000 description 11
- 150000002148 esters Chemical class 0.000 description 11
- 125000001424 substituent group Chemical group 0.000 description 11
- 208000024891 symptom Diseases 0.000 description 11
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 10
- 241000282414 Homo sapiens Species 0.000 description 10
- 230000002421 anti-septic effect Effects 0.000 description 10
- 230000000903 blocking effect Effects 0.000 description 10
- 230000003203 everyday effect Effects 0.000 description 10
- 238000002347 injection Methods 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 10
- 229940098779 methanesulfonic acid Drugs 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 102000005962 receptors Human genes 0.000 description 10
- 108020003175 receptors Proteins 0.000 description 10
- 229920002477 rna polymer Polymers 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 9
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 9
- 238000007911 parenteral administration Methods 0.000 description 9
- 231100000572 poisoning Toxicity 0.000 description 9
- 230000000607 poisoning effect Effects 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 8
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 8
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 8
- 125000003118 aryl group Chemical group 0.000 description 8
- 239000002585 base Substances 0.000 description 8
- 239000001530 fumaric acid Substances 0.000 description 8
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 8
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 8
- 210000003928 nasal cavity Anatomy 0.000 description 8
- 229940068196 placebo Drugs 0.000 description 8
- 239000000902 placebo Substances 0.000 description 8
- 102000004196 processed proteins & peptides Human genes 0.000 description 8
- 229940002612 prodrug Drugs 0.000 description 8
- 239000000651 prodrug Substances 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 230000001105 regulatory effect Effects 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 7
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 7
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 7
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 7
- 230000001476 alcoholic effect Effects 0.000 description 7
- 239000002775 capsule Substances 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 239000003085 diluting agent Substances 0.000 description 7
- 239000000839 emulsion Substances 0.000 description 7
- 235000013922 glutamic acid Nutrition 0.000 description 7
- 239000004220 glutamic acid Substances 0.000 description 7
- 235000012054 meals Nutrition 0.000 description 7
- 108020004707 nucleic acids Proteins 0.000 description 7
- 102000039446 nucleic acids Human genes 0.000 description 7
- 150000007523 nucleic acids Chemical class 0.000 description 7
- 229920001184 polypeptide Polymers 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 210000000582 semen Anatomy 0.000 description 7
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 7
- 210000001215 vagina Anatomy 0.000 description 7
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 6
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 6
- 235000015165 citric acid Nutrition 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 238000010586 diagram Methods 0.000 description 6
- 239000008187 granular material Substances 0.000 description 6
- 230000035987 intoxication Effects 0.000 description 6
- 231100000566 intoxication Toxicity 0.000 description 6
- 210000001259 mesencephalon Anatomy 0.000 description 6
- 210000000214 mouth Anatomy 0.000 description 6
- 239000002773 nucleotide Substances 0.000 description 6
- 125000003729 nucleotide group Chemical group 0.000 description 6
- 210000001009 nucleus accumben Anatomy 0.000 description 6
- 239000006072 paste Substances 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 239000003380 propellant Substances 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 238000005728 strengthening Methods 0.000 description 6
- 239000000829 suppository Substances 0.000 description 6
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 5
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 5
- 239000004472 Lysine Substances 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 241000700157 Rattus norvegicus Species 0.000 description 5
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 5
- 125000000217 alkyl group Chemical group 0.000 description 5
- 125000000539 amino acid group Chemical group 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 229960002896 clonidine Drugs 0.000 description 5
- 239000011248 coating agent Substances 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 238000002651 drug therapy Methods 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 235000013355 food flavoring agent Nutrition 0.000 description 5
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 5
- 229960002885 histidine Drugs 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 229960003646 lysine Drugs 0.000 description 5
- 239000011976 maleic acid Substances 0.000 description 5
- 238000007726 management method Methods 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 230000004060 metabolic process Effects 0.000 description 5
- 210000002569 neuron Anatomy 0.000 description 5
- 230000035479 physiological effects, processes and functions Effects 0.000 description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 239000001117 sulphuric acid Substances 0.000 description 5
- 235000011149 sulphuric acid Nutrition 0.000 description 5
- 235000015112 vegetable and seed oil Nutrition 0.000 description 5
- 239000008158 vegetable oil Substances 0.000 description 5
- 239000000080 wetting agent Substances 0.000 description 5
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 4
- 239000004475 Arginine Substances 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 4
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 4
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 4
- MITFXPHMIHQXPI-UHFFFAOYSA-N Oraflex Chemical compound N=1C2=CC(C(C(O)=O)C)=CC=C2OC=1C1=CC=C(Cl)C=C1 MITFXPHMIHQXPI-UHFFFAOYSA-N 0.000 description 4
- 206010033307 Overweight Diseases 0.000 description 4
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 4
- KLBQZWRITKRQQV-UHFFFAOYSA-N Thioridazine Chemical compound C12=CC(SC)=CC=C2SC2=CC=CC=C2N1CCC1CCCCN1C KLBQZWRITKRQQV-UHFFFAOYSA-N 0.000 description 4
- GFBKORZTTCHDGY-UWVJOHFNSA-N Thiothixene Chemical compound C12=CC(S(=O)(=O)N(C)C)=CC=C2SC2=CC=CC=C2\C1=C\CCN1CCN(C)CC1 GFBKORZTTCHDGY-UWVJOHFNSA-N 0.000 description 4
- 230000009102 absorption Effects 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 235000010489 acacia gum Nutrition 0.000 description 4
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 4
- 229950005506 acetylmethadol Drugs 0.000 description 4
- 230000000996 additive effect Effects 0.000 description 4
- 125000001931 aliphatic group Chemical group 0.000 description 4
- 125000003277 amino group Chemical group 0.000 description 4
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 4
- 229960003121 arginine Drugs 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000007767 bonding agent Substances 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 125000000392 cycloalkenyl group Chemical group 0.000 description 4
- 230000002939 deleterious effect Effects 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 239000002270 dispersing agent Substances 0.000 description 4
- DLNKOYKMWOXYQA-UHFFFAOYSA-N dl-pseudophenylpropanolamine Natural products CC(N)C(O)C1=CC=CC=C1 DLNKOYKMWOXYQA-UHFFFAOYSA-N 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 229960002464 fluoxetine Drugs 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 229960002870 gabapentin Drugs 0.000 description 4
- 229960003878 haloperidol Drugs 0.000 description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 239000002502 liposome Substances 0.000 description 4
- 229940057995 liquid paraffin Drugs 0.000 description 4
- 239000006194 liquid suspension Substances 0.000 description 4
- 239000007937 lozenge Substances 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 239000002858 neurotransmitter agent Substances 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- 230000008520 organization Effects 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- DHHVAGZRUROJKS-UHFFFAOYSA-N phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 description 4
- 229960005190 phenylalanine Drugs 0.000 description 4
- DLNKOYKMWOXYQA-APPZFPTMSA-N phenylpropanolamine Chemical compound C[C@@H](N)[C@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-APPZFPTMSA-N 0.000 description 4
- 229960000395 phenylpropanolamine Drugs 0.000 description 4
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 4
- OLTAWOVKGWWERU-UHFFFAOYSA-N proxazole Chemical compound C=1C=CC=CC=1C(CC)C1=NOC(CCN(CC)CC)=N1 OLTAWOVKGWWERU-UHFFFAOYSA-N 0.000 description 4
- 229960001801 proxazole Drugs 0.000 description 4
- 230000002787 reinforcement Effects 0.000 description 4
- WVYADZUPLLSGPU-UHFFFAOYSA-N salsalate Chemical compound OC(=O)C1=CC=CC=C1OC(=O)C1=CC=CC=C1O WVYADZUPLLSGPU-UHFFFAOYSA-N 0.000 description 4
- 208000016686 tic disease Diseases 0.000 description 4
- 229960004441 tyrosine Drugs 0.000 description 4
- 238000004260 weight control Methods 0.000 description 4
- DBGIVFWFUFKIQN-UHFFFAOYSA-N (+-)-Fenfluramine Chemical compound CCNC(C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-UHFFFAOYSA-N 0.000 description 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 3
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 3
- YFGHCGITMMYXAQ-UHFFFAOYSA-N 2-[(diphenylmethyl)sulfinyl]acetamide Chemical compound C=1C=CC=CC=1C(S(=O)CC(=O)N)C1=CC=CC=C1 YFGHCGITMMYXAQ-UHFFFAOYSA-N 0.000 description 3
- KQROHCSYOGBQGJ-UHFFFAOYSA-N 5-Hydroxytryptophol Chemical compound C1=C(O)C=C2C(CCO)=CNC2=C1 KQROHCSYOGBQGJ-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 108020004635 Complementary DNA Proteins 0.000 description 3
- 206010013654 Drug abuse Diseases 0.000 description 3
- 208000030814 Eating disease Diseases 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 208000019454 Feeding and Eating disease Diseases 0.000 description 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 3
- 108020004206 Gamma-glutamyltransferase Proteins 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
- ZPXSCAKFGYXMGA-UHFFFAOYSA-N Mazindol Chemical compound N12CCN=C2C2=CC=CC=C2C1(O)C1=CC=C(Cl)C=C1 ZPXSCAKFGYXMGA-UHFFFAOYSA-N 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
- 108020004459 Small interfering RNA Proteins 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 3
- 239000004473 Threonine Substances 0.000 description 3
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 235000004279 alanine Nutrition 0.000 description 3
- 230000008485 antagonism Effects 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 235000003704 aspartic acid Nutrition 0.000 description 3
- 238000013542 behavioral therapy Methods 0.000 description 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 3
- 229960001058 bupropion Drugs 0.000 description 3
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 description 3
- 238000010804 cDNA synthesis Methods 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 229960004170 clozapine Drugs 0.000 description 3
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 125000000753 cycloalkyl group Chemical group 0.000 description 3
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 3
- 229960003529 diazepam Drugs 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 235000014632 disordered eating Nutrition 0.000 description 3
- 239000006196 drop Substances 0.000 description 3
- 206010013663 drug dependence Diseases 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 239000011737 fluorine Substances 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 102000006640 gamma-Glutamyltransferase Human genes 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 239000007902 hard capsule Substances 0.000 description 3
- 230000003862 health status Effects 0.000 description 3
- 125000001072 heteroaryl group Chemical group 0.000 description 3
- 125000005241 heteroarylamino group Chemical class 0.000 description 3
- 125000000623 heterocyclic group Chemical group 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 229960000310 isoleucine Drugs 0.000 description 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 3
- 239000000787 lecithin Substances 0.000 description 3
- 235000010445 lecithin Nutrition 0.000 description 3
- 229940067606 lecithin Drugs 0.000 description 3
- 229960003136 leucine Drugs 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 229960000299 mazindol Drugs 0.000 description 3
- 229930182817 methionine Natural products 0.000 description 3
- 239000002480 mineral oil Substances 0.000 description 3
- 235000010446 mineral oil Nutrition 0.000 description 3
- 229960001165 modafinil Drugs 0.000 description 3
- 239000002777 nucleoside Substances 0.000 description 3
- 150000003833 nucleoside derivatives Chemical class 0.000 description 3
- 229940124636 opioid drug Drugs 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 238000001050 pharmacotherapy Methods 0.000 description 3
- 229950010883 phencyclidine Drugs 0.000 description 3
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 3
- 229960002702 piroxicam Drugs 0.000 description 3
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 3
- 108091033319 polynucleotide Proteins 0.000 description 3
- 102000040430 polynucleotide Human genes 0.000 description 3
- 239000002157 polynucleotide Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 3
- 239000003369 serotonin 5-HT3 receptor antagonist Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000007901 soft capsule Substances 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 125000005017 substituted alkenyl group Chemical group 0.000 description 3
- 125000000547 substituted alkyl group Chemical group 0.000 description 3
- 239000001384 succinic acid Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 3
- 229960002784 thioridazine Drugs 0.000 description 3
- 238000011200 topical administration Methods 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 2
- DBGIVFWFUFKIQN-VIFPVBQESA-N (+)-Fenfluramine Chemical compound CCN[C@@H](C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-VIFPVBQESA-N 0.000 description 2
- WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 description 2
- IOVGROKTTNBUGK-SJKOYZFVSA-N (1S,2R)-ritodrine Chemical compound N([C@H](C)[C@@H](O)C=1C=CC(O)=CC=1)CCC1=CC=C(O)C=C1 IOVGROKTTNBUGK-SJKOYZFVSA-N 0.000 description 2
- ZERWDZDNDJBYKA-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)ON1C(=O)CCC1=O ZERWDZDNDJBYKA-UHFFFAOYSA-N 0.000 description 2
- RJMIEHBSYVWVIN-LLVKDONJSA-N (2r)-2-[4-(3-oxo-1h-isoindol-2-yl)phenyl]propanoic acid Chemical compound C1=CC([C@H](C(O)=O)C)=CC=C1N1C(=O)C2=CC=CC=C2C1 RJMIEHBSYVWVIN-LLVKDONJSA-N 0.000 description 2
- XYRIRLDHOQSNLW-UHFFFAOYSA-N (3-oxo-1h-2-benzofuran-1-yl) 2-[1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]acetate Chemical compound CC1=C(CC(=O)OC2C3=CC=CC=C3C(=O)O2)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 XYRIRLDHOQSNLW-UHFFFAOYSA-N 0.000 description 2
- SHCYQUDTKWHARF-UHFFFAOYSA-N (3-oxo-1h-2-benzofuran-1-yl) 2-acetyloxybenzoate Chemical compound CC(=O)OC1=CC=CC=C1C(=O)OC1C2=CC=CC=C2C(=O)O1 SHCYQUDTKWHARF-UHFFFAOYSA-N 0.000 description 2
- PPQZABOURJVKNI-UHFFFAOYSA-N (4-fluorophenyl)-[4-(4-fluorophenyl)-4-hydroxy-1-methylpiperidin-3-yl]methanone Chemical compound C1N(C)CCC(O)(C=2C=CC(F)=CC=2)C1C(=O)C1=CC=C(F)C=C1 PPQZABOURJVKNI-UHFFFAOYSA-N 0.000 description 2
- VVLJQSJNPKNTAT-SNVBAGLBSA-N (5S)-5-phenyl-2,3,5,6-tetrahydro-1H-imidazo[1,2-a]imidazole Chemical compound C1([C@@H]2N3CCNC3=NC2)=CC=CC=C1 VVLJQSJNPKNTAT-SNVBAGLBSA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- WSPOMRSOLSGNFJ-AUWJEWJLSA-N (Z)-chlorprothixene Chemical compound C1=C(Cl)C=C2C(=C/CCN(C)C)\C3=CC=CC=C3SC2=C1 WSPOMRSOLSGNFJ-AUWJEWJLSA-N 0.000 description 2
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 2
- ZHXUEUKVDMWSKV-UHFFFAOYSA-N 1-(3,5-ditert-butyl-4-hydroxyphenyl)hex-5-yn-1-one Chemical compound CC(C)(C)C1=CC(C(=O)CCCC#C)=CC(C(C)(C)C)=C1O ZHXUEUKVDMWSKV-UHFFFAOYSA-N 0.000 description 2
- KFNNPQDSPLWLCX-UHFFFAOYSA-N 1-[1-(4-chlorophenyl)cyclobutyl]-n,n,3-trimethylbutan-1-amine;hydron;chloride;hydrate Chemical compound O.Cl.C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 KFNNPQDSPLWLCX-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- KLIVRBFRQSOGQI-UHFFFAOYSA-N 2-(11-oxo-6h-benzo[c][1]benzothiepin-3-yl)acetic acid Chemical compound S1CC2=CC=CC=C2C(=O)C2=CC=C(CC(=O)O)C=C12 KLIVRBFRQSOGQI-UHFFFAOYSA-N 0.000 description 2
- UEIBTMGAIXZRBV-UHFFFAOYSA-N 2-(3-phenoxypropyl)guanidine Chemical compound NC(N)=NCCCOC1=CC=CC=C1 UEIBTMGAIXZRBV-UHFFFAOYSA-N 0.000 description 2
- BUUODSZYUAZDIF-AOMKIAJQSA-N 2-[(1s,4r)-4-benzyl-1-ethyl-4,9-dihydro-3h-pyrano[3,4-b]indol-1-yl]acetic acid Chemical compound C([C@H]1CO[C@](C2=C1C1=CC=CC=C1N2)(CC(O)=O)CC)C1=CC=CC=C1 BUUODSZYUAZDIF-AOMKIAJQSA-N 0.000 description 2
- DWWHMKBNNNZGHF-UHFFFAOYSA-N 2-[1-(2,6-dichlorophenoxy)ethyl]-4,5-dihydro-1h-imidazole;hydron;chloride Chemical compound Cl.N=1CCNC=1C(C)OC1=C(Cl)C=CC=C1Cl DWWHMKBNNNZGHF-UHFFFAOYSA-N 0.000 description 2
- ANMLJLFWUCQGKZ-UHFFFAOYSA-N 2-[3-(trifluoromethyl)anilino]-3-pyridinecarboxylic acid (3-oxo-1H-isobenzofuran-1-yl) ester Chemical compound FC(F)(F)C1=CC=CC(NC=2C(=CC=CN=2)C(=O)OC2C3=CC=CC=C3C(=O)O2)=C1 ANMLJLFWUCQGKZ-UHFFFAOYSA-N 0.000 description 2
- XILVEPYQJIOVNB-UHFFFAOYSA-N 2-[3-(trifluoromethyl)anilino]benzoic acid 2-(2-hydroxyethoxy)ethyl ester Chemical compound OCCOCCOC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 XILVEPYQJIOVNB-UHFFFAOYSA-N 0.000 description 2
- XNMQEEKYCVKGBD-UHFFFAOYSA-N 2-butyne Chemical compound CC#CC XNMQEEKYCVKGBD-UHFFFAOYSA-N 0.000 description 2
- AIDLAEPHWROGFI-UHFFFAOYSA-N 2-methylbenzene-1,3-dicarboxylic acid Chemical compound CC1=C(C(O)=O)C=CC=C1C(O)=O AIDLAEPHWROGFI-UHFFFAOYSA-N 0.000 description 2
- JXZZEXZZKAWDSP-UHFFFAOYSA-N 3-(2-(4-Benzamidopiperid-1-yl)ethyl)indole Chemical compound C1CN(CCC=2C3=CC=CC=C3NC=2)CCC1NC(=O)C1=CC=CC=C1 JXZZEXZZKAWDSP-UHFFFAOYSA-N 0.000 description 2
- AKUVRZKNLXYTJX-UHFFFAOYSA-N 3-benzylazetidine Chemical compound C=1C=CC=CC=1CC1CNC1 AKUVRZKNLXYTJX-UHFFFAOYSA-N 0.000 description 2
- GUJRSXAPGDDABA-NSHDSACASA-N 3-bromo-N-[[(2S)-1-ethyl-2-pyrrolidinyl]methyl]-2,6-dimethoxybenzamide Chemical compound CCN1CCC[C@H]1CNC(=O)C1=C(OC)C=CC(Br)=C1OC GUJRSXAPGDDABA-NSHDSACASA-N 0.000 description 2
- PIAMNHTVFPWVHG-UHFFFAOYSA-N 4-(4-chlorophenyl)-5-methyl-1h-imidazole;hydrochloride Chemical compound Cl.N1C=NC(C=2C=CC(Cl)=CC=2)=C1C PIAMNHTVFPWVHG-UHFFFAOYSA-N 0.000 description 2
- 102000035037 5-HT3 receptors Human genes 0.000 description 2
- 108091005477 5-HT3 receptors Proteins 0.000 description 2
- JMHFFDIMOUKDCZ-NTXHZHDSSA-N 61214-51-5 Chemical compound C([C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)[C@@H](C)O)C1=CC=CC=C1 JMHFFDIMOUKDCZ-NTXHZHDSSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 235000019489 Almond oil Nutrition 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- 208000027448 Attention Deficit and Disruptive Behavior disease Diseases 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- KPYSYYIEGFHWSV-UHFFFAOYSA-N Baclofen Chemical compound OC(=O)CC(CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-UHFFFAOYSA-N 0.000 description 2
- HNNIWKQLJSNAEQ-UHFFFAOYSA-N Benzydamine hydrochloride Chemical compound Cl.C12=CC=CC=C2C(OCCCN(C)C)=NN1CC1=CC=CC=C1 HNNIWKQLJSNAEQ-UHFFFAOYSA-N 0.000 description 2
- 102400000748 Beta-endorphin Human genes 0.000 description 2
- 101800005049 Beta-endorphin Proteins 0.000 description 2
- RKLNONIVDFXQRX-UHFFFAOYSA-N Bromperidol Chemical compound C1CC(O)(C=2C=CC(Br)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 RKLNONIVDFXQRX-UHFFFAOYSA-N 0.000 description 2
- 206010006550 Bulimia nervosa Diseases 0.000 description 2
- KAKZBPTYRLMSJV-UHFFFAOYSA-N Butadiene Chemical compound C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 description 2
- 239000002080 C09CA02 - Eprosartan Substances 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- VPGRYOFKCNULNK-ACXQXYJUSA-N Deoxycorticosterone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)COC(=O)C)[C@@]1(C)CC2 VPGRYOFKCNULNK-ACXQXYJUSA-N 0.000 description 2
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 208000026331 Disruptive, Impulse Control, and Conduct disease Diseases 0.000 description 2
- JRWZLRBJNMZMFE-UHFFFAOYSA-N Dobutamine Chemical compound C=1C=C(O)C(O)=CC=1CCNC(C)CCC1=CC=C(O)C=C1 JRWZLRBJNMZMFE-UHFFFAOYSA-N 0.000 description 2
- 241000792859 Enema Species 0.000 description 2
- RHAXSHUQNIEUEY-UHFFFAOYSA-N Epirizole Chemical compound COC1=CC(C)=NN1C1=NC(C)=CC(OC)=N1 RHAXSHUQNIEUEY-UHFFFAOYSA-N 0.000 description 2
- 208000001836 Firesetting Behavior Diseases 0.000 description 2
- PLDUPXSUYLZYBN-UHFFFAOYSA-N Fluphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 PLDUPXSUYLZYBN-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 102000005915 GABA Receptors Human genes 0.000 description 2
- 108010005551 GABA Receptors Proteins 0.000 description 2
- 102400000321 Glucagon Human genes 0.000 description 2
- 108060003199 Glucagon Proteins 0.000 description 2
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- WDZVGELJXXEGPV-YIXHJXPBSA-N Guanabenz Chemical compound NC(N)=N\N=C\C1=C(Cl)C=CC=C1Cl WDZVGELJXXEGPV-YIXHJXPBSA-N 0.000 description 2
- WYCLKVQLVUQKNZ-UHFFFAOYSA-N Halazepam Chemical compound N=1CC(=O)N(CC(F)(F)F)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 WYCLKVQLVUQKNZ-UHFFFAOYSA-N 0.000 description 2
- RPTUSVTUFVMDQK-UHFFFAOYSA-N Hidralazin Chemical compound C1=CC=C2C(NN)=NN=CC2=C1 RPTUSVTUFVMDQK-UHFFFAOYSA-N 0.000 description 2
- 206010020651 Hyperkinesia Diseases 0.000 description 2
- 208000000269 Hyperkinesis Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 2
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 2
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- GQWNECFJGBQMBO-UHFFFAOYSA-N Molindone hydrochloride Chemical compound Cl.O=C1C=2C(CC)=C(C)NC=2CCC1CN1CCOCC1 GQWNECFJGBQMBO-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- DJDFFEBSKJCGHC-UHFFFAOYSA-N Naphazoline Chemical compound Cl.C=1C=CC2=CC=CC=C2C=1CC1=NCCN1 DJDFFEBSKJCGHC-UHFFFAOYSA-N 0.000 description 2
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 2
- PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 description 2
- FELGMEQIXOGIFQ-UHFFFAOYSA-N Ondansetron Chemical compound CC1=NC=CN1CC1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-UHFFFAOYSA-N 0.000 description 2
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 102000019280 Pancreatic lipases Human genes 0.000 description 2
- 108050006759 Pancreatic lipases Proteins 0.000 description 2
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 2
- 206010034158 Pathological gambling Diseases 0.000 description 2
- RGCVKNLCSQQDEP-UHFFFAOYSA-N Perphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 RGCVKNLCSQQDEP-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GMZVRMREEHBGGF-UHFFFAOYSA-N Piracetam Chemical compound NC(=O)CN1CCCC1=O GMZVRMREEHBGGF-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920001214 Polysorbate 60 Polymers 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- MWQCHHACWWAQLJ-UHFFFAOYSA-N Prazepam Chemical compound O=C1CN=C(C=2C=CC=CC=2)C2=CC(Cl)=CC=C2N1CC1CC1 MWQCHHACWWAQLJ-UHFFFAOYSA-N 0.000 description 2
- 102000011195 Profilin Human genes 0.000 description 2
- 108050001408 Profilin Proteins 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 208000002847 Surgical Wound Diseases 0.000 description 2
- 239000000150 Sympathomimetic Substances 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- BZKPWHYZMXOIDC-UHFFFAOYSA-N acetazolamide Chemical compound CC(=O)NC1=NN=C(S(N)(=O)=O)S1 BZKPWHYZMXOIDC-UHFFFAOYSA-N 0.000 description 2
- NUKVZKPNSKJGBK-SPIKMXEPSA-N acetophenazine dimaleate Chemical compound [H+].[H+].[H+].[H+].[O-]C(=O)\C=C/C([O-])=O.[O-]C(=O)\C=C/C([O-])=O.C12=CC(C(=O)C)=CC=C2SC2=CC=CC=C2N1CCCN1CCN(CCO)CC1 NUKVZKPNSKJGBK-SPIKMXEPSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 229960003148 adinazolam Drugs 0.000 description 2
- GJSLOMWRLALDCT-UHFFFAOYSA-N adinazolam Chemical compound C12=CC(Cl)=CC=C2N2C(CN(C)C)=NN=C2CN=C1C1=CC=CC=C1 GJSLOMWRLALDCT-UHFFFAOYSA-N 0.000 description 2
- 208000029650 alcohol withdrawal Diseases 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 150000003973 alkyl amines Chemical class 0.000 description 2
- 239000008168 almond oil Substances 0.000 description 2
- VLSMHEGGTFMBBZ-UHFFFAOYSA-N alpha-Kainic acid Natural products CC(=C)C1CNC(C(O)=O)C1CC(O)=O VLSMHEGGTFMBBZ-UHFFFAOYSA-N 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 2
- 229960004538 alprazolam Drugs 0.000 description 2
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 2
- 229960003805 amantadine Drugs 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 229960002519 amoxapine Drugs 0.000 description 2
- QWGDMFLQWFTERH-UHFFFAOYSA-N amoxapine Chemical compound C12=CC(Cl)=CC=C2OC2=CC=CC=C2N=C1N1CCNCC1 QWGDMFLQWFTERH-UHFFFAOYSA-N 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 239000000939 antiparkinson agent Substances 0.000 description 2
- 229940125688 antiparkinson agent Drugs 0.000 description 2
- 229960000794 baclofen Drugs 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- 229960005430 benoxaprofen Drugs 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 229960001689 benzydamine hydrochloride Drugs 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 229960002781 bisoprolol Drugs 0.000 description 2
- VHYCDWMUTMEGQY-UHFFFAOYSA-N bisoprolol Chemical compound CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1 VHYCDWMUTMEGQY-UHFFFAOYSA-N 0.000 description 2
- 229960004037 bromperidol Drugs 0.000 description 2
- 239000006189 buccal tablet Substances 0.000 description 2
- 229940046011 buccal tablet Drugs 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229960001736 buprenorphine Drugs 0.000 description 2
- KDKYADYSIPSCCQ-UHFFFAOYSA-N but-1-yne Chemical group CCC#C KDKYADYSIPSCCQ-UHFFFAOYSA-N 0.000 description 2
- ZRIHAIZYIMGOAB-UHFFFAOYSA-N butabarbital Chemical compound CCC(C)C1(CC)C(=O)NC(=O)NC1=O ZRIHAIZYIMGOAB-UHFFFAOYSA-N 0.000 description 2
- QTNZYVAMNRDUAD-UHFFFAOYSA-N butacetin Chemical compound CC(=O)NC1=CC=C(OC(C)(C)C)C=C1 QTNZYVAMNRDUAD-UHFFFAOYSA-N 0.000 description 2
- 229950011189 butacetin Drugs 0.000 description 2
- 229960001948 caffeine Drugs 0.000 description 2
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 229960000623 carbamazepine Drugs 0.000 description 2
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 229960001076 chlorpromazine Drugs 0.000 description 2
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 2
- 229960001657 chlorpromazine hydrochloride Drugs 0.000 description 2
- 229960001552 chlorprothixene Drugs 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 239000007859 condensation product Substances 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- XLJMAIOERFSOGZ-UHFFFAOYSA-N cyanic acid Chemical compound OC#N XLJMAIOERFSOGZ-UHFFFAOYSA-N 0.000 description 2
- 229960002433 cysteine Drugs 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 229960003914 desipramine Drugs 0.000 description 2
- 229960000632 dexamfetamine Drugs 0.000 description 2
- 229960004597 dexfenfluramine Drugs 0.000 description 2
- 229960003428 dexibuprofen Drugs 0.000 description 2
- HEFNNWSXXWATRW-JTQLQIEISA-N dexibuprofen Chemical compound CC(C)CC1=CC=C([C@H](C)C(O)=O)C=C1 HEFNNWSXXWATRW-JTQLQIEISA-N 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 229960005081 diclofenamide Drugs 0.000 description 2
- GJQPMPFPNINLKP-UHFFFAOYSA-N diclofenamide Chemical compound NS(=O)(=O)C1=CC(Cl)=C(Cl)C(S(N)(=O)=O)=C1 GJQPMPFPNINLKP-UHFFFAOYSA-N 0.000 description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
- 229960000616 diflunisal Drugs 0.000 description 2
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- CGDDQFMPGMYYQP-UHFFFAOYSA-N disopyramide phosphate Chemical compound OP(O)(O)=O.C=1C=CC=NC=1C(C(N)=O)(CCN(C(C)C)C(C)C)C1=CC=CC=C1 CGDDQFMPGMYYQP-UHFFFAOYSA-N 0.000 description 2
- 229960001863 disopyramide phosphate Drugs 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 2
- 229960002029 endralazine Drugs 0.000 description 2
- ALAXZYHFVBSJKZ-UHFFFAOYSA-N endralazine Chemical compound C1CC=2N=NC(NN)=CC=2CN1C(=O)C1=CC=CC=C1 ALAXZYHFVBSJKZ-UHFFFAOYSA-N 0.000 description 2
- 239000007920 enema Substances 0.000 description 2
- 229940095399 enema Drugs 0.000 description 2
- 229950003801 epirizole Drugs 0.000 description 2
- OROAFUQRIXKEMV-LDADJPATSA-N eprosartan Chemical compound C=1C=C(C(O)=O)C=CC=1CN1C(CCCC)=NC=C1\C=C(C(O)=O)/CC1=CC=CS1 OROAFUQRIXKEMV-LDADJPATSA-N 0.000 description 2
- 229960004563 eprosartan Drugs 0.000 description 2
- WKRLQDKEXYKHJB-HFTRVMKXSA-N equilin Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4C3=CCC2=C1 WKRLQDKEXYKHJB-HFTRVMKXSA-N 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 229960005309 estradiol Drugs 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 229960001493 etofenamate Drugs 0.000 description 2
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 2
- 239000002360 explosive Substances 0.000 description 2
- 150000002191 fatty alcohols Chemical class 0.000 description 2
- 229960001582 fenfluramine Drugs 0.000 description 2
- IVLVTNPOHDFFCJ-UHFFFAOYSA-N fentanyl citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 IVLVTNPOHDFFCJ-UHFFFAOYSA-N 0.000 description 2
- 229950004322 flazalone Drugs 0.000 description 2
- NOOCSNJCXJYGPE-UHFFFAOYSA-N flunixin Chemical compound C1=CC=C(C(F)(F)F)C(C)=C1NC1=NC=CC=C1C(O)=O NOOCSNJCXJYGPE-UHFFFAOYSA-N 0.000 description 2
- 229960000588 flunixin Drugs 0.000 description 2
- MGCCHNLNRBULBU-WZTVWXICSA-N flunixin meglumine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.C1=CC=C(C(F)(F)F)C(C)=C1NC1=NC=CC=C1C(O)=O MGCCHNLNRBULBU-WZTVWXICSA-N 0.000 description 2
- 229960000469 flunixin meglumine Drugs 0.000 description 2
- 229960002690 fluphenazine Drugs 0.000 description 2
- 229960001258 fluphenazine hydrochloride Drugs 0.000 description 2
- 229960002390 flurbiprofen Drugs 0.000 description 2
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 2
- 229960004666 glucagon Drugs 0.000 description 2
- 125000005456 glyceride group Chemical group 0.000 description 2
- 239000004519 grease Substances 0.000 description 2
- YUFWAVFNITUSHI-UHFFFAOYSA-N guanethidine monosulfate Chemical compound [H+].[H+].[O-]S([O-])(=O)=O.NC(=N)NCCN1CCCCCCC1 YUFWAVFNITUSHI-UHFFFAOYSA-N 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 229950010491 guanoxyfen Drugs 0.000 description 2
- 229960002158 halazepam Drugs 0.000 description 2
- ICJBPZBRDLONIF-UHFFFAOYSA-N hexane-1,1,1,2,2,3-hexol Chemical compound CCCC(O)C(O)(O)C(O)(O)O ICJBPZBRDLONIF-UHFFFAOYSA-N 0.000 description 2
- 230000013632 homeostatic process Effects 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- PPHCXMVJHQJEAK-UHFFFAOYSA-N hydron;n-[2-(4-pyrimidin-2-ylpiperazin-1-yl)ethyl]adamantane-1-carboxamide;chloride Chemical compound Cl.C1C(C2)CC(C3)CC2CC13C(=O)NCCN(CC1)CCN1C1=NC=CC=N1 PPHCXMVJHQJEAK-UHFFFAOYSA-N 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- CYWFCPPBTWOZSF-UHFFFAOYSA-N ibufenac Chemical compound CC(C)CC1=CC=C(CC(O)=O)C=C1 CYWFCPPBTWOZSF-UHFFFAOYSA-N 0.000 description 2
- 229950009183 ibufenac Drugs 0.000 description 2
- 229960001680 ibuprofen Drugs 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 229960004187 indoprofen Drugs 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- VLSMHEGGTFMBBZ-OOZYFLPDSA-N kainic acid Chemical compound CC(=C)[C@H]1CN[C@H](C(O)=O)[C@H]1CC(O)=O VLSMHEGGTFMBBZ-OOZYFLPDSA-N 0.000 description 2
- 229950006874 kainic acid Drugs 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 206010023461 kleptomania Diseases 0.000 description 2
- 229960004502 levodopa Drugs 0.000 description 2
- 229960004400 levonorgestrel Drugs 0.000 description 2
- 239000006193 liquid solution Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- OXROWJKCGCOJDO-JLHYYAGUSA-N lornoxicam Chemical compound O=C1C=2SC(Cl)=CC=2S(=O)(=O)N(C)\C1=C(\O)NC1=CC=CC=N1 OXROWJKCGCOJDO-JLHYYAGUSA-N 0.000 description 2
- 229960002202 lornoxicam Drugs 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- GQVWFGYYMWLERN-UHFFFAOYSA-J magnesium;2-carboxyphenolate;2-hydroxyethyl(trimethyl)azanium;sulfate;tetrahydrate Chemical compound O.O.O.O.[Mg+2].[O-]S([O-])(=O)=O.C[N+](C)(C)CCO.C[N+](C)(C)CCO.OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O GQVWFGYYMWLERN-UHFFFAOYSA-J 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229960004090 maprotiline Drugs 0.000 description 2
- QSLMDECMDJKHMQ-GSXCWMCISA-N maprotiline Chemical compound C12=CC=CC=C2[C@@]2(CCCNC)C3=CC=CC=C3[C@@H]1CC2 QSLMDECMDJKHMQ-GSXCWMCISA-N 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- MPQWSYJGFLADEW-UHFFFAOYSA-N medroxalol Chemical compound C=1C=C2OCOC2=CC=1CCC(C)NCC(O)C1=CC=C(O)C(C(N)=O)=C1 MPQWSYJGFLADEW-UHFFFAOYSA-N 0.000 description 2
- 229950008578 medroxalol Drugs 0.000 description 2
- HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 2
- 229960003464 mefenamic acid Drugs 0.000 description 2
- 230000004630 mental health Effects 0.000 description 2
- SLVMESMUVMCQIY-UHFFFAOYSA-N mesoridazine Chemical compound CN1CCCCC1CCN1C2=CC(S(C)=O)=CC=C2SC2=CC=CC=C21 SLVMESMUVMCQIY-UHFFFAOYSA-N 0.000 description 2
- 229960000300 mesoridazine Drugs 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 229960001252 methamphetamine Drugs 0.000 description 2
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 239000011859 microparticle Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229960004684 molindone hydrochloride Drugs 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- NKDJNEGDJVXHKM-UHFFFAOYSA-N n,2-dimethyl-4,5,6,7-tetrahydroindazol-3-amine Chemical compound C1CCCC2=NN(C)C(NC)=C21 NKDJNEGDJVXHKM-UHFFFAOYSA-N 0.000 description 2
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 229960002009 naproxen Drugs 0.000 description 2
- CDBRNDSHEYLDJV-FVGYRXGTSA-M naproxen sodium Chemical compound [Na+].C1=C([C@H](C)C([O-])=O)C=CC2=CC(OC)=CC=C21 CDBRNDSHEYLDJV-FVGYRXGTSA-M 0.000 description 2
- 229960003940 naproxen sodium Drugs 0.000 description 2
- CMWTZPSULFXXJA-VIFPVBQESA-M naproxen(1-) Chemical compound C1=C([C@H](C)C([O-])=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-M 0.000 description 2
- LTRANDSQVZFZDG-SNVBAGLBSA-N naproxol Chemical compound C1=C([C@H](C)CO)C=CC2=CC(OC)=CC=C21 LTRANDSQVZFZDG-SNVBAGLBSA-N 0.000 description 2
- 229950006890 naproxol Drugs 0.000 description 2
- 229960002362 neostigmine Drugs 0.000 description 2
- LULNWZDBKTWDGK-UHFFFAOYSA-M neostigmine bromide Chemical compound [Br-].CN(C)C(=O)OC1=CC=CC([N+](C)(C)C)=C1 LULNWZDBKTWDGK-UHFFFAOYSA-M 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 2
- 229960005017 olanzapine Drugs 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 229960002085 oxycodone Drugs 0.000 description 2
- 229940116369 pancreatic lipase Drugs 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 229960002296 paroxetine Drugs 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 229960000762 perphenazine Drugs 0.000 description 2
- 229960003562 phentermine Drugs 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- PIJVFDBKTWXHHD-HIFRSBDPSA-N physostigmine Chemical compound C12=CC(OC(=O)NC)=CC=C2N(C)[C@@H]2[C@@]1(C)CCN2C PIJVFDBKTWXHHD-HIFRSBDPSA-N 0.000 description 2
- 229940023488 pill Drugs 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- YVUQSNJEYSNKRX-UHFFFAOYSA-N pimozide Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)CCCN1CCC(N2C(NC3=CC=CC=C32)=O)CC1 YVUQSNJEYSNKRX-UHFFFAOYSA-N 0.000 description 2
- 229960003634 pimozide Drugs 0.000 description 2
- 229960004526 piracetam Drugs 0.000 description 2
- 229960003073 pirfenidone Drugs 0.000 description 2
- ISWRGOKTTBVCFA-UHFFFAOYSA-N pirfenidone Chemical compound C1=C(C)C=CC(=O)N1C1=CC=CC=C1 ISWRGOKTTBVCFA-UHFFFAOYSA-N 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 229960003389 pramiracetam Drugs 0.000 description 2
- ZULJGOSFKWFVRX-UHFFFAOYSA-N pramiracetam Chemical compound CC(C)N(C(C)C)CCNC(=O)CN1CCCC1=O ZULJGOSFKWFVRX-UHFFFAOYSA-N 0.000 description 2
- 229960004856 prazepam Drugs 0.000 description 2
- 239000000186 progesterone Substances 0.000 description 2
- 229960003387 progesterone Drugs 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 201000004645 pyromania Diseases 0.000 description 2
- 239000002516 radical scavenger Substances 0.000 description 2
- 229960003448 remoxipride Drugs 0.000 description 2
- 230000008521 reorganization Effects 0.000 description 2
- 229950000125 salcolex Drugs 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 229960000953 salsalate Drugs 0.000 description 2
- 230000036186 satiety Effects 0.000 description 2
- 235000019627 satiety Nutrition 0.000 description 2
- MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 description 2
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 2
- 229960004425 sibutramine Drugs 0.000 description 2
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 2
- 229960003466 sibutramine hydrochloride Drugs 0.000 description 2
- SEEXPXUCHVGZGU-UHFFFAOYSA-M sodium;2-[5-(4-chlorobenzoyl)-1,4-dimethylpyrrol-2-yl]acetate Chemical compound [Na+].C1=C(CC([O-])=O)N(C)C(C(=O)C=2C=CC(Cl)=CC=2)=C1C SEEXPXUCHVGZGU-UHFFFAOYSA-M 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 239000001593 sorbitan monooleate Substances 0.000 description 2
- 235000011069 sorbitan monooleate Nutrition 0.000 description 2
- 229940035049 sorbitan monooleate Drugs 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000006190 sub-lingual tablet Substances 0.000 description 2
- 229940098466 sublingual tablet Drugs 0.000 description 2
- 208000011117 substance-related disease Diseases 0.000 description 2
- 125000003107 substituted aryl group Chemical group 0.000 description 2
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 230000001975 sympathomimetic effect Effects 0.000 description 2
- 230000005062 synaptic transmission Effects 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 229950005100 talmetacin Drugs 0.000 description 2
- 229960005262 talniflumate Drugs 0.000 description 2
- 229950005400 talosalate Drugs 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 229950003441 tebufelone Drugs 0.000 description 2
- 229960003676 tenidap Drugs 0.000 description 2
- LXIKEPCNDFVJKC-QXMHVHEDSA-N tenidap Chemical compound C12=CC(Cl)=CC=C2N(C(=O)N)C(=O)\C1=C(/O)C1=CC=CS1 LXIKEPCNDFVJKC-QXMHVHEDSA-N 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 229960000882 thiothixene hydrochloride Drugs 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- CVWILQHZFWRYPB-UHFFFAOYSA-N tiamenidine Chemical compound CC1=CSC(Cl)=C1NC1=NCCN1 CVWILQHZFWRYPB-UHFFFAOYSA-N 0.000 description 2
- 229950000164 tiamenidine Drugs 0.000 description 2
- 229950002345 tiopinac Drugs 0.000 description 2
- 229960005013 tiotixene Drugs 0.000 description 2
- 229960002872 tocainide Drugs 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- XSCGXQMFQXDFCW-UHFFFAOYSA-N triflupromazine Chemical compound C1=C(C(F)(F)F)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 XSCGXQMFQXDFCW-UHFFFAOYSA-N 0.000 description 2
- 229960003904 triflupromazine Drugs 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 229960002431 trimipramine Drugs 0.000 description 2
- ZSCDBOWYZJWBIY-UHFFFAOYSA-N trimipramine Chemical compound C1CC2=CC=CC=C2N(CC(CN(C)C)C)C2=CC=CC=C21 ZSCDBOWYZJWBIY-UHFFFAOYSA-N 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 229960004688 venlafaxine Drugs 0.000 description 2
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 2
- JOLJIIDDOBNFHW-UHFFFAOYSA-N xanomeline Chemical compound CCCCCCOC1=NSN=C1C1=CCCN(C)C1 JOLJIIDDOBNFHW-UHFFFAOYSA-N 0.000 description 2
- 229950006755 xanomeline Drugs 0.000 description 2
- 229960003516 zomepirac sodium Drugs 0.000 description 2
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 1
- YQYVFVRQLZMJKJ-JBBXEZCESA-N (+)-cyclazocine Chemical compound C([C@@]1(C)C2=CC(O)=CC=C2C[C@@H]2[C@@H]1C)CN2CC1CC1 YQYVFVRQLZMJKJ-JBBXEZCESA-N 0.000 description 1
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 1
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- GEFQWZLICWMTKF-CDUCUWFYSA-N (-)-alpha-Methylnoradrenaline Chemical compound C[C@H](N)[C@H](O)C1=CC=C(O)C(O)=C1 GEFQWZLICWMTKF-CDUCUWFYSA-N 0.000 description 1
- QZRUMKUMFJJARD-OMMJFLKZSA-N (-)-butaclamol hydrochloride Chemical compound Cl.C12=CC=CC=C2CCC2=CC=CC3=C2[C@@H]1CN1CC[C@@](C(C)(C)C)(O)C[C@@H]13 QZRUMKUMFJJARD-OMMJFLKZSA-N 0.000 description 1
- UIKROCXWUNQSPJ-VIFPVBQESA-N (-)-cotinine Chemical compound C1CC(=O)N(C)[C@@H]1C1=CC=CN=C1 UIKROCXWUNQSPJ-VIFPVBQESA-N 0.000 description 1
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- AGSIRJFXAANBMW-UHFFFAOYSA-N (1-hydroxynaphthalen-2-yl)iminourea Chemical compound NC(=O)N=NC1=C(O)C2=CC=CC=C2C=C1 AGSIRJFXAANBMW-UHFFFAOYSA-N 0.000 description 1
- BFCDFTHTSVTWOG-YLJYHZDGSA-N (1S,2R)-2-(octylamino)-1-[4-(propan-2-ylthio)phenyl]-1-propanol Chemical compound CCCCCCCCN[C@H](C)[C@@H](O)C1=CC=C(SC(C)C)C=C1 BFCDFTHTSVTWOG-YLJYHZDGSA-N 0.000 description 1
- IGLYMJRIWWIQQE-QUOODJBBSA-N (1S,2R)-2-phenylcyclopropan-1-amine (1R,2S)-2-phenylcyclopropan-1-amine Chemical compound N[C@H]1C[C@@H]1C1=CC=CC=C1.N[C@@H]1C[C@H]1C1=CC=CC=C1 IGLYMJRIWWIQQE-QUOODJBBSA-N 0.000 description 1
- SMZVRZPJXBGNFT-LBPRGKRZSA-N (1r)-1-(1,3-dioxan-5-yl)-n,n-dimethyl-1-pyridin-3-ylmethanamine Chemical compound C1([C@@H](N(C)C)C=2C=NC=CC=2)COCOC1 SMZVRZPJXBGNFT-LBPRGKRZSA-N 0.000 description 1
- ZNMXKJDERFMXNF-ZETCQYMHSA-N (1r)-1-(2-hydroxy-1,3,2-benzodioxaborol-5-yl)-2-(methylamino)ethanol Chemical compound CNC[C@H](O)C1=CC=C2OB(O)OC2=C1 ZNMXKJDERFMXNF-ZETCQYMHSA-N 0.000 description 1
- RJNRORZRFGUAKL-ADMBVFOFSA-N (1r)-1-[(3ar,5r,6s,6ar)-6-[3-(dimethylamino)propoxy]-2,2-dimethyl-3a,5,6,6a-tetrahydrofuro[2,3-d][1,3]dioxol-5-yl]ethane-1,2-diol;hydrochloride Chemical compound Cl.O1C(C)(C)O[C@@H]2[C@@H](OCCCN(C)C)[C@@H]([C@H](O)CO)O[C@@H]21 RJNRORZRFGUAKL-ADMBVFOFSA-N 0.000 description 1
- NVXPZMLRGBVYQV-WMLDXEAASA-N (1r,4s)-n-methyl-4-phenyl-1,2,3,4-tetrahydronaphthalen-1-amine Chemical compound C1([C@@H]2CC[C@H](C3=CC=CC=C32)NC)=CC=CC=C1 NVXPZMLRGBVYQV-WMLDXEAASA-N 0.000 description 1
- OTZOPAFTLUOBOM-LYCTWNKOSA-N (1r,5s)-1-(4-methylphenyl)-3-azabicyclo[3.1.0]hexane;hydrochloride Chemical compound Cl.C1=CC(C)=CC=C1[C@]1(CNC2)[C@@H]2C1 OTZOPAFTLUOBOM-LYCTWNKOSA-N 0.000 description 1
- JMVGSDHINNGCAC-GOFCXKROSA-N (1s)-1-[(3r)-2,3-dihydro-1,4-benzodioxin-3-yl]-2-[[(2r)-2-[(3s)-2,3-dihydro-1,4-benzodioxin-3-yl]-2-hydroxyethyl]amino]ethanol Chemical compound C1OC2=CC=CC=C2O[C@H]1[C@@H](O)CNC[C@@H](O)[C@H]1OC2=CC=CC=C2OC1 JMVGSDHINNGCAC-GOFCXKROSA-N 0.000 description 1
- SNMPZBCEJSLAEK-DOXZYTNZSA-N (1s,15r,20s)-3-methyl-11,12,14,15,16,17,18,19,20,21-decahydro-1h-yohimban Chemical compound C12=CC=CC=C2N(C)C2=C1CCN1C[C@@H]3CCCC[C@H]3C[C@H]12 SNMPZBCEJSLAEK-DOXZYTNZSA-N 0.000 description 1
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- LJZCWOISXLZEEU-UHFFFAOYSA-M (2-hydroxy-3-naphthalen-1-yloxypropyl)-dimethyl-propan-2-ylazanium;chloride Chemical compound [Cl-].C1=CC=C2C(OCC(O)C[N+](C)(C)C(C)C)=CC=CC2=C1 LJZCWOISXLZEEU-UHFFFAOYSA-M 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- HJOUSWJOPKLCGA-SOFGYWHQSA-N (2e)-2-(aminomethylidene)-3h-inden-1-one Chemical compound C1=CC=C2C(=O)C(=C/N)/CC2=C1 HJOUSWJOPKLCGA-SOFGYWHQSA-N 0.000 description 1
- VXLBSYHAEKDUSU-JXMROGBWSA-N (2e)-2-(fluoromethylidene)-4-(4-fluorophenyl)butan-1-amine Chemical compound NC\C(=C\F)CCC1=CC=C(F)C=C1 VXLBSYHAEKDUSU-JXMROGBWSA-N 0.000 description 1
- HQMDHDKBZGKPGS-RFVHGSKJSA-N (2r)-1-(2,5-dimethoxy-4-methylphenyl)butan-2-amine;hydrochloride Chemical compound Cl.CC[C@@H](N)CC1=CC(OC)=C(C)C=C1OC HQMDHDKBZGKPGS-RFVHGSKJSA-N 0.000 description 1
- YWPHCCPCQOJSGZ-LLVKDONJSA-N (2r)-2-[(2-ethoxyphenoxy)methyl]morpholine Chemical compound CCOC1=CC=CC=C1OC[C@@H]1OCCNC1 YWPHCCPCQOJSGZ-LLVKDONJSA-N 0.000 description 1
- VYPKEODFNOEZGS-VIFPVBQESA-N (2r)-2-acetamido-3-(2-hydroxybenzoyl)sulfanylpropanoic acid Chemical compound CC(=O)N[C@H](C(O)=O)CSC(=O)C1=CC=CC=C1O VYPKEODFNOEZGS-VIFPVBQESA-N 0.000 description 1
- BUJAGSGYPOAWEI-SECBINFHSA-N (2r)-2-amino-n-(2,6-dimethylphenyl)propanamide Chemical compound C[C@@H](N)C(=O)NC1=C(C)C=CC=C1C BUJAGSGYPOAWEI-SECBINFHSA-N 0.000 description 1
- VZGOQPXIRAHJLV-LREBCSMRSA-N (2r,3r)-2,3-dihydroxybutanedioic acid;3-[2-[4-(4-fluorobenzoyl)piperidin-1-yl]ethyl]-2-sulfanylidene-1h-quinazolin-4-one Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(F)=CC=C1C(=O)C1CCN(CCN2C(C3=CC=CC=C3NC2=S)=O)CC1 VZGOQPXIRAHJLV-LREBCSMRSA-N 0.000 description 1
- YLXIPWWIOISBDD-NDAAPVSOSA-N (2r,3r)-2,3-dihydroxybutanedioic acid;4-[(1r)-1-hydroxy-2-(methylamino)ethyl]benzene-1,2-diol Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.CNC[C@H](O)C1=CC=C(O)C(O)=C1 YLXIPWWIOISBDD-NDAAPVSOSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- BAVDEDVBIHTHJQ-UVJOBNTFSA-N (2s)-1-[(2s)-6-amino-2-[[(1s)-1-carboxy-3-phenylpropyl]amino]hexanoyl]pyrrolidine-2-carboxylic acid;hydrate Chemical compound O.C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 BAVDEDVBIHTHJQ-UVJOBNTFSA-N 0.000 description 1
- ZDRRIRUAESZNIH-BZGUUIOASA-N (2s)-1-[(4r,7s,10s,13s,16s,19r)-19-amino-7-(2-amino-2-oxoethyl)-13-[(2s)-butan-2-yl]-10-[(1r)-1-hydroxyethyl]-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-n-[(2s)-1-[(2-amino-2-oxoethyl)amino]- Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)[C@@H](C)O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZDRRIRUAESZNIH-BZGUUIOASA-N 0.000 description 1
- RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 description 1
- GYPWNVSWCIMIHQ-GRTNUQQKSA-N (2s)-2-[(4s)-2,2-diphenyl-1,3-dioxolan-4-yl]piperidine;hydrochloride Chemical compound Cl.C([C@H]1[C@@H]2OC(OC2)(C=2C=CC=CC=2)C=2C=CC=CC=2)CCCN1 GYPWNVSWCIMIHQ-GRTNUQQKSA-N 0.000 description 1
- MDKGKXOCJGEUJW-VIFPVBQESA-N (2s)-2-[4-(thiophene-2-carbonyl)phenyl]propanoic acid Chemical compound C1=CC([C@@H](C(O)=O)C)=CC=C1C(=O)C1=CC=CS1 MDKGKXOCJGEUJW-VIFPVBQESA-N 0.000 description 1
- AUDFHJLSHQWFQQ-SFHVURJKSA-N (2s)-2-[[2-[1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]acetyl]amino]-3-hydroxypropanoic acid Chemical compound CC1=C(CC(=O)N[C@@H](CO)C(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 AUDFHJLSHQWFQQ-SFHVURJKSA-N 0.000 description 1
- YKFCISHFRZHKHY-NGQGLHOPSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoic acid;trihydrate Chemical compound O.O.O.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1 YKFCISHFRZHKHY-NGQGLHOPSA-N 0.000 description 1
- KNHOFQRNQBONFF-RWGZXCQOSA-N (2s)-2-benzyl-n-[(2s)-1-[[(2s,3r,4s)-1-cyclohexyl-3,4-dihydroxy-6-methylheptan-2-yl]amino]-1-oxo-3-(1,3-thiazol-4-yl)propan-2-yl]-3-(4-methylpiperazin-1-yl)sulfonylpropanamide;hydrochloride Chemical compound Cl.C([C@@H]([C@@H](O)[C@@H](O)CC(C)C)NC(=O)[C@H](CC=1N=CSC=1)NC(=O)[C@H](CC=1C=CC=CC=1)CS(=O)(=O)N1CCN(C)CC1)C1CCCCC1 KNHOFQRNQBONFF-RWGZXCQOSA-N 0.000 description 1
- UGSLDMJXBQKDCT-WOPDTQHZSA-N (2s)-5-oxo-n-[(1s,2r)-2-phenylcyclopropyl]pyrrolidine-2-carboxamide Chemical compound C1([C@H]2C[C@@H]2NC(=O)[C@H]2NC(=O)CC2)=CC=CC=C1 UGSLDMJXBQKDCT-WOPDTQHZSA-N 0.000 description 1
- BXCQMQVEMFYKJC-WDEREUQCSA-N (2s)-n-[(2r)-1-[(2-amino-2-oxoethyl)amino]-4-methyl-1-oxopentan-2-yl]-n-methylpyrrolidine-2-carboxamide Chemical compound NC(=O)CNC(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H]1CCCN1 BXCQMQVEMFYKJC-WDEREUQCSA-N 0.000 description 1
- WZIUXGZIVZDXIG-WUUYCOTASA-N (2s,3s)-2,3-dihydroxybutanedioic acid;4-[2-[4-(4-hydroxyphenyl)butan-2-ylamino]ethyl]benzene-1,2-diol Chemical compound OC(=O)[C@@H](O)[C@H](O)C(O)=O.C=1C=C(O)C(O)=CC=1CCNC(C)CCC1=CC=C(O)C=C1 WZIUXGZIVZDXIG-WUUYCOTASA-N 0.000 description 1
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 1
- PAXRPWSXCPTPCA-NTCAYCPXSA-N (3e)-1-(2,6-dimethylphenyl)-3-(1-methylpyrrolidin-2-ylidene)urea Chemical compound CN1CCC\C1=N/C(=O)NC1=C(C)C=CC=C1C PAXRPWSXCPTPCA-NTCAYCPXSA-N 0.000 description 1
- DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 description 1
- FJIKWRGCXUCUIG-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1-methyl-3h-1,4-benzodiazepin-2-one Chemical compound O=C([C@H](O)N=1)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1Cl FJIKWRGCXUCUIG-HNNXBMFYSA-N 0.000 description 1
- VZVRZTZPHOHSCK-YVLHZVERSA-N (3z)-3-(12h-[1]benzofuro[3,2-c][1]benzoxepin-6-ylidene)-n,n-dimethylpropan-1-amine Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=C1C1=CC=CC=C1O2 VZVRZTZPHOHSCK-YVLHZVERSA-N 0.000 description 1
- BVNJBATUHVXZKP-QXMHVHEDSA-N (3z)-6-chloro-5-fluoro-3-[hydroxy(thiophen-2-yl)methylidene]-2-oxoindole-1-carboxamide Chemical compound C12=CC(F)=C(Cl)C=C2N(C(=O)N)C(=O)\C1=C(/O)C1=CC=CS1 BVNJBATUHVXZKP-QXMHVHEDSA-N 0.000 description 1
- DITYEPYMBCHKLF-UHFFFAOYSA-N (4-chlorophenyl)-(4,5-dihydro-1h-imidazol-2-yl)-pyridin-2-ylmethanol Chemical compound C=1C=C(Cl)C=CC=1C(C=1N=CC=CC=1)(O)C1=NCCN1 DITYEPYMBCHKLF-UHFFFAOYSA-N 0.000 description 1
- ZDHHGGFQZRPUSN-UHFFFAOYSA-N (4-chlorophenyl)-[3-(2h-tetrazol-5-ylmethyl)indol-1-yl]methanone Chemical compound C1=CC(Cl)=CC=C1C(=O)N1C2=CC=CC=C2C(CC2=NNN=N2)=C1 ZDHHGGFQZRPUSN-UHFFFAOYSA-N 0.000 description 1
- XMUZRUCADGTCPX-UHFFFAOYSA-N (4-fluorophenyl)-[1-[3-[2-(trifluoromethyl)phenothiazin-10-yl]propyl]piperidin-4-yl]methanone Chemical compound C1=CC(F)=CC=C1C(=O)C1CCN(CCCN2C3=CC(=CC=C3SC3=CC=CC=C32)C(F)(F)F)CC1 XMUZRUCADGTCPX-UHFFFAOYSA-N 0.000 description 1
- HJHVRVJTYPKTHX-HTMVYDOJSA-N (4ar,8ar)-5-propyl-1,4,4a,6,7,8,8a,9-octahydropyrazolo[3,4-g]quinoline;hydrochloride Chemical compound Cl.C([C@H]1CCCN([C@@H]1C1)CCC)C2=C1C=NN2 HJHVRVJTYPKTHX-HTMVYDOJSA-N 0.000 description 1
- SFILABVANJHLDH-XOZOLZJESA-N (4as,8as)-3-ethyl-2,6-dimethyl-4a,5,7,8,8a,9-hexahydro-1h-pyrrolo[2,3-g]isoquinolin-4-one;hydrochloride Chemical compound Cl.C([C@H]1C2)CN(C)C[C@H]1C(=O)C1=C2NC(C)=C1CC SFILABVANJHLDH-XOZOLZJESA-N 0.000 description 1
- JMPUQJQXECRLKY-IKADHJCRSA-N (4r,4ar,5s,7ar,12bs)-3-(cyclopropylmethyl)-5-ethyl-9-methoxy-1,2,4,4a,5,6,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one Chemical compound C([C@@]12[C@@H]3[C@H]4CC=5C2=C(C(=CC=5)OC)O[C@H]1C(=O)C[C@@H]3CC)CN4CC1CC1 JMPUQJQXECRLKY-IKADHJCRSA-N 0.000 description 1
- ZGSZBVAEVPSPFM-HYTSPMEMSA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,5,6,7,7a,13-octahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;(2r,3r)-2,3-dihydroxybutanedioic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC ZGSZBVAEVPSPFM-HYTSPMEMSA-N 0.000 description 1
- WRRSFOZOETZUPG-FFHNEAJVSA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;hydrate Chemical compound O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC WRRSFOZOETZUPG-FFHNEAJVSA-N 0.000 description 1
- DKSZLDSPXIWGFO-BLOJGBSASA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;phosphoric acid;hydrate Chemical compound O.OP(O)(O)=O.OP(O)(O)=O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC DKSZLDSPXIWGFO-BLOJGBSASA-N 0.000 description 1
- BCXHDORHMMZBBZ-DORFAMGDSA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;sulfuric acid Chemical compound OS(O)(=O)=O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC BCXHDORHMMZBBZ-DORFAMGDSA-N 0.000 description 1
- PJDUKHQNUMOJLL-OPHZJPRHSA-N (4r,4as,7ar,12bs)-4a,9-dihydroxy-3-(3-methylbut-2-enyl)-2,4,5,6,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one;hydrochloride Chemical compound Cl.O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(CC=C(C)C)[C@@H]3CC5=CC=C4O PJDUKHQNUMOJLL-OPHZJPRHSA-N 0.000 description 1
- JFTOCKFCHJCDDX-UVTDQMKNSA-N (4z)-4-benzylidene-5,6,7,8-tetrahydroisoquinoline-1,3-dione Chemical compound C1CCCC2=C1C(=O)NC(=O)\C2=C/C1=CC=CC=C1 JFTOCKFCHJCDDX-UVTDQMKNSA-N 0.000 description 1
- UJEPHPADGSWWRM-LDYMZIIASA-N (5R,6S)-5-methyl-6-phenylmorpholin-3-one Chemical compound C[C@H]1NC(=O)CO[C@H]1C1=CC=CC=C1 UJEPHPADGSWWRM-LDYMZIIASA-N 0.000 description 1
- TUFADSGTJUOBEH-ZWNOBZJWSA-N (5aR,9aR)-6-propyl-5a,7,8,9,9a,10-hexahydro-5H-pyrido[2,3-g]quinazolin-2-amine Chemical compound NC1=NC=C2C[C@H]3N(CCC)CCC[C@@H]3CC2=N1 TUFADSGTJUOBEH-ZWNOBZJWSA-N 0.000 description 1
- KPJZHOPZRAFDTN-ZRGWGRIASA-N (6aR,9R)-N-[(2S)-1-hydroxybutan-2-yl]-4,7-dimethyl-6,6a,8,9-tetrahydroindolo[4,3-fg]quinoline-9-carboxamide Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@H](CO)CC)C2)=C3C2=CN(C)C3=C1 KPJZHOPZRAFDTN-ZRGWGRIASA-N 0.000 description 1
- KEMOOQHMCGCZKH-JMUQELJHSA-N (6ar,9r,10ar)-n-cyclohexyl-7-methyl-4-propan-2-yl-6,6a,8,9,10,10a-hexahydroindolo[4,3-fg]quinoline-9-carboxamide Chemical compound O=C([C@@H]1C[C@H]2[C@H](N(C1)C)CC1=CN(C=3C=CC=C2C1=3)C(C)C)NC1CCCCC1 KEMOOQHMCGCZKH-JMUQELJHSA-N 0.000 description 1
- LAZPBGZRMVRFKY-PPHPATTJSA-N (6r)-6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazole;hydrochloride Chemical compound Cl.C1([C@@H]2CN3CCSC3=N2)=CC=CC=C1 LAZPBGZRMVRFKY-PPHPATTJSA-N 0.000 description 1
- VDNZZIYSCXESNI-ILSZZQPISA-N (6s,8s,9s,10r,11s,13s,14s,17s)-17-acetyl-11-hydroxy-6,10,13-trimethyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@H](C(C)=O)CC[C@H]21 VDNZZIYSCXESNI-ILSZZQPISA-N 0.000 description 1
- JTVLYHXMPUSZIT-VKAVYKQESA-N (6z)-6-[butylamino-(2-chlorophenyl)methylidene]-4-chlorocyclohexa-2,4-dien-1-one Chemical compound C=1C=CC=C(Cl)C=1C(/NCCCC)=C1\C=C(Cl)C=CC1=O JTVLYHXMPUSZIT-VKAVYKQESA-N 0.000 description 1
- GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 description 1
- OKWSMPYQIYKVDC-CXSFZGCWSA-N (8s,9r,10s,11s,13s,14s,16r,17r)-9,11-dichloro-17-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2Cl OKWSMPYQIYKVDC-CXSFZGCWSA-N 0.000 description 1
- MCKJPJYRCPANCC-XLXYOEISSA-N (8s,9s,10r,11s,13s,14s,17r)-11,17-dihydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene-17-carboxylic acid Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(O)=O)[C@@H]4[C@@H]3CCC2=C1 MCKJPJYRCPANCC-XLXYOEISSA-N 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- KWTSXDURSIMDCE-MRVPVSSYSA-N (R)-amphetamine Chemical compound C[C@@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-MRVPVSSYSA-N 0.000 description 1
- PPKXEPBICJTCRU-XMZRARIVSA-N (R,R)-tramadol hydrochloride Chemical compound Cl.COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 PPKXEPBICJTCRU-XMZRARIVSA-N 0.000 description 1
- BGRJTUBHPOOWDU-NSHDSACASA-N (S)-(-)-sulpiride Chemical compound CCN1CCC[C@H]1CNC(=O)C1=CC(S(N)(=O)=O)=CC=C1OC BGRJTUBHPOOWDU-NSHDSACASA-N 0.000 description 1
- UUDAMDVQRQNNHZ-UHFFFAOYSA-N (S)-AMPA Chemical compound CC=1ONC(=O)C=1CC(N)C(O)=O UUDAMDVQRQNNHZ-UHFFFAOYSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- ZXKXJHAOUFHNAS-FVGYRXGTSA-N (S)-fenfluramine hydrochloride Chemical compound [Cl-].CC[NH2+][C@@H](C)CC1=CC=CC(C(F)(F)F)=C1 ZXKXJHAOUFHNAS-FVGYRXGTSA-N 0.000 description 1
- PVHUJELLJLJGLN-INIZCTEOSA-N (S)-nitrendipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC([N+]([O-])=O)=C1 PVHUJELLJLJGLN-INIZCTEOSA-N 0.000 description 1
- KOHIRBRYDXPAMZ-YHBROIRLSA-N (S,R,R,R)-nebivolol Chemical compound C1CC2=CC(F)=CC=C2O[C@H]1[C@H](O)CNC[C@@H](O)[C@H]1OC2=CC=C(F)C=C2CC1 KOHIRBRYDXPAMZ-YHBROIRLSA-N 0.000 description 1
- ZEHYJZXQEQOSON-AATRIKPKSA-N (e)-1-chloro-3-ethylpent-1-en-4-yn-3-ol Chemical compound CCC(O)(C#C)\C=C\Cl ZEHYJZXQEQOSON-AATRIKPKSA-N 0.000 description 1
- QECAKYKTTYQVKX-RMKNXTFCSA-N (e)-3-(2,5-dihydropyrrol-1-yl)-1-(3,4,5-trimethoxyphenyl)prop-2-en-1-one Chemical compound COC1=C(OC)C(OC)=CC(C(=O)\C=C\N2CC=CC2)=C1 QECAKYKTTYQVKX-RMKNXTFCSA-N 0.000 description 1
- LRLKZVMLJBNNPE-SNAWJCMRSA-N (e)-3-(3,4,5-trimethoxyphenyl)prop-2-enamide Chemical compound COC1=CC(\C=C\C(N)=O)=CC(OC)=C1OC LRLKZVMLJBNNPE-SNAWJCMRSA-N 0.000 description 1
- XWBHHRBXVHYWQU-UHFFFAOYSA-N (e)-[amino-(2,6-dichloroanilino)methylidene]urea;hydron;chloride Chemical compound Cl.NC(=O)\N=C(/N)NC1=C(Cl)C=CC=C1Cl XWBHHRBXVHYWQU-UHFFFAOYSA-N 0.000 description 1
- BACLFYJGAMBEIX-WLHGVMLRSA-L (e)-but-2-enedioate;2-(5-methyl-2-phenyl-1h-imidazol-4-yl)acetonitrile Chemical compound [O-]C(=O)\C=C\C([O-])=O.N#CCC1=C(C)NC(C=2C=CC=CC=2)=N1 BACLFYJGAMBEIX-WLHGVMLRSA-L 0.000 description 1
- OGIANCVCVVXZKS-WLHGVMLRSA-N (e)-but-2-enedioic acid;2-(2,2-diphenylcyclopropyl)-4,5-dihydro-1h-imidazole Chemical compound OC(=O)\C=C\C(O)=O.C=1C=CC=CC=1C1(C=2C=CC=CC=2)CC1C1=NCCN1 OGIANCVCVVXZKS-WLHGVMLRSA-N 0.000 description 1
- QEDVGROSOZBGOZ-WXXKFALUSA-N (e)-but-2-enedioic acid;n-[2-[[2-hydroxy-3-(4-hydroxyphenoxy)propyl]amino]ethyl]morpholine-4-carboxamide Chemical compound OC(=O)\C=C\C(O)=O.C=1C=C(O)C=CC=1OCC(O)CNCCNC(=O)N1CCOCC1.C=1C=C(O)C=CC=1OCC(O)CNCCNC(=O)N1CCOCC1 QEDVGROSOZBGOZ-WXXKFALUSA-N 0.000 description 1
- KKMOBFCMCCFTDX-WLHGVMLRSA-N (e)-but-2-enedioic acid;n-[3-(diethylamino)propyl]-2-(4,5-diphenylpyrazol-1-yl)acetamide Chemical compound OC(=O)\C=C\C(O)=O.CCN(CC)CCCNC(=O)CN1N=CC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 KKMOBFCMCCFTDX-WLHGVMLRSA-N 0.000 description 1
- ZOFVDTOFQPSUIK-OMMCMWGNSA-N (e)-but-2-enedioic acid;n-[4-[(1r)-4-(dibutylamino)-1-hydroxybutyl]phenyl]methanesulfonamide Chemical compound OC(=O)\C=C\C(O)=O.CCCCN(CCCC)CCC[C@@H](O)C1=CC=C(NS(C)(=O)=O)C=C1.CCCCN(CCCC)CCC[C@@H](O)C1=CC=C(NS(C)(=O)=O)C=C1 ZOFVDTOFQPSUIK-OMMCMWGNSA-N 0.000 description 1
- NCOOUEIQXVWKTO-QPJJXVBHSA-N (e)-n-cyclopropyl-3-(3-fluorophenyl)prop-2-enamide Chemical compound FC1=CC=CC(\C=C\C(=O)NC2CC2)=C1 NCOOUEIQXVWKTO-QPJJXVBHSA-N 0.000 description 1
- TYNKKGLBKXZIHX-XLOMBBFOSA-N (z)-but-2-enedioic acid;(5r)-7,8-dimethoxy-3-methyl-5-phenyl-1,2,4,5-tetrahydro-3-benzazepine Chemical compound OC(=O)\C=C/C(O)=O.C1([C@H]2CN(C)CCC=3C=C(C(=CC=32)OC)OC)=CC=CC=C1 TYNKKGLBKXZIHX-XLOMBBFOSA-N 0.000 description 1
- WVYWSPZQGQMPKW-SPIKMXEPSA-N (z)-but-2-enedioic acid;1-[10-[3-(4-methylpiperazin-1-yl)propyl]phenothiazin-2-yl]butan-1-one Chemical compound OC(=O)\C=C/C(O)=O.OC(=O)\C=C/C(O)=O.C12=CC(C(=O)CCC)=CC=C2SC2=CC=CC=C2N1CCCN1CCN(C)CC1 WVYWSPZQGQMPKW-SPIKMXEPSA-N 0.000 description 1
- OQIHDZMOAKTHKW-WPJOOPQGSA-N (z)-but-2-enedioic acid;1-cyclohexyl-n-[(1s,5r)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl]-4-oxoquinoline-3-carboxamide Chemical compound OC(=O)\C=C/C(O)=O.C([C@H]1CC[C@@H](C2)N1C)C2NC(=O)C(C(C1=CC=CC=C11)=O)=CN1C1CCCCC1 OQIHDZMOAKTHKW-WPJOOPQGSA-N 0.000 description 1
- JDZOTSLZMQDFLG-BTJKTKAUSA-N (z)-but-2-enedioic acid;2-(2,2-dicyclohexylethyl)piperidine Chemical compound OC(=O)\C=C/C(O)=O.C1CCCNC1CC(C1CCCCC1)C1CCCCC1 JDZOTSLZMQDFLG-BTJKTKAUSA-N 0.000 description 1
- QYJJDHZHSCTBII-BTJKTKAUSA-N (z)-but-2-enedioic acid;2-piperazin-1-ylquinoline Chemical compound OC(=O)\C=C/C(O)=O.C1CNCCN1C1=CC=C(C=CC=C2)C2=N1 QYJJDHZHSCTBII-BTJKTKAUSA-N 0.000 description 1
- TZNOWAJJWCGILX-BTJKTKAUSA-N (z)-but-2-enedioic acid;3-o-ethyl 5-o-methyl 2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound OC(=O)\C=C/C(O)=O.CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl TZNOWAJJWCGILX-BTJKTKAUSA-N 0.000 description 1
- VVNCUDFIJWCVHI-BTJKTKAUSA-N (z)-but-2-enedioic acid;5-(4-methylpiperazin-1-yl)imidazo[2,1-b][1,3,5]benzothiadiazepine Chemical compound OC(=O)\C=C/C(O)=O.C1CN(C)CCN1C1=NC2=CC=CC=C2SC2=NC=CN12 VVNCUDFIJWCVHI-BTJKTKAUSA-N 0.000 description 1
- DPYIXBFZUMCMJM-BTJKTKAUSA-N (z)-but-2-enedioic acid;ethyl n-[2-amino-6-[(4-fluorophenyl)methylamino]pyridin-3-yl]carbamate Chemical compound OC(=O)\C=C/C(O)=O.N1=C(N)C(NC(=O)OCC)=CC=C1NCC1=CC=C(F)C=C1 DPYIXBFZUMCMJM-BTJKTKAUSA-N 0.000 description 1
- ZEUQHGFLDLNEOB-CHHFXETESA-N (z)-but-2-enedioic acid;n-(3,4-dichlorophenyl)-n-[(1r,2r)-2-(dimethylamino)cyclopentyl]propanamide Chemical compound OC(=O)\C=C/C(O)=O.C=1C=C(Cl)C(Cl)=CC=1N(C(=O)CC)[C@@H]1CCC[C@H]1N(C)C ZEUQHGFLDLNEOB-CHHFXETESA-N 0.000 description 1
- WIUYTBGLPMBEKI-BTJKTKAUSA-N (z)-but-2-enedioic acid;n-[2-(diethylamino)ethyl]-2-hydroxybenzamide Chemical compound OC(=O)\C=C/C(O)=O.CCN(CC)CCNC(=O)C1=CC=CC=C1O WIUYTBGLPMBEKI-BTJKTKAUSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- BEQLOSVHRBTANS-UHFFFAOYSA-N 1,1,1,2,2,3,3,4,4,5,5,6,6-tridecafluoro-8-iodododecane Chemical compound CCCCC(I)CC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F BEQLOSVHRBTANS-UHFFFAOYSA-N 0.000 description 1
- BQNSLJQRJAJITR-UHFFFAOYSA-N 1,1,2-trichloro-1,2-difluoroethane Chemical compound FC(Cl)C(F)(Cl)Cl BQNSLJQRJAJITR-UHFFFAOYSA-N 0.000 description 1
- TZJUVVIWVWFLCD-UHFFFAOYSA-N 1,1-dioxo-2-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-1,2-benzothiazol-3-one Chemical compound O=S1(=O)C2=CC=CC=C2C(=O)N1CCCCN(CC1)CCN1C1=NC=CC=N1 TZJUVVIWVWFLCD-UHFFFAOYSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- IWEGDQUCWQFKHS-UHFFFAOYSA-N 1-(1,3-dioxolan-2-ylmethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole Chemical compound O1C(C)(C)C(C)(C)OB1C1=CN(CC2OCCO2)N=C1 IWEGDQUCWQFKHS-UHFFFAOYSA-N 0.000 description 1
- VPBLOJFGPORKQA-UHFFFAOYSA-N 1-(1-adamantyl)azetidine-2-carboxylic acid Chemical compound OC(=O)C1CCN1C1(C2)CC(C3)CC2CC3C1 VPBLOJFGPORKQA-UHFFFAOYSA-N 0.000 description 1
- WHJSFPCTWYLZRC-UHFFFAOYSA-N 1-(2,6-dimethylphenyl)-3-[3-(propan-2-ylamino)propyl]urea Chemical compound CC(C)NCCCNC(=O)NC1=C(C)C=CC=C1C WHJSFPCTWYLZRC-UHFFFAOYSA-N 0.000 description 1
- RJWVPIGRUWQLIB-UHFFFAOYSA-N 1-(2,6-dimethylphenyl)-3-[3-(propan-2-ylamino)propyl]urea;4-methylbenzenesulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1.CC(C)NCCCNC(=O)NC1=C(C)C=CC=C1C RJWVPIGRUWQLIB-UHFFFAOYSA-N 0.000 description 1
- KJBSVTAYVZKMDM-UHFFFAOYSA-N 1-(2-nitrophenyl)cyclopropane-1-carboxylic acid Chemical compound C=1C=CC=C([N+]([O-])=O)C=1C1(C(=O)O)CC1 KJBSVTAYVZKMDM-UHFFFAOYSA-N 0.000 description 1
- JIGAQXOHSFIRIS-UHFFFAOYSA-N 1-(3,4-dimethoxyphenyl)-n-(6,7-dimethoxyquinolin-4-yl)methanimine Chemical compound C1=C(OC)C(OC)=CC=C1C=NC1=CC=NC2=CC(OC)=C(OC)C=C12 JIGAQXOHSFIRIS-UHFFFAOYSA-N 0.000 description 1
- UNFQKKSADLVQJE-UHFFFAOYSA-N 1-(3-chlorophenyl)-3-(3-methyl-5-oxo-4h-imidazol-2-yl)urea;hydrate Chemical compound O.CN1CC(=O)N=C1NC(=O)NC1=CC=CC(Cl)=C1 UNFQKKSADLVQJE-UHFFFAOYSA-N 0.000 description 1
- SFIKANRWMMAUGN-UHFFFAOYSA-N 1-(3-chlorophenyl)-3-[2-(dimethylamino)ethyl]imidazolidin-2-one;hydrochloride Chemical compound Cl.O=C1N(CCN(C)C)CCN1C1=CC=CC(Cl)=C1 SFIKANRWMMAUGN-UHFFFAOYSA-N 0.000 description 1
- WEJDYJKJPUPMLH-UHFFFAOYSA-N 1-(4-chlorophenyl)-2-methylpropan-2-amine;hydrochloride Chemical compound Cl.CC(C)(N)CC1=CC=C(Cl)C=C1 WEJDYJKJPUPMLH-UHFFFAOYSA-N 0.000 description 1
- YYGANUVABKDFDW-UHFFFAOYSA-N 1-(4-chlorophenyl)-3-azabicyclo[3.1.0]hexane-2,4-dione Chemical compound C1=CC(Cl)=CC=C1C1(C(NC2=O)=O)C2C1 YYGANUVABKDFDW-UHFFFAOYSA-N 0.000 description 1
- GLPUBCPQWZZFNJ-UHFFFAOYSA-N 1-(5-bicyclo[2.2.1]hept-2-enyl)-1-phenyl-3-piperidin-1-ylpropan-1-ol;2-hydroxypropanoic acid Chemical compound CC(O)C(O)=O.C1C(C=C2)CC2C1C(C=1C=CC=CC=1)(O)CCN1CCCCC1 GLPUBCPQWZZFNJ-UHFFFAOYSA-N 0.000 description 1
- QFKMDZYQWDSMPA-UHFFFAOYSA-N 1-(octylamino)-3-(4-propan-2-ylsulfanylphenoxy)propan-2-ol;hydrochloride Chemical compound Cl.CCCCCCCCNCC(O)COC1=CC=C(SC(C)C)C=C1 QFKMDZYQWDSMPA-UHFFFAOYSA-N 0.000 description 1
- DHJWBCUZURVUCT-UHFFFAOYSA-N 1-(propan-2-ylamino)-3-(1,3-thiazol-2-yloxy)propan-2-ol;hydrochloride Chemical compound Cl.CC(C)NCC(O)COC1=NC=CS1 DHJWBCUZURVUCT-UHFFFAOYSA-N 0.000 description 1
- BAFOEQOGYLVKNR-UHFFFAOYSA-N 1-(tert-butylamino)-3-[2-(6-hydrazinylpyridazin-3-yl)phenoxy]propan-2-ol;hydrate;dihydrochloride Chemical compound O.Cl.Cl.CC(C)(C)NCC(O)COC1=CC=CC=C1C1=CC=C(NN)N=N1 BAFOEQOGYLVKNR-UHFFFAOYSA-N 0.000 description 1
- DOWWDQZIFWLREB-FYWRMAATSA-N 1-[(2e)-2-benzylidenecyclohexyl]azetidine Chemical compound C1CCN1C(CCCC\1)C/1=C/C1=CC=CC=C1 DOWWDQZIFWLREB-FYWRMAATSA-N 0.000 description 1
- LVEGWDSAJVVBHT-UHFFFAOYSA-N 1-[(4-methoxyphenyl)methyl]-2,3-dimethylguanidine;sulfuric acid Chemical compound OS(O)(=O)=O.CNC(=NC)NCC1=CC=C(OC)C=C1.CNC(=NC)NCC1=CC=C(OC)C=C1 LVEGWDSAJVVBHT-UHFFFAOYSA-N 0.000 description 1
- HIQONTNPQNNMST-UBKPWBPPSA-N 1-[(e)-[5-(3,4-dichlorophenyl)furan-2-yl]methylideneamino]imidazolidine-2,4-dione Chemical compound C1=C(Cl)C(Cl)=CC=C1C(O1)=CC=C1\C=N\N1C(=O)NC(=O)C1 HIQONTNPQNNMST-UBKPWBPPSA-N 0.000 description 1
- OZOMQRBLCMDCEG-CHHVJCJISA-N 1-[(z)-[5-(4-nitrophenyl)furan-2-yl]methylideneamino]imidazolidine-2,4-dione Chemical compound C1=CC([N+](=O)[O-])=CC=C1C(O1)=CC=C1\C=N/N1C(=O)NC(=O)C1 OZOMQRBLCMDCEG-CHHVJCJISA-N 0.000 description 1
- BTFMCMVEUCGQDX-UHFFFAOYSA-N 1-[10-[3-[4-(2-hydroxyethyl)-1-piperidinyl]propyl]-2-phenothiazinyl]ethanone Chemical compound C12=CC(C(=O)C)=CC=C2SC2=CC=CC=C2N1CCCN1CCC(CCO)CC1 BTFMCMVEUCGQDX-UHFFFAOYSA-N 0.000 description 1
- CMKAKNPPMGLPRW-BTJKTKAUSA-N 1-[2-(benzenesulfonyl)ethyl]-3-[2-(diethylamino)ethyl]-1-propan-2-ylurea;(z)-but-2-enedioic acid Chemical compound OC(=O)\C=C/C(O)=O.CCN(CC)CCNC(=O)N(C(C)C)CCS(=O)(=O)C1=CC=CC=C1 CMKAKNPPMGLPRW-BTJKTKAUSA-N 0.000 description 1
- CAEGSEJNBXUDOD-UHFFFAOYSA-N 1-[4,4-bis(4-fluorophenyl)butyl]-4-[2-(2,6-dichloroanilino)-2-oxoethyl]piperazine-2-carboxamide;hydrate;dihydrochloride Chemical compound O.Cl.Cl.C1CN(CCCC(C=2C=CC(F)=CC=2)C=2C=CC(F)=CC=2)C(C(=O)N)CN1CC(=O)NC1=C(Cl)C=CC=C1Cl CAEGSEJNBXUDOD-UHFFFAOYSA-N 0.000 description 1
- MDLAAYDRRZXJIF-UHFFFAOYSA-N 1-[4,4-bis(4-fluorophenyl)butyl]-4-[4-chloro-3-(trifluoromethyl)phenyl]-4-piperidinol Chemical compound C1CC(O)(C=2C=C(C(Cl)=CC=2)C(F)(F)F)CCN1CCCC(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 MDLAAYDRRZXJIF-UHFFFAOYSA-N 0.000 description 1
- HITUQCDKZKCYIZ-UHFFFAOYSA-N 1-[4-[bis(4-fluorophenyl)methyl]piperazin-1-yl]-3-(7h-purin-6-ylsulfanyl)propan-2-ol;butanedioic acid Chemical compound OC(=O)CCC(O)=O.N=1C=NC=2N=CNC=2C=1SCC(O)CN(CC1)CCN1C(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 HITUQCDKZKCYIZ-UHFFFAOYSA-N 0.000 description 1
- JOROEVAWQLGPFQ-UHFFFAOYSA-N 1-benzhydryl-4-methylpiperazine;2-hydroxypropanoic acid Chemical compound CC(O)C(O)=O.C1CN(C)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 JOROEVAWQLGPFQ-UHFFFAOYSA-N 0.000 description 1
- VRJCKJKZCZLXBK-UHFFFAOYSA-N 1-benzyl-3-(2-pyridin-4-ylethyl)indole Chemical compound C=1N(CC=2C=CC=CC=2)C2=CC=CC=C2C=1CCC1=CC=NC=C1 VRJCKJKZCZLXBK-UHFFFAOYSA-N 0.000 description 1
- IVVNZDGDKPTYHK-JTQLQIEISA-N 1-cyano-2-[(2s)-3,3-dimethylbutan-2-yl]-3-pyridin-4-ylguanidine Chemical compound CC(C)(C)[C@H](C)N=C(NC#N)NC1=CC=NC=C1 IVVNZDGDKPTYHK-JTQLQIEISA-N 0.000 description 1
- GJHKWLSRHNWTAN-UHFFFAOYSA-N 1-ethoxy-4-(4-pentylcyclohexyl)benzene Chemical compound C1CC(CCCCC)CCC1C1=CC=C(OCC)C=C1 GJHKWLSRHNWTAN-UHFFFAOYSA-N 0.000 description 1
- YETULFFXNIHQLK-UHFFFAOYSA-N 1-ethynyl-4-(2-fluorophenyl)benzene Chemical compound FC1=CC=CC=C1C1=CC=C(C#C)C=C1 YETULFFXNIHQLK-UHFFFAOYSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- JUTDWYGWGYSOSZ-UHFFFAOYSA-N 1-methoxypropan-2-yl 2-cyanoacetate Chemical compound COCC(C)OC(=O)CC#N JUTDWYGWGYSOSZ-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- HYYDHUILGLWOOP-UHFFFAOYSA-N 1-phenyl-2-(pyridin-2-ylamino)ethanol;hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(O)CNC1=CC=CC=N1 HYYDHUILGLWOOP-UHFFFAOYSA-N 0.000 description 1
- OHHIAWWXDMYFGP-UHFFFAOYSA-N 1-phenyl-2-(pyrimidin-2-ylamino)ethanol Chemical compound C=1C=CC=CC=1C(O)CNC1=NC=CC=N1 OHHIAWWXDMYFGP-UHFFFAOYSA-N 0.000 description 1
- SSUPWSZOVWZDRV-UHFFFAOYSA-N 1-phenylpent-4-en-2-ylazanium;chloride Chemical compound Cl.C=CCC(N)CC1=CC=CC=C1 SSUPWSZOVWZDRV-UHFFFAOYSA-N 0.000 description 1
- ULIDRMKBVYYVIQ-UHFFFAOYSA-N 1-phenyltetrazol-5-amine Chemical compound NC1=NN=NN1C1=CC=CC=C1 ULIDRMKBVYYVIQ-UHFFFAOYSA-N 0.000 description 1
- PGFVMQPOOFLBBI-UHFFFAOYSA-N 10-[3-(4-cyclopropylpiperazin-1-yl)propyl]-2-(trifluoromethyl)phenothiazine;dihydrochloride Chemical compound Cl.Cl.C12=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C2N1CCCN(CC1)CCN1C1CC1 PGFVMQPOOFLBBI-UHFFFAOYSA-N 0.000 description 1
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 1
- WHBHBVVOGNECLV-OBQKJFGGSA-N 11-deoxycortisol Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 WHBHBVVOGNECLV-OBQKJFGGSA-N 0.000 description 1
- OUILVKYDBNPYBM-UHFFFAOYSA-N 130-81-4 Chemical compound [Br-].C12CCCC2CCC2=[N+]1CCC1=CC(O)=CC=C12 OUILVKYDBNPYBM-UHFFFAOYSA-N 0.000 description 1
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 1
- RYWZPRVUQHMJFF-KSZLIROESA-N 17alpha-Dihydroequilenin Chemical compound OC1=CC=C2C(CC[C@]3([C@H]4CC[C@H]3O)C)=C4C=CC2=C1 RYWZPRVUQHMJFF-KSZLIROESA-N 0.000 description 1
- RYWZPRVUQHMJFF-UHFFFAOYSA-N 17alpha-Dihydroequilenin Natural products OC1=CC=C2C(CCC3(C4CCC3O)C)=C4C=CC2=C1 RYWZPRVUQHMJFF-UHFFFAOYSA-N 0.000 description 1
- 229930182834 17alpha-Estradiol Natural products 0.000 description 1
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-SFFUCWETSA-N 17α-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-SFFUCWETSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- KAESVJOAVNADME-UHFFFAOYSA-N 1H-pyrrole Natural products C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 1
- KYWMWUUMCDZISK-UHFFFAOYSA-N 2,2,5,5-tetrakis(trifluoromethyl)-1h-imidazol-4-amine Chemical compound NC1=NC(C(F)(F)F)(C(F)(F)F)NC1(C(F)(F)F)C(F)(F)F KYWMWUUMCDZISK-UHFFFAOYSA-N 0.000 description 1
- JGOAIQNSOGZNBX-UHFFFAOYSA-N 2,2-diphenylacetic acid 2-(diethylamino)ethyl ester Chemical compound C=1C=CC=CC=1C(C(=O)OCCN(CC)CC)C1=CC=CC=C1 JGOAIQNSOGZNBX-UHFFFAOYSA-N 0.000 description 1
- SRETXDDCKMOQNE-UHFFFAOYSA-N 2,3-bis(4-methoxyphenyl)-1h-indole Chemical compound C1=CC(OC)=CC=C1C1=C(C=2C=CC(OC)=CC=2)C2=CC=CC=C2N1 SRETXDDCKMOQNE-UHFFFAOYSA-N 0.000 description 1
- SWYJYGCPTGKBDS-UHFFFAOYSA-N 2,3-dihydroxypropyl 2-(3-chloro-2-methylanilino)pyridine-3-carboxylate Chemical compound CC1=C(Cl)C=CC=C1NC1=NC=CC=C1C(=O)OCC(O)CO SWYJYGCPTGKBDS-UHFFFAOYSA-N 0.000 description 1
- RKGYKBFILSMGSV-UHFFFAOYSA-N 2,3-dimethyl-4-phenyl-4,5-dihydro-1,3-benzodiazepine;hydrochloride Chemical compound Cl.C1C2=CC=CC=C2N=C(C)N(C)C1C1=CC=CC=C1 RKGYKBFILSMGSV-UHFFFAOYSA-N 0.000 description 1
- RNIPJYFZGXJSDD-UHFFFAOYSA-N 2,4,5-triphenyl-1h-imidazole Chemical compound C1=CC=CC=C1C1=NC(C=2C=CC=CC=2)=C(C=2C=CC=CC=2)N1 RNIPJYFZGXJSDD-UHFFFAOYSA-N 0.000 description 1
- JMBYBVLCYODBJQ-HFMPRLQTSA-N 2-(1-benzofuran-4-yl)-n-methyl-n-[(5r,7s,8s)-7-pyrrolidin-1-yl-1-oxaspiro[4.5]decan-8-yl]acetamide Chemical compound C([C@@H]([C@H](C1)N2CCCC2)N(C)C(=O)CC=2C=3C=COC=3C=CC=2)C[C@]21CCCO2 JMBYBVLCYODBJQ-HFMPRLQTSA-N 0.000 description 1
- IZGMROSLQHXRDZ-UHFFFAOYSA-N 2-(1-propyl-4,9-dihydro-3h-pyrano[3,4-b]indol-1-yl)acetic acid Chemical compound N1C2=CC=CC=C2C2=C1C(CCC)(CC(O)=O)OCC2 IZGMROSLQHXRDZ-UHFFFAOYSA-N 0.000 description 1
- FHIKZROVIDCMJA-UHFFFAOYSA-N 2-(2,2-diphenylpentanoyloxy)ethyl-diethylazanium;chloride Chemical compound Cl.C=1C=CC=CC=1C(C(=O)OCCN(CC)CC)(CCC)C1=CC=CC=C1 FHIKZROVIDCMJA-UHFFFAOYSA-N 0.000 description 1
- UXABARREKCJULM-UHFFFAOYSA-N 2-(2,3-dihydro-1,4-benzodioxin-3-ylmethyl)-1-ethylimidazole Chemical compound CCN1C=CN=C1CC1OC2=CC=CC=C2OC1 UXABARREKCJULM-UHFFFAOYSA-N 0.000 description 1
- NSGHAKPGHCNTPS-UHFFFAOYSA-N 2-(2,3-dihydro-1,4-benzodioxin-3-ylmethyl)guanidine;sulfuric acid Chemical compound [O-]S([O-])(=O)=O.C1=CC=C2OC(CN=C([NH3+])N)COC2=C1.C1=CC=C2OC(CN=C([NH3+])N)COC2=C1 NSGHAKPGHCNTPS-UHFFFAOYSA-N 0.000 description 1
- BCPFWSWROVXGQA-UHFFFAOYSA-N 2-(2,4,4-trimethylpentan-2-yl)guanidine Chemical compound CC(C)(C)CC(C)(C)N=C(N)N BCPFWSWROVXGQA-UHFFFAOYSA-N 0.000 description 1
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 1
- JQUKCPUPFALELS-UHFFFAOYSA-N 2-(2-methoxy-4-methylsulfinylphenyl)-3H-imidazo[4,5-c]pyridine Chemical compound COC1=CC(S(C)=O)=CC=C1C1=NC2=CC=NC=C2N1 JQUKCPUPFALELS-UHFFFAOYSA-N 0.000 description 1
- CWWCQGGNKDBSNT-UHFFFAOYSA-N 2-(2-phenoxyphenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC=C1OC1=CC=CC=C1 CWWCQGGNKDBSNT-UHFFFAOYSA-N 0.000 description 1
- QSIVIHAAKDQDHY-UHFFFAOYSA-N 2-(3,4-dihydronaphthalen-2-ylmethyl)-4,5-dihydro-1h-imidazole;hydrochloride Chemical compound Cl.C=1C2=CC=CC=C2CCC=1CC1=NCCN1 QSIVIHAAKDQDHY-UHFFFAOYSA-N 0.000 description 1
- ATLSSFQKJXKSHB-UHFFFAOYSA-N 2-(3-ethylsulfinylpropyl)-3,4-dihydro-1h-isoquinoline;hydron;chloride Chemical compound Cl.C1=CC=C2CN(CCCS(=O)CC)CCC2=C1 ATLSSFQKJXKSHB-UHFFFAOYSA-N 0.000 description 1
- LEBFQNREPOQDII-UHFFFAOYSA-N 2-(3-fluorobenzo[b][1]benzoxepin-5-yl)sulfanyl-n-methylethanamine Chemical compound CNCCSC1=CC2=CC=CC=C2OC2=CC=C(F)C=C12 LEBFQNREPOQDII-UHFFFAOYSA-N 0.000 description 1
- ODZUWQAFWMLWCF-UHFFFAOYSA-N 2-(3-phenyl-1-benzofuran-7-yl)propanoic acid Chemical compound C=1OC=2C(C(C(O)=O)C)=CC=CC=2C=1C1=CC=CC=C1 ODZUWQAFWMLWCF-UHFFFAOYSA-N 0.000 description 1
- OTRQRKIYHATFKM-UHFFFAOYSA-N 2-(5-methyl-2-phenyl-1h-imidazol-4-yl)acetonitrile Chemical compound N#CCC1=C(C)NC(C=2C=CC=CC=2)=N1 OTRQRKIYHATFKM-UHFFFAOYSA-N 0.000 description 1
- LRXFKKPEBXIPMW-UHFFFAOYSA-N 2-(9h-fluoren-2-yl)propanoic acid Chemical compound C1=CC=C2C3=CC=C(C(C(O)=O)C)C=C3CC2=C1 LRXFKKPEBXIPMW-UHFFFAOYSA-N 0.000 description 1
- VARKFMHUVKZOHE-UHFFFAOYSA-N 2-(butan-2-ylamino)-2-oxoacetic acid Chemical compound CCC(C)NC(=O)C(O)=O VARKFMHUVKZOHE-UHFFFAOYSA-N 0.000 description 1
- KMYDNZZJBUDBTI-UHFFFAOYSA-N 2-(diethylamino)ethyl 1-(3-methylbutyl)cyclohexane-1-carboxylate;hydrochloride Chemical compound Cl.CCN(CC)CCOC(=O)C1(CCC(C)C)CCCCC1 KMYDNZZJBUDBTI-UHFFFAOYSA-N 0.000 description 1
- MNIDQQFSKKUQGQ-UHFFFAOYSA-N 2-(diethylamino)ethyl 2-[3,5-diiodo-4-(3-iodo-4-methoxyphenoxy)phenyl]acetate;hydrochloride Chemical compound Cl.IC1=CC(CC(=O)OCCN(CC)CC)=CC(I)=C1OC1=CC=C(OC)C(I)=C1 MNIDQQFSKKUQGQ-UHFFFAOYSA-N 0.000 description 1
- SNUBSRMFCPAKSI-UHFFFAOYSA-N 2-(dimethylamino)ethanol;2-(4-phenylphenyl)butanoic acid Chemical compound CN(C)CCO.C1=CC(C(C(O)=O)CC)=CC=C1C1=CC=CC=C1 SNUBSRMFCPAKSI-UHFFFAOYSA-N 0.000 description 1
- WINSLRIENGBHSH-ASZYJFLUSA-N 2-[(2r,3s,4s,5r,6s)-2,4-dihydroxy-6-[(1r)-1-[(2s,5r,7s,8r,9s)-7-hydroxy-2-[(2r,5s)-5-[(2r,3s,5r)-5-[(2s,3s,5r,6s)-6-hydroxy-3,5,6-trimethyloxan-2-yl]-3-[(2s,5s,6r)-5-methoxy-6-methyloxan-2-yl]oxyoxolan-2-yl]-5-methyloxolan-2-yl]-2,8-dimethyl-1,10-dioxaspi Chemical compound O1[C@H](C)[C@@H](OC)CC[C@@H]1O[C@@H]1[C@H]([C@@]2(C)O[C@H](CC2)[C@@]2(C)O[C@]3(O[C@@H]([C@H](C)[C@@H](O)C3)[C@@H](C)[C@H]3[C@@H]([C@@H](O)[C@H](C)[C@@](O)(CC(O)=O)O3)OC)CC2)O[C@@H]([C@@H]2[C@H](C[C@@H](C)[C@@](C)(O)O2)C)C1 WINSLRIENGBHSH-ASZYJFLUSA-N 0.000 description 1
- YGWFCQYETHJKNX-UHFFFAOYSA-N 2-[(4-tert-butyl-2,6-dimethylphenyl)methyl]-4,5-dihydro-1h-imidazol-3-ium;chloride Chemical compound [Cl-].CC1=CC(C(C)(C)C)=CC(C)=C1CC1=NCC[NH2+]1 YGWFCQYETHJKNX-UHFFFAOYSA-N 0.000 description 1
- PRKWVSHZYDOZLP-UHFFFAOYSA-N 2-[(6,7-dichloro-2-methyl-1-oxo-2-phenyl-3h-inden-5-yl)oxy]acetic acid Chemical compound C1C2=CC(OCC(O)=O)=C(Cl)C(Cl)=C2C(=O)C1(C)C1=CC=CC=C1 PRKWVSHZYDOZLP-UHFFFAOYSA-N 0.000 description 1
- FEDJGPQLLNQAIY-UHFFFAOYSA-N 2-[(6-oxo-1h-pyridazin-3-yl)oxy]acetic acid Chemical compound OC(=O)COC=1C=CC(=O)NN=1 FEDJGPQLLNQAIY-UHFFFAOYSA-N 0.000 description 1
- DCXHLPGLBYHNMU-UHFFFAOYSA-N 2-[1-(4-azidobenzoyl)-5-methoxy-2-methylindol-3-yl]acetic acid Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(N=[N+]=[N-])C=C1 DCXHLPGLBYHNMU-UHFFFAOYSA-N 0.000 description 1
- OLLMPVQGLMNQQK-UHFFFAOYSA-N 2-[2-(2,6-dichlorophenoxy)ethylamino]guanidine;sulfuric acid Chemical compound OS(O)(=O)=O.NC(N)=NNCCOC1=C(Cl)C=CC=C1Cl.NC(N)=NNCCOC1=C(Cl)C=CC=C1Cl OLLMPVQGLMNQQK-UHFFFAOYSA-N 0.000 description 1
- NCEAPFRHADKEHP-UHFFFAOYSA-N 2-[2-hydroxy-3-[[1-(1h-indol-3-yl)-2-methylpropan-2-yl]amino]propoxy]benzonitrile;hydrochloride Chemical compound Cl.C=1NC2=CC=CC=C2C=1CC(C)(C)NCC(O)COC1=CC=CC=C1C#N NCEAPFRHADKEHP-UHFFFAOYSA-N 0.000 description 1
- CVOCKGAVXLCEGM-UHFFFAOYSA-N 2-[3-(3-azabicyclo[2.2.2]octan-3-yl)-1,1-diphenylpropyl]-5-methyl-1,3,4-oxadiazole Chemical compound O1C(C)=NN=C1C(C=1C=CC=CC=1)(C=1C=CC=CC=1)CCN1C(CC2)CCC2C1 CVOCKGAVXLCEGM-UHFFFAOYSA-N 0.000 description 1
- IDCAZKFFVIMCCS-UHFFFAOYSA-N 2-[3-(4-chlorophenyl)-4-imino-2-oxoimidazolidin-1-yl]acetonitrile Chemical compound C1=CC(Cl)=CC=C1N1C(=O)N(CC#N)CC1=N IDCAZKFFVIMCCS-UHFFFAOYSA-N 0.000 description 1
- BHKPQZVLIZKSAG-UHFFFAOYSA-N 2-[3-[4-(3-chlorophenyl)piperazin-1-yl]propyl]-4,5-diethyl-1,2,4-triazol-3-one;hydron;chloride Chemical compound Cl.O=C1N(CC)C(CC)=NN1CCCN1CCN(C=2C=C(Cl)C=CC=2)CC1 BHKPQZVLIZKSAG-UHFFFAOYSA-N 0.000 description 1
- NLGUJWNOGYWZBI-UHFFFAOYSA-N 2-[3-chloro-4-(thiophene-2-carbonyl)phenyl]propanoic acid Chemical compound ClC1=CC(C(C(O)=O)C)=CC=C1C(=O)C1=CC=CS1 NLGUJWNOGYWZBI-UHFFFAOYSA-N 0.000 description 1
- DLTOEESOSYKJBK-UHFFFAOYSA-N 2-[4-(3-benzo[b][1]benzazepin-11-ylpropyl)piperazin-1-yl]ethanol;hydron;dichloride Chemical compound Cl.Cl.C1CN(CCO)CCN1CCCN1C2=CC=CC=C2C=CC2=CC=CC=C21 DLTOEESOSYKJBK-UHFFFAOYSA-N 0.000 description 1
- JIEKMACRVQTPRC-UHFFFAOYSA-N 2-[4-(4-chlorophenyl)-2-phenyl-5-thiazolyl]acetic acid Chemical compound OC(=O)CC=1SC(C=2C=CC=CC=2)=NC=1C1=CC=C(Cl)C=C1 JIEKMACRVQTPRC-UHFFFAOYSA-N 0.000 description 1
- URBVIISFALGUAB-LZWUXPCZSA-N 2-[4-[(3z)-3-(2-chloro-6h-benzo[c][1]benzoxepin-11-ylidene)propyl]piperazin-1-yl]ethanol;dihydrochloride Chemical compound Cl.Cl.C1CN(CCO)CCN1CC\C=C\1C2=CC(Cl)=CC=C2OCC2=CC=CC=C2/1 URBVIISFALGUAB-LZWUXPCZSA-N 0.000 description 1
- QKKLKGVIECOSRM-CODXZCKSSA-N 2-[4-[3-(2-chlorophenothiazin-10-yl)propyl]piperazin-1-yl]ethanol;4-[2-[(8s,9s,10r,11s,13s,14s,17r)-11,17-dihydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthren-17-yl]-2-oxoethoxy]-4-oxobutanoic acid Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21.O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)COC(=O)CCC(O)=O)[C@@H]4[C@@H]3CCC2=C1 QKKLKGVIECOSRM-CODXZCKSSA-N 0.000 description 1
- ZBIAKUMOEKILTF-UHFFFAOYSA-N 2-[4-[4,4-bis(4-fluorophenyl)butyl]-1-piperazinyl]-N-(2,6-dimethylphenyl)acetamide Chemical compound CC1=CC=CC(C)=C1NC(=O)CN1CCN(CCCC(C=2C=CC(F)=CC=2)C=2C=CC(F)=CC=2)CC1 ZBIAKUMOEKILTF-UHFFFAOYSA-N 0.000 description 1
- LNXXSBRGLBOASF-UHFFFAOYSA-N 2-[[2-(4-chlorophenyl)-4-methyl-1,3-oxazol-5-yl]methoxy]-2-methylpropanoic acid Chemical compound O1C(COC(C)(C)C(O)=O)=C(C)N=C1C1=CC=C(Cl)C=C1 LNXXSBRGLBOASF-UHFFFAOYSA-N 0.000 description 1
- YMJMZFPZRVMNCH-FMIVXFBMSA-N 2-[methyl-[(e)-3-phenylprop-2-enyl]amino]-1-phenylpropan-1-ol Chemical compound C=1C=CC=CC=1/C=C/CN(C)C(C)C(O)C1=CC=CC=C1 YMJMZFPZRVMNCH-FMIVXFBMSA-N 0.000 description 1
- XKSAJZSJKURQRX-UHFFFAOYSA-N 2-acetyloxy-5-(4-fluorophenyl)benzoic acid Chemical compound C1=C(C(O)=O)C(OC(=O)C)=CC=C1C1=CC=C(F)C=C1 XKSAJZSJKURQRX-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- MCSJGXLZPITMIH-UHFFFAOYSA-N 2-aminobutane-1,1,1-triol Chemical class CCC(N)C(O)(O)O MCSJGXLZPITMIH-UHFFFAOYSA-N 0.000 description 1
- GXEUNRBWEAIPCN-UHFFFAOYSA-N 2-chloro-2-(3-chloro-4-cyclohexylphenyl)acetic acid Chemical compound ClC1=CC(C(Cl)C(=O)O)=CC=C1C1CCCCC1 GXEUNRBWEAIPCN-UHFFFAOYSA-N 0.000 description 1
- NJYBZXINKWROMG-UHFFFAOYSA-N 2-chloro-5-(dimethylaminocarbamoyl)benzenesulfonamide Chemical compound CN(C)NC(=O)C1=CC=C(Cl)C(S(N)(=O)=O)=C1 NJYBZXINKWROMG-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-MICDWDOJSA-N 2-deuterioacetic acid Chemical compound [2H]CC(O)=O QTBSBXVTEAMEQO-MICDWDOJSA-N 0.000 description 1
- HIONZHUOISVAJK-UHFFFAOYSA-M 2-ethyl-2-methyl-3,4-dihydro-1h-isoquinolin-2-ium;4-methylbenzenesulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1.C1=CC=C2C[N+](CC)(C)CCC2=C1 HIONZHUOISVAJK-UHFFFAOYSA-M 0.000 description 1
- GNXFOGHNGIVQEH-UHFFFAOYSA-N 2-hydroxy-3-(2-methoxyphenoxy)propyl carbamate Chemical compound COC1=CC=CC=C1OCC(O)COC(N)=O GNXFOGHNGIVQEH-UHFFFAOYSA-N 0.000 description 1
- UBUJQGDIGRPIEZ-LJTMIZJLSA-N 2-hydroxybenzoic acid;(2r,3r,4r,5s)-6-(methylamino)hexane-1,2,3,4,5-pentol Chemical compound OC(=O)C1=CC=CC=C1O.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO UBUJQGDIGRPIEZ-LJTMIZJLSA-N 0.000 description 1
- NKQVYJRZBVRXRU-UHFFFAOYSA-N 2-methyl-2-(methylamino)propanenitrile Chemical compound CNC(C)(C)C#N NKQVYJRZBVRXRU-UHFFFAOYSA-N 0.000 description 1
- GJXZNORUUOVBKP-UHFFFAOYSA-N 2-methyl-3-piperidin-1-ylpyrazine;sulfuric acid Chemical compound OS(O)(=O)=O.CC1=NC=CN=C1N1CCCCC1 GJXZNORUUOVBKP-UHFFFAOYSA-N 0.000 description 1
- NZXHFDXOCVIYLO-UHFFFAOYSA-N 2-methyl-4-oxo-6-(pyridin-3-ylmethylamino)-1h-pyrimidine-5-carbonitrile Chemical compound N1C(C)=NC(=O)C(C#N)=C1NCC1=CC=CN=C1 NZXHFDXOCVIYLO-UHFFFAOYSA-N 0.000 description 1
- PUHMYHQVPODHCZ-UHFFFAOYSA-N 2-methyl-5-(4-methylpiperazin-1-yl)-11h-[1,2,4]triazolo[1,5-c][1,3]benzodiazepine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2CC2=NC(C)=NN12 PUHMYHQVPODHCZ-UHFFFAOYSA-N 0.000 description 1
- UJABSZITRMATFL-UHFFFAOYSA-N 2-methyl-5-phenylfuran-3-carbonyl chloride Chemical compound ClC(=O)C1=C(C)OC(C=2C=CC=CC=2)=C1 UJABSZITRMATFL-UHFFFAOYSA-N 0.000 description 1
- DHAXFWAIZHJURV-UHFFFAOYSA-N 2-phenoxyethyl 1-(3-cyano-3,3-diphenylpropyl)-4-phenylpiperidine-4-carboxylate;hydrochloride Chemical compound Cl.C1CN(CCC(C#N)(C=2C=CC=CC=2)C=2C=CC=CC=2)CCC1(C=1C=CC=CC=1)C(=O)OCCOC1=CC=CC=C1 DHAXFWAIZHJURV-UHFFFAOYSA-N 0.000 description 1
- FWIIHEJLRNKGDU-UHFFFAOYSA-N 2-phenylcyclopentan-1-amine;hydrochloride Chemical compound Cl.NC1CCCC1C1=CC=CC=C1 FWIIHEJLRNKGDU-UHFFFAOYSA-N 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- KHEVPDFAQFJIGK-UHFFFAOYSA-N 2-sulfooxyethanesulfonic acid Chemical compound OS(=O)(=O)CCOS(O)(=O)=O KHEVPDFAQFJIGK-UHFFFAOYSA-N 0.000 description 1
- LZCQFJKUAIWHRW-UHFFFAOYSA-N 3,3-dimethyl-5-(6-oxo-4,5-dihydro-1h-pyridazin-3-yl)-1h-indol-2-one Chemical compound C1=C2C(C)(C)C(=O)NC2=CC=C1C1=NNC(=O)CC1 LZCQFJKUAIWHRW-UHFFFAOYSA-N 0.000 description 1
- VYVKHNNGDFVQGA-UHFFFAOYSA-N 3,4-dimethoxybenzoic acid 4-[ethyl-[1-(4-methoxyphenyl)propan-2-yl]amino]butyl ester Chemical compound C=1C=C(OC)C=CC=1CC(C)N(CC)CCCCOC(=O)C1=CC=C(OC)C(OC)=C1 VYVKHNNGDFVQGA-UHFFFAOYSA-N 0.000 description 1
- PYSICVOJSJMFKP-UHFFFAOYSA-N 3,5-dibromo-2-chloropyridine Chemical compound ClC1=NC=C(Br)C=C1Br PYSICVOJSJMFKP-UHFFFAOYSA-N 0.000 description 1
- OHXPGWPVLFPUSM-KLRNGDHRSA-N 3,7,12-trioxo-5beta-cholanic acid Chemical compound C1CC(=O)C[C@H]2CC(=O)[C@H]3[C@@H]4CC[C@H]([C@@H](CCC(O)=O)C)[C@@]4(C)C(=O)C[C@@H]3[C@]21C OHXPGWPVLFPUSM-KLRNGDHRSA-N 0.000 description 1
- HRCGIZACAMIMII-UHFFFAOYSA-N 3-(1-methyl-3-propylpyrrolidin-3-yl)phenol;hydrochloride Chemical compound Cl.C=1C=CC(O)=CC=1C1(CCC)CCN(C)C1 HRCGIZACAMIMII-UHFFFAOYSA-N 0.000 description 1
- UERHIZBSLAGDLU-UHFFFAOYSA-N 3-(2,3,4,5,6,7,8,8a-octahydro-1h-pyrrolo[1,2-a]pyrazine-2,5-diium-2-yl)-1-(2-chlorophenothiazin-10-yl)propan-1-one;dichloride Chemical compound Cl.Cl.C1CN2CCCC2CN1CCC(=O)N1C2=CC=CC=C2SC2=CC=C(Cl)C=C21 UERHIZBSLAGDLU-UHFFFAOYSA-N 0.000 description 1
- MPJUSISYVXABBH-UHFFFAOYSA-N 3-(3-ethyl-1-methylazepan-3-yl)phenol;hydron;chloride Chemical compound Cl.C=1C=CC(O)=CC=1C1(CC)CCCCN(C)C1 MPJUSISYVXABBH-UHFFFAOYSA-N 0.000 description 1
- VXMYWVMXSWJFCV-UHFFFAOYSA-N 3-(4-imidazol-1-ylphenyl)-4,5-dihydro-1h-pyridazin-6-one Chemical compound N1C(=O)CCC(C=2C=CC(=CC=2)N2C=NC=C2)=N1 VXMYWVMXSWJFCV-UHFFFAOYSA-N 0.000 description 1
- ZGEGOFCLSWVVKG-UHFFFAOYSA-N 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5-propan-2-ylimidazo[1,5-a]quinoxalin-4-one Chemical compound C=12C(=O)N(C(C)C)C3=CC=CC=C3N2C=NC=1C(N=1)=NOC=1C1CC1 ZGEGOFCLSWVVKG-UHFFFAOYSA-N 0.000 description 1
- RTOHPIRUUAKHOZ-BBRMVZONSA-N 3-[(3r,4s)-1,3-dimethyl-4-propylpiperidin-4-yl]phenol Chemical compound C=1C=CC(O)=CC=1[C@@]1(CCC)CCN(C)C[C@@H]1C RTOHPIRUUAKHOZ-BBRMVZONSA-N 0.000 description 1
- XBNIHQOJYIOGEU-HWKASLJMSA-N 3-[(r)-dimethylamino-[(1r,2r)-2-hydroxycyclohexyl]methyl]phenol;hydrochloride Chemical compound Cl.C([C@@H]1[C@@H](N(C)C)C=2C=C(O)C=CC=2)CCC[C@H]1O XBNIHQOJYIOGEU-HWKASLJMSA-N 0.000 description 1
- NVDBBGBUTKLRSN-UHFFFAOYSA-N 3-[1-(2-phenoxyethyl)piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound O=C1NC2=CC=CC=C2N1C(CC1)CCN1CCOC1=CC=CC=C1 NVDBBGBUTKLRSN-UHFFFAOYSA-N 0.000 description 1
- VEUGOXRZHKYDED-UHFFFAOYSA-N 3-[1-[3-(6-fluoro-1,2-benzoxazol-3-yl)propyl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound C12=CC=CC=C2NC(=O)N1C(CC1)CCN1CCCC1=NOC2=CC(F)=CC=C21 VEUGOXRZHKYDED-UHFFFAOYSA-N 0.000 description 1
- FEBOTPHFXYHVPL-UHFFFAOYSA-N 3-[1-[4-(4-fluorophenyl)-4-oxobutyl]-4-piperidinyl]-1H-benzimidazol-2-one Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCC(N2C(NC3=CC=CC=C32)=O)CC1 FEBOTPHFXYHVPL-UHFFFAOYSA-N 0.000 description 1
- QUGOVTRSGWYKSQ-UHFFFAOYSA-N 3-[3-[4-(3-chlorophenyl)piperazin-1-yl]propyl]-1h-quinazoline-2,4-dione;hydrochloride Chemical compound Cl.ClC1=CC=CC(N2CCN(CCCN3C(C4=CC=CC=C4NC3=O)=O)CC2)=C1 QUGOVTRSGWYKSQ-UHFFFAOYSA-N 0.000 description 1
- WXFFTUKVTRHPLQ-KPSZGOFPSA-N 3-[4-[(3e)-3-(2-chlorothioxanthen-9-ylidene)propyl]piperazin-1-yl]-n-methylpropanamide Chemical compound C1CN(CCC(=O)NC)CCN1CC\C=C/1C2=CC(Cl)=CC=C2SC2=CC=CC=C2\1 WXFFTUKVTRHPLQ-KPSZGOFPSA-N 0.000 description 1
- OWCJBBJRJRGZOJ-UHFFFAOYSA-N 3-[4-[4-(2-propylsulfanylphenyl)piperazin-1-yl]butyl]-1h-quinazoline-2,4-dione;hydrochloride Chemical compound Cl.CCCSC1=CC=CC=C1N1CCN(CCCCN2C(C3=CC=CC=C3NC2=O)=O)CC1 OWCJBBJRJRGZOJ-UHFFFAOYSA-N 0.000 description 1
- PLZMRGRLCWCLFW-UHFFFAOYSA-N 3-[5-(3-bromophenyl)tetrazol-2-yl]-1-piperidin-1-ylpropan-1-one Chemical compound BrC1=CC=CC(C2=NN(CCC(=O)N3CCCCC3)N=N2)=C1 PLZMRGRLCWCLFW-UHFFFAOYSA-N 0.000 description 1
- YLJRTDTWWRXOFG-UHFFFAOYSA-N 3-[5-(4-chlorophenyl)furan-2-yl]-3-hydroxypropanoic acid Chemical compound O1C(C(CC(O)=O)O)=CC=C1C1=CC=C(Cl)C=C1 YLJRTDTWWRXOFG-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- BJUHVJHOJBHLJS-UHFFFAOYSA-N 3-benzhydrylidene-1-ethylpyrrolidine Chemical compound C1N(CC)CCC1=C(C=1C=CC=CC=1)C1=CC=CC=C1 BJUHVJHOJBHLJS-UHFFFAOYSA-N 0.000 description 1
- NCPBMOFVRBEVJY-QPJJXVBHSA-N 3-chloro-6-[4-[(e)-3-phenylprop-2-enyl]piperazin-1-yl]pyridazine Chemical compound N1=NC(Cl)=CC=C1N1CCN(C\C=C\C=2C=CC=CC=2)CC1 NCPBMOFVRBEVJY-QPJJXVBHSA-N 0.000 description 1
- XHZFHAGIQPYPAM-UHFFFAOYSA-N 3-hydroxy-1-[(4-methoxyphenyl)methyl]piperidin-2-one Chemical compound C1=CC(OC)=CC=C1CN1C(=O)C(O)CCC1 XHZFHAGIQPYPAM-UHFFFAOYSA-N 0.000 description 1
- DDOCDXCKSVDRHL-UHFFFAOYSA-N 3-methyl-3-[3-(methylamino)propyl]-1-phenylindol-2-one;hydrochloride Chemical compound Cl.C12=CC=CC=C2C(CCCNC)(C)C(=O)N1C1=CC=CC=C1 DDOCDXCKSVDRHL-UHFFFAOYSA-N 0.000 description 1
- SUCNEHPNQBBVHQ-UHFFFAOYSA-N 3-methyl-6-(6-oxo-4,5-dihydro-1h-pyridazin-3-yl)-1,4-dihydroquinazolin-2-one Chemical compound C=1C=C2NC(=O)N(C)CC2=CC=1C1=NNC(=O)CC1 SUCNEHPNQBBVHQ-UHFFFAOYSA-N 0.000 description 1
- WQRPHHIOZYGAMQ-UHFFFAOYSA-N 3-methyl-n-phenylbutanamide Chemical compound CC(C)CC(=O)NC1=CC=CC=C1 WQRPHHIOZYGAMQ-UHFFFAOYSA-N 0.000 description 1
- MSBSMNOJAAJSGG-UHFFFAOYSA-N 3-morpholin-4-yl-1,2,3-benzotriazin-4-one Chemical compound N1=NC2=CC=CC=C2C(=O)N1N1CCOCC1 MSBSMNOJAAJSGG-UHFFFAOYSA-N 0.000 description 1
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 1
- MVQVNTPHUGQQHK-UHFFFAOYSA-N 3-pyridinemethanol Chemical compound OCC1=CC=CN=C1 MVQVNTPHUGQQHK-UHFFFAOYSA-N 0.000 description 1
- MUOSVLIKDZRWMP-UHFFFAOYSA-N 39022-39-4 Chemical compound Cl.C12=CC=CC=C2C2(CC(O)CNC)C3=CC=CC=C3C1CC2 MUOSVLIKDZRWMP-UHFFFAOYSA-N 0.000 description 1
- DAIZVBCVNQSHLI-UHFFFAOYSA-N 4,4-diphenyl-1-(propan-2-ylamino)butan-2-ol Chemical compound C=1C=CC=CC=1C(CC(O)CNC(C)C)C1=CC=CC=C1 DAIZVBCVNQSHLI-UHFFFAOYSA-N 0.000 description 1
- RZCJLMTXBMNRAD-UHFFFAOYSA-N 4-(2-aminopropyl)phenol;hydrobromide Chemical compound Br.CC(N)CC1=CC=C(O)C=C1 RZCJLMTXBMNRAD-UHFFFAOYSA-N 0.000 description 1
- QUXRAOQDUJFWIA-UHFFFAOYSA-N 4-(2-chloroxanthen-9-ylidene)-1-methylpiperidine Chemical compound C1CN(C)CCC1=C1C2=CC(Cl)=CC=C2OC2=CC=CC=C21 QUXRAOQDUJFWIA-UHFFFAOYSA-N 0.000 description 1
- NJERAXSSDSHLGE-UHFFFAOYSA-N 4-(2-fluorophenyl)-1,3,8-trimethyl-6h-pyrazolo[3,4-e][1,4]diazepin-7-one;hydrochloride Chemical compound Cl.N=1CC(=O)N(C)C(N(N=C2C)C)=C2C=1C1=CC=CC=C1F NJERAXSSDSHLGE-UHFFFAOYSA-N 0.000 description 1
- GLQPTZAAUROJMO-UHFFFAOYSA-N 4-(3,4-dimethoxyphenyl)benzaldehyde Chemical compound C1=C(OC)C(OC)=CC=C1C1=CC=C(C=O)C=C1 GLQPTZAAUROJMO-UHFFFAOYSA-N 0.000 description 1
- HBLQZEWZVJXHKQ-UHFFFAOYSA-M 4-(4-chlorophenyl)butyl-diethyl-heptylazanium;dihydrogen phosphate Chemical compound OP(O)([O-])=O.CCCCCCC[N+](CC)(CC)CCCCC1=CC=C(Cl)C=C1 HBLQZEWZVJXHKQ-UHFFFAOYSA-M 0.000 description 1
- PCTRYMLLRKWXGF-UHFFFAOYSA-N 4-(butylamino)-1-ethyl-6-methyl-5-pyrazolo[3,4-b]pyridinecarboxylic acid ethyl ester Chemical compound CCCCNC1=C(C(=O)OCC)C(C)=NC2=C1C=NN2CC PCTRYMLLRKWXGF-UHFFFAOYSA-N 0.000 description 1
- AWGQDASDKPZSII-UHFFFAOYSA-N 4-(dibenzo[1,2-a:1',2'-e][7]annulen-11-ylidene)-n,n-dimethylbut-2-yn-1-amine;hydrochloride Chemical compound Cl.C1=CC2=CC=CC=C2C(=CC#CCN(C)C)C2=CC=CC=C21 AWGQDASDKPZSII-UHFFFAOYSA-N 0.000 description 1
- MFKCGXDCHAFQQZ-RTBURBONSA-N 4-(dimethylamino)-n-(2,6-dimethylphenyl)-1-[(1r,2r)-2-hydroxycyclohexyl]piperidine-4-carboxamide Chemical compound C1CC(N(C)C)(C(=O)NC=2C(=CC=CC=2C)C)CCN1[C@@H]1CCCC[C@H]1O MFKCGXDCHAFQQZ-RTBURBONSA-N 0.000 description 1
- WOVTUUKKGNHVFZ-UHFFFAOYSA-N 4-(fluoren-9-ylidenemethyl)benzenecarboximidamide Chemical compound C1=CC(C(=N)N)=CC=C1C=C1C2=CC=CC=C2C2=CC=CC=C21 WOVTUUKKGNHVFZ-UHFFFAOYSA-N 0.000 description 1
- RFMZRLGPSDNVKE-UHFFFAOYSA-N 4-(methanesulfonamido)-n-propan-2-yl-n-[2-(propan-2-ylamino)ethyl]benzenesulfonamide;hydrochloride Chemical compound Cl.CC(C)NCCN(C(C)C)S(=O)(=O)C1=CC=C(NS(C)(=O)=O)C=C1 RFMZRLGPSDNVKE-UHFFFAOYSA-N 0.000 description 1
- YKFROQCFVXOUPW-UHFFFAOYSA-N 4-(methylthio) aniline Chemical compound CSC1=CC=C(N)C=C1 YKFROQCFVXOUPW-UHFFFAOYSA-N 0.000 description 1
- WDXYIFGETVGLBZ-MERQFXBCSA-N 4-[(2s)-2-hydroxy-3-(propan-2-ylamino)propoxy]phenol;hydrochloride Chemical compound Cl.CC(C)NC[C@H](O)COC1=CC=C(O)C=C1 WDXYIFGETVGLBZ-MERQFXBCSA-N 0.000 description 1
- KUYSNZZXTMKUTK-UHFFFAOYSA-N 4-[2-(6,7-dimethoxy-1-methyl-3,4-dihydro-1h-isoquinolin-2-yl)ethyl]aniline Chemical compound CC1C=2C=C(OC)C(OC)=CC=2CCN1CCC1=CC=C(N)C=C1 KUYSNZZXTMKUTK-UHFFFAOYSA-N 0.000 description 1
- BTCHMHMCMKZOQS-UHFFFAOYSA-N 4-[2-(7,8-dimethoxy-1,2,4,5-tetrahydro-3-benzazepin-3-yl)ethyl]aniline Chemical compound C1CC=2C=C(OC)C(OC)=CC=2CCN1CCC1=CC=C(N)C=C1 BTCHMHMCMKZOQS-UHFFFAOYSA-N 0.000 description 1
- XSGHHWMGNIMZCA-FPOQQNBBSA-N 4-[2-[4-(4-hydroxyphenyl)butan-2-ylamino]ethyl]benzene-1,2-diol;(2r,3r,4r,5r)-2,3,5,6-tetrahydroxy-4-[(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexanoic acid Chemical compound C=1C=C(O)C(O)=CC=1CCNC(C)CCC1=CC=C(O)C=C1.OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O XSGHHWMGNIMZCA-FPOQQNBBSA-N 0.000 description 1
- XSGHHWMGNIMZCA-QCCNJQOUSA-N 4-[2-[[(2s)-4-(4-hydroxyphenyl)butan-2-yl]amino]ethyl]benzene-1,2-diol;(2r,3r,4r,5r)-2,3,5,6-tetrahydroxy-4-[(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexanoic acid Chemical compound C([C@H](C)NCCC=1C=C(O)C(O)=CC=1)CC1=CC=C(O)C=C1.OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O XSGHHWMGNIMZCA-QCCNJQOUSA-N 0.000 description 1
- ZIJIVCQJKDRJOL-UHFFFAOYSA-N 4-[4-(4-chlorobenzoyl)piperidin-1-yl]-1-(4-fluorophenyl)butan-1-one;hydrochloride Chemical compound Cl.C1=CC(F)=CC=C1C(=O)CCCN1CCC(C(=O)C=2C=CC(Cl)=CC=2)CC1 ZIJIVCQJKDRJOL-UHFFFAOYSA-N 0.000 description 1
- WCIBOXFOUGQLFC-UHFFFAOYSA-N 4-[4-(4-fluorobenzoyl)piperidin-1-yl]-1-(4-fluorophenyl)butan-1-one Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCC(C(=O)C=2C=CC(F)=CC=2)CC1 WCIBOXFOUGQLFC-UHFFFAOYSA-N 0.000 description 1
- MNEIBEWKVRSDEX-UHFFFAOYSA-N 4-[4-[4-chloro-3-(trifluoromethyl)phenyl]-4-hydroxypiperidin-1-yl]-1-(4-fluorophenyl)butan-1-one;hydrochloride Chemical compound [Cl-].C1CC(O)(C=2C=C(C(Cl)=CC=2)C(F)(F)F)CC[NH+]1CCCC(=O)C1=CC=C(F)C=C1 MNEIBEWKVRSDEX-UHFFFAOYSA-N 0.000 description 1
- WPYGCZCMGMVGNO-UHFFFAOYSA-N 4-[4-[4-chloro-3-(trifluoromethyl)phenyl]-4-hydroxypiperidin-1-yl]-n,n-dimethyl-2,2-diphenylbutanamide Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N(C)C)CCN(CC1)CCC1(O)C1=CC=C(Cl)C(C(F)(F)F)=C1 WPYGCZCMGMVGNO-UHFFFAOYSA-N 0.000 description 1
- OYGDOCFZQVGFIP-UHFFFAOYSA-N 4-[8-fluoro-5-(4-fluorophenyl)-3,4-dihydro-1h-pyrido[4,3-b]indol-2-yl]-1-(4-fluorophenyl)butan-1-ol Chemical compound C=1C=C(F)C=CC=1C(O)CCCN(C1)CCC2=C1C1=CC(F)=CC=C1N2C1=CC=C(F)C=C1 OYGDOCFZQVGFIP-UHFFFAOYSA-N 0.000 description 1
- IYEWBJUCJHKLHD-UHFFFAOYSA-N 4-acetamido-n-[2-(diethylamino)ethyl]benzamide;hydron;chloride Chemical compound Cl.CCN(CC)CCNC(=O)C1=CC=C(NC(C)=O)C=C1 IYEWBJUCJHKLHD-UHFFFAOYSA-N 0.000 description 1
- IGGKTAIAQUIFKQ-WLHGVMLRSA-N 4-amino-5-chloro-n-(1,2-diethylpyrazolidin-4-yl)-2-methoxybenzamide;(e)-but-2-enedioic acid Chemical compound OC(=O)\C=C\C(O)=O.C1N(CC)N(CC)CC1NC(=O)C1=CC(Cl)=C(N)C=C1OC IGGKTAIAQUIFKQ-WLHGVMLRSA-N 0.000 description 1
- DBQMQBCSKXTCIJ-MRXNPFEDSA-N 4-amino-n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-5-chloro-2-(cyclopropylmethoxy)benzamide Chemical compound N([C@H]1C2CCN(CC2)C1)C(=O)C=1C=C(Cl)C(N)=CC=1OCC1CC1 DBQMQBCSKXTCIJ-MRXNPFEDSA-N 0.000 description 1
- LBXHRAWDUMTPSE-AOOOYVTPSA-N 4-chloro-N-[(2S,6R)-2,6-dimethyl-1-piperidinyl]-3-sulfamoylbenzamide Chemical compound C[C@H]1CCC[C@@H](C)N1NC(=O)C1=CC=C(Cl)C(S(N)(=O)=O)=C1 LBXHRAWDUMTPSE-AOOOYVTPSA-N 0.000 description 1
- REQFWARMBJWJAQ-UHFFFAOYSA-N 4-chloro-n-methyl-3-(methylsulfamoyl)benzamide Chemical compound CNC(=O)C1=CC=C(Cl)C(S(=O)(=O)NC)=C1 REQFWARMBJWJAQ-UHFFFAOYSA-N 0.000 description 1
- LQVMQEYROPXMQH-UHFFFAOYSA-N 4-dibenzofuran-2-yl-4-oxobutanoic acid Chemical compound C1=CC=C2C3=CC(C(=O)CCC(=O)O)=CC=C3OC2=C1 LQVMQEYROPXMQH-UHFFFAOYSA-N 0.000 description 1
- WYOMHOATUARGQV-UHFFFAOYSA-N 4-ethyl-3-methyl-3-phenylpyrrolidine-2,5-dione Chemical compound CCC1C(=O)NC(=O)C1(C)C1=CC=CC=C1 WYOMHOATUARGQV-UHFFFAOYSA-N 0.000 description 1
- OQGWJZOWLHWFME-UHFFFAOYSA-N 4-ethyl-5-(pyridine-4-carbonyl)-1,3-dihydroimidazol-2-one Chemical compound N1C(=O)NC(C(=O)C=2C=CN=CC=2)=C1CC OQGWJZOWLHWFME-UHFFFAOYSA-N 0.000 description 1
- SYCHUQUJURZQMO-UHFFFAOYSA-N 4-hydroxy-2-methyl-1,1-dioxo-n-(1,3-thiazol-2-yl)-1$l^{6},2-benzothiazine-3-carboxamide Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=CS1 SYCHUQUJURZQMO-UHFFFAOYSA-N 0.000 description 1
- LBYXPDAENJSHDD-UHFFFAOYSA-N 4-hydroxy-3-methoxy-n-[2-[2-(1-methylpiperidin-2-yl)ethyl]phenyl]benzamide Chemical compound C1=C(O)C(OC)=CC(C(=O)NC=2C(=CC=CC=2)CCC2N(CCCC2)C)=C1 LBYXPDAENJSHDD-UHFFFAOYSA-N 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- HCIFDIMOPGHYSI-UHFFFAOYSA-N 4-methylbenzenesulfonic acid;n-methyl-3-(3-methyl-1-phenyl-2h-indol-3-yl)propan-1-amine Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1.C12=CC=CC=C2C(CCCNC)(C)CN1C1=CC=CC=C1 HCIFDIMOPGHYSI-UHFFFAOYSA-N 0.000 description 1
- TYJOQICPGZGYDT-UHFFFAOYSA-N 4-methylsulfonylbenzenesulfonyl chloride Chemical compound CS(=O)(=O)C1=CC=C(S(Cl)(=O)=O)C=C1 TYJOQICPGZGYDT-UHFFFAOYSA-N 0.000 description 1
- HSHNITRMYYLLCV-UHFFFAOYSA-N 4-methylumbelliferone Chemical compound C1=C(O)C=CC2=C1OC(=O)C=C2C HSHNITRMYYLLCV-UHFFFAOYSA-N 0.000 description 1
- XWVOEFLBOSSYGM-UHFFFAOYSA-N 4-morpholinyl-(3,4,5-trimethoxyphenyl)methanone Chemical compound COC1=C(OC)C(OC)=CC(C(=O)N2CCOCC2)=C1 XWVOEFLBOSSYGM-UHFFFAOYSA-N 0.000 description 1
- KWFFVBCJCQQAIV-UHFFFAOYSA-N 4-phenylcyclohexan-1-amine;2-(4-phenylphenyl)butanoic acid Chemical compound C1CC(N)CCC1C1=CC=CC=C1.C1=CC(C(C(O)=O)CC)=CC=C1C1=CC=CC=C1 KWFFVBCJCQQAIV-UHFFFAOYSA-N 0.000 description 1
- XBGQGAPUUJJOTA-KWLUMGGGSA-N 4b52439y33 Chemical compound O.C([C@@H]1C2)C3=CC=CC=C3C[C@@]1(C(=O)CO)[C@]1(C)[C@@H]2[C@H](CCC=2[C@@]3(C=CC(=O)C=2)C)[C@]3(F)[C@@H](O)C1 XBGQGAPUUJJOTA-KWLUMGGGSA-N 0.000 description 1
- CXSJGNHRBWJXEA-UHFFFAOYSA-N 5,12-dihydrophthalazino[3,2-b]phthalazine-7,14-dione Chemical compound C1C2=CC=CC=C2C(=O)N2N1C(=O)C1=CC=CC=C1C2 CXSJGNHRBWJXEA-UHFFFAOYSA-N 0.000 description 1
- JXNQXJVDHXGEPU-UHFFFAOYSA-N 5,5-diphenyl-2-(2-piperidin-1-ylethyl)-1,3-dioxolan-4-one;hydron;chloride Chemical compound Cl.O1C(C=2C=CC=CC=2)(C=2C=CC=CC=2)C(=O)OC1CCN1CCCCC1 JXNQXJVDHXGEPU-UHFFFAOYSA-N 0.000 description 1
- FBZHCUQUPMUOCR-UHFFFAOYSA-N 5,6-bis[4-(dimethylamino)phenyl]-2-methyl-1,2,4-triazin-3-one Chemical compound C1=CC(N(C)C)=CC=C1C1=NN(C)C(=O)N=C1C1=CC=C(N(C)C)C=C1 FBZHCUQUPMUOCR-UHFFFAOYSA-N 0.000 description 1
- XYAANYFFYIRFND-UHFFFAOYSA-N 5,6-dimethoxy-3-[2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]-2-methyl-1h-indole Chemical compound C1=2C=C(OC)C(OC)=CC=2NC(C)=C1CCN(CC1)CCN1C1=CC=CC=C1OC XYAANYFFYIRFND-UHFFFAOYSA-N 0.000 description 1
- FGBFEFJZYZDLSZ-UHFFFAOYSA-N 5,7-dimethoxy-2,3-dimethyl-2,3-dihydroinden-1-one Chemical compound COC1=CC(OC)=CC2=C1C(=O)C(C)C2C FGBFEFJZYZDLSZ-UHFFFAOYSA-N 0.000 description 1
- FYUZOMGBPKUZNJ-UHFFFAOYSA-N 5-(2-nitrophenyl)furan-2-carboximidamide Chemical compound O1C(C(=N)N)=CC=C1C1=CC=CC=C1[N+]([O-])=O FYUZOMGBPKUZNJ-UHFFFAOYSA-N 0.000 description 1
- HEOZYYOUKGGSBJ-UHFFFAOYSA-N 5-(4-methoxybenzoyl)-2,3-dihydro-1h-pyrrolizine-1-carboxylic acid Chemical compound C1=CC(OC)=CC=C1C(=O)C1=CC=C2N1CCC2C(O)=O HEOZYYOUKGGSBJ-UHFFFAOYSA-N 0.000 description 1
- FWRWEZVGVJKNMU-UHFFFAOYSA-N 5-(dipropylamino)-5,6-dihydro-4h-phenalen-2-ol;hydrobromide Chemical compound Br.OC1=CC(CC(N(CCC)CCC)C2)=C3C2=CC=CC3=C1 FWRWEZVGVJKNMU-UHFFFAOYSA-N 0.000 description 1
- NYUJOGMUKNKJAT-UHFFFAOYSA-N 5-[3-(dimethylamino)propyl]phenanthridin-6-one;hydrate;hydrochloride Chemical compound O.Cl.C1=CC=C2C(=O)N(CCCN(C)C)C3=CC=CC=C3C2=C1 NYUJOGMUKNKJAT-UHFFFAOYSA-N 0.000 description 1
- YOIOINQCJZQHPS-YDBXVIRUSA-N 5-[[[(1s,2s,3s)-2-hydroxy-3-phenoxycyclopentyl]amino]methyl]-2-methyl-6,7-dihydro-5h-1-benzothiophen-4-one;hydrochloride Chemical compound Cl.O([C@H]1CC[C@@H]([C@@H]1O)NCC1CCC2=C(C1=O)C=C(S2)C)C1=CC=CC=C1 YOIOINQCJZQHPS-YDBXVIRUSA-N 0.000 description 1
- XWSCOGPKWVNQSV-UHFFFAOYSA-N 5-bromo-2,3-dichloropyridine Chemical compound ClC1=CC(Br)=CN=C1Cl XWSCOGPKWVNQSV-UHFFFAOYSA-N 0.000 description 1
- VWXGRWMELBPMCU-UHFFFAOYSA-N 5-chloro-1-[3-(dimethylamino)propyl]-3-phenylbenzimidazol-2-one Chemical compound O=C1N(CCCN(C)C)C2=CC=C(Cl)C=C2N1C1=CC=CC=C1 VWXGRWMELBPMCU-UHFFFAOYSA-N 0.000 description 1
- NBAHQCCWEKHGTD-UHFFFAOYSA-N 5-fluoro-1h-pyrimidin-6-one Chemical compound OC1=NC=NC=C1F NBAHQCCWEKHGTD-UHFFFAOYSA-N 0.000 description 1
- PFBZWBJAFXWUSF-UHFFFAOYSA-N 5-ht 5-hydroxytryptamine Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1.C1=C(O)C=C2C(CCN)=CNC2=C1 PFBZWBJAFXWUSF-UHFFFAOYSA-N 0.000 description 1
- OCCZJXAHSUCJSA-UHFFFAOYSA-N 5-methyl-1h-1,6-naphthyridin-2-one Chemical compound N1C(=O)C=CC2=C1C=CN=C2C OCCZJXAHSUCJSA-UHFFFAOYSA-N 0.000 description 1
- XKFPYPQQHFEXRZ-UHFFFAOYSA-N 5-methyl-N'-(phenylmethyl)-3-isoxazolecarbohydrazide Chemical compound O1C(C)=CC(C(=O)NNCC=2C=CC=CC=2)=N1 XKFPYPQQHFEXRZ-UHFFFAOYSA-N 0.000 description 1
- RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 description 1
- UBOIMZIXNXGQOH-RTWVSBIPSA-N 58497-00-0 Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)CC)[C@@]2(C)C[C@@H]1O UBOIMZIXNXGQOH-RTWVSBIPSA-N 0.000 description 1
- TZBDXWBBMOEVPI-XBQQDWOSSA-N 58524-83-7 Chemical compound O=C([C@]12[C@@]3(C)C[C@H](O)[C@]4(F)[C@@]5(C)C=CC(=O)C=C5[C@@H](F)C[C@H]4[C@@H]3C[C@H]1OC(O2)(C)C)COC(=O)C1CC1 TZBDXWBBMOEVPI-XBQQDWOSSA-N 0.000 description 1
- NXRJFNBTRPERHV-UHFFFAOYSA-N 6,7-dichloro-3-cyclopent-3-en-1-yl-4h-1$l^{6},2,4-benzothiadiazine 1,1-dioxide Chemical compound N=1S(=O)(=O)C=2C=C(Cl)C(Cl)=CC=2NC=1C1CC=CC1 NXRJFNBTRPERHV-UHFFFAOYSA-N 0.000 description 1
- LJEPCGWMLNUFDA-UHFFFAOYSA-N 6,7-dimethoxy-2-(4-prop-2-enylpiperazin-1-yl)quinazolin-4-amine;dihydrochloride Chemical compound Cl.Cl.N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N1CCN(CC=C)CC1 LJEPCGWMLNUFDA-UHFFFAOYSA-N 0.000 description 1
- UZVYGOXJMRZJFK-UHFFFAOYSA-N 6,7-dimethoxyquinolin-4-amine Chemical compound C1=CC(N)=C2C=C(OC)C(OC)=CC2=N1 UZVYGOXJMRZJFK-UHFFFAOYSA-N 0.000 description 1
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 1
- SRTBBLNAKMLZTN-UHFFFAOYSA-N 6-amino-2,3-dichlorobenzoic acid Chemical compound NC1=CC=C(Cl)C(Cl)=C1C(O)=O SRTBBLNAKMLZTN-UHFFFAOYSA-N 0.000 description 1
- VGLGVJVUHYTIIU-UHFFFAOYSA-N 6-chloro-1,1-dioxo-3-[(prop-2-enylthio)methyl]-3,4-dihydro-2H-1$l^{6},2,4-benzothiadiazine-7-sulfonamide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NC(CSCC=C)NS2(=O)=O VGLGVJVUHYTIIU-UHFFFAOYSA-N 0.000 description 1
- BDNLIZHZILNCGI-UHFFFAOYSA-N 6-chloro-2-methyl-1,1-dioxo-3-(prop-2-enylsulfanylmethyl)-3,4-dihydro-1$l^{6},2,4-benzothiadiazine-7-sulfonamide Chemical compound ClC1=C(S(N)(=O)=O)C=C2S(=O)(=O)N(C)C(CSCC=C)NC2=C1 BDNLIZHZILNCGI-UHFFFAOYSA-N 0.000 description 1
- BKYKPTRYDKTTJY-UHFFFAOYSA-N 6-chloro-3-(cyclopentylmethyl)-1,1-dioxo-3,4-dihydro-2H-1$l^{6},2,4-benzothiadiazine-7-sulfonamide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(S(N2)(=O)=O)=C1NC2CC1CCCC1 BKYKPTRYDKTTJY-UHFFFAOYSA-N 0.000 description 1
- DBESQBZOXMCXPV-UHFFFAOYSA-N 6-chloro-3-[3-[4-(4-fluorobenzoyl)piperidin-1-yl]propyl]-1h-benzimidazol-2-one Chemical compound C1=CC(F)=CC=C1C(=O)C1CCN(CCCN2C(NC3=CC(Cl)=CC=C32)=O)CC1 DBESQBZOXMCXPV-UHFFFAOYSA-N 0.000 description 1
- OAIZNWQBWDHNIH-UHFFFAOYSA-N 6-chloro-4-phenyl-1-(2,2,2-trifluoroethyl)quinazolin-2-one Chemical compound N=1C(=O)N(CC(F)(F)F)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 OAIZNWQBWDHNIH-UHFFFAOYSA-N 0.000 description 1
- IUIYEHXOIMMQJY-NGXOUOCZSA-N 60135-22-0 Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)C(OC)OC)[C@@]2(C)C[C@@H]1O IUIYEHXOIMMQJY-NGXOUOCZSA-N 0.000 description 1
- XZPGINPFWXLYNW-UHFFFAOYSA-N 7-(4-methyl-6-oxo-4,5-dihydro-1h-pyridazin-3-yl)-4h-1,4-benzoxazin-3-one Chemical compound CC1CC(=O)NN=C1C1=CC=C(NC(=O)CO2)C2=C1 XZPGINPFWXLYNW-UHFFFAOYSA-N 0.000 description 1
- KUYDFFZBJGJAPK-UHFFFAOYSA-N 7-bromo-3,4-dihydro-1h-isoquinoline-2-carboximidamide;sulfuric acid Chemical compound OS(O)(=O)=O.C1=C(Br)C=C2CN(C(=N)N)CCC2=C1.C1=C(Br)C=C2CN(C(=N)N)CCC2=C1 KUYDFFZBJGJAPK-UHFFFAOYSA-N 0.000 description 1
- XWXVKXXKKLBDDJ-UHFFFAOYSA-N 7-chloro-3,3a-dihydro-2h-[1,2]oxazolo[3,2-b][1,3]benzoxazin-9-one Chemical compound O1C2CCON2C(=O)C2=CC(Cl)=CC=C21 XWXVKXXKKLBDDJ-UHFFFAOYSA-N 0.000 description 1
- CABBDKQGQDDPQA-UHFFFAOYSA-N 7-fluoro-2-methyl-4-(4-methylpiperazin-1-yl)-5h-thieno[3,2-c][1,5]benzodiazepine Chemical compound C1CN(C)CCN1C1=C(C=C(C)S2)C2=NC2=CC=C(F)C=C2N1 CABBDKQGQDDPQA-UHFFFAOYSA-N 0.000 description 1
- HCKFPALGXKOOBK-NRYMJLQJSA-N 7332-27-6 Chemical compound C1([C@]2(O[C@]3([C@@]4(C)C[C@H](O)[C@]5(F)[C@@]6(C)C=CC(=O)C=C6CC[C@H]5[C@@H]4C[C@H]3O2)C(=O)CO)C)=CC=CC=C1 HCKFPALGXKOOBK-NRYMJLQJSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- OZSPQIXKOVJJGE-UHFFFAOYSA-N 8-(2-ethoxyethyl)-7-phenyl-[1,2,4]triazolo[1,5-c]pyrimidin-5-amine Chemical compound N1=C(N)N2N=CN=C2C(CCOCC)=C1C1=CC=CC=C1 OZSPQIXKOVJJGE-UHFFFAOYSA-N 0.000 description 1
- BVMYCHKQPGEOSI-UHFFFAOYSA-N 8-[2-(2,3-dihydro-1,4-benzodioxin-3-ylmethylamino)ethyl]-8-azaspiro[4.5]decane-7,9-dione Chemical compound C1C(=O)N(CCNCC2OC3=CC=CC=C3OC2)C(=O)CC21CCCC2 BVMYCHKQPGEOSI-UHFFFAOYSA-N 0.000 description 1
- QOYHHIBFXOOADH-UHFFFAOYSA-N 8-[4,4-bis(4-fluorophenyl)butyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)CCCN1CCC2(C(NCN2C=2C=CC=CC=2)=O)CC1 QOYHHIBFXOOADH-UHFFFAOYSA-N 0.000 description 1
- ZFZPJDFBJFHYIV-UHFFFAOYSA-N 8-[4-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]butyl]-8-azaspiro[4.5]decane-7,9-dione Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2C3=CC=CC=C3SN=2)C(=O)CC21CCCC2 ZFZPJDFBJFHYIV-UHFFFAOYSA-N 0.000 description 1
- XYTNPORBXPAQMP-UHFFFAOYSA-N 8-chloro-5-methoxy-n,n-dimethyl-1,2,3,4-tetrahydronaphthalen-1-amine;hydrochloride Chemical compound [Cl-].C[NH+](C)C1CCCC2=C1C(Cl)=CC=C2OC XYTNPORBXPAQMP-UHFFFAOYSA-N 0.000 description 1
- CYAQJBUCOCJWET-UHFFFAOYSA-N 8-fluoro-2-(2-pyridin-4-ylethyl)-1,3,4,5-tetrahydropyrido[4,3-b]indole;hydrochloride Chemical compound Cl.C1C=2C3=CC(F)=CC=C3NC=2CCN1CCC1=CC=NC=C1 CYAQJBUCOCJWET-UHFFFAOYSA-N 0.000 description 1
- IOEPXYJOHIZYGQ-UHFFFAOYSA-N 8-methyl-6-(4-methylpiperazin-1-yl)benzo[b][1,4]benzothiazepine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2SC2=CC=C(C)C=C12 IOEPXYJOHIZYGQ-UHFFFAOYSA-N 0.000 description 1
- ZWHRZGHGYMUSRM-VWDRLOGHSA-N 9-[3-[(3r,5s)-3,5-dimethylpiperazin-1-yl]propyl]carbazole;hydron;dichloride Chemical compound Cl.Cl.C1[C@@H](C)N[C@@H](C)CN1CCCN1C2=CC=CC=C2C2=CC=CC=C21 ZWHRZGHGYMUSRM-VWDRLOGHSA-N 0.000 description 1
- MKBLHFILKIKSQM-UHFFFAOYSA-N 9-methyl-3-[(2-methyl-1h-imidazol-3-ium-3-yl)methyl]-2,3-dihydro-1h-carbazol-4-one;chloride Chemical compound Cl.CC1=NC=CN1CC1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 MKBLHFILKIKSQM-UHFFFAOYSA-N 0.000 description 1
- PQJUJGAVDBINPI-UHFFFAOYSA-N 9H-thioxanthene Chemical compound C1=CC=C2CC3=CC=CC=C3SC2=C1 PQJUJGAVDBINPI-UHFFFAOYSA-N 0.000 description 1
- ZOCUOMKMBMEYQV-GSLJADNHSA-N 9alpha-Fluoro-11beta,17alpha,21-trihydroxypregna-1,4-diene-3,20-dione 21-acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ZOCUOMKMBMEYQV-GSLJADNHSA-N 0.000 description 1
- 235000007173 Abies balsamea Nutrition 0.000 description 1
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 244000152526 Agathosma crenulata Species 0.000 description 1
- 235000013388 Agathosma crenulata Nutrition 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 229940097693 Aldehyde dehydrogenase inhibitor Drugs 0.000 description 1
- FDQGNLOWMMVRQL-UHFFFAOYSA-N Allobarbital Chemical compound C=CCC1(CC=C)C(=O)NC(=O)NC1=O FDQGNLOWMMVRQL-UHFFFAOYSA-N 0.000 description 1
- RXAVJRAUFOPBOO-UHFFFAOYSA-N Alpertine Chemical compound CCOC(=O)C=1NC2=CC(OC)=C(OC)C=C2C=1CCN(CC1)CCN1C1=CC=CC=C1 RXAVJRAUFOPBOO-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- KFYRPLNVJVHZGT-UHFFFAOYSA-N Amitriptyline hydrochloride Chemical compound Cl.C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KFYRPLNVJVHZGT-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 241000272525 Anas platyrhynchos Species 0.000 description 1
- 108010072661 Angiotensin Amide Proteins 0.000 description 1
- 241000272814 Anser sp. Species 0.000 description 1
- KIPFVRHNAAZJOD-UHFFFAOYSA-N Aprindine hydrochloride Chemical compound Cl.C1C2=CC=CC=C2CC1N(CCCN(CC)CC)C1=CC=CC=C1 KIPFVRHNAAZJOD-UHFFFAOYSA-N 0.000 description 1
- NAPNOSFRRMHNBJ-UHFFFAOYSA-N Arprinocid Chemical compound C1=NC=2C(N)=NC=NC=2N1CC1=C(F)C=CC=C1Cl NAPNOSFRRMHNBJ-UHFFFAOYSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 206010003805 Autism Diseases 0.000 description 1
- 208000020706 Autistic disease Diseases 0.000 description 1
- RQBNXPJPWKUTOG-UHFFFAOYSA-N Azabon Chemical compound C1=CC(N)=CC=C1S(=O)(=O)N1CC(CC2)CCC2C1 RQBNXPJPWKUTOG-UHFFFAOYSA-N 0.000 description 1
- MREBEPTUUMTTIA-PCLIKHOPSA-N Azimilide Chemical compound C1CN(C)CCN1CCCCN1C(=O)N(\N=C\C=2OC(=CC=2)C=2C=CC(Cl)=CC=2)CC1=O MREBEPTUUMTTIA-PCLIKHOPSA-N 0.000 description 1
- 239000004857 Balsam Substances 0.000 description 1
- 235000009269 Barosma crenulata Nutrition 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- DHHFDKNIEVKVKS-FMOSSLLZSA-N Betanin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)O)=CC(C[C@H]2C([O-])=O)=C1[N+]2=C\C=C\1C=C(C(O)=O)N[C@H](C(O)=O)C/1 DHHFDKNIEVKVKS-FMOSSLLZSA-N 0.000 description 1
- DHHFDKNIEVKVKS-MVUYWVKGSA-N Betanin Natural products O=C(O)[C@@H]1NC(C(=O)O)=C/C(=C\C=[N+]/2\[C@@H](C(=O)[O-])Cc3c\2cc(O)c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)c3)/C1 DHHFDKNIEVKVKS-MVUYWVKGSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000995051 Brenda Species 0.000 description 1
- 108010004032 Bromelains Proteins 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- UMSGKTJDUHERQW-UHFFFAOYSA-N Brotizolam Chemical compound C1=2C=C(Br)SC=2N2C(C)=NN=C2CN=C1C1=CC=CC=C1Cl UMSGKTJDUHERQW-UHFFFAOYSA-N 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- VKSPIPWLHGKJQO-UHFFFAOYSA-N Bupicomide Chemical compound CCCCC1=CC=C(C(N)=O)N=C1 VKSPIPWLHGKJQO-UHFFFAOYSA-N 0.000 description 1
- QORQZMBCPRBCAB-UHFFFAOYSA-M Butabarbital sodium Chemical compound [Na+].CCC(C)C1(CC)C(=O)NC([O-])=NC1=O QORQZMBCPRBCAB-UHFFFAOYSA-M 0.000 description 1
- WLYWZMQECNKDLI-UHFFFAOYSA-N Buterizine Chemical compound C=1C=C2N(CC)C(CCCC)=NC2=CC=1CN(CC1)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 WLYWZMQECNKDLI-UHFFFAOYSA-N 0.000 description 1
- ILTUUTWIVSCOPH-UHFFFAOYSA-N C(CCCCCCCCCCCCCCC)O.[O].C=C Chemical compound C(CCCCCCCCCCCCCCC)O.[O].C=C ILTUUTWIVSCOPH-UHFFFAOYSA-N 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 239000002083 C09CA01 - Losartan Substances 0.000 description 1
- 239000002081 C09CA05 - Tasosartan Substances 0.000 description 1
- ZXFWJPKXEMFBOG-LWVMDMHWSA-N CC(O)=O.CC[C@H](C)[C@@H]1NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)CNC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CSSC[C@H](NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)CNC1=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CCCNC(N)=N Chemical compound CC(O)=O.CC[C@H](C)[C@@H]1NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)CNC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CSSC[C@H](NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)CNC1=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CCCNC(N)=N ZXFWJPKXEMFBOG-LWVMDMHWSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- KSQIAZKOUOEHSA-UHFFFAOYSA-N Carbocromen hydrochloride Chemical compound [Cl-].CC1=C(CC[NH+](CC)CC)C(=O)OC2=CC(OCC(=O)OCC)=CC=C21 KSQIAZKOUOEHSA-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 101710167917 Carbonic anhydrase 2 Proteins 0.000 description 1
- 102100024633 Carbonic anhydrase 2 Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- IFYLTXNCFVRALQ-OALUTQOASA-N Ceronapril Chemical compound O([C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)P(O)(=O)CCCCC1=CC=CC=C1 IFYLTXNCFVRALQ-OALUTQOASA-N 0.000 description 1
- 108010010737 Ceruletide Proteins 0.000 description 1
- MMNICIJVQJJHHF-UHFFFAOYSA-N Cetiedil Chemical compound C1CCCCC1C(C1=CSC=C1)C(=O)OCCN1CCCCCC1 MMNICIJVQJJHHF-UHFFFAOYSA-N 0.000 description 1
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- PCLITLDOTJTVDJ-UHFFFAOYSA-N Chlormethiazole Chemical compound CC=1N=CSC=1CCCl PCLITLDOTJTVDJ-UHFFFAOYSA-N 0.000 description 1
- RKWGIWYCVPQPMF-UHFFFAOYSA-N Chloropropamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 description 1
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 1
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- IPOBOOXFSRWSHL-UHFFFAOYSA-N Cibenzoline Chemical compound C=1C=CC=CC=1C1(C=2C=CC=CC=2)CC1C1=NCCN1 IPOBOOXFSRWSHL-UHFFFAOYSA-N 0.000 description 1
- CVKNDPRBJVBDSS-UHFFFAOYSA-N Cicletanine Chemical compound O1CC2=C(O)C(C)=NC=C2C1C1=CC=C(Cl)C=C1 CVKNDPRBJVBDSS-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- VCMZUKHJKLNFPH-JXMROGBWSA-N Cinperene Chemical compound O=C1NC(=O)CCC1(C=1C=CC=CC=1)C1CCN(C\C=C\C=2C=CC=CC=2)CC1 VCMZUKHJKLNFPH-JXMROGBWSA-N 0.000 description 1
- KATBVKFXGKGUFE-UHFFFAOYSA-N Cintazone Chemical compound C12=CC=CC=C2N2C(=O)C(CCCCC)C(=O)N2C=C1C1=CC=CC=C1 KATBVKFXGKGUFE-UHFFFAOYSA-N 0.000 description 1
- GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 description 1
- ZNIFSRGNXRYGHF-UHFFFAOYSA-N Clonidine hydrochloride Chemical compound Cl.ClC1=CC=CC(Cl)=C1NC1=NCCN1 ZNIFSRGNXRYGHF-UHFFFAOYSA-N 0.000 description 1
- 241001327942 Clonorchis Species 0.000 description 1
- KAAZGXDPUNNEFN-UHFFFAOYSA-N Clotiapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2SC2=CC=C(Cl)C=C12 KAAZGXDPUNNEFN-UHFFFAOYSA-N 0.000 description 1
- 208000022497 Cocaine-Related disease Diseases 0.000 description 1
- 108091033380 Coding strand Proteins 0.000 description 1
- 208000027691 Conduct disease Diseases 0.000 description 1
- 208000022540 Consciousness disease Diseases 0.000 description 1
- YXKFATPOEMHNMJ-KJEYTGHBSA-N Cormethasone acetate Chemical compound C1C(F)(F)C2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COC(C)=O)(O)[C@@]1(C)C[C@@H]2O YXKFATPOEMHNMJ-KJEYTGHBSA-N 0.000 description 1
- 108010091893 Cosyntropin Proteins 0.000 description 1
- UIKROCXWUNQSPJ-UHFFFAOYSA-N Cotinine Natural products C1CC(=O)N(C)C1C1=CC=CN=C1 UIKROCXWUNQSPJ-UHFFFAOYSA-N 0.000 description 1
- XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 description 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- 101150049660 DRD2 gene Proteins 0.000 description 1
- FMGSKLZLMKYGDP-UHFFFAOYSA-N Dehydroepiandrosterone Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CC=C21 FMGSKLZLMKYGDP-UHFFFAOYSA-N 0.000 description 1
- FDJCVHVKXFIEPJ-JCNFZFLDSA-N Delapril hydrochloride Chemical compound Cl.C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N(CC(O)=O)C1CC2=CC=CC=C2C1)CC1=CC=CC=C1 FDJCVHVKXFIEPJ-JCNFZFLDSA-N 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- RJPZIQRLRMWPRF-UHFFFAOYSA-N Dibenzepin hydrochloride Chemical compound [Cl-].C[NH+](C)CCN1C(=O)C2=CC=CC=C2N(C)C2=CC=CC=C21 RJPZIQRLRMWPRF-UHFFFAOYSA-N 0.000 description 1
- WUVPAYPBMZMHJO-IMNLCBETSA-N Dicirenone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)C(=O)OC(C)C)C[C@@]21CCC(=O)O1 WUVPAYPBMZMHJO-IMNLCBETSA-N 0.000 description 1
- WYQPLTPSGFELIB-JTQPXKBDSA-N Difluprednate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2CC[C@@](C(=O)COC(C)=O)(OC(=O)CCC)[C@@]2(C)C[C@@H]1O WYQPLTPSGFELIB-JTQPXKBDSA-N 0.000 description 1
- 240000001879 Digitalis lutea Species 0.000 description 1
- WDJUZGPOPHTGOT-OAXVISGBSA-N Digitoxin Natural products O([C@H]1[C@@H](C)O[C@@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@@](C)([C@H](C6=CC(=O)OC6)CC5)CC4)CC3)CC2)C[C@H]1O)[C@H]1O[C@@H](C)[C@H](O[C@H]2O[C@@H](C)[C@@H](O)[C@@H](O)C2)[C@@H](O)C1 WDJUZGPOPHTGOT-OAXVISGBSA-N 0.000 description 1
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
- CTENFNNZBMHDDG-UHFFFAOYSA-N Dopamine hydrochloride Chemical compound Cl.NCCC1=CC=C(O)C(O)=C1 CTENFNNZBMHDDG-UHFFFAOYSA-N 0.000 description 1
- 229940094659 Dopamine reuptake inhibitor Drugs 0.000 description 1
- MHNSPTUQQIYJOT-SJDTYFKWSA-N Doxepin Hydrochloride Chemical compound Cl.C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 MHNSPTUQQIYJOT-SJDTYFKWSA-N 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 108010061435 Enalapril Proteins 0.000 description 1
- 108010066671 Enalaprilat Proteins 0.000 description 1
- KQXVERRYBYGQJZ-WRPDIKACSA-N Enalkiren Chemical compound C1=CC(OC)=CC=C1C[C@H](NC(=O)CC(C)(C)N)C(=O)N[C@H](C(=O)N[C@@H](CC1CCCCC1)[C@@H](O)[C@@H](O)CC(C)C)CC1=CN=CN1 KQXVERRYBYGQJZ-WRPDIKACSA-N 0.000 description 1
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 1
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical group C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 239000005770 Eugenol Substances 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108010045937 Felypressin Proteins 0.000 description 1
- NIGWMJHCCYYCSF-UHFFFAOYSA-N Fenclonine Chemical compound OC(=O)C(N)CC1=CC=C(Cl)C=C1 NIGWMJHCCYYCSF-UHFFFAOYSA-N 0.000 description 1
- CVKUMNRCIJMVAR-UHFFFAOYSA-N Fenoldopam mesylate Chemical compound CS(O)(=O)=O.C1=CC(O)=CC=C1C1C2=CC(O)=C(O)C(Cl)=C2CCNC1 CVKUMNRCIJMVAR-UHFFFAOYSA-N 0.000 description 1
- 108010029961 Filgrastim Proteins 0.000 description 1
- DJBNUMBKLMJRSA-UHFFFAOYSA-N Flecainide Chemical compound FC(F)(F)COC1=CC=C(OCC(F)(F)F)C(C(=O)NCC2NCCCC2)=C1 DJBNUMBKLMJRSA-UHFFFAOYSA-N 0.000 description 1
- APQPGQGAWABJLN-UHFFFAOYSA-N Floctafenine Chemical compound OCC(O)COC(=O)C1=CC=CC=C1NC1=CC=NC2=C(C(F)(F)F)C=CC=C12 APQPGQGAWABJLN-UHFFFAOYSA-N 0.000 description 1
- CXLOIJUDIPVKOU-UHFFFAOYSA-N Fludorex Chemical compound CNCC(OC)C1=CC=CC(C(F)(F)F)=C1 CXLOIJUDIPVKOU-UHFFFAOYSA-N 0.000 description 1
- RXKMOPXNWTYEHI-RDRKJGRWSA-N Flunarizine hydrochloride Chemical compound Cl.Cl.C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)N1CCN(C\C=C\C=2C=CC=CC=2)CC1 RXKMOPXNWTYEHI-RDRKJGRWSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- ZIIJJOPLRSCQNX-UHFFFAOYSA-N Flurazepam hydrochloride Chemical compound Cl.Cl.N=1CC(=O)N(CCN(CC)CC)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1F ZIIJJOPLRSCQNX-UHFFFAOYSA-N 0.000 description 1
- LFMYNZPAVPMEGP-PIDGMYBPSA-N Fluvoxamine maleate Chemical compound OC(=O)\C=C/C(O)=O.COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 LFMYNZPAVPMEGP-PIDGMYBPSA-N 0.000 description 1
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
- 229940098788 GABA receptor antagonist Drugs 0.000 description 1
- 108700012941 GNRH1 Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 102000018899 Glutamate Receptors Human genes 0.000 description 1
- 108010027915 Glutamate Receptors Proteins 0.000 description 1
- JMBQKKAJIKAWKF-UHFFFAOYSA-N Glutethimide Chemical compound C=1C=CC=CC=1C1(CC)CCC(=O)NC1=O JMBQKKAJIKAWKF-UHFFFAOYSA-N 0.000 description 1
- 102400000932 Gonadoliberin-1 Human genes 0.000 description 1
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- MUQNGPZZQDCDFT-JNQJZLCISA-N Halcinonide Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CCl)[C@@]1(C)C[C@@H]2O MUQNGPZZQDCDFT-JNQJZLCISA-N 0.000 description 1
- YCISZOVUHXIOFY-HKXOFBAYSA-N Halopredone acetate Chemical compound C1([C@H](F)C2)=CC(=O)C(Br)=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2CC[C@](OC(C)=O)(C(=O)COC(=O)C)[C@@]2(C)C[C@@H]1O YCISZOVUHXIOFY-HKXOFBAYSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 1
- 102000000543 Histamine Receptors Human genes 0.000 description 1
- 108010002059 Histamine Receptors Proteins 0.000 description 1
- 101500026183 Homo sapiens Gonadoliberin-1 Proteins 0.000 description 1
- 240000000387 Hydrophyllum virginianum Species 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 244000018716 Impatiens biflora Species 0.000 description 1
- MADRVGBADLFHMO-UHFFFAOYSA-N Indeloxazine Chemical compound C=1C=CC=2C=CCC=2C=1OCC1CNCCO1 MADRVGBADLFHMO-UHFFFAOYSA-N 0.000 description 1
- 208000001271 Inhalant Abuse Diseases 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000014429 Insulin-like growth factor Human genes 0.000 description 1
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 1
- 108700021006 Interleukin-1 receptor antagonist Proteins 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- ZAGRKAFMISFKIO-UHFFFAOYSA-N Isolysergic acid Natural products C1=CC(C2=CC(CN(C2C2)C)C(O)=O)=C3C2=CNC3=C1 ZAGRKAFMISFKIO-UHFFFAOYSA-N 0.000 description 1
- 229930194542 Keto Natural products 0.000 description 1
- LJCWONGJFPCTTL-ZETCQYMHSA-N L-4-hydroxyphenylglycine Chemical compound OC(=O)[C@@H](N)C1=CC=C(O)C=C1 LJCWONGJFPCTTL-ZETCQYMHSA-N 0.000 description 1
- WXFIGDLSSYIKKV-RCOVLWMOSA-N L-Metaraminol Chemical compound C[C@H](N)[C@H](O)C1=CC=CC(O)=C1 WXFIGDLSSYIKKV-RCOVLWMOSA-N 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- BVHLGVCQOALMSV-JEDNCBNOSA-N L-lysine hydrochloride Chemical compound Cl.NCCCC[C@H](N)C(O)=O BVHLGVCQOALMSV-JEDNCBNOSA-N 0.000 description 1
- NHTGHBARYWONDQ-JTQLQIEISA-N L-α-methyl-Tyrosine Chemical compound OC(=O)[C@](N)(C)CC1=CC=C(O)C=C1 NHTGHBARYWONDQ-JTQLQIEISA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 108010062867 Lenograstim Proteins 0.000 description 1
- YEJCDKJIEMIWRQ-UHFFFAOYSA-N Linopirdine Chemical compound O=C1N(C=2C=CC=CC=2)C2=CC=CC=C2C1(CC=1C=CN=CC=1)CC1=CC=NC=C1 YEJCDKJIEMIWRQ-UHFFFAOYSA-N 0.000 description 1
- LKYWLLWWYBVUPP-XOCLESOZSA-L Liotrix Chemical compound [Na+].[Na+].IC1=CC(C[C@H](N)C([O-])=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1.IC1=CC(C[C@H](N)C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 LKYWLLWWYBVUPP-XOCLESOZSA-L 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 108010007859 Lisinopril Proteins 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 102000009151 Luteinizing Hormone Human genes 0.000 description 1
- 108010073521 Luteinizing Hormone Proteins 0.000 description 1
- MQHWFIOJQSCFNM-UHFFFAOYSA-L Magnesium salicylate Chemical compound [Mg+2].OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O MQHWFIOJQSCFNM-UHFFFAOYSA-L 0.000 description 1
- 241001284140 Malenka Species 0.000 description 1
- 208000003863 Marijuana Abuse Diseases 0.000 description 1
- LEROTMJVBFSIMP-UHFFFAOYSA-N Mebutamate Chemical compound NC(=O)OCC(C)(C(C)CC)COC(N)=O LEROTMJVBFSIMP-UHFFFAOYSA-N 0.000 description 1
- PKVZBNCYEICAQP-UHFFFAOYSA-N Mecamylamine hydrochloride Chemical compound Cl.C1CC2C(C)(C)C(NC)(C)C1C2 PKVZBNCYEICAQP-UHFFFAOYSA-N 0.000 description 1
- SBDNJUWAMKYJOX-UHFFFAOYSA-N Meclofenamic Acid Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C(O)=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-N 0.000 description 1
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 1
- NPPQSCRMBWNHMW-UHFFFAOYSA-N Meprobamate Chemical compound NC(=O)OCC(C)(CCC)COC(N)=O NPPQSCRMBWNHMW-UHFFFAOYSA-N 0.000 description 1
- IMWZZHHPURKASS-UHFFFAOYSA-N Metaxalone Chemical compound CC1=CC(C)=CC(OCC2OC(=O)NC2)=C1 IMWZZHHPURKASS-UHFFFAOYSA-N 0.000 description 1
- JEYCTXHKTXCGPB-UHFFFAOYSA-N Methaqualone Chemical compound CC1=CC=CC=C1N1C(=O)C2=CC=CC=C2N=C1C JEYCTXHKTXCGPB-UHFFFAOYSA-N 0.000 description 1
- CESYKOGBSMNBPD-UHFFFAOYSA-N Methyclothiazide Chemical compound ClC1=C(S(N)(=O)=O)C=C2S(=O)(=O)N(C)C(CCl)NC2=C1 CESYKOGBSMNBPD-UHFFFAOYSA-N 0.000 description 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
- LWYXFDXUMVEZKS-ZVFOLQIPSA-N Methysergide maleate Chemical compound OC(=O)\C=C/C(O)=O.C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@H](CO)CC)C2)=C3C2=CN(C)C3=C1 LWYXFDXUMVEZKS-ZVFOLQIPSA-N 0.000 description 1
- RGHAZVBIOOEVQX-UHFFFAOYSA-N Metoprolol succinate Chemical compound OC(=O)CCC(O)=O.COCCC1=CC=C(OCC(O)CNC(C)C)C=C1.COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 RGHAZVBIOOEVQX-UHFFFAOYSA-N 0.000 description 1
- HBNPJJILLOYFJU-VMPREFPWSA-N Mibefradil Chemical compound C1CC2=CC(F)=CC=C2[C@H](C(C)C)[C@@]1(OC(=O)COC)CCN(C)CCCC1=NC2=CC=CC=C2N1 HBNPJJILLOYFJU-VMPREFPWSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 1
- KLPWJLBORRMFGK-UHFFFAOYSA-N Molindone Chemical compound O=C1C=2C(CC)=C(C)NC=2CCC1CN1CCOCC1 KLPWJLBORRMFGK-UHFFFAOYSA-N 0.000 description 1
- ZDZXCYHMVFLGMT-BTJKTKAUSA-N Monatepil maleate Chemical compound OC(=O)\C=C/C(O)=O.C1=CC(F)=CC=C1N1CCN(CCCC(=O)NC2C3=CC=CC=C3SCC3=CC=CC=C32)CC1 ZDZXCYHMVFLGMT-BTJKTKAUSA-N 0.000 description 1
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 1
- OPZKBPQVWDSATI-KHPPLWFESA-N N-Vanillyloleamide Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)NCC1=CC=C(O)C(OC)=C1 OPZKBPQVWDSATI-KHPPLWFESA-N 0.000 description 1
- HUNIPYLVUPMFCZ-UHFFFAOYSA-N N-[2-(diethylamino)ethyl]-2-(4-methoxyphenoxy)acetamide Chemical compound CCN(CC)CCNC(=O)COC1=CC=C(OC)C=C1 HUNIPYLVUPMFCZ-UHFFFAOYSA-N 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- GIYXAJPCNFJEHY-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]-1-propanamine hydrochloride (1:1) Chemical compound Cl.C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 GIYXAJPCNFJEHY-UHFFFAOYSA-N 0.000 description 1
- BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 1
- KBAFPSLPKGSANY-UHFFFAOYSA-N Naftidrofuryl Chemical compound C=1C=CC2=CC=CC=C2C=1CC(C(=O)OCCN(CC)CC)CC1CCCO1 KBAFPSLPKGSANY-UHFFFAOYSA-N 0.000 description 1
- VHKXXVVRRDYCIK-CWCPJSEDSA-N Narasin Chemical compound C[C@H]1C[C@H](C)[C@H]([C@@H](CC)C(O)=O)O[C@H]1[C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)[C@@H]1[C@@H](C)C[C@@H](C)[C@@]2(C=C[C@@H](O)[C@@]3(O[C@@](C)(CC3)[C@@H]3O[C@@H](C)[C@@](O)(CC)CC3)O2)O1 VHKXXVVRRDYCIK-CWCPJSEDSA-N 0.000 description 1
- VHKXXVVRRDYCIK-UHFFFAOYSA-N Narasin Natural products CC1CC(C)C(C(CC)C(O)=O)OC1C(C)C(O)C(C)C(=O)C(CC)C1C(C)CC(C)C2(C=CC(O)C3(OC(C)(CC3)C3OC(C)C(O)(CC)CC3)O2)O1 VHKXXVVRRDYCIK-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- YSEXMKHXIOCEJA-FVFQAYNVSA-N Nicergoline Chemical compound C([C@@H]1C[C@]2([C@H](N(C)C1)CC=1C3=C2C=CC=C3N(C)C=1)OC)OC(=O)C1=CN=CC(Br)=C1 YSEXMKHXIOCEJA-FVFQAYNVSA-N 0.000 description 1
- 206010057852 Nicotine dependence Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- ICTXHFFSOAJUMG-SLHNCBLASA-N Norethynodrel Chemical compound C1CC(=O)CC2=C1[C@H]1CC[C@](C)([C@](CC3)(O)C#C)[C@@H]3[C@@H]1CC2 ICTXHFFSOAJUMG-SLHNCBLASA-N 0.000 description 1
- WSEQDEFUEFCRLT-MULMSPGLSA-N OCCNCCO.CC(OC(=O)[C@]1(C)CC[C@H](C(O)=O)C1(C)C)c1ccc(C)cc1 Chemical group OCCNCCO.CC(OC(=O)[C@]1(C)CC[C@H](C(O)=O)C1(C)C)c1ccc(C)cc1 WSEQDEFUEFCRLT-MULMSPGLSA-N 0.000 description 1
- 206010029897 Obsessive thoughts Diseases 0.000 description 1
- ZZQNEJILGNNOEP-UHFFFAOYSA-N Ocaperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC3=C(C)N=C4N(C3=O)C=CC=C4C)=NOC2=C1 ZZQNEJILGNNOEP-UHFFFAOYSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108010093625 Opioid Peptides Proteins 0.000 description 1
- 102000001490 Opioid Peptides Human genes 0.000 description 1
- 229940123257 Opioid receptor antagonist Drugs 0.000 description 1
- 102000002512 Orexin Human genes 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229940087098 Oxidase inhibitor Drugs 0.000 description 1
- BCGJBQBWUGVESK-KCTCKCTRSA-N Oxymorphone hydrochloride Chemical compound Cl.O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BCGJBQBWUGVESK-KCTCKCTRSA-N 0.000 description 1
- XCWPUUGSGHNIDZ-UHFFFAOYSA-N Oxypertine Chemical compound C1=2C=C(OC)C(OC)=CC=2NC(C)=C1CCN(CC1)CCN1C1=CC=CC=C1 XCWPUUGSGHNIDZ-UHFFFAOYSA-N 0.000 description 1
- 102400000050 Oxytocin Human genes 0.000 description 1
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 1
- 101800000989 Oxytocin Proteins 0.000 description 1
- DPWPWRLQFGFJFI-UHFFFAOYSA-N Pargyline Chemical compound C#CCN(C)CC1=CC=CC=C1 DPWPWRLQFGFJFI-UHFFFAOYSA-N 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 description 1
- 108091093037 Peptide nucleic acid Proteins 0.000 description 1
- PWRPUAKXMQAFCJ-UHFFFAOYSA-N Perlapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2CC2=CC=CC=C12 PWRPUAKXMQAFCJ-UHFFFAOYSA-N 0.000 description 1
- MFOCDFTXLCYLKU-CMPLNLGQSA-N Phendimetrazine Chemical compound O1CCN(C)[C@@H](C)[C@@H]1C1=CC=CC=C1 MFOCDFTXLCYLKU-CMPLNLGQSA-N 0.000 description 1
- RMUCZJUITONUFY-UHFFFAOYSA-N Phenelzine Chemical compound NNCCC1=CC=CC=C1 RMUCZJUITONUFY-UHFFFAOYSA-N 0.000 description 1
- VBCPVIWPDJVHAN-UHFFFAOYSA-N Phenoxybenzamine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C[NH+](CCCl)C(C)COC1=CC=CC=C1 VBCPVIWPDJVHAN-UHFFFAOYSA-N 0.000 description 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
- PIJVFDBKTWXHHD-UHFFFAOYSA-N Physostigmine Natural products C12=CC(OC(=O)NC)=CC=C2N(C)C2C1(C)CCN2C PIJVFDBKTWXHHD-UHFFFAOYSA-N 0.000 description 1
- XRKXJJYSKUIIEN-LLVKDONJSA-N Pivopril Chemical compound CC(C)(C)C(=O)SC[C@@H](C)C(=O)N(CC(O)=O)C1CCCC1 XRKXJJYSKUIIEN-LLVKDONJSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- CYLWJCABXYDINA-UHFFFAOYSA-N Polythiazide Polymers ClC1=C(S(N)(=O)=O)C=C2S(=O)(=O)N(C)C(CSCC(F)(F)F)NC2=C1 CYLWJCABXYDINA-UHFFFAOYSA-N 0.000 description 1
- IFFPICMESYHZPQ-UHFFFAOYSA-N Prenylamine Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)CCNC(C)CC1=CC=CC=C1 IFFPICMESYHZPQ-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- RETPFDTUCPKFEC-UHFFFAOYSA-N Primidolol Chemical compound CC1=CC=CC=C1OCC(O)CNCCN1C(=O)NC(=O)C(C)=C1 RETPFDTUCPKFEC-UHFFFAOYSA-N 0.000 description 1
- KNAHARQHSZJURB-UHFFFAOYSA-N Propylthiouracile Chemical compound CCCC1=CC(=O)NC(=S)N1 KNAHARQHSZJURB-UHFFFAOYSA-N 0.000 description 1
- MYEJFUXQJGHEQK-ALRJYLEOSA-N Proscillaridin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1C=C2CC[C@H]3[C@@]4(O)CC[C@H](C5=COC(=O)C=C5)[C@@]4(C)CC[C@@H]3[C@@]2(C)CC1 MYEJFUXQJGHEQK-ALRJYLEOSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 1
- 241000274582 Pycnanthus angolensis Species 0.000 description 1
- VNYBTNPBYXSMOO-UHFFFAOYSA-M Pyridostigmine bromide Chemical compound [Br-].CN(C)C(=O)OC1=CC=C[N+](C)=C1 VNYBTNPBYXSMOO-UHFFFAOYSA-M 0.000 description 1
- FCLZCOCSZQNREK-UHFFFAOYSA-N Pyrrolidine, hydrochloride Chemical compound Cl.C1CCNC1 FCLZCOCSZQNREK-UHFFFAOYSA-N 0.000 description 1
- IKMPWMZBZSAONZ-UHFFFAOYSA-N Quazepam Chemical compound FC1=CC=CC=C1C1=NCC(=S)N(CC(F)(F)F)C2=CC=C(Cl)C=C12 IKMPWMZBZSAONZ-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 102000003743 Relaxin Human genes 0.000 description 1
- 108090000103 Relaxin Proteins 0.000 description 1
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 1
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 1
- PPTYJKAXVCCBDU-UHFFFAOYSA-N Rohypnol Chemical compound N=1CC(=O)N(C)C2=CC=C([N+]([O-])=O)C=C2C=1C1=CC=CC=C1F PPTYJKAXVCCBDU-UHFFFAOYSA-N 0.000 description 1
- XDXHAEQXIBQUEZ-UHFFFAOYSA-N Ropinirole hydrochloride Chemical compound Cl.CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2 XDXHAEQXIBQUEZ-UHFFFAOYSA-N 0.000 description 1
- UHSKFQJFRQCDBE-UHFFFAOYSA-N Ropinirole hydrochloride Natural products CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2 UHSKFQJFRQCDBE-UHFFFAOYSA-N 0.000 description 1
- QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 description 1
- CNIIGCLFLJGOGP-UHFFFAOYSA-N SJ000285664 Natural products C=1C=CC2=CC=CC=C2C=1CC1=NCCN1 CNIIGCLFLJGOGP-UHFFFAOYSA-N 0.000 description 1
- SKZKKFZAGNVIMN-UHFFFAOYSA-N Salicilamide Chemical compound NC(=O)C1=CC=CC=C1O SKZKKFZAGNVIMN-UHFFFAOYSA-N 0.000 description 1
- 108010083387 Saralasin Proteins 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 108010087230 Sincalide Proteins 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 1
- 208000033039 Somatisation disease Diseases 0.000 description 1
- 208000027520 Somatoform disease Diseases 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- 208000003028 Stuttering Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- OJCZPLDERGDQRJ-UHFFFAOYSA-N Sufentanil citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C1CN(CCC=2SC=CC=2)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 OJCZPLDERGDQRJ-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- IWDUZEHNLHFBRZ-UHFFFAOYSA-N Suritozole Chemical compound CN1C(=S)N(C)N=C1C1=CC=CC(F)=C1 IWDUZEHNLHFBRZ-UHFFFAOYSA-N 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 208000037063 Thinness Diseases 0.000 description 1
- YCNTYPIGYVTFBO-UHFFFAOYSA-N Tinabinol Chemical compound CC1(C)OC2=CC(C(C)C(C)CCCCC)=CC(O)=C2C2=C1SCCC2 YCNTYPIGYVTFBO-UHFFFAOYSA-N 0.000 description 1
- MULPYFRDYRZMDS-UHFFFAOYSA-N Tiodazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=NN=C(SC)O1 MULPYFRDYRZMDS-UHFFFAOYSA-N 0.000 description 1
- 208000025569 Tobacco Use disease Diseases 0.000 description 1
- 206010043903 Tobacco abuse Diseases 0.000 description 1
- RHTNTTODYGNRSP-UHFFFAOYSA-N Tolazoline hydrochloride Chemical compound Cl.C=1C=CC=CC=1CC1=NCCN1 RHTNTTODYGNRSP-UHFFFAOYSA-N 0.000 description 1
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 1
- 208000000323 Tourette Syndrome Diseases 0.000 description 1
- 208000016620 Tourette disease Diseases 0.000 description 1
- RZOXEODOFNEZRS-UHFFFAOYSA-N Tramazoline hydrochloride Chemical compound [Cl-].N1CCN=C1[NH2+]C1=CC=CC2=C1CCCC2 RZOXEODOFNEZRS-UHFFFAOYSA-N 0.000 description 1
- 108010015865 Transferrins Proteins 0.000 description 1
- 102000002070 Transferrins Human genes 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- MBBOMCVGYCRMEA-UHFFFAOYSA-N Tryptophol Natural products C1=CC=C2C(CCO)=CNC2=C1 MBBOMCVGYCRMEA-UHFFFAOYSA-N 0.000 description 1
- 108010047196 Urofollitropin Proteins 0.000 description 1
- ZVNYJIZDIRKMBF-UHFFFAOYSA-N Vesnarinone Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)N1CCN(C=2C=C3CCC(=O)NC3=CC=2)CC1 ZVNYJIZDIRKMBF-UHFFFAOYSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 206010048010 Withdrawal syndrome Diseases 0.000 description 1
- DXPOSRCHIDYWHW-UHFFFAOYSA-N Xamoterol Chemical compound C=1C=C(O)C=CC=1OCC(O)CNCCNC(=O)N1CCOCC1 DXPOSRCHIDYWHW-UHFFFAOYSA-N 0.000 description 1
- IUSFTUWHKCSCDY-QTKZZPNDSA-N [(2s,3s)-5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3-dihydro-1,5-benzothiazepin-3-yl] acetate;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 IUSFTUWHKCSCDY-QTKZZPNDSA-N 0.000 description 1
- ZSYULWHBPBAOKV-TXEJJXNPSA-N [(3ar,6as)-1,3,3a,4,6,6a-hexahydrofuro[3,4-c]pyrrol-5-yl]-phenylmethanone Chemical compound C([C@H]1COC[C@H]1C1)N1C(=O)C1=CC=CC=C1 ZSYULWHBPBAOKV-TXEJJXNPSA-N 0.000 description 1
- NSOGAHPJIFTUHV-DVTLTWPTSA-N [(6s,6ar,9r,10ar)-9-hydroxy-6-methyl-3-(5-phenylpentan-2-yloxy)-5,6,6a,7,8,9,10,10a-octahydrophenanthridin-1-yl] acetate;hydrochloride Chemical compound Cl.C=1([C@@H]2C[C@H](O)CC[C@H]2[C@H](C)NC=1C=1)C(OC(C)=O)=CC=1OC(C)CCCC1=CC=CC=C1 NSOGAHPJIFTUHV-DVTLTWPTSA-N 0.000 description 1
- QNBVYCDYFJUNLO-UHDJGPCESA-N [(e)-(1-methylpyridin-2-ylidene)methyl]-oxoazanium;iodide Chemical compound [I-].CN1C=CC=C\C1=C/[NH+]=O QNBVYCDYFJUNLO-UHDJGPCESA-N 0.000 description 1
- FZSPJBYOKQPKCD-VIFPVBQESA-N [1-(4-chlorophenyl)-2-methylpropan-2-yl] (2s)-2-aminopropanoate Chemical compound C[C@H](N)C(=O)OC(C)(C)CC1=CC=C(Cl)C=C1 FZSPJBYOKQPKCD-VIFPVBQESA-N 0.000 description 1
- QJGVXJYGDBSPSJ-UHFFFAOYSA-N [1-(6,7-dimethoxyphthalazin-1-yl)piperidin-4-yl] n-ethylcarbamate Chemical compound C1CC(OC(=O)NCC)CCN1C1=NN=CC2=CC(OC)=C(OC)C=C12 QJGVXJYGDBSPSJ-UHFFFAOYSA-N 0.000 description 1
- MJDIWCQJUPYRAF-UHFFFAOYSA-N [1-[1-(dimethylamino)propan-2-yl]-2-phenylcyclohexyl] acetate;hydrochloride Chemical compound Cl.CN(C)CC(C)C1(OC(C)=O)CCCCC1C1=CC=CC=C1 MJDIWCQJUPYRAF-UHFFFAOYSA-N 0.000 description 1
- FBRAWBYQGRLCEK-UHFFFAOYSA-N [17-(2-chloroacetyl)-9-fluoro-10,13,16-trimethyl-3,11-dioxo-7,8,12,14,15,16-hexahydro-6h-cyclopenta[a]phenanthren-17-yl] butanoate Chemical compound C1CC2=CC(=O)C=CC2(C)C2(F)C1C1CC(C)C(C(=O)CCl)(OC(=O)CCC)C1(C)CC2=O FBRAWBYQGRLCEK-UHFFFAOYSA-N 0.000 description 1
- DPHFJXVKASDMBW-RQRKFSSASA-N [2-[(8s,9r,10s,11s,13s,14s,16r,17r)-9-fluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] acetate;hydrate Chemical compound O.C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COC(C)=O)(O)[C@@]1(C)C[C@@H]2O DPHFJXVKASDMBW-RQRKFSSASA-N 0.000 description 1
- MGOGSSZOPFFXLA-UHFFFAOYSA-N [4-(4-fluorophenyl)sulfonylpiperazin-1-yl]-[4-[[7-(trifluoromethyl)quinolin-4-yl]amino]phenyl]methanone;hydrochloride Chemical compound Cl.C1=CC(F)=CC=C1S(=O)(=O)N1CCN(C(=O)C=2C=CC(NC=3C4=CC=C(C=C4N=CC=3)C(F)(F)F)=CC=2)CC1 MGOGSSZOPFFXLA-UHFFFAOYSA-N 0.000 description 1
- DXHWOBBGGCYHNV-UHFFFAOYSA-N [4-[3-(dibutylamino)propoxy]phenyl]-(2-ethylindolizin-3-yl)methanone;hydron;chloride Chemical compound Cl.C1=CC(OCCCN(CCCC)CCCC)=CC=C1C(=O)C1=C(CC)C=C2N1C=CC=C2 DXHWOBBGGCYHNV-UHFFFAOYSA-N 0.000 description 1
- QTBMDDQRDDABNC-UHFFFAOYSA-N [4-dibutoxyphosphoryl-3-(dibutoxyphosphorylmethyl)butoxy]benzene Chemical compound CCCCOP(=O)(OCCCC)CC(CP(=O)(OCCCC)OCCCC)CCOC1=CC=CC=C1 QTBMDDQRDDABNC-UHFFFAOYSA-N 0.000 description 1
- QOWPUUFVFLIYRR-UHFFFAOYSA-N [6-(methylamino)-4,4-diphenylheptan-3-yl] acetate;hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(CC(C)[NH2+]C)(C(OC(C)=O)CC)C1=CC=CC=C1 QOWPUUFVFLIYRR-UHFFFAOYSA-N 0.000 description 1
- CBWUNQZJGJFJLZ-UHFFFAOYSA-N [Cl].Cl Chemical compound [Cl].Cl CBWUNQZJGJFJLZ-UHFFFAOYSA-N 0.000 description 1
- ZALMZWWJQXBYQA-UHFFFAOYSA-N [N].[Cl] Chemical compound [N].[Cl] ZALMZWWJQXBYQA-UHFFFAOYSA-N 0.000 description 1
- BQODPTQLXVVEJG-UHFFFAOYSA-N [O].C=C Chemical group [O].C=C BQODPTQLXVVEJG-UHFFFAOYSA-N 0.000 description 1
- INMBONSHXVMDSX-UHFFFAOYSA-N [amino-[(2,6-dimethylphenyl)carbamoylamino]methylidene]-methylazanium;chloride Chemical compound Cl.CN=C(N)NC(=O)NC1=C(C)C=CC=C1C INMBONSHXVMDSX-UHFFFAOYSA-N 0.000 description 1
- 230000004308 accommodation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229960003216 aceclidine Drugs 0.000 description 1
- 229960000571 acetazolamide Drugs 0.000 description 1
- WRJPSSPFHGNBMG-UHFFFAOYSA-N acetic acid 1-azabicyclo[2.2.2]octan-3-yl ester Chemical compound C1CC2C(OC(=O)C)CN1CC2 WRJPSSPFHGNBMG-UHFFFAOYSA-N 0.000 description 1
- RRNJROHIFSLGRA-JEDNCBNOSA-N acetic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.NCCCC[C@H](N)C(O)=O RRNJROHIFSLGRA-JEDNCBNOSA-N 0.000 description 1
- YBZYNINTWCLDQA-UHKVWXOHSA-N acetic acid;(2s)-2-[[(2s)-1-[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-5-(diaminomethylideneamino)-2-[[2-(methylamino)acetyl]amino]pentanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylbutanoyl]amino]-3-(1h-imidazol-5-yl)prop Chemical compound O.CC(O)=O.C([C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CNC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(O)=O)C1=CC=C(O)C=C1 YBZYNINTWCLDQA-UHKVWXOHSA-N 0.000 description 1
- TUQLBJAHRWROHB-UHFFFAOYSA-N acetic acid;1-(1h-indol-3-yl)butan-2-amine Chemical compound CC(O)=O.C1=CC=C2C(CC(N)CC)=CNC2=C1 TUQLBJAHRWROHB-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 229960001466 acetohexamide Drugs 0.000 description 1
- VGZSUPCWNCWDAN-UHFFFAOYSA-N acetohexamide Chemical compound C1=CC(C(=O)C)=CC=C1S(=O)(=O)NC(=O)NC1CCCCC1 VGZSUPCWNCWDAN-UHFFFAOYSA-N 0.000 description 1
- 229960004035 acetophenazine maleate Drugs 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- JUGOREOARAHOCO-UHFFFAOYSA-M acetylcholine chloride Chemical compound [Cl-].CC(=O)OCC[N+](C)(C)C JUGOREOARAHOCO-UHFFFAOYSA-M 0.000 description 1
- XBMIVRRWGCYBTQ-UHFFFAOYSA-N acetylmethadol Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(OC(C)=O)CC)C1=CC=CC=C1 XBMIVRRWGCYBTQ-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- QAHRRCMLXFLZTF-FYYLOGMGSA-N actisomide Chemical compound C1([C@]2(C(N=C(C)N3CCCC[C@@H]32)=O)CCN(C(C)C)C(C)C)=CC=CC=C1 QAHRRCMLXFLZTF-FYYLOGMGSA-N 0.000 description 1
- 229950010296 actisomide Drugs 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- ACLJAFRNPZVVIW-ADFGDECNSA-N actodigin Chemical compound O([C@@H]1C[C@H]2CC[C@@H]3[C@@H]([C@]2(CC1)C)CC[C@]1([C@]3(O)CC[C@@H]1C=1C(OCC=1)=O)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O ACLJAFRNPZVVIW-ADFGDECNSA-N 0.000 description 1
- 229950004735 actodigin Drugs 0.000 description 1
- YAJCHEVQCOHZDC-QMMNLEPNSA-N actrapid Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3N=CNC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@H](C)CC)[C@H](C)CC)[C@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C(N)=O)C1=CNC=N1 YAJCHEVQCOHZDC-QMMNLEPNSA-N 0.000 description 1
- 208000024716 acute asthma Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000005076 adamantyloxycarbonyl group Chemical group C12(CC3CC(CC(C1)C3)C2)OC(=O)* 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 229960004512 adiphenine Drugs 0.000 description 1
- PZMVOUYYNKPMSI-UHFFFAOYSA-N adrenalone Chemical compound CNCC(=O)C1=CC=C(O)C(O)=C1 PZMVOUYYNKPMSI-UHFFFAOYSA-N 0.000 description 1
- 229960002892 adrenalone Drugs 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229960003225 alaproclate Drugs 0.000 description 1
- 229960005142 alclofenac Drugs 0.000 description 1
- ARHWPKZXBHOEEE-UHFFFAOYSA-N alclofenac Chemical compound OC(=O)CC1=CC=C(OCC=C)C(Cl)=C1 ARHWPKZXBHOEEE-UHFFFAOYSA-N 0.000 description 1
- 229960000552 alclometasone Drugs 0.000 description 1
- FJXOGVLKCZQRDN-PHCHRAKRSA-N alclometasone Chemical compound C([C@H]1Cl)C2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O FJXOGVLKCZQRDN-PHCHRAKRSA-N 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- CPYGBGOXCJJJGC-GKLGUMFISA-L alcuronium chloride Chemical compound [Cl-].[Cl-].C/1([C@@H]23)=C\N([C@H]4\5)C6=CC=CC=C6[C@]4(CC[N@@+]4(CC=C)C\C6=C\CO)[C@@H]4C[C@@H]6C/5=C/N3C3=CC=CC=C3[C@@]22CC[N@@+]3(CC=C)C/C(=C/CO)[C@@H]\1C[C@H]32 CPYGBGOXCJJJGC-GKLGUMFISA-L 0.000 description 1
- 229960001358 alcuronium chloride Drugs 0.000 description 1
- 239000003187 aldehyde dehydrogenase inhibitor Substances 0.000 description 1
- LSWBQIAZNGURQV-WTBIUSKOSA-N algestone acetonide Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)C)[C@@]1(C)CC2 LSWBQIAZNGURQV-WTBIUSKOSA-N 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229950009255 alipamide Drugs 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 229960000880 allobarbital Drugs 0.000 description 1
- 229950003674 alonimid Drugs 0.000 description 1
- 229950002215 alpertine Drugs 0.000 description 1
- 102000004139 alpha-Amylases Human genes 0.000 description 1
- 108090000637 alpha-Amylases Proteins 0.000 description 1
- 229940024171 alpha-amylase Drugs 0.000 description 1
- JRTIDHTUMYMPRU-UHFFFAOYSA-N alpidem Chemical compound N1=C2C=CC(Cl)=CN2C(CC(=O)N(CCC)CCC)=C1C1=CC=C(Cl)C=C1 JRTIDHTUMYMPRU-UHFFFAOYSA-N 0.000 description 1
- 229950008673 alpidem Drugs 0.000 description 1
- 229960000711 alprostadil Drugs 0.000 description 1
- 229950007522 altizide Drugs 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- NSZFBGIRFCHKOE-LFZVSNMSSA-N amcinafal Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(CC)(CC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O NSZFBGIRFCHKOE-LFZVSNMSSA-N 0.000 description 1
- 229950004850 amcinafal Drugs 0.000 description 1
- 229950003408 amcinafide Drugs 0.000 description 1
- 229950010679 amesergide Drugs 0.000 description 1
- VBZDETYCYXPOAK-OVCLIPMQSA-N amfecloral Chemical compound ClC(Cl)(Cl)/C=N/C(C)CC1=CC=CC=C1 VBZDETYCYXPOAK-OVCLIPMQSA-N 0.000 description 1
- 229950002414 amfecloral Drugs 0.000 description 1
- QZNJPJDUBTYMRS-UHFFFAOYSA-M amfenac sodium hydrate Chemical compound O.[Na+].NC1=C(CC([O-])=O)C=CC=C1C(=O)C1=CC=CC=C1 QZNJPJDUBTYMRS-UHFFFAOYSA-M 0.000 description 1
- WHHHJDGNBVQNAU-UHFFFAOYSA-N amfonelic acid Chemical compound N1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC=C1CC1=CC=CC=C1 WHHHJDGNBVQNAU-UHFFFAOYSA-N 0.000 description 1
- 229950007829 amfonelic acid Drugs 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 1
- 229960003437 aminoglutethimide Drugs 0.000 description 1
- PECIYKGSSMCNHN-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=NC=N[C]21.O=C1N(C)C(=O)N(C)C2=NC=N[C]21 PECIYKGSSMCNHN-UHFFFAOYSA-N 0.000 description 1
- 229960003556 aminophylline Drugs 0.000 description 1
- SYAKTDIEAPMBAL-UHFFFAOYSA-N aminorex Chemical compound O1C(N)=NCC1C1=CC=CC=C1 SYAKTDIEAPMBAL-UHFFFAOYSA-N 0.000 description 1
- 229950002544 aminorex Drugs 0.000 description 1
- IYIKLHRQXLHMJQ-UHFFFAOYSA-N amiodarone Chemical compound CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCCN(CC)CC)C(I)=C1 IYIKLHRQXLHMJQ-UHFFFAOYSA-N 0.000 description 1
- 229960005260 amiodarone Drugs 0.000 description 1
- 229950002364 amiquinsin Drugs 0.000 description 1
- 229960000836 amitriptyline Drugs 0.000 description 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
- 229960005119 amitriptyline hydrochloride Drugs 0.000 description 1
- 229960000528 amlodipine Drugs 0.000 description 1
- ZPBWCRDSRKPIDG-UHFFFAOYSA-N amlodipine benzenesulfonate Chemical compound OS(=O)(=O)C1=CC=CC=C1.CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl ZPBWCRDSRKPIDG-UHFFFAOYSA-N 0.000 description 1
- 229960004005 amlodipine besylate Drugs 0.000 description 1
- NNAIYOXJNVGUOM-UHFFFAOYSA-N amperozide Chemical compound C1CN(C(=O)NCC)CCN1CCCC(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 NNAIYOXJNVGUOM-UHFFFAOYSA-N 0.000 description 1
- 229950000388 amperozide Drugs 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- UUINNXPPLPDRQX-UHFFFAOYSA-N ampyzine Chemical compound CN(C)C1=CN=CC=N1 UUINNXPPLPDRQX-UHFFFAOYSA-N 0.000 description 1
- 229950004525 ampyzine Drugs 0.000 description 1
- 229960002105 amrinone Drugs 0.000 description 1
- RNLQIBCLLYYYFJ-UHFFFAOYSA-N amrinone Chemical compound N1C(=O)C(N)=CC(C=2C=CN=CC=2)=C1 RNLQIBCLLYYYFJ-UHFFFAOYSA-N 0.000 description 1
- 108010005565 anaritide Proteins 0.000 description 1
- AEMFNILZOJDQLW-QAGGRKNESA-N androst-4-ene-3,17-dione Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 AEMFNILZOJDQLW-QAGGRKNESA-N 0.000 description 1
- 229960003473 androstanolone Drugs 0.000 description 1
- 229960005471 androstenedione Drugs 0.000 description 1
- AEMFNILZOJDQLW-UHFFFAOYSA-N androstenedione Natural products O=C1CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 AEMFNILZOJDQLW-UHFFFAOYSA-N 0.000 description 1
- 229960001119 angiotensinamide Drugs 0.000 description 1
- FFMONIZWAPKQCW-CGHBYZBKSA-N angiotensinamide Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(N)=O)C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1[N]C=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=C(O)C=C1 FFMONIZWAPKQCW-CGHBYZBKSA-N 0.000 description 1
- LKYQLAWMNBFNJT-UHFFFAOYSA-N anileridine Chemical compound C1CC(C(=O)OCC)(C=2C=CC=CC=2)CCN1CCC1=CC=C(N)C=C1 LKYQLAWMNBFNJT-UHFFFAOYSA-N 0.000 description 1
- 229960002512 anileridine Drugs 0.000 description 1
- ZYTHLJLPPSSDIP-UHFFFAOYSA-N anileridine dihydrochloride Chemical compound Cl.Cl.C1CC(C(=O)OCC)(C=2C=CC=CC=2)CCN1CCC1=CC=C(N)C=C1 ZYTHLJLPPSSDIP-UHFFFAOYSA-N 0.000 description 1
- 229960004812 anileridine hydrochloride Drugs 0.000 description 1
- GNCHTURXQMPGMG-UHFFFAOYSA-N anilopam Chemical compound CC1CC2=CC(OC)=CC=C2CCN1CCC1=CC=C(N)C=C1 GNCHTURXQMPGMG-UHFFFAOYSA-N 0.000 description 1
- 229950006347 anilopam Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- PHFDAOXXIZOUIX-UHFFFAOYSA-N anipamil Chemical compound C=1C=CC(OC)=CC=1C(CCCCCCCCCCCC)(C#N)CCCN(C)CCC1=CC=CC(OC)=C1 PHFDAOXXIZOUIX-UHFFFAOYSA-N 0.000 description 1
- 229950011530 anipamil Drugs 0.000 description 1
- 229960000793 aniracetam Drugs 0.000 description 1
- ZXNRTKGTQJPIJK-UHFFFAOYSA-N aniracetam Chemical compound C1=CC(OC)=CC=C1C(=O)N1C(=O)CCC1 ZXNRTKGTQJPIJK-UHFFFAOYSA-N 0.000 description 1
- 229950004699 anirolac Drugs 0.000 description 1
- HDNJXZZJFPCFHG-UHFFFAOYSA-N anitrazafen Chemical compound C1=CC(OC)=CC=C1C1=NN=C(C)N=C1C1=CC=C(OC)C=C1 HDNJXZZJFPCFHG-UHFFFAOYSA-N 0.000 description 1
- 229950002412 anitrazafen Drugs 0.000 description 1
- 230000002075 anti-alcohol Effects 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000002605 anti-dotal effect Effects 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000000883 anti-obesity agent Substances 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940125710 antiobesity agent Drugs 0.000 description 1
- VEQOALNAAJBPNY-UHFFFAOYSA-N antipyrine Chemical compound CN1C(C)=CC(=O)N1C1=CC=CC=C1 VEQOALNAAJBPNY-UHFFFAOYSA-N 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 229960004957 aprindine Drugs 0.000 description 1
- NZLBHDRPUJLHCE-UHFFFAOYSA-N aprindine Chemical compound C1C2=CC=CC=C2CC1N(CCCN(CC)CC)C1=CC=CC=C1 NZLBHDRPUJLHCE-UHFFFAOYSA-N 0.000 description 1
- 229960001622 aprindine hydrochloride Drugs 0.000 description 1
- MNHDDERDSNZCCK-UHFFFAOYSA-N aptazapine Chemical compound C1C2=CC=CC=C2N2CCN(C)CC2C2=CC=CN21 MNHDDERDSNZCCK-UHFFFAOYSA-N 0.000 description 1
- 229950011611 aptazapine Drugs 0.000 description 1
- 229960001488 arbutamine Drugs 0.000 description 1
- IIRWWTKISYTTBL-SFHVURJKSA-N arbutamine Chemical compound C([C@H](O)C=1C=C(O)C(O)=CC=1)NCCCCC1=CC=C(O)C=C1 IIRWWTKISYTTBL-SFHVURJKSA-N 0.000 description 1
- 150000004982 aromatic amines Chemical class 0.000 description 1
- 229950002343 arprinocid Drugs 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229960002430 atomoxetine Drugs 0.000 description 1
- VHGCDTVCOLNTBX-QGZVFWFLSA-N atomoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=CC=C1C VHGCDTVCOLNTBX-QGZVFWFLSA-N 0.000 description 1
- 229950003139 azabon Drugs 0.000 description 1
- CDFTVVPIMLXJRX-HNNXBMFYSA-N azaloxan Chemical compound O=C1NCCN1C1CCN(CC[C@@H]2OC3=CC=CC=C3OC2)CC1 CDFTVVPIMLXJRX-HNNXBMFYSA-N 0.000 description 1
- 229950003696 azaloxan Drugs 0.000 description 1
- XTKDAFGWCDAMPY-UHFFFAOYSA-N azaperone Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCN(C=2N=CC=CC=2)CC1 XTKDAFGWCDAMPY-UHFFFAOYSA-N 0.000 description 1
- 229950003616 azaperone Drugs 0.000 description 1
- 229960001671 azapropazone Drugs 0.000 description 1
- WOIIIUDZSOLAIW-NSHDSACASA-N azapropazone Chemical compound C1=C(C)C=C2N3C(=O)[C@H](CC=C)C(=O)N3C(N(C)C)=NC2=C1 WOIIIUDZSOLAIW-NSHDSACASA-N 0.000 description 1
- FEJCIXJKPISCJV-UHFFFAOYSA-N azepindole Chemical compound C1CCNCC2=CC3=CC=CC=C3N21 FEJCIXJKPISCJV-UHFFFAOYSA-N 0.000 description 1
- 229950008946 azepindole Drugs 0.000 description 1
- 229950001786 azimilide Drugs 0.000 description 1
- PURLIDJZFQYODX-UHFFFAOYSA-N azipramine hydrochloride Chemical compound Cl.C=1C(C2=3)=CC=CC=3CCC3=CC=CC=C3N2C=1CCN(C)CC1=CC=CC=C1 PURLIDJZFQYODX-UHFFFAOYSA-N 0.000 description 1
- DMLAVOWQYNRWNQ-UHFFFAOYSA-N azobenzene Chemical compound C1=CC=CC=C1N=NC1=CC=CC=C1 DMLAVOWQYNRWNQ-UHFFFAOYSA-N 0.000 description 1
- 229960000560 balsalazide disodium Drugs 0.000 description 1
- PARMADWNFXEEFC-UHFFFAOYSA-N bamethan sulfate Chemical compound [O-]S([O-])(=O)=O.CCCC[NH2+]CC(O)C1=CC=C(O)C=C1.CCCC[NH2+]CC(O)C1=CC=C(O)C=C1 PARMADWNFXEEFC-UHFFFAOYSA-N 0.000 description 1
- 229960004731 bamethan sulfate Drugs 0.000 description 1
- HNYOPLTXPVRDBG-UHFFFAOYSA-M barbiturate Chemical compound O=C1CC(=O)[N-]C(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-M 0.000 description 1
- 229940125717 barbiturate Drugs 0.000 description 1
- 229950003585 batelapine Drugs 0.000 description 1
- 239000001654 beetroot red Substances 0.000 description 1
- 235000012677 beetroot red Nutrition 0.000 description 1
- 229950000537 belfosdil Drugs 0.000 description 1
- 229950004294 bemitradine Drugs 0.000 description 1
- 229950005840 bemoradan Drugs 0.000 description 1
- 229950001500 bendacalol Drugs 0.000 description 1
- 229960005149 bendazac Drugs 0.000 description 1
- BYFMCKSPFYVMOU-UHFFFAOYSA-N bendazac Chemical compound C12=CC=CC=C2C(OCC(=O)O)=NN1CC1=CC=CC=C1 BYFMCKSPFYVMOU-UHFFFAOYSA-N 0.000 description 1
- 229960003515 bendroflumethiazide Drugs 0.000 description 1
- HDWIHXWEUNVBIY-UHFFFAOYSA-N bendroflumethiazidum Chemical compound C1=C(C(F)(F)F)C(S(=O)(=O)N)=CC(S(N2)(=O)=O)=C1NC2CC1=CC=CC=C1 HDWIHXWEUNVBIY-UHFFFAOYSA-N 0.000 description 1
- 229960002507 benperidol Drugs 0.000 description 1
- AIZFEOPQVZBNGH-UHFFFAOYSA-N bentazepam Chemical compound C1=2C=3CCCCC=3SC=2NC(=O)CN=C1C1=CC=CC=C1 AIZFEOPQVZBNGH-UHFFFAOYSA-N 0.000 description 1
- 229950001957 bentazepam Drugs 0.000 description 1
- CPFJLLXFNPCTDW-BWSPSPBFSA-N benzatropine mesylate Chemical compound CS([O-])(=O)=O.O([C@H]1C[C@H]2CC[C@@H](C1)[NH+]2C)C(C=1C=CC=CC=1)C1=CC=CC=C1 CPFJLLXFNPCTDW-BWSPSPBFSA-N 0.000 description 1
- ZEIRZVOXNZUBOB-UHFFFAOYSA-N benzene 2H-thiazine Chemical compound S1NC=CC=C1.C1=CC=CC=C1 ZEIRZVOXNZUBOB-UHFFFAOYSA-N 0.000 description 1
- MBUHKUFSGVDYAP-UHFFFAOYSA-N benzene;2,3-dihydroxybutanedioic acid Chemical compound C1=CC=CC=C1.OC(=O)C(O)C(O)C(O)=O MBUHKUFSGVDYAP-UHFFFAOYSA-N 0.000 description 1
- 229950003745 benzfetamine Drugs 0.000 description 1
- 229950000834 benzindopyrine Drugs 0.000 description 1
- GNRXCIONJWKSEA-UHFFFAOYSA-N benzoctamine Chemical compound C12=CC=CC=C2C2(CNC)C3=CC=CC=C3C1CC2 GNRXCIONJWKSEA-UHFFFAOYSA-N 0.000 description 1
- 229960001303 benzoctamine Drugs 0.000 description 1
- 150000001557 benzodiazepines Chemical class 0.000 description 1
- 125000003310 benzodiazepinyl group Chemical group N1N=C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- VXJABHHJLXLNMP-UHFFFAOYSA-N benzoic acid [2-methyl-2-(propylamino)propyl] ester Chemical compound CCCNC(C)(C)COC(=O)C1=CC=CC=C1 VXJABHHJLXLNMP-UHFFFAOYSA-N 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- YXKTVDFXDRQTKV-HNNXBMFYSA-N benzphetamine Chemical compound C([C@H](C)N(C)CC=1C=CC=CC=1)C1=CC=CC=C1 YXKTVDFXDRQTKV-HNNXBMFYSA-N 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 229960004156 bepridil hydrochloride Drugs 0.000 description 1
- UEECHQPWQHYEDE-UHFFFAOYSA-N bepridil hydrochloride monohydrate Chemical compound [H+].O.[Cl-].C1CCCN1C(COCC(C)C)CN(C=1C=CC=CC=1)CC1=CC=CC=C1 UEECHQPWQHYEDE-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 235000002185 betanin Nutrition 0.000 description 1
- CHDPSNLJFOQTRK-UHFFFAOYSA-N betaxolol hydrochloride Chemical compound [Cl-].C1=CC(OCC(O)C[NH2+]C(C)C)=CC=C1CCOCC1CC1 CHDPSNLJFOQTRK-UHFFFAOYSA-N 0.000 description 1
- 229960004347 betaxolol hydrochloride Drugs 0.000 description 1
- XXRMYXBSBOVVBH-UHFFFAOYSA-N bethanechol chloride Chemical compound [Cl-].C[N+](C)(C)CC(C)OC(N)=O XXRMYXBSBOVVBH-UHFFFAOYSA-N 0.000 description 1
- 229960002123 bethanechol chloride Drugs 0.000 description 1
- NIVZHWNOUVJHKV-UHFFFAOYSA-N bethanidine Chemical compound CN\C(=N/C)NCC1=CC=CC=C1 NIVZHWNOUVJHKV-UHFFFAOYSA-N 0.000 description 1
- 229940007994 bethanidine sulfate Drugs 0.000 description 1
- 229960003588 bevantolol Drugs 0.000 description 1
- HXLAFSUPPDYFEO-UHFFFAOYSA-N bevantolol Chemical compound C1=C(OC)C(OC)=CC=C1CCNCC(O)COC1=CC=CC(C)=C1 HXLAFSUPPDYFEO-UHFFFAOYSA-N 0.000 description 1
- 125000002527 bicyclic carbocyclic group Chemical group 0.000 description 1
- GTEPPJFJSNSNIH-UHFFFAOYSA-N bidisomide Chemical compound C=1C=CC=C(Cl)C=1C(CCN(C(C)C)C(C)=O)(C(N)=O)CCN1CCCCC1 GTEPPJFJSNSNIH-UHFFFAOYSA-N 0.000 description 1
- 229950001203 bidisomide Drugs 0.000 description 1
- 229950005615 binospirone Drugs 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000036983 biotransformation Effects 0.000 description 1
- YSXKPIUOCJLQIE-UHFFFAOYSA-N biperiden Chemical compound C1C(C=C2)CC2C1C(C=1C=CC=CC=1)(O)CCN1CCCCC1 YSXKPIUOCJLQIE-UHFFFAOYSA-N 0.000 description 1
- 229960003003 biperiden Drugs 0.000 description 1
- 229960000749 biperiden hydrochloride Drugs 0.000 description 1
- 229960003268 biperiden lactate Drugs 0.000 description 1
- QRZAKQDHEVVFRX-UHFFFAOYSA-N biphenyl-4-ylacetic acid Chemical compound C1=CC(CC(=O)O)=CC=C1C1=CC=CC=C1 QRZAKQDHEVVFRX-UHFFFAOYSA-N 0.000 description 1
- IEPBPSSCIZTJIF-UHFFFAOYSA-N bis(2,2,2-trichloroethyl) carbonate Chemical compound ClC(Cl)(Cl)COC(=O)OCC(Cl)(Cl)Cl IEPBPSSCIZTJIF-UHFFFAOYSA-N 0.000 description 1
- UIDLJTHRRPMIQP-UHFFFAOYSA-L bis[2-[4-(2-methylpropyl)phenyl]propanoyloxy]aluminum;hydrate Chemical compound O.C1=CC(CC(C)C)=CC=C1C(C)C(=O)O[Al]OC(=O)C(C)C1=CC=C(CC(C)C)C=C1 UIDLJTHRRPMIQP-UHFFFAOYSA-L 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 108010006025 bovine growth hormone Proteins 0.000 description 1
- LWUDDYHYYNNIQI-ZDUSSCGKSA-N bretazenil Chemical compound O=C1C2=C(Br)C=CC=C2N2C=NC(C(=O)OC(C)(C)C)=C2[C@@H]2CCCN21 LWUDDYHYYNNIQI-ZDUSSCGKSA-N 0.000 description 1
- 229950010832 bretazenil Drugs 0.000 description 1
- 229960001724 brimonidine tartrate Drugs 0.000 description 1
- WZXHSWVDAYOFPE-UHFFFAOYSA-N brofaromine Chemical compound C=1C2=CC(OC)=CC(Br)=C2OC=1C1CCNCC1 WZXHSWVDAYOFPE-UHFFFAOYSA-N 0.000 description 1
- 229950004068 brofaromine Drugs 0.000 description 1
- FNXLCIKXHOPCKH-UHFFFAOYSA-N bromamine Chemical compound BrN FNXLCIKXHOPCKH-UHFFFAOYSA-N 0.000 description 1
- 235000019835 bromelain Nutrition 0.000 description 1
- HZFGMQJYAFHESD-UHFFFAOYSA-M bromfenac sodium Chemical compound [Na+].NC1=C(CC([O-])=O)C=CC=C1C(=O)C1=CC=C(Br)C=C1 HZFGMQJYAFHESD-UHFFFAOYSA-M 0.000 description 1
- 229960002716 bromfenac sodium Drugs 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 1
- 229960002802 bromocriptine Drugs 0.000 description 1
- LHMHCLYDBQOYTO-UHFFFAOYSA-N bromofluoromethane Chemical compound FCBr LHMHCLYDBQOYTO-UHFFFAOYSA-N 0.000 description 1
- 229950011622 broperamole Drugs 0.000 description 1
- 229960003051 brotizolam Drugs 0.000 description 1
- 229950003382 bucainide Drugs 0.000 description 1
- 210000005178 buccal mucosa Anatomy 0.000 description 1
- 229940062650 buchu Drugs 0.000 description 1
- DYGLNTZLBQBOPT-UHFFFAOYSA-N bucromarone Chemical compound C1=C(C)C(OCCCN(CCCC)CCCC)=C(C)C=C1C(=O)C1=CC(=O)C2=CC=CC=C2O1 DYGLNTZLBQBOPT-UHFFFAOYSA-N 0.000 description 1
- 229950005745 bucromarone Drugs 0.000 description 1
- 229960004436 budesonide Drugs 0.000 description 1
- 238000011095 buffer preparation Methods 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 229950008162 bupicomide Drugs 0.000 description 1
- QWCRAEMEVRGPNT-UHFFFAOYSA-N buspirone Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 description 1
- 229960002495 buspirone Drugs 0.000 description 1
- 229940068366 butabarbital sodium Drugs 0.000 description 1
- UZVHFVZFNXBMQJ-UHFFFAOYSA-N butalbital Chemical compound CC(C)CC1(CC=C)C(=O)NC(=O)NC1=O UZVHFVZFNXBMQJ-UHFFFAOYSA-N 0.000 description 1
- 229960002546 butalbital Drugs 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- WAHFGTZTVZRLEY-UHFFFAOYSA-N butanedioic acid;piperidin-1-yl-[3-[[4-(2-propan-2-yloxyphenyl)piperazin-1-yl]methyl]phenyl]methanone Chemical compound OC(=O)CCC(O)=O.CC(C)OC1=CC=CC=C1N1CCN(CC=2C=C(C=CC=2)C(=O)N2CCCCC2)CC1 WAHFGTZTVZRLEY-UHFFFAOYSA-N 0.000 description 1
- DVLBYTMYSMAKHP-UHFFFAOYSA-N butaperazine Chemical compound C12=CC(C(=O)CCC)=CC=C2SC2=CC=CC=C2N1CCCN1CCN(C)CC1 DVLBYTMYSMAKHP-UHFFFAOYSA-N 0.000 description 1
- 229960000608 butaperazine Drugs 0.000 description 1
- 229950005337 buterizine Drugs 0.000 description 1
- 229950000699 butixirate Drugs 0.000 description 1
- HGBFRHCDYZJRAO-UHFFFAOYSA-N butizide Chemical compound ClC1=C(S(N)(=O)=O)C=C2S(=O)(=O)NC(CC(C)C)NC2=C1 HGBFRHCDYZJRAO-UHFFFAOYSA-N 0.000 description 1
- 229950008955 butizide Drugs 0.000 description 1
- 229950011520 butopamine Drugs 0.000 description 1
- IFKLAQQSCNILHL-QHAWAJNXSA-N butorphanol Chemical compound N1([C@@H]2CC3=CC=C(C=C3[C@@]3([C@]2(CCCC3)O)CC1)O)CC1CCC1 IFKLAQQSCNILHL-QHAWAJNXSA-N 0.000 description 1
- 229960001113 butorphanol Drugs 0.000 description 1
- GMTYREVWZXJPLF-AFHUBHILSA-N butorphanol D-tartrate Chemical compound OC(=O)[C@@H](O)[C@H](O)C(O)=O.N1([C@@H]2CC3=CC=C(C=C3[C@@]3([C@]2(CCCC3)O)CC1)O)CC1CCC1 GMTYREVWZXJPLF-AFHUBHILSA-N 0.000 description 1
- 229960001590 butorphanol tartrate Drugs 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- ZTWZVMIYIIVABD-OEMFJLHTSA-N candoxatril Chemical compound C([C@@H](COCCOC)C(=O)OC=1C=C2CCCC2=CC=1)C1(C(=O)N[C@@H]2CC[C@@H](CC2)C(O)=O)CCCC1 ZTWZVMIYIIVABD-OEMFJLHTSA-N 0.000 description 1
- 229950004548 candoxatril Drugs 0.000 description 1
- ACZWIDANLCXHBM-HRCADAONSA-N candoxatrilat Chemical compound N([C@@H]1CC[C@@H](CC1)C(O)=O)C(=O)C1(C[C@@H](COCCOC)C(O)=O)CCCC1 ACZWIDANLCXHBM-HRCADAONSA-N 0.000 description 1
- 229950001305 candoxatrilat Drugs 0.000 description 1
- 201000009322 cannabis abuse Diseases 0.000 description 1
- 201000001843 cannabis dependence Diseases 0.000 description 1
- 125000001314 canonical amino-acid group Chemical group 0.000 description 1
- UJVLDDZCTMKXJK-WNHSNXHDSA-N canrenone Chemical compound C([C@H]1[C@H]2[C@@H]([C@]3(CCC(=O)C=C3C=C2)C)CC[C@@]11C)C[C@@]11CCC(=O)O1 UJVLDDZCTMKXJK-WNHSNXHDSA-N 0.000 description 1
- 229960005057 canrenone Drugs 0.000 description 1
- 229950007443 capobenic acid Drugs 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- HLSLSXBFTXUKCY-UHFFFAOYSA-N capuride Chemical compound CCC(C)C(CC)C(=O)NC(N)=O HLSLSXBFTXUKCY-UHFFFAOYSA-N 0.000 description 1
- 229950003152 capuride Drugs 0.000 description 1
- 229960004484 carbachol Drugs 0.000 description 1
- AIXAANGOTKPUOY-UHFFFAOYSA-N carbachol Chemical compound [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 description 1
- 229940054025 carbamate anxiolytics Drugs 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 229960004105 carbasalate calcium Drugs 0.000 description 1
- 229950009114 carbazeran Drugs 0.000 description 1
- ITMSAWKLJVGBIT-UHFFFAOYSA-N carbocloral Chemical compound CCOC(=O)NC(O)C(Cl)(Cl)Cl ITMSAWKLJVGBIT-UHFFFAOYSA-N 0.000 description 1
- 229950003854 carbocloral Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 229950009852 carfenazine Drugs 0.000 description 1
- 229950004689 carfentanil Drugs 0.000 description 1
- 229960004587 carisoprodol Drugs 0.000 description 1
- OFZCIYFFPZCNJE-UHFFFAOYSA-N carisoprodol Chemical compound NC(=O)OCC(C)(CCC)COC(=O)NC(C)C OFZCIYFFPZCNJE-UHFFFAOYSA-N 0.000 description 1
- 229950004799 carmantadine Drugs 0.000 description 1
- KYCBWEZLKCTALM-UHFFFAOYSA-N caroxazone Chemical compound C1=CC=C2OC(=O)N(CC(=O)N)CC2=C1 KYCBWEZLKCTALM-UHFFFAOYSA-N 0.000 description 1
- 229950006044 caroxazone Drugs 0.000 description 1
- TVPJGGZLZLUPOB-SPIKMXEPSA-N carphenazine maleate Chemical compound OC(=O)\C=C/C(O)=O.OC(=O)\C=C/C(O)=O.C12=CC(C(=O)CC)=CC=C2SC2=CC=CC=C2N1CCCN1CCN(CCO)CC1 TVPJGGZLZLUPOB-SPIKMXEPSA-N 0.000 description 1
- IVUMCTKHWDRRMH-UHFFFAOYSA-N carprofen Chemical compound C1=CC(Cl)=C[C]2C3=CC=C(C(C(O)=O)C)C=C3N=C21 IVUMCTKHWDRRMH-UHFFFAOYSA-N 0.000 description 1
- 229960003184 carprofen Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- IQNQAOGGWGCROX-UHFFFAOYSA-N cartazolate Chemical compound CCCCNC1=C(C(=O)OCC)C=NC2=C1C=NN2CC IQNQAOGGWGCROX-UHFFFAOYSA-N 0.000 description 1
- 229950007168 cartazolate Drugs 0.000 description 1
- NPAKNKYSJIDKMW-UHFFFAOYSA-N carvedilol Chemical compound COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=NC3=CC=C[CH]C3=C12 NPAKNKYSJIDKMW-UHFFFAOYSA-N 0.000 description 1
- 229960004195 carvedilol Drugs 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 229940083181 centrally acting adntiadrenergic agent methyldopa Drugs 0.000 description 1
- 239000007766 cera flava Substances 0.000 description 1
- 229950005749 ceronapril Drugs 0.000 description 1
- YRALAIOMGQZKOW-HYAOXDFASA-N ceruletide Chemical compound C([C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)[C@@H](C)O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(OS(O)(=O)=O)C=C1 YRALAIOMGQZKOW-HYAOXDFASA-N 0.000 description 1
- 229960001706 ceruletide Drugs 0.000 description 1
- FHDKSYKZXIFRKJ-CBCFNHQSSA-N ceruletide diethylamine Chemical compound CCNCC.C([C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)[C@@H](C)O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(OS(O)(=O)=O)C=C1 FHDKSYKZXIFRKJ-CBCFNHQSSA-N 0.000 description 1
- 108700043358 ceruletide diethylamine Proteins 0.000 description 1
- 229940095561 ceruletide diethylamine Drugs 0.000 description 1
- 229960003549 cetiedil Drugs 0.000 description 1
- CKMOQBVBEGCJGW-UHFFFAOYSA-L chembl1200760 Chemical compound [Na+].[Na+].C1=C(C([O-])=O)C(O)=CC=C1N=NC1=CC=C(C(=O)NCCC([O-])=O)C=C1 CKMOQBVBEGCJGW-UHFFFAOYSA-L 0.000 description 1
- UKFDTMNJMKWWNK-UHFFFAOYSA-N chembl2104165 Chemical compound C12=CC(Cl)=CC=C2N\C(=N\CC2CC2)C[N+]([O-])=C1C1=CC=CC=C1 UKFDTMNJMKWWNK-UHFFFAOYSA-N 0.000 description 1
- MPSLGGPOYBRWKD-ZKUJQEIMSA-N chembl2107675 Chemical compound OC(=O)\C=C/C(O)=O.C1=CC=C2N3CC[C@H]4N(C(C)C)CCN(CC)[C@@H]4C3=C(C)C2=C1 MPSLGGPOYBRWKD-ZKUJQEIMSA-N 0.000 description 1
- WRNQYBXJRPAGNS-DQRAZIAOSA-N chembl2110888 Chemical compound C1CN(CCCCCC)CCN1C(=N/CC(C)C)\C1=CC=CC=C1 WRNQYBXJRPAGNS-DQRAZIAOSA-N 0.000 description 1
- PBKVEOSEPXMKDN-LZHUFOCISA-N chembl2311030 Chemical compound CS(O)(=O)=O.CS(O)(=O)=O.CS(O)(=O)=O.CS(O)(=O)=O.C1=CC([C@H]2C[C@H](CN(C)[C@@H]2C2)C(=O)N[C@]3(C(=O)N4[C@H](C(N5CCC[C@H]5[C@]4(O)O3)=O)C(C)C)C(C)C)=C3C2=CNC3=C1.C1=CC([C@H]2C[C@H](CN(C)[C@@H]2C2)C(=O)N[C@]3(C(=O)N4[C@H](C(N5CCC[C@H]5[C@]4(O)O3)=O)C(C)CC)C(C)C)=C3C2=CNC3=C1.C1=CC([C@H]2C[C@H](CN(C)[C@@H]2C2)C(=O)N[C@]3(C(=O)N4[C@H](C(N5CCC[C@H]5[C@]4(O)O3)=O)CC(C)C)C(C)C)=C3C2=CNC3=C1.C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](C(N21)=O)(NC(=O)[C@H]1CN(C)[C@H]2[C@@H](C=3C=CC=C4NC=C(C=34)C2)C1)C(C)C)C1=CC=CC=C1 PBKVEOSEPXMKDN-LZHUFOCISA-N 0.000 description 1
- WRJDCGFHAICFLO-NXVVXOECSA-N chembl75797 Chemical compound C1=C(OC)C(OC)=CC=C1CC\N=C\1N(C)CCC/1 WRJDCGFHAICFLO-NXVVXOECSA-N 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- ONAOIDNSINNZOA-UHFFFAOYSA-N chloral betaine Chemical compound OC(O)C(Cl)(Cl)Cl.C[N+](C)(C)CC([O-])=O ONAOIDNSINNZOA-UHFFFAOYSA-N 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 229960004782 chlordiazepoxide Drugs 0.000 description 1
- ANTSCNMPPGJYLG-UHFFFAOYSA-N chlordiazepoxide Chemical compound O=N=1CC(NC)=NC2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 ANTSCNMPPGJYLG-UHFFFAOYSA-N 0.000 description 1
- DMLFJMQTNDSRFU-UHFFFAOYSA-N chlordiazepoxide hydrochloride Chemical compound Cl.O=N=1CC(NC)=NC2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 DMLFJMQTNDSRFU-UHFFFAOYSA-N 0.000 description 1
- 229960004725 chlordiazepoxide hydrochloride Drugs 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- MIRLXDYNHXUKAP-UHFFFAOYSA-N chlorobenzene 1H-pyrrole Chemical compound N1C=CC=C1.ClC1=CC=CC=C1 MIRLXDYNHXUKAP-UHFFFAOYSA-N 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- 229960004878 chlorphenesin carbamate Drugs 0.000 description 1
- SKPLBLUECSEIFO-UHFFFAOYSA-N chlorphenesin carbamate Chemical compound NC(=O)OCC(O)COC1=CC=C(Cl)C=C1 SKPLBLUECSEIFO-UHFFFAOYSA-N 0.000 description 1
- 229960001761 chlorpropamide Drugs 0.000 description 1
- TZFWDZFKRBELIQ-UHFFFAOYSA-N chlorzoxazone Chemical compound ClC1=CC=C2OC(O)=NC2=C1 TZFWDZFKRBELIQ-UHFFFAOYSA-N 0.000 description 1
- 229960003633 chlorzoxazone Drugs 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960004757 cibenzoline Drugs 0.000 description 1
- VKQDZNZTPGLGFD-UHFFFAOYSA-N ciclazindol Chemical compound C12=NCCCN2C2=CC=CC=C2C1(O)C1=CC=CC(Cl)=C1 VKQDZNZTPGLGFD-UHFFFAOYSA-N 0.000 description 1
- 229950009468 ciclazindol Drugs 0.000 description 1
- 229960001932 cicletanine Drugs 0.000 description 1
- 229950002545 cicloprofen Drugs 0.000 description 1
- SGEKLKJQLHJVDK-LJQANCHMSA-N ciladopa Chemical compound C1=C(OC)C(OC)=CC=C1[C@H](O)CN1CCN(C=2C(C=CC=CC=2)=O)CC1 SGEKLKJQLHJVDK-LJQANCHMSA-N 0.000 description 1
- 229950006515 ciladopa Drugs 0.000 description 1
- 229960005025 cilazapril Drugs 0.000 description 1
- JQRZBPFGBRIWSN-YOTVLOEGSA-N cilazapril monohydrate Chemical compound O.C([C@@H](C(=O)OCC)N[C@@H]1C(N2[C@@H](CCCN2CCC1)C(O)=O)=O)CC1=CC=CC=C1 JQRZBPFGBRIWSN-YOTVLOEGSA-N 0.000 description 1
- MQILJMOEUMZBHK-FIMMUYGNSA-N cilobamine Chemical compound C1([C@]2(O)C3CCC(CC3)[C@H]2NC(C)C)=CC=C(Cl)C(Cl)=C1 MQILJMOEUMZBHK-FIMMUYGNSA-N 0.000 description 1
- 229950007728 cilobamine Drugs 0.000 description 1
- 229950010783 cinflumide Drugs 0.000 description 1
- 229960001750 cinnamedrine Drugs 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 229950005723 cinnopentazone Drugs 0.000 description 1
- 229950000031 cinperene Drugs 0.000 description 1
- 229950004582 cintramide Drugs 0.000 description 1
- KFIQKMINEHFZSM-HKUYNNGSSA-N ciprefadol Chemical compound OC1=CC=CC([C@]23[C@@H](CCCC2)CN(CC2CC2)CC3)=C1 KFIQKMINEHFZSM-HKUYNNGSSA-N 0.000 description 1
- 229950009302 ciprefadol Drugs 0.000 description 1
- 229950002649 ciprocinonide Drugs 0.000 description 1
- 229950008526 ciproximide Drugs 0.000 description 1
- UVTLONZTPXCUPU-ZNMIVQPWSA-N ciramadol Chemical compound C([C@@H]1[C@@H](N(C)C)C=2C=C(O)C=CC=2)CCC[C@H]1O UVTLONZTPXCUPU-ZNMIVQPWSA-N 0.000 description 1
- 229950007653 ciramadol Drugs 0.000 description 1
- DCSUBABJRXZOMT-IRLDBZIGSA-N cisapride Chemical compound C([C@@H]([C@@H](CC1)NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)OC)N1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-IRLDBZIGSA-N 0.000 description 1
- 229960005132 cisapride Drugs 0.000 description 1
- DCSUBABJRXZOMT-UHFFFAOYSA-N cisapride Natural products C1CC(NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)C(OC)CN1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-UHFFFAOYSA-N 0.000 description 1
- 229950005384 cliprofen Drugs 0.000 description 1
- CBGUOGMQLZIXBE-XGQKBEPLSA-N clobetasol propionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CBGUOGMQLZIXBE-XGQKBEPLSA-N 0.000 description 1
- 229960004703 clobetasol propionate Drugs 0.000 description 1
- 229960005465 clobetasone butyrate Drugs 0.000 description 1
- 229950010571 clodanolene Drugs 0.000 description 1
- 229950000802 clofilium phosphate Drugs 0.000 description 1
- JFRLWWDJCFYFSU-UHFFFAOYSA-N clomacran Chemical compound C1=C(Cl)C=C2C(CCCN(C)C)C3=CC=CC=C3NC2=C1 JFRLWWDJCFYFSU-UHFFFAOYSA-N 0.000 description 1
- 229950001885 clomacran Drugs 0.000 description 1
- 229960004414 clomethiazole Drugs 0.000 description 1
- GKIRPKYJQBWNGO-OCEACIFDSA-N clomifene Chemical compound C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(\Cl)C1=CC=CC=C1 GKIRPKYJQBWNGO-OCEACIFDSA-N 0.000 description 1
- 229960003608 clomifene Drugs 0.000 description 1
- HAHOPPGVHWVBRR-UHFFFAOYSA-N clominorex Chemical compound O1C(N)=NCC1C1=CC=C(Cl)C=C1 HAHOPPGVHWVBRR-UHFFFAOYSA-N 0.000 description 1
- 229950000352 clominorex Drugs 0.000 description 1
- 229960004606 clomipramine Drugs 0.000 description 1
- 229960001564 clomipramine hydrochloride Drugs 0.000 description 1
- DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 description 1
- 229960003120 clonazepam Drugs 0.000 description 1
- 229960002925 clonidine hydrochloride Drugs 0.000 description 1
- SUAJWTBTMNHVBZ-UHFFFAOYSA-N clonitrate Chemical compound [O-][N+](=O)OCC(CCl)O[N+]([O-])=O SUAJWTBTMNHVBZ-UHFFFAOYSA-N 0.000 description 1
- 229950004347 clonitrate Drugs 0.000 description 1
- 229950001923 clonixeril Drugs 0.000 description 1
- CLOMYZFHNHFSIQ-UHFFFAOYSA-N clonixin Chemical compound CC1=C(Cl)C=CC=C1NC1=NC=CC=C1C(O)=O CLOMYZFHNHFSIQ-UHFFFAOYSA-N 0.000 description 1
- 229960001209 clonixin Drugs 0.000 description 1
- 229960004070 clopamide Drugs 0.000 description 1
- 229960001184 clopenthixol Drugs 0.000 description 1
- JCZYXTVBWHAWLL-UHFFFAOYSA-N clopimozide Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)CCCN1CCC(N2C(NC3=CC(Cl)=CC=C32)=O)CC1 JCZYXTVBWHAWLL-UHFFFAOYSA-N 0.000 description 1
- 229950007971 clopimozide Drugs 0.000 description 1
- 229950004183 clopipazan Drugs 0.000 description 1
- SJCRQMUYEQHNTC-UHFFFAOYSA-N clopirac Chemical compound CC1=CC(CC(O)=O)=C(C)N1C1=CC=C(Cl)C=C1 SJCRQMUYEQHNTC-UHFFFAOYSA-N 0.000 description 1
- 229950009185 clopirac Drugs 0.000 description 1
- 229950004984 cloral betaine Drugs 0.000 description 1
- 229950001542 cloretate Drugs 0.000 description 1
- 229960003864 clotiapine Drugs 0.000 description 1
- 229950011341 cloticasone Drugs 0.000 description 1
- 229950009899 clotixamide Drugs 0.000 description 1
- 201000001272 cocaine abuse Diseases 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Natural products C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 1
- 229960004415 codeine phosphate Drugs 0.000 description 1
- 229960003871 codeine sulfate Drugs 0.000 description 1
- 238000009225 cognitive behavioral therapy Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 230000002079 cooperative effect Effects 0.000 description 1
- 229950008484 corbadrine Drugs 0.000 description 1
- 229960001970 corticorelin ovine Drugs 0.000 description 1
- 108700033697 corticorelin ovine Proteins 0.000 description 1
- 229950002276 cortodoxone Drugs 0.000 description 1
- ZOEFCCMDUURGSE-SQKVDDBVSA-N cosyntropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 ZOEFCCMDUURGSE-SQKVDDBVSA-N 0.000 description 1
- 229950006073 cotinine Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229950002213 cyclazocine Drugs 0.000 description 1
- VXEAYBOGHINOKW-UHFFFAOYSA-N cyclobenzaprine hydrochloride Chemical compound Cl.C1=CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 VXEAYBOGHINOKW-UHFFFAOYSA-N 0.000 description 1
- 229960000500 cyclobenzaprine hydrochloride Drugs 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- ZHPBLHYKDKSZCQ-UHFFFAOYSA-N cyclooctylmethanol Chemical compound OCC1CCCCCCC1 ZHPBLHYKDKSZCQ-UHFFFAOYSA-N 0.000 description 1
- 229960003206 cyclopenthiazide Drugs 0.000 description 1
- BOCUKUHCLICSIY-QJWLJZLASA-N cyclothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(S(N2)(=O)=O)=C1NC2C1[C@H](C=C2)C[C@H]2C1 BOCUKUHCLICSIY-QJWLJZLASA-N 0.000 description 1
- 229960003176 cyclothiazide Drugs 0.000 description 1
- 229950010040 cyprazepam Drugs 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- POZRVZJJTULAOH-LHZXLZLDSA-N danazol Chemical compound C1[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=CC2=C1C=NO2 POZRVZJJTULAOH-LHZXLZLDSA-N 0.000 description 1
- 229960000766 danazol Drugs 0.000 description 1
- 229960001987 dantrolene Drugs 0.000 description 1
- LTWQNYPDAUSXBC-CDJGKPBYSA-L dantrolene sodium hemiheptahydrate Chemical compound O.O.O.O.O.O.O.[Na+].[Na+].C1=CC([N+](=O)[O-])=CC=C1C(O1)=CC=C1\C=N\N1C(=O)[N-]C(=O)C1.C1=CC([N+](=O)[O-])=CC=C1C(O1)=CC=C1\C=N\N1C(=O)[N-]C(=O)C1 LTWQNYPDAUSXBC-CDJGKPBYSA-L 0.000 description 1
- 229960004962 dapiprazole hydrochloride Drugs 0.000 description 1
- USRHYDPUVLEVMC-FQEVSTJZSA-N dapoxetine Chemical compound C1([C@H](CCOC=2C3=CC=CC=C3C=CC=2)N(C)C)=CC=CC=C1 USRHYDPUVLEVMC-FQEVSTJZSA-N 0.000 description 1
- 229960005217 dapoxetine Drugs 0.000 description 1
- QERUYFVNIOLCHV-UHFFFAOYSA-N darodipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OCC)C1C1=CC=CC2=NON=C12 QERUYFVNIOLCHV-UHFFFAOYSA-N 0.000 description 1
- 229950009702 darodipine Drugs 0.000 description 1
- 229950010693 dazadrol Drugs 0.000 description 1
- OBATZBGFDSVCJD-UHFFFAOYSA-N de-O-acetyl-lanatoside C Natural products CC1OC(OC2CC3C(C4C(C5(CCC(C5(C)C(O)C4)C=4COC(=O)C=4)O)CC3)(C)CC2)CC(O)C1OC(OC1C)CC(O)C1OC(OC1C)CC(O)C1OC1OC(CO)C(O)C(O)C1O OBATZBGFDSVCJD-UHFFFAOYSA-N 0.000 description 1
- JWPGJSVJDAJRLW-UHFFFAOYSA-N debrisoquin Chemical compound C1=CC=C2CN(C(=N)N)CCC2=C1 JWPGJSVJDAJRLW-UHFFFAOYSA-N 0.000 description 1
- 229960004096 debrisoquine Drugs 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 1
- 239000000850 decongestant Substances 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- FBHSPRKOSMHSIF-GRMWVWQJSA-N deflazacort Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(C)=N[C@@]3(C(=O)COC(=O)C)[C@@]1(C)C[C@@H]2O FBHSPRKOSMHSIF-GRMWVWQJSA-N 0.000 description 1
- 229960001145 deflazacort Drugs 0.000 description 1
- 229960002997 dehydrocholic acid Drugs 0.000 description 1
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- YHKBUDZECQDYBR-UHFFFAOYSA-L demecarium bromide Chemical compound [Br-].[Br-].C=1C=CC([N+](C)(C)C)=CC=1OC(=O)N(C)CCCCCCCCCCN(C)C(=O)OC1=CC=CC([N+](C)(C)C)=C1 YHKBUDZECQDYBR-UHFFFAOYSA-L 0.000 description 1
- 229960003715 demecarium bromide Drugs 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- OBATZBGFDSVCJD-LALPQLPRSA-N deslanoside Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@@H]1C)O[C@H]1[C@@H](O)C[C@@H](O[C@@H]1C)O[C@H]1[C@@H](O)C[C@@H](O[C@@H]1C)O[C@@H]1C[C@@H]2[C@]([C@@H]3[C@H]([C@]4(CC[C@@H]([C@@]4(C)[C@H](O)C3)C=3COC(=O)C=3)O)CC2)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O OBATZBGFDSVCJD-LALPQLPRSA-N 0.000 description 1
- 229960001324 deslanoside Drugs 0.000 description 1
- 229960002593 desoximetasone Drugs 0.000 description 1
- VWVSBHGCDBMOOT-IIEHVVJPSA-N desoximetasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@H](C(=O)CO)[C@@]1(C)C[C@@H]2O VWVSBHGCDBMOOT-IIEHVVJPSA-N 0.000 description 1
- 229960003654 desoxycortone Drugs 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229960003657 dexamethasone acetate Drugs 0.000 description 1
- CIWBQSYVNNPZIQ-PKWREOPISA-N dexamethasone dipropionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CIWBQSYVNNPZIQ-PKWREOPISA-N 0.000 description 1
- 229950000250 dexamethasone dipropionate Drugs 0.000 description 1
- LSZSZUUPKKTESX-GOXMAUIJSA-N dexclamol hcl Chemical compound Cl.C12=CC=CC=C2CCC2=CC=CC3=C2[C@@H]1CN1CC[C@@](C(C)C)(O)C[C@@H]13 LSZSZUUPKKTESX-GOXMAUIJSA-N 0.000 description 1
- 229950005512 dexpemedolac Drugs 0.000 description 1
- 229960003461 dezocine Drugs 0.000 description 1
- VTMVHDZWSFQSQP-VBNZEHGJSA-N dezocine Chemical compound C1CCCC[C@H]2CC3=CC=C(O)C=C3[C@]1(C)[C@H]2N VTMVHDZWSFQSQP-VBNZEHGJSA-N 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 125000005265 dialkylamine group Chemical group 0.000 description 1
- 125000005131 dialkylammonium group Chemical group 0.000 description 1
- ZICQBHNGXDOVJF-UHFFFAOYSA-N diamantane Chemical compound C1C2C3CC(C4)CC2C2C4C3CC1C2 ZICQBHNGXDOVJF-UHFFFAOYSA-N 0.000 description 1
- 229960002069 diamorphine Drugs 0.000 description 1
- 125000005266 diarylamine group Chemical class 0.000 description 1
- 229960004042 diazoxide Drugs 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- ATKXDQOHNICLQW-UHFFFAOYSA-N dichloralphenazone Chemical compound OC(O)C(Cl)(Cl)Cl.OC(O)C(Cl)(Cl)Cl.CN1C(C)=CC(=O)N1C1=CC=CC=C1 ATKXDQOHNICLQW-UHFFFAOYSA-N 0.000 description 1
- 229960005422 dichloralphenazone Drugs 0.000 description 1
- 229950001803 dicirenone Drugs 0.000 description 1
- KXZOIWWTXOCYKR-UHFFFAOYSA-M diclofenac potassium Chemical compound [K+].[O-]C(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl KXZOIWWTXOCYKR-UHFFFAOYSA-M 0.000 description 1
- 229960004515 diclofenac potassium Drugs 0.000 description 1
- 229960001193 diclofenac sodium Drugs 0.000 description 1
- VMZCXIGDNRMWGI-GEEYTBSJSA-N diethyl 2-[(dimethylamino)methyl]-6-methyl-4-[2-[(e)-3-[(2-methylpropan-2-yl)oxy]-3-oxoprop-1-enyl]phenyl]-1,4-dihydropyridine-3,5-dicarboxylate;hydrochloride Chemical compound Cl.CCOC(=O)C1=C(C)NC(CN(C)C)=C(C(=O)OCC)C1C1=CC=CC=C1\C=C\C(=O)OC(C)(C)C VMZCXIGDNRMWGI-GEEYTBSJSA-N 0.000 description 1
- 229960004890 diethylpropion Drugs 0.000 description 1
- XXEPPPIWZFICOJ-UHFFFAOYSA-N diethylpropion Chemical compound CCN(CC)C(C)C(=O)C1=CC=CC=C1 XXEPPPIWZFICOJ-UHFFFAOYSA-N 0.000 description 1
- 229960005259 diethylpropion hydrochloride Drugs 0.000 description 1
- RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 1
- 229960000452 diethylstilbestrol Drugs 0.000 description 1
- UFIVBRCCIRTJTN-UHFFFAOYSA-N difenoxin Chemical compound C1CC(C(=O)O)(C=2C=CC=CC=2)CCN1CCC(C#N)(C=1C=CC=CC=1)C1=CC=CC=C1 UFIVBRCCIRTJTN-UHFFFAOYSA-N 0.000 description 1
- 229960005493 difenoxin Drugs 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 229960004875 difluprednate Drugs 0.000 description 1
- 229950007956 diftalone Drugs 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- WDJUZGPOPHTGOT-XUDUSOBPSA-N digitoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)CC5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O WDJUZGPOPHTGOT-XUDUSOBPSA-N 0.000 description 1
- 229960000648 digitoxin Drugs 0.000 description 1
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 1
- 229960005156 digoxin Drugs 0.000 description 1
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 1
- 229960002705 dihydrocodeine bitartrate Drugs 0.000 description 1
- MUCZHBLJLSDCSD-UHFFFAOYSA-N diisopropyl fluorophosphate Chemical compound CC(C)OP(F)(=O)OC(C)C MUCZHBLJLSDCSD-UHFFFAOYSA-N 0.000 description 1
- WQVZLXWQESQGIF-WJKBNZMCSA-N dilevalol hydrochloride Chemical compound Cl.C([C@@H](C)NC[C@H](O)C=1C=C(C(O)=CC=1)C(N)=O)CC1=CC=CC=C1 WQVZLXWQESQGIF-WJKBNZMCSA-N 0.000 description 1
- 229960005316 diltiazem hydrochloride Drugs 0.000 description 1
- 229960001758 diltiazem malate Drugs 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- GAVBHVRHVQMWEI-UHFFFAOYSA-N dimefadane Chemical compound C12=CC=CC=C2C(N(C)C)CC1C1=CC=CC=C1 GAVBHVRHVQMWEI-UHFFFAOYSA-N 0.000 description 1
- 229950010893 dimefadane Drugs 0.000 description 1
- 229960000809 dimefline Drugs 0.000 description 1
- ZXFQRFXLFWWKLX-UHFFFAOYSA-N dimefline Chemical compound CN(C)CC=1C(OC)=CC=C(C(C=2C)=O)C=1OC=2C1=CC=CC=C1 ZXFQRFXLFWWKLX-UHFFFAOYSA-N 0.000 description 1
- VWNWVCJGUMZDIU-UHFFFAOYSA-N dimetotiazine Chemical compound C1=C(S(=O)(=O)N(C)C)C=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 VWNWVCJGUMZDIU-UHFFFAOYSA-N 0.000 description 1
- 229960001640 dimetotiazine Drugs 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 229960005234 diphenoxylate hydrochloride Drugs 0.000 description 1
- ZKNXZJZQQIQXOD-UHFFFAOYSA-N diphenyl-(2-pyridin-4-ylcyclopropyl)methanol;hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(C=1C=CC=CC=1)(O)C1CC1C1=CC=NC=C1 ZKNXZJZQQIQXOD-UHFFFAOYSA-N 0.000 description 1
- MZNZKBJIWPGRID-UHFFFAOYSA-N diphenylphosphorylmethyl(diphenyl)phosphane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=O)CP(C=1C=CC=CC=1)C1=CC=CC=C1 MZNZKBJIWPGRID-UHFFFAOYSA-N 0.000 description 1
- OCUJLLGVOUDECM-UHFFFAOYSA-N dipivefrin Chemical compound CNCC(O)C1=CC=C(OC(=O)C(C)(C)C)C(OC(=O)C(C)(C)C)=C1 OCUJLLGVOUDECM-UHFFFAOYSA-N 0.000 description 1
- 229960000966 dipivefrine Drugs 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- 229960002768 dipyridamole Drugs 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- YKFWMDHZMQLWBO-UHFFFAOYSA-N disobutamide Chemical compound C=1C=CC=C(Cl)C=1C(CCN(C(C)C)C(C)C)(C(N)=O)CCN1CCCCC1 YKFWMDHZMQLWBO-UHFFFAOYSA-N 0.000 description 1
- 229950000781 disobutamide Drugs 0.000 description 1
- XEYBHCRIKKKOSS-UHFFFAOYSA-N disodium;azanylidyneoxidanium;iron(2+);pentacyanide Chemical compound [Na+].[Na+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].[O+]#N XEYBHCRIKKKOSS-UHFFFAOYSA-N 0.000 description 1
- 229960001066 disopyramide Drugs 0.000 description 1
- UVTNFZQICZKOEM-UHFFFAOYSA-N disopyramide Chemical compound C=1C=CC=NC=1C(C(N)=O)(CCN(C(C)C)C(C)C)C1=CC=CC=C1 UVTNFZQICZKOEM-UHFFFAOYSA-N 0.000 description 1
- 208000035548 disruptive behavior disease Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 108010083220 ditekiren Proteins 0.000 description 1
- 229950010513 ditekiren Drugs 0.000 description 1
- 229960001089 dobutamine Drugs 0.000 description 1
- 229960001654 dobutamine hydrochloride Drugs 0.000 description 1
- IXTMWRCNAAVVAI-UHFFFAOYSA-N dofetilide Chemical compound C=1C=C(NS(C)(=O)=O)C=CC=1CCN(C)CCOC1=CC=C(NS(C)(=O)=O)C=C1 IXTMWRCNAAVVAI-UHFFFAOYSA-N 0.000 description 1
- 229960002994 dofetilide Drugs 0.000 description 1
- 229950004251 dopamantine Drugs 0.000 description 1
- 229960001149 dopamine hydrochloride Drugs 0.000 description 1
- 239000000221 dopamine uptake inhibitor Substances 0.000 description 1
- 229960001857 dopexamine Drugs 0.000 description 1
- RYBJORHCUPVNMB-UHFFFAOYSA-N dopexamine Chemical compound C1=C(O)C(O)=CC=C1CCNCCCCCCNCCC1=CC=CC=C1 RYBJORHCUPVNMB-UHFFFAOYSA-N 0.000 description 1
- 229960000409 dopexamine hydrochloride Drugs 0.000 description 1
- OSRUSFPMRGDLAG-QMGYSKNISA-N dorzolamide hydrochloride Chemical compound [Cl-].CC[NH2+][C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S(N)(=O)=O)S2 OSRUSFPMRGDLAG-QMGYSKNISA-N 0.000 description 1
- 229960002506 dorzolamide hydrochloride Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229960003891 doxapram hydrochloride Drugs 0.000 description 1
- ZOMBFZRWMLIDPX-UHFFFAOYSA-N doxapram hydrochloride monohydrate Chemical compound O.[Cl-].C=1C=CC=CC=1C1(C=2C=CC=CC=2)C(=O)N(CC)CC1CC[NH+]1CCOCC1 ZOMBFZRWMLIDPX-UHFFFAOYSA-N 0.000 description 1
- 229960005426 doxepin Drugs 0.000 description 1
- ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 description 1
- 229960002861 doxepin hydrochloride Drugs 0.000 description 1
- 229950005497 doxpicomine Drugs 0.000 description 1
- UODXSCCNACAPCE-UHFFFAOYSA-N draft:flumetramide Chemical compound C1=CC(C(F)(F)F)=CC=C1C1OCC(=O)NC1 UODXSCCNACAPCE-UHFFFAOYSA-N 0.000 description 1
- 229950006157 drinidene Drugs 0.000 description 1
- 235000021271 drinking Nutrition 0.000 description 1
- 230000004590 drinking behavior Effects 0.000 description 1
- 229950009000 drobuline Drugs 0.000 description 1
- GZBONOYGBJSTHF-QLRNAMTQSA-N drocinonide Chemical compound C([C@@H]1CC2)C(=O)CC[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O GZBONOYGBJSTHF-QLRNAMTQSA-N 0.000 description 1
- 229950006082 drocinonide Drugs 0.000 description 1
- RMEDXOLNCUSCGS-UHFFFAOYSA-N droperidol Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CC=C(N2C(NC3=CC=CC=C32)=O)CC1 RMEDXOLNCUSCGS-UHFFFAOYSA-N 0.000 description 1
- 229960000394 droperidol Drugs 0.000 description 1
- HTAFVGKAHGNWQO-UHFFFAOYSA-N droprenilamine Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)CCNC(C)CC1CCCCC1 HTAFVGKAHGNWQO-UHFFFAOYSA-N 0.000 description 1
- 229950011072 droprenilamine Drugs 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000003255 drug test Methods 0.000 description 1
- 229960002496 duloxetine hydrochloride Drugs 0.000 description 1
- 229950003644 duoperone Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- ODUOJXZPIYUATO-LJQANCHMSA-N ecadotril Chemical compound C([C@H](CSC(=O)C)C(=O)NCC(=O)OCC=1C=CC=CC=1)C1=CC=CC=C1 ODUOJXZPIYUATO-LJQANCHMSA-N 0.000 description 1
- 229950001184 ecadotril Drugs 0.000 description 1
- HWXXPLRSBHPGSF-KNOXWWKRSA-N edifolone Chemical compound C([C@@H]1[C@@H]([C@]2(CC3)CCN)CC[C@]4([C@H]1CCC41OCCO1)C)C=C2CC13OCCO1 HWXXPLRSBHPGSF-KNOXWWKRSA-N 0.000 description 1
- 229950007218 edifolone Drugs 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 229950010961 enadoline Drugs 0.000 description 1
- OYFJQPXVCSSHAI-QFPUQLAESA-N enalapril maleate Chemical compound OC(=O)\C=C/C(O)=O.C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 OYFJQPXVCSSHAI-QFPUQLAESA-N 0.000 description 1
- 229960000309 enalapril maleate Drugs 0.000 description 1
- 229960002680 enalaprilat Drugs 0.000 description 1
- LZFZMUMEGBBDTC-QEJZJMRPSA-N enalaprilat (anhydrous) Chemical compound C([C@H](N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 LZFZMUMEGBBDTC-QEJZJMRPSA-N 0.000 description 1
- 108010049503 enalkiren Proteins 0.000 description 1
- 229950008153 enalkiren Drugs 0.000 description 1
- OJIIZIWOLTYOBS-UHFFFAOYSA-N encainide hydrochloride Chemical compound Cl.C1=CC(OC)=CC=C1C(=O)NC1=CC=CC=C1CCC1N(C)CCCC1 OJIIZIWOLTYOBS-UHFFFAOYSA-N 0.000 description 1
- 229960004121 encainide hydrochloride Drugs 0.000 description 1
- 229950002791 encyprate Drugs 0.000 description 1
- 229950009346 endrisone Drugs 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229950002798 enlimomab Drugs 0.000 description 1
- 229960000972 enoximone Drugs 0.000 description 1
- ZJKNESGOIKRXQY-UHFFFAOYSA-N enoximone Chemical compound C1=CC(SC)=CC=C1C(=O)C1=C(C)NC(=O)N1 ZJKNESGOIKRXQY-UHFFFAOYSA-N 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 229960004842 ephedrine sulfate Drugs 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 230000001037 epileptic effect Effects 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 229960000404 epinephryl borate Drugs 0.000 description 1
- RINBGYCKMGDWPY-UHFFFAOYSA-N epitizide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NC(CSCC(F)(F)F)NS2(=O)=O RINBGYCKMGDWPY-UHFFFAOYSA-N 0.000 description 1
- 229950010350 epitizide Drugs 0.000 description 1
- CJMJLDQKTOJACI-BGQAIRJTSA-N ergotamine d-tartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2C(C=3C=CC=C4NC=C(C=34)C2)=C1)C)C1=CC=CC=C1.C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2C(C=3C=CC=C4NC=C(C=34)C2)=C1)C)C1=CC=CC=C1 CJMJLDQKTOJACI-BGQAIRJTSA-N 0.000 description 1
- 229960005450 eritrityl tetranitrate Drugs 0.000 description 1
- SNFOERUNNSHUGP-ZXZARUISSA-N erythrityl tetranitrate Chemical compound [O-][N+](=O)OC[C@@H](O[N+]([O-])=O)[C@@H](O[N+]([O-])=O)CO[N+]([O-])=O SNFOERUNNSHUGP-ZXZARUISSA-N 0.000 description 1
- 229960002336 estazolam Drugs 0.000 description 1
- CDCHDCWJMGXXRH-UHFFFAOYSA-N estazolam Chemical compound C=1C(Cl)=CC=C(N2C=NN=C2CN=2)C=1C=2C1=CC=CC=C1 CDCHDCWJMGXXRH-UHFFFAOYSA-N 0.000 description 1
- NLLMJANWPUQQTA-SPUZQDLCSA-N estra-1,3,5(10),7-tetraene-3,17alpha-diol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@@H](CC4)O)[C@@H]4C3=CCC2=C1 NLLMJANWPUQQTA-SPUZQDLCSA-N 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 229960003399 estrone Drugs 0.000 description 1
- 229960005180 etamivan Drugs 0.000 description 1
- BQJODPIMMWWMFC-UHFFFAOYSA-N etamivan Chemical compound CCN(CC)C(=O)C1=CC=C(O)C(OC)=C1 BQJODPIMMWWMFC-UHFFFAOYSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 229960004447 ethchlorvynol Drugs 0.000 description 1
- XOYZXBWFPQSUTG-RQCPZROWSA-N ethene;ethenyl (e)-but-2-enoate;furan-2,5-dione Chemical compound C=C.O=C1OC(=O)C=C1.C\C=C\C(=O)OC=C XOYZXBWFPQSUTG-RQCPZROWSA-N 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 229960002568 ethinylestradiol Drugs 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- MUWDJVKYGSDUSH-KALLACGZSA-N ethyl (1s,2r)-2-(dimethylamino)-1-phenylcyclohex-3-ene-1-carboxylate;hydron;chloride Chemical compound Cl.C=1C=CC=CC=1[C@@]1(C(=O)OCC)CCC=C[C@H]1N(C)C MUWDJVKYGSDUSH-KALLACGZSA-N 0.000 description 1
- QSRVZCCJDKYRRF-YDALLXLXSA-N ethyl (2s)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoate;hydrochloride Chemical compound Cl.CCOC(=O)[C@@](C)(N)CC1=CC=C(O)C(O)=C1 QSRVZCCJDKYRRF-YDALLXLXSA-N 0.000 description 1
- UAXYBJSAPFTPNB-KHPPLWFESA-N ethyl (2z)-2-(3-ethyl-4-oxo-5-piperidin-1-yl-1,3-thiazolidin-2-ylidene)acetate Chemical compound O=C1N(CC)C(=C/C(=O)OCC)/SC1N1CCCCC1 UAXYBJSAPFTPNB-KHPPLWFESA-N 0.000 description 1
- GQJUGJHJUZSJLZ-UHFFFAOYSA-N ethyl 1-ethyl-4-(2-propan-2-ylidenehydrazinyl)pyrazolo[3,4-b]pyridine-5-carboxylate;hydrochloride Chemical compound Cl.CCOC(=O)C1=CN=C2N(CC)N=CC2=C1NN=C(C)C GQJUGJHJUZSJLZ-UHFFFAOYSA-N 0.000 description 1
- OBNCKNCVKJNDBV-UHFFFAOYSA-N ethyl butyrate Chemical compound CCCC(=O)OCC OBNCKNCVKJNDBV-UHFFFAOYSA-N 0.000 description 1
- ULANGSAJTINEBA-UHFFFAOYSA-N ethyl n-(3-benzoylphenyl)-n-(trifluoromethylsulfonyl)carbamate Chemical compound CCOC(=O)N(S(=O)(=O)C(F)(F)F)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 ULANGSAJTINEBA-UHFFFAOYSA-N 0.000 description 1
- YLVGWMCQIWELEA-UHFFFAOYSA-N ethyl n-[2-(dimethylamino)ethyl]-n-[3-(trifluoromethyl)phenyl]carbamate;hydrochloride Chemical compound Cl.CCOC(=O)N(CCN(C)C)C1=CC=CC(C(F)(F)F)=C1 YLVGWMCQIWELEA-UHFFFAOYSA-N 0.000 description 1
- OGXBVBBMMWSZJO-UHFFFAOYSA-N ethyl n-benzyl-n-cyclopropylcarbamate Chemical compound C1CC1N(C(=O)OCC)CC1=CC=CC=C1 OGXBVBBMMWSZJO-UHFFFAOYSA-N 0.000 description 1
- IOCHDYUJEBGIKB-UHFFFAOYSA-M ethyl-[(3-methoxyphenyl)methyl]-dimethylazanium;4-methylbenzenesulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1.CC[N+](C)(C)CC1=CC=CC(OC)=C1 IOCHDYUJEBGIKB-UHFFFAOYSA-M 0.000 description 1
- 229960001003 etilamfetamine Drugs 0.000 description 1
- YAGBSNMZQKEFCO-UHFFFAOYSA-N etilamfetamine Chemical compound CCNC(C)CC1=CC=CC=C1 YAGBSNMZQKEFCO-UHFFFAOYSA-N 0.000 description 1
- 229960005293 etodolac Drugs 0.000 description 1
- XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 1
- NPUKDXXFDDZOKR-LLVKDONJSA-N etomidate Chemical compound CCOC(=O)C1=CN=CN1[C@H](C)C1=CC=CC=C1 NPUKDXXFDDZOKR-LLVKDONJSA-N 0.000 description 1
- 229960001690 etomidate Drugs 0.000 description 1
- 229950005957 etryptamine Drugs 0.000 description 1
- 229960002217 eugenol Drugs 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 229960000192 felbinac Drugs 0.000 description 1
- 229960003580 felodipine Drugs 0.000 description 1
- SFKQVVDKFKYTNA-DZCXQCEKSA-N felypressin Chemical compound NCCCC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](N)CSSC1 SFKQVVDKFKYTNA-DZCXQCEKSA-N 0.000 description 1
- 229960001527 felypressin Drugs 0.000 description 1
- 229950003579 fenamole Drugs 0.000 description 1
- 229960001395 fenbufen Drugs 0.000 description 1
- ZPAKPRAICRBAOD-UHFFFAOYSA-N fenbufen Chemical compound C1=CC(C(=O)CCC(=O)O)=CC=C1C1=CC=CC=C1 ZPAKPRAICRBAOD-UHFFFAOYSA-N 0.000 description 1
- HPLFQKUIHGZHPH-UHFFFAOYSA-N fencibutirol Chemical compound C1CC(C(C(O)=O)CC)(O)CCC1C1=CC=CC=C1 HPLFQKUIHGZHPH-UHFFFAOYSA-N 0.000 description 1
- 229950000795 fencibutirol Drugs 0.000 description 1
- IDKAXRLETRCXKS-UHFFFAOYSA-N fenclofenac Chemical compound OC(=O)CC1=CC=CC=C1OC1=CC=C(Cl)C=C1Cl IDKAXRLETRCXKS-UHFFFAOYSA-N 0.000 description 1
- 229950006236 fenclofenac Drugs 0.000 description 1
- 229950003853 fenclonine Drugs 0.000 description 1
- 229950003537 fenclorac Drugs 0.000 description 1
- HAWWPSYXSLJRBO-UHFFFAOYSA-N fendosal Chemical compound C1=C(O)C(C(=O)O)=CC(N2C(=CC=3C4=CC=CC=C4CCC=32)C=2C=CC=CC=2)=C1 HAWWPSYXSLJRBO-UHFFFAOYSA-N 0.000 description 1
- 229950005416 fendosal Drugs 0.000 description 1
- 229960001877 fenfluramine hydrochloride Drugs 0.000 description 1
- 229950004395 fengabine Drugs 0.000 description 1
- 229950011506 fenimide Drugs 0.000 description 1
- HEXAHJRXDZDVLR-HZPDHXFCSA-N fenisorex Chemical compound C1([C@@H]2C3=CC(F)=CC=C3C[C@@H](O2)NC)=CC=CC=C1 HEXAHJRXDZDVLR-HZPDHXFCSA-N 0.000 description 1
- 229950000734 fenisorex Drugs 0.000 description 1
- 229950011062 fenmetramide Drugs 0.000 description 1
- 229950002489 fenobam Drugs 0.000 description 1
- 229960004009 fenoldopam mesylate Drugs 0.000 description 1
- 229960001419 fenoprofen Drugs 0.000 description 1
- 229960005341 fenoprofen calcium Drugs 0.000 description 1
- VHUXSAWXWSTUOD-UHFFFAOYSA-L fenoprofen calcium (anhydrous) Chemical compound [Ca+2].[O-]C(=O)C(C)C1=CC=CC(OC=2C=CC=CC=2)=C1.[O-]C(=O)C(C)C1=CC=CC(OC=2C=CC=CC=2)=C1 VHUXSAWXWSTUOD-UHFFFAOYSA-L 0.000 description 1
- 229960002428 fentanyl Drugs 0.000 description 1
- 229960004207 fentanyl citrate Drugs 0.000 description 1
- 229960002679 fentiazac Drugs 0.000 description 1
- 229950003541 fenyripol Drugs 0.000 description 1
- NELSQLPTEWCHQW-UHFFFAOYSA-N fezolamine Chemical compound N=1N(CCCN(C)C)C=C(C=2C=CC=CC=2)C=1C1=CC=CC=C1 NELSQLPTEWCHQW-UHFFFAOYSA-N 0.000 description 1
- 229950000761 fezolamine Drugs 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229960004177 filgrastim Drugs 0.000 description 1
- 210000004905 finger nail Anatomy 0.000 description 1
- XOEVKNFZUQEERE-UHFFFAOYSA-N flavoxate hydrochloride Chemical compound Cl.C1=CC=C2C(=O)C(C)=C(C=3C=CC=CC=3)OC2=C1C(=O)OCCN1CCCCC1 XOEVKNFZUQEERE-UHFFFAOYSA-N 0.000 description 1
- 229960003064 flavoxate hydrochloride Drugs 0.000 description 1
- 229960003670 flecainide acetate Drugs 0.000 description 1
- 229960003240 floctafenine Drugs 0.000 description 1
- RSXGUJLKWYUPMC-UHFFFAOYSA-N flordipine Chemical compound CC1=C(C(=O)OCC)C(C=2C(=CC=CC=2)C(F)(F)F)C(C(=O)OCC)=C(C)N1CCN1CCOCC1 RSXGUJLKWYUPMC-UHFFFAOYSA-N 0.000 description 1
- 229950009366 flordipine Drugs 0.000 description 1
- UYGONJYYUKVHDD-UHFFFAOYSA-N flosequinan Chemical compound C1=C(F)C=C2N(C)C=C(S(C)=O)C(=O)C2=C1 UYGONJYYUKVHDD-UHFFFAOYSA-N 0.000 description 1
- 229960001606 flosequinan Drugs 0.000 description 1
- BYZCJOHDXLROEC-RBWIMXSLSA-N fluazacort Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)=N[C@@]3(C(=O)COC(=O)C)[C@@]1(C)C[C@@H]2O BYZCJOHDXLROEC-RBWIMXSLSA-N 0.000 description 1
- 229950002335 fluazacort Drugs 0.000 description 1
- FXNCRITWFOVSEP-UHFFFAOYSA-N flucindole Chemical compound N1C2=C(F)C=C(F)C=C2C2=C1CCC(N(C)C)C2 FXNCRITWFOVSEP-UHFFFAOYSA-N 0.000 description 1
- 229950001600 flucindole Drugs 0.000 description 1
- 229950002723 fludorex Drugs 0.000 description 1
- SYWHXTATXSMDSB-GSLJADNHSA-N fludrocortisone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O SYWHXTATXSMDSB-GSLJADNHSA-N 0.000 description 1
- LPEPZBJOKDYZAD-UHFFFAOYSA-N flufenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 LPEPZBJOKDYZAD-UHFFFAOYSA-N 0.000 description 1
- 229960004369 flufenamic acid Drugs 0.000 description 1
- 229950007979 flufenisal Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229950006843 flumetramide Drugs 0.000 description 1
- 229950005785 flumezapine Drugs 0.000 description 1
- NMGYDYBWRZHLHR-UHFFFAOYSA-N fluminorex Chemical compound O1C(N)=NCC1C1=CC=C(C(F)(F)F)C=C1 NMGYDYBWRZHLHR-UHFFFAOYSA-N 0.000 description 1
- 229950007852 fluminorex Drugs 0.000 description 1
- OPYFPDBMMYUPME-UHFFFAOYSA-N flumizole Chemical compound C1=CC(OC)=CC=C1C1=C(C=2C=CC(OC)=CC=2)NC(C(F)(F)F)=N1 OPYFPDBMMYUPME-UHFFFAOYSA-N 0.000 description 1
- 229950005288 flumizole Drugs 0.000 description 1
- 229950002998 flumoxonide Drugs 0.000 description 1
- 229960002807 flunarizine hydrochloride Drugs 0.000 description 1
- WEGNFRKBIKYVLC-XTLNBZDDSA-N flunisolide acetate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)C)[C@@]2(C)C[C@@H]1O WEGNFRKBIKYVLC-XTLNBZDDSA-N 0.000 description 1
- 229960002200 flunitrazepam Drugs 0.000 description 1
- XWTIDFOGTCVGQB-FHIVUSPVSA-N fluocortin butyl Chemical group C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@@H](C)[C@H](C(=O)C(=O)OCCCC)[C@@]2(C)C[C@@H]1O XWTIDFOGTCVGQB-FHIVUSPVSA-N 0.000 description 1
- 229950008509 fluocortin butyl Drugs 0.000 description 1
- 229960003336 fluorocortisol acetate Drugs 0.000 description 1
- 125000003784 fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
- YRFXGQHBPBMFHW-SBTZIJSASA-N fluorometholone acetate Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@]2(F)[C@@H](O)C[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 YRFXGQHBPBMFHW-SBTZIJSASA-N 0.000 description 1
- 229960001629 fluorometholone acetate Drugs 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 229960005051 fluostigmine Drugs 0.000 description 1
- 229960000389 fluoxetine hydrochloride Drugs 0.000 description 1
- XSOUHEXVEOQRKJ-IUCAKERBSA-N fluparoxan Chemical compound O1[C@H]2CNC[C@@H]2OC2=C1C=CC=C2F XSOUHEXVEOQRKJ-IUCAKERBSA-N 0.000 description 1
- 229950006702 fluparoxan Drugs 0.000 description 1
- 229950005771 fluperamide Drugs 0.000 description 1
- VIQCGTZFEYDQMR-UHFFFAOYSA-N fluphenazine decanoate Chemical compound C1CN(CCOC(=O)CCCCCCCCC)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 VIQCGTZFEYDQMR-UHFFFAOYSA-N 0.000 description 1
- 229960001374 fluphenazine decanoate Drugs 0.000 description 1
- 229960001655 flupirtine maleate Drugs 0.000 description 1
- ZWOUXWWGKJBAHQ-UHFFFAOYSA-N fluproquazone Chemical compound N=1C(=O)N(C(C)C)C2=CC(C)=CC=C2C=1C1=CC=C(F)C=C1 ZWOUXWWGKJBAHQ-UHFFFAOYSA-N 0.000 description 1
- 229950004250 fluproquazone Drugs 0.000 description 1
- 229950007253 fluquazone Drugs 0.000 description 1
- 229950007978 fluradoline Drugs 0.000 description 1
- 229960003628 flurazepam hydrochloride Drugs 0.000 description 1
- 229950003750 fluretofen Drugs 0.000 description 1
- KGPPDNUWZNWPSI-UHFFFAOYSA-N flurotyl Chemical group FC(F)(F)COCC(F)(F)F KGPPDNUWZNWPSI-UHFFFAOYSA-N 0.000 description 1
- 229950000929 flurotyl Drugs 0.000 description 1
- RIOZXKPJYKSKJV-UHFFFAOYSA-N fluspiperone Chemical compound C1=CC(F)=CC=C1N1C2(CCN(CCCC(=O)C=3C=CC(F)=CC=3)CC2)C(=O)NC1 RIOZXKPJYKSKJV-UHFFFAOYSA-N 0.000 description 1
- 229950002809 fluspiperone Drugs 0.000 description 1
- 229960003532 fluspirilene Drugs 0.000 description 1
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 description 1
- 229960000289 fluticasone propionate Drugs 0.000 description 1
- 229950004565 flutroline Drugs 0.000 description 1
- 229960004038 fluvoxamine Drugs 0.000 description 1
- CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 description 1
- 229960002107 fluvoxamine maleate Drugs 0.000 description 1
- 229940028334 follicle stimulating hormone Drugs 0.000 description 1
- 235000019264 food flavour enhancer Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- JMYCGCXYZZHWMO-UHFFFAOYSA-N fosazepam Chemical compound N=1CC(=O)N(CP(C)(=O)C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 JMYCGCXYZZHWMO-UHFFFAOYSA-N 0.000 description 1
- 229950006306 fosazepam Drugs 0.000 description 1
- 229960001880 fosinopril sodium Drugs 0.000 description 1
- WOIWWYDXDVSWAZ-RTWAWAEBSA-N fosinoprilat Chemical compound C([C@@H](C[C@H]1C(=O)O)C2CCCCC2)N1C(=O)CP(O)(=O)CCCCC1=CC=CC=C1 WOIWWYDXDVSWAZ-RTWAWAEBSA-N 0.000 description 1
- 229960003018 fosinoprilat Drugs 0.000 description 1
- FVYRUSCZCWSFLT-UHFFFAOYSA-N fostedil Chemical compound C1=CC(CP(=O)(OCC)OCC)=CC=C1C1=NC2=CC=CC=C2S1 FVYRUSCZCWSFLT-UHFFFAOYSA-N 0.000 description 1
- 229950006562 fostedil Drugs 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 229950008156 furaprofen Drugs 0.000 description 1
- 229950006099 furobufen Drugs 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- AJDSHXKJJDQZCJ-UHFFFAOYSA-N gamfexine Chemical compound C=1C=CC=CC=1C(CCN(C)C)C1CCCCC1 AJDSHXKJJDQZCJ-UHFFFAOYSA-N 0.000 description 1
- 229950004524 gamfexine Drugs 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- KJROJWRPNPSEGV-UHFFFAOYSA-N gevotroline hydrochloride Chemical compound Cl.C1C=2C3=CC(F)=CC=C3NC=2CCN1CCCC1=CC=CN=C1 KJROJWRPNPSEGV-UHFFFAOYSA-N 0.000 description 1
- 210000004195 gingiva Anatomy 0.000 description 1
- 229950003791 glemanserin Drugs 0.000 description 1
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 1
- 229960001381 glipizide Drugs 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 229960002972 glutethimide Drugs 0.000 description 1
- UHUSDOQQWJGJQS-UHFFFAOYSA-N glycerol 1,2-dioctadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(CO)OC(=O)CCCCCCCCCCCCCCCCC UHUSDOQQWJGJQS-UHFFFAOYSA-N 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
- 229960001442 gonadorelin Drugs 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 229960004553 guanabenz Drugs 0.000 description 1
- 229960003050 guanabenz acetate Drugs 0.000 description 1
- WQVAYGCXSJMPRT-UHFFFAOYSA-N guanacline Chemical compound CC1=CCN(CCN=C(N)N)CC1 WQVAYGCXSJMPRT-UHFFFAOYSA-N 0.000 description 1
- 229950006795 guanacline Drugs 0.000 description 1
- RTEVGQJRTFFMLL-UHFFFAOYSA-N guanadrel sulfate Chemical compound OS(O)(=O)=O.O1C(CN=C(N)N)COC11CCCCC1.O1C(CN=C(N)N)COC11CCCCC1 RTEVGQJRTFFMLL-UHFFFAOYSA-N 0.000 description 1
- 229960004032 guanadrel sulfate Drugs 0.000 description 1
- VZVGEDRCVUKSEL-UHFFFAOYSA-N guancidine Chemical compound CCC(C)(C)N=C(N)NC#N VZVGEDRCVUKSEL-UHFFFAOYSA-N 0.000 description 1
- 229950007639 guancidine Drugs 0.000 description 1
- 229960000789 guanidine hydrochloride Drugs 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 229950000289 guanoctine Drugs 0.000 description 1
- 229960001016 guanoxabenz Drugs 0.000 description 1
- QKIQJNNDIWGVEH-UUILKARUSA-N guanoxabenz Chemical compound ONC(/N)=N/N=C/C1=C(Cl)C=CC=C1Cl QKIQJNNDIWGVEH-UUILKARUSA-N 0.000 description 1
- 229960002383 halcinonide Drugs 0.000 description 1
- 201000002270 hallucinogen abuse Diseases 0.000 description 1
- 201000006138 hallucinogen dependence Diseases 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 229950006397 halopemide Drugs 0.000 description 1
- 229950004611 halopredone acetate Drugs 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 230000037219 healthy weight Effects 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- WDEFPRUEZRUYNW-UHFFFAOYSA-L hexafluronium bromide Chemical compound [Br-].[Br-].C12=CC=CC=C2C2=CC=CC=C2C1[N+](C)(C)CCCCCC[N+](C)(C)C1C2=CC=CC=C2C2=CC=CC=C21 WDEFPRUEZRUYNW-UHFFFAOYSA-L 0.000 description 1
- 229950002056 hexafluronium bromide Drugs 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- KRQAMFQCSAJCRH-UHFFFAOYSA-N hexobendine Chemical compound COC1=C(OC)C(OC)=CC(C(=O)OCCCN(C)CCN(C)CCCOC(=O)C=2C=C(OC)C(OC)=C(OC)C=2)=C1 KRQAMFQCSAJCRH-UHFFFAOYSA-N 0.000 description 1
- 229960002212 hexobendine Drugs 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229960001660 histamine phosphate Drugs 0.000 description 1
- ZHIBQGJKHVBLJJ-UHFFFAOYSA-N histamine phosphate Chemical compound OP(O)(O)=O.OP(O)(O)=O.NCCC1=CNC=N1 ZHIBQGJKHVBLJJ-UHFFFAOYSA-N 0.000 description 1
- 229940084986 human chorionic gonadotropin Drugs 0.000 description 1
- 229960002474 hydralazine Drugs 0.000 description 1
- 229960005384 hydralazine hydrochloride Drugs 0.000 description 1
- ZUXNZUWOTSUBMN-UHFFFAOYSA-N hydralazine hydrochloride Chemical compound Cl.C1=CC=C2C(NN)=NN=CC2=C1 ZUXNZUWOTSUBMN-UHFFFAOYSA-N 0.000 description 1
- 229960000443 hydrochloric acid Drugs 0.000 description 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- XHILEZUETWRSHC-NRGUFEMZSA-N hydromorphone hydrochloride Chemical compound [H+].[Cl-].O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O XHILEZUETWRSHC-NRGUFEMZSA-N 0.000 description 1
- WXMXALSEIGHTOR-UHFFFAOYSA-N hydron;(2-hydroxy-2-methylpropyl) 4-(4-amino-6,7,8-trimethoxyquinazolin-2-yl)piperazine-1-carboxylate;chloride;hydrate Chemical compound O.Cl.N1=C2C(OC)=C(OC)C(OC)=CC2=C(N)N=C1N1CCN(C(=O)OCC(C)(C)O)CC1 WXMXALSEIGHTOR-UHFFFAOYSA-N 0.000 description 1
- ZUFVXZVXEJHHBN-UHFFFAOYSA-N hydron;1,2,3,4-tetrahydroacridin-9-amine;chloride Chemical compound [Cl-].C1=CC=C2C([NH3+])=C(CCCC3)C3=NC2=C1 ZUFVXZVXEJHHBN-UHFFFAOYSA-N 0.000 description 1
- MWRACNBZNVAJHE-UHFFFAOYSA-N hydron;1-(4-methylphenyl)-2-pyrrolidin-1-ylpentan-1-one;chloride Chemical compound Cl.C=1C=C(C)C=CC=1C(=O)C(CCC)N1CCCC1 MWRACNBZNVAJHE-UHFFFAOYSA-N 0.000 description 1
- DNSCECUSJKDSKP-UHFFFAOYSA-N hydron;2-(pentylamino)acetamide;chloride Chemical compound Cl.CCCCCNCC(N)=O DNSCECUSJKDSKP-UHFFFAOYSA-N 0.000 description 1
- ZIODNPFQZIHCOE-UHFFFAOYSA-N hydron;3-[2-[4-(2-methylphenyl)piperazin-1-yl]ethyl]-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyridine;chloride Chemical compound Cl.CC1=CC=CC=C1N1CCN(CCC=2N3CCCCC3=NN=2)CC1 ZIODNPFQZIHCOE-UHFFFAOYSA-N 0.000 description 1
- SXZRLCAHCIRKJU-UHFFFAOYSA-N hydron;3-[3-(4-phenylpiperazin-1-yl)propyl]-1h-quinazoline-2,4-dione;chloride Chemical compound Cl.O=C1NC2=CC=CC=C2C(=O)N1CCCN(CC1)CCN1C1=CC=CC=C1 SXZRLCAHCIRKJU-UHFFFAOYSA-N 0.000 description 1
- KTOGVIILDSYTNS-UHFFFAOYSA-N hydron;4-[1-hydroxy-2-(propan-2-ylamino)ethyl]phenol;chloride Chemical compound Cl.CC(C)NCC(O)C1=CC=C(O)C=C1 KTOGVIILDSYTNS-UHFFFAOYSA-N 0.000 description 1
- IYHQTOOPUMZKRX-UHFFFAOYSA-N hydron;5-(4-methoxyphenyl)-5-phenyl-3-[3-(4-phenylpiperidin-1-yl)propyl]imidazolidine-2,4-dione;chloride Chemical compound Cl.C1=CC(OC)=CC=C1C1(C=2C=CC=CC=2)C(=O)N(CCCN2CCC(CC2)C=2C=CC=CC=2)C(=O)N1 IYHQTOOPUMZKRX-UHFFFAOYSA-N 0.000 description 1
- CNNVSINJDJNHQK-UHFFFAOYSA-N hydron;5-methyl-1-phenyl-1,3,4,6-tetrahydro-2,5-benzoxazocine;chloride Chemical compound [Cl-].C12=CC=CC=C2C[NH+](C)CCOC1C1=CC=CC=C1 CNNVSINJDJNHQK-UHFFFAOYSA-N 0.000 description 1
- JUMYIBMBTDDLNG-OJERSXHUSA-N hydron;methyl (2r)-2-phenyl-2-[(2r)-piperidin-2-yl]acetate;chloride Chemical compound Cl.C([C@@H]1[C@H](C(=O)OC)C=2C=CC=CC=2)CCCN1 JUMYIBMBTDDLNG-OJERSXHUSA-N 0.000 description 1
- MSYBLBLAMDYKKZ-UHFFFAOYSA-N hydron;pyridine-3-carbonyl chloride;chloride Chemical compound Cl.ClC(=O)C1=CC=CN=C1 MSYBLBLAMDYKKZ-UHFFFAOYSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 229940018465 hydroxyamphetamine hydrobromide Drugs 0.000 description 1
- 229960001396 hymecromone Drugs 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 229950011445 ilonidap Drugs 0.000 description 1
- 229960003162 iloperidone Drugs 0.000 description 1
- XMXHEBAFVSFQEX-UHFFFAOYSA-N iloperidone Chemical compound COC1=CC(C(C)=O)=CC=C1OCCCN1CCC(C=2C3=CC=C(F)C=C3ON=2)CC1 XMXHEBAFVSFQEX-UHFFFAOYSA-N 0.000 description 1
- 229950000254 imazodan Drugs 0.000 description 1
- 229950008608 imiloxan Drugs 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 229960004801 imipramine Drugs 0.000 description 1
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
- XZZXIYZZBJDEEP-UHFFFAOYSA-N imipramine hydrochloride Chemical compound [Cl-].C1CC2=CC=CC=C2N(CCC[NH+](C)C)C2=CC=CC=C21 XZZXIYZZBJDEEP-UHFFFAOYSA-N 0.000 description 1
- 229960002102 imipramine hydrochloride Drugs 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 229950009607 indacrinone Drugs 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- NDDAHWYSQHTHNT-UHFFFAOYSA-N indapamide Chemical compound CC1CC2=CC=CC=C2N1NC(=O)C1=CC=C(Cl)C(S(N)(=O)=O)=C1 NDDAHWYSQHTHNT-UHFFFAOYSA-N 0.000 description 1
- 229960004569 indapamide Drugs 0.000 description 1
- UCEWGESNIULAGX-UHFFFAOYSA-N indecainide Chemical compound C1=CC=C2C(CCCNC(C)C)(C(N)=O)C3=CC=CC=C3C2=C1 UCEWGESNIULAGX-UHFFFAOYSA-N 0.000 description 1
- 229950004448 indecainide Drugs 0.000 description 1
- 229960004333 indeloxazine Drugs 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 229950009856 indolidan Drugs 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 229960004260 indomethacin sodium Drugs 0.000 description 1
- 229960002056 indoramin Drugs 0.000 description 1
- 229950008443 indoxole Drugs 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229960005436 inositol nicotinate Drugs 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 229950004152 insulin human Drugs 0.000 description 1
- 239000003407 interleukin 1 receptor blocking agent Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229950004204 intrazole Drugs 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 229960002844 iprindole Drugs 0.000 description 1
- PLIGPBGDXASWPX-UHFFFAOYSA-N iprindole Chemical compound C1CCCCCC2=C1N(CCCN(C)C)C1=CC=CC=C12 PLIGPBGDXASWPX-UHFFFAOYSA-N 0.000 description 1
- 229950003599 ipsapirone Drugs 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 229960002672 isocarboxazid Drugs 0.000 description 1
- 229960003317 isoflupredone acetate Drugs 0.000 description 1
- 229950011537 isomazole Drugs 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 description 1
- YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 description 1
- 229960003827 isosorbide mononitrate Drugs 0.000 description 1
- QFGMXJOBTNZHEL-UHFFFAOYSA-N isoxepac Chemical compound O1CC2=CC=CC=C2C(=O)C2=CC(CC(=O)O)=CC=C21 QFGMXJOBTNZHEL-UHFFFAOYSA-N 0.000 description 1
- 229950011455 isoxepac Drugs 0.000 description 1
- YYUAYBYLJSNDCX-UHFFFAOYSA-N isoxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC=1C=C(C)ON=1 YYUAYBYLJSNDCX-UHFFFAOYSA-N 0.000 description 1
- 229950002252 isoxicam Drugs 0.000 description 1
- 229960004164 isoxsuprine hydrochloride Drugs 0.000 description 1
- 230000009916 joint effect Effects 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- FPCCSQOGAWCVBH-UHFFFAOYSA-N ketanserin Chemical compound C1=CC(F)=CC=C1C(=O)C1CCN(CCN2C(C3=CC=CC=C3NC2=O)=O)CC1 FPCCSQOGAWCVBH-UHFFFAOYSA-N 0.000 description 1
- 229960005417 ketanserin Drugs 0.000 description 1
- HQBZLVPZOGIAIQ-SDDDUWNISA-N ketazocine Chemical compound N1([C@H]2[C@@H]([C@](CC1)(C)C=1C(=CC=C(O)C=1)C2=O)C)CC1CC1 HQBZLVPZOGIAIQ-SDDDUWNISA-N 0.000 description 1
- 229950007980 ketazocine Drugs 0.000 description 1
- 229950002510 ketimipramine Drugs 0.000 description 1
- PXHIRIWYXDUSMR-UHFFFAOYSA-N ketipramine Chemical compound C1C(=O)C2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 PXHIRIWYXDUSMR-UHFFFAOYSA-N 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- ORMBBVGVPWUEMQ-QKLQHJQFSA-N ketorfanol Chemical compound C([C@]12CC(=O)CC[C@H]1[C@H]1CC=3C=CC=C(C2=3)O)CN1CC1CC1 ORMBBVGVPWUEMQ-QKLQHJQFSA-N 0.000 description 1
- 229950011541 ketorfanol Drugs 0.000 description 1
- BWHLPLXXIDYSNW-UHFFFAOYSA-N ketorolac tromethamine Chemical compound OCC(N)(CO)CO.OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 BWHLPLXXIDYSNW-UHFFFAOYSA-N 0.000 description 1
- 229960004384 ketorolac tromethamine Drugs 0.000 description 1
- GKQPCPXONLDCMU-CCEZHUSRSA-N lacidipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OCC)C1C1=CC=CC=C1\C=C\C(=O)OC(C)(C)C GKQPCPXONLDCMU-CCEZHUSRSA-N 0.000 description 1
- 229960004340 lacidipine Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 description 1
- 229960000511 lactulose Drugs 0.000 description 1
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 description 1
- 229950005862 lazabemide Drugs 0.000 description 1
- 229950009632 leniquinsin Drugs 0.000 description 1
- 229960002618 lenograstim Drugs 0.000 description 1
- 229950008108 lenperone Drugs 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 229950005223 levamfetamine Drugs 0.000 description 1
- 229950000966 levdobutamine Drugs 0.000 description 1
- 229960004002 levetiracetam Drugs 0.000 description 1
- HPHUVLMMVZITSG-ZCFIWIBFSA-N levetiracetam Chemical compound CC[C@H](C(N)=O)N1CCCC1=O HPHUVLMMVZITSG-ZCFIWIBFSA-N 0.000 description 1
- FFVXQGMUHIJQAO-BFKQJKLPSA-N levonantradol Chemical compound C([C@@H](C)OC=1C=C(OC(C)=O)C=2[C@@H]3C[C@H](O)CC[C@H]3[C@H](C)NC=2C=1)CCC1=CC=CC=C1 FFVXQGMUHIJQAO-BFKQJKLPSA-N 0.000 description 1
- 229950005812 levonantradol Drugs 0.000 description 1
- RWTWIZDKEIWLKQ-IWWMGODWSA-N levorphan tartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1C2=CC=C(O)C=C2[C@]23CCN(C)[C@H]1[C@@H]2CCCC3 RWTWIZDKEIWLKQ-IWWMGODWSA-N 0.000 description 1
- 229960005157 levorphanol tartrate Drugs 0.000 description 1
- 229960003918 levothyroxine sodium Drugs 0.000 description 1
- ANMYAHDLKVNJJO-LTCKWSDVSA-M levothyroxine sodium hydrate Chemical compound O.[Na+].IC1=CC(C[C@H](N)C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 ANMYAHDLKVNJJO-LTCKWSDVSA-M 0.000 description 1
- 229960005045 lidamidine Drugs 0.000 description 1
- 229960001941 lidoflazine Drugs 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 229960004248 linopirdine Drugs 0.000 description 1
- SBXXSUDPJJJJLC-YDALLXLXSA-M liothyronine sodium Chemical compound [Na+].IC1=CC(C[C@H](N)C([O-])=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 SBXXSUDPJJJJLC-YDALLXLXSA-M 0.000 description 1
- 229960002394 lisinopril Drugs 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 229950009035 lixazinone Drugs 0.000 description 1
- ZWZIQPOLMDPIQM-UHFFFAOYSA-N lofepramine hydrochloride Chemical compound Cl.C12=CC=CC=C2CCC2=CC=CC=C2N1CCCN(C)CC(=O)C1=CC=C(Cl)C=C1 ZWZIQPOLMDPIQM-UHFFFAOYSA-N 0.000 description 1
- 229960001370 lofepramine hydrochloride Drugs 0.000 description 1
- 229960005209 lofexidine Drugs 0.000 description 1
- 229960002058 lofexidine hydrochloride Drugs 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- PGYPOBZJRVSMDS-UHFFFAOYSA-N loperamide hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N(C)C)CCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 PGYPOBZJRVSMDS-UHFFFAOYSA-N 0.000 description 1
- 229960002983 loperamide hydrochloride Drugs 0.000 description 1
- 229960004391 lorazepam Drugs 0.000 description 1
- PTEUWWFEEPASRM-UHFFFAOYSA-N lorbamate Chemical compound NC(=O)OCC(C)(CCC)COC(=O)NC1CC1 PTEUWWFEEPASRM-UHFFFAOYSA-N 0.000 description 1
- 229950007718 lorbamate Drugs 0.000 description 1
- 229950002290 lorcinadol Drugs 0.000 description 1
- 229960004033 lormetazepam Drugs 0.000 description 1
- MJRPHRMGEKCADU-JVLSTEMRSA-N lortalamine Chemical compound C12=CC(Cl)=CC=C2O[C@]23CCN(C)C[C@@H]2[C@H]1CC(=O)N3 MJRPHRMGEKCADU-JVLSTEMRSA-N 0.000 description 1
- 229950004863 lortalamine Drugs 0.000 description 1
- 229960000519 losartan potassium Drugs 0.000 description 1
- 229960001798 loteprednol Drugs 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 229960000423 loxapine Drugs 0.000 description 1
- YQZBAXDVDZTKEQ-UHFFFAOYSA-N loxapine succinate Chemical compound [H+].[H+].[O-]C(=O)CCC([O-])=O.C1CN(C)CCN1C1=NC2=CC=CC=C2OC2=CC=C(Cl)C=C12 YQZBAXDVDZTKEQ-UHFFFAOYSA-N 0.000 description 1
- ZAGRKAFMISFKIO-QMTHXVAHSA-N lysergic acid Chemical compound C1=CC(C2=C[C@H](CN([C@@H]2C2)C)C(O)=O)=C3C2=CNC3=C1 ZAGRKAFMISFKIO-QMTHXVAHSA-N 0.000 description 1
- 229960005357 lysine acetate Drugs 0.000 description 1
- 229960005337 lysine hydrochloride Drugs 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 229940072082 magnesium salicylate Drugs 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229950002900 maletamer Drugs 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 229960003577 mebeverine Drugs 0.000 description 1
- 229960004119 mebutamate Drugs 0.000 description 1
- 229960001263 mecamylamine hydrochloride Drugs 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229960003803 meclofenamic acid Drugs 0.000 description 1
- SFITWQDBYUMAPS-UHFFFAOYSA-N mecloqualone Chemical compound CC1=NC2=CC=CC=C2C(=O)N1C1=CC=CC=C1Cl SFITWQDBYUMAPS-UHFFFAOYSA-N 0.000 description 1
- 229950007403 mecloqualone Drugs 0.000 description 1
- 229950001137 meclorisone Drugs 0.000 description 1
- 229950001826 medorinone Drugs 0.000 description 1
- 229960004616 medroxyprogesterone Drugs 0.000 description 1
- FRQMUZJSZHZSGN-HBNHAYAOSA-N medroxyprogesterone Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](O)(C(C)=O)CC[C@H]21 FRQMUZJSZHZSGN-HBNHAYAOSA-N 0.000 description 1
- 229950009541 mefenidil Drugs 0.000 description 1
- 229960004952 mefenorex hydrochloride Drugs 0.000 description 1
- 229950007518 mefexamide Drugs 0.000 description 1
- 229960001786 megestrol Drugs 0.000 description 1
- JBVNBBXAMBZTMQ-CEGNMAFCSA-N megestrol Chemical compound C1=CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 JBVNBBXAMBZTMQ-CEGNMAFCSA-N 0.000 description 1
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 1
- 229960004640 memantine Drugs 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- ZWLPJYVIMWAEDC-UHFFFAOYSA-N menabitan Chemical compound C=12C(CN(CC#C)CC3)=C3C(C)(C)OC2=CC(C(C)C(C)CCCCC)=CC=1OC(=O)C(C)CCN1CCCCC1C ZWLPJYVIMWAEDC-UHFFFAOYSA-N 0.000 description 1
- 229950011107 menabitan Drugs 0.000 description 1
- 229950009531 meobentine Drugs 0.000 description 1
- RXQCGGRTAILOIN-UHFFFAOYSA-N mephentermine Chemical compound CNC(C)(C)CC1=CC=CC=C1 RXQCGGRTAILOIN-UHFFFAOYSA-N 0.000 description 1
- 229960002928 mephentermine sulfate Drugs 0.000 description 1
- 229960004815 meprobamate Drugs 0.000 description 1
- 229950007594 meprylcaine Drugs 0.000 description 1
- 229960004473 meptazinol hydrochloride Drugs 0.000 description 1
- OJGJQQNLRVNIKE-UHFFFAOYSA-N meseclazone Chemical compound O1C2=CC=C(Cl)C=C2C(=O)N2C1CC(C)O2 OJGJQQNLRVNIKE-UHFFFAOYSA-N 0.000 description 1
- 229950000701 meseclazone Drugs 0.000 description 1
- CRJHBCPQHRVYBS-UHFFFAOYSA-N mesoridazine besylate Chemical compound OS(=O)(=O)C1=CC=CC=C1.CN1CCCCC1CCN1C2=CC(S(C)=O)=CC=C2SC2=CC=CC=C21 CRJHBCPQHRVYBS-UHFFFAOYSA-N 0.000 description 1
- IMSSROKUHAOUJS-MJCUULBUSA-N mestranol Chemical compound C1C[C@]2(C)[C@@](C#C)(O)CC[C@H]2[C@@H]2CCC3=CC(OC)=CC=C3[C@H]21 IMSSROKUHAOUJS-MJCUULBUSA-N 0.000 description 1
- 229960001390 mestranol Drugs 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- DJGAAPFSPWAYTJ-UHFFFAOYSA-M metamizole sodium Chemical compound [Na+].O=C1C(N(CS([O-])(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 DJGAAPFSPWAYTJ-UHFFFAOYSA-M 0.000 description 1
- 229960000509 metaxalone Drugs 0.000 description 1
- 229960002931 methacholine chloride Drugs 0.000 description 1
- JHPHVAVFUYTVCL-UHFFFAOYSA-M methacholine chloride Chemical compound [Cl-].C[N+](C)(C)CC(C)OC(C)=O JHPHVAVFUYTVCL-UHFFFAOYSA-M 0.000 description 1
- 229960001797 methadone Drugs 0.000 description 1
- FJQXCDYVZAHXNS-UHFFFAOYSA-N methadone hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 FJQXCDYVZAHXNS-UHFFFAOYSA-N 0.000 description 1
- 229960005189 methadone hydrochloride Drugs 0.000 description 1
- TWXDDNPPQUTEOV-FVGYRXGTSA-N methamphetamine hydrochloride Chemical compound Cl.CN[C@@H](C)CC1=CC=CC=C1 TWXDDNPPQUTEOV-FVGYRXGTSA-N 0.000 description 1
- WSFSSNUMVMOOMR-BJUDXGSMSA-N methanone Chemical class O=[11CH2] WSFSSNUMVMOOMR-BJUDXGSMSA-N 0.000 description 1
- 229960002803 methaqualone Drugs 0.000 description 1
- FLOSMHQXBMRNHR-DAXSKMNVSA-N methazolamide Chemical compound CC(=O)\N=C1/SC(S(N)(=O)=O)=NN1C FLOSMHQXBMRNHR-DAXSKMNVSA-N 0.000 description 1
- 229960004083 methazolamide Drugs 0.000 description 1
- PMRYVIKBURPHAH-UHFFFAOYSA-N methimazole Chemical compound CN1C=CNC1=S PMRYVIKBURPHAH-UHFFFAOYSA-N 0.000 description 1
- 229960002330 methocarbamol Drugs 0.000 description 1
- VRQVVMDWGGWHTJ-CQSZACIVSA-N methotrimeprazine Chemical compound C1=CC=C2N(C[C@H](C)CN(C)C)C3=CC(OC)=CC=C3SC2=C1 VRQVVMDWGGWHTJ-CQSZACIVSA-N 0.000 description 1
- 229940042053 methotrimeprazine Drugs 0.000 description 1
- 229960003739 methyclothiazide Drugs 0.000 description 1
- CBKLICUQYUTWQL-XWGBWKJCSA-N methyl (3s,4r)-3-methyl-1-(2-phenylethyl)-4-(n-propanoylanilino)piperidine-4-carboxylate;oxalic acid Chemical compound OC(=O)C(O)=O.CCC(=O)N([C@]1([C@H](CN(CCC=2C=CC=CC=2)CC1)C)C(=O)OC)C1=CC=CC=C1 CBKLICUQYUTWQL-XWGBWKJCSA-N 0.000 description 1
- YDSDEBIZUNNPOB-JVVVGQRLSA-N methyl 1-(2-phenylethyl)-4-(n-propanoylanilino)piperidine-4-carboxylate Chemical compound C1CN(CCC=2C=CC=CC=2)CCC1(C(=O)O[11CH3])N(C(=O)CC)C1=CC=CC=C1 YDSDEBIZUNNPOB-JVVVGQRLSA-N 0.000 description 1
- VKQFCGNPDRICFG-UHFFFAOYSA-N methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)C)C1C1=CC=CC=C1[N+]([O-])=O VKQFCGNPDRICFG-UHFFFAOYSA-N 0.000 description 1
- KLGSBANGKXGRTA-UHFFFAOYSA-N methyl 3-amino-2-(5-methoxy-1h-indol-3-yl)propanoate;hydrochloride Chemical compound Cl.C1=C(OC)C=C2C(C(CN)C(=O)OC)=CNC2=C1 KLGSBANGKXGRTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-N methyl sulfate Chemical compound COS(O)(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-N 0.000 description 1
- 230000001035 methylating effect Effects 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229960001823 methyldopate hydrochloride Drugs 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 229960001033 methylphenidate hydrochloride Drugs 0.000 description 1
- YACKEPLHDIMKIO-UHFFFAOYSA-L methylphosphonate(2-) Chemical compound CP([O-])([O-])=O YACKEPLHDIMKIO-UHFFFAOYSA-L 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- PSCNNGGPKIBAHB-WFVOKNHCSA-N methylprednisolone 21-suleptanic acid ester Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCCCCCC(=O)N(C)CCS(O)(=O)=O)CC[C@H]21 PSCNNGGPKIBAHB-WFVOKNHCSA-N 0.000 description 1
- 229950010796 methylprednisolone suleptanate Drugs 0.000 description 1
- 229960001186 methysergide Drugs 0.000 description 1
- 229960004377 methysergide maleate Drugs 0.000 description 1
- 229950002918 metiapine Drugs 0.000 description 1
- BQIPXWYNLPYNHW-UHFFFAOYSA-N metipranolol Chemical compound CC(C)NCC(O)COC1=CC(C)=C(OC(C)=O)C(C)=C1C BQIPXWYNLPYNHW-UHFFFAOYSA-N 0.000 description 1
- 229960002704 metipranolol Drugs 0.000 description 1
- 229960001980 metirosine Drugs 0.000 description 1
- 229960002939 metizoline Drugs 0.000 description 1
- NDNKHWUXXOFHTD-UHFFFAOYSA-N metizoline Chemical compound CC=1SC2=CC=CC=C2C=1CC1=NCCN1 NDNKHWUXXOFHTD-UHFFFAOYSA-N 0.000 description 1
- FWDIKROEWJOQIQ-JMBSJVKXSA-N metkefamide Chemical compound C([C@@H](C(=O)N(C)[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](C)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 FWDIKROEWJOQIQ-JMBSJVKXSA-N 0.000 description 1
- 229950000889 metkefamide Drugs 0.000 description 1
- YBCPYHQFUMNOJG-UHFFFAOYSA-N metofoline Chemical compound C1=2C=C(OC)C(OC)=CC=2CCN(C)C1CCC1=CC=C(Cl)C=C1 YBCPYHQFUMNOJG-UHFFFAOYSA-N 0.000 description 1
- 229950009818 metofoline Drugs 0.000 description 1
- JYCITEUSLNKPHC-URNBORRASA-N metogest Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC(C)(C)[C@H](O)[C@@]1(C)CC2 JYCITEUSLNKPHC-URNBORRASA-N 0.000 description 1
- 229950011474 metogest Drugs 0.000 description 1
- AQCHWTWZEMGIFD-UHFFFAOYSA-N metolazone Chemical compound CC1NC2=CC(Cl)=C(S(N)(=O)=O)C=C2C(=O)N1C1=CC=CC=C1C AQCHWTWZEMGIFD-UHFFFAOYSA-N 0.000 description 1
- 229960002817 metolazone Drugs 0.000 description 1
- 229960002237 metoprolol Drugs 0.000 description 1
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 1
- 229950004836 metrazifone Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- VLPIATFUUWWMKC-UHFFFAOYSA-N mexiletine Chemical compound CC(N)COC1=C(C)C=CC=C1C VLPIATFUUWWMKC-UHFFFAOYSA-N 0.000 description 1
- 229960001070 mexiletine hydrochloride Drugs 0.000 description 1
- 229950006383 mexrenoate potassium Drugs 0.000 description 1
- 229960004438 mibefradil Drugs 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229950010642 midaflur Drugs 0.000 description 1
- 229950003397 milenperone Drugs 0.000 description 1
- 229950004518 milipertine Drugs 0.000 description 1
- 229960003574 milrinone Drugs 0.000 description 1
- PZRHRDRVRGEVNW-UHFFFAOYSA-N milrinone Chemical compound N1C(=O)C(C#N)=CC(C=2C=CN=CC=2)=C1C PZRHRDRVRGEVNW-UHFFFAOYSA-N 0.000 description 1
- 229950001985 mimbane Drugs 0.000 description 1
- 229960004758 minaprine Drugs 0.000 description 1
- LDMWSLGGVTVJPG-UHFFFAOYSA-N minaprine Chemical compound CC1=CC(C=2C=CC=CC=2)=NN=C1NCCN1CCOCC1 LDMWSLGGVTVJPG-UHFFFAOYSA-N 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 229940064639 minipress Drugs 0.000 description 1
- 229960003632 minoxidil Drugs 0.000 description 1
- 229960001785 mirtazapine Drugs 0.000 description 1
- RONZAEMNMFQXRA-UHFFFAOYSA-N mirtazapine Chemical compound C1C2=CC=CN=C2N2CCN(C)CC2C2=CC=CC=C21 RONZAEMNMFQXRA-UHFFFAOYSA-N 0.000 description 1
- 229950005607 mixidine Drugs 0.000 description 1
- YHXISWVBGDMDLQ-UHFFFAOYSA-N moclobemide Chemical compound C1=CC(Cl)=CC=C1C(=O)NCCN1CCOCC1 YHXISWVBGDMDLQ-UHFFFAOYSA-N 0.000 description 1
- 229960004644 moclobemide Drugs 0.000 description 1
- 229950000439 modecainide Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229950010854 mofegiline Drugs 0.000 description 1
- 229960003063 molgramostim Drugs 0.000 description 1
- 108010032806 molgramostim Proteins 0.000 description 1
- 229950005152 molinazone Drugs 0.000 description 1
- 229960004938 molindone Drugs 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 229960002608 moracizine Drugs 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- FUBVWMNBEHXPSU-UHFFFAOYSA-N moricizine Chemical compound C12=CC(NC(=O)OCC)=CC=C2SC2=CC=CC=C2N1C(=O)CCN1CCOCC1 FUBVWMNBEHXPSU-UHFFFAOYSA-N 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 229960004715 morphine sulfate Drugs 0.000 description 1
- GRVOTVYEFDAHCL-RTSZDRIGSA-N morphine sulfate pentahydrate Chemical compound O.O.O.O.O.OS(O)(=O)=O.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O GRVOTVYEFDAHCL-RTSZDRIGSA-N 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- IOZWXJXXVLARQC-KURKYZTESA-N moxazocine Chemical compound C([C@@]1(C)C2=CC(O)=CC=C2C[C@@H]2[C@H]1OC)CN2CC1CC1 IOZWXJXXVLARQC-KURKYZTESA-N 0.000 description 1
- 229950005103 moxazocine Drugs 0.000 description 1
- 102000051367 mu Opioid Receptors Human genes 0.000 description 1
- RLWRMIYXDPXIEX-UHFFFAOYSA-N muzolimine Chemical compound C=1C=C(Cl)C(Cl)=CC=1C(C)N1N=C(N)CC1=O RLWRMIYXDPXIEX-UHFFFAOYSA-N 0.000 description 1
- 229960001788 muzolimine Drugs 0.000 description 1
- MFZCIDXOLLEMOO-GYSGTQPESA-N myo-inositol hexanicotinate Chemical compound O([C@H]1[C@@H]([C@H]([C@@H](OC(=O)C=2C=NC=CC=2)[C@@H](OC(=O)C=2C=NC=CC=2)[C@@H]1OC(=O)C=1C=NC=CC=1)OC(=O)C=1C=NC=CC=1)OC(=O)C=1C=NC=CC=1)C(=O)C1=CC=CN=C1 MFZCIDXOLLEMOO-GYSGTQPESA-N 0.000 description 1
- WEDBCIMSKMMRAG-UHFFFAOYSA-N n,n'-dimethyl-2-naphthalen-2-ylethanimidamide;hydrochloride Chemical compound [Cl-].C1=CC=CC2=CC(CC([NH2+]C)=NC)=CC=C21 WEDBCIMSKMMRAG-UHFFFAOYSA-N 0.000 description 1
- FUSALJQLPCXPMH-UHFFFAOYSA-N n,n,2-trimethyl-3,4-dihydro-2h-chromen-3-amine;hydrochloride Chemical compound Cl.C1=CC=C2CC(N(C)C)C(C)OC2=C1 FUSALJQLPCXPMH-UHFFFAOYSA-N 0.000 description 1
- OMMBWIJMWMSGBX-UHFFFAOYSA-N n,n-diethyl-2-(5-imino-3-phenyl-1,2,4-oxadiazol-4-yl)ethanamine;hydrochloride Chemical compound [Cl-].O1C(=N)N(CC[NH+](CC)CC)C(C=2C=CC=CC=2)=N1 OMMBWIJMWMSGBX-UHFFFAOYSA-N 0.000 description 1
- WZXJEMXDECWINY-UHFFFAOYSA-N n,n-dimethyl-2,3,4,9-tetrahydro-1h-carbazol-3-amine Chemical compound N1C2=CC=CC=C2C2=C1CCC(N(C)C)C2 WZXJEMXDECWINY-UHFFFAOYSA-N 0.000 description 1
- OZWMTVPSSFWHIM-UHFFFAOYSA-N n,n-dimethyl-2-(1-methyl-4,9-dihydro-3h-indeno[2,1-c]pyran-1-yl)ethanamine;hydrochloride Chemical compound Cl.C1C2=CC=CC=C2C2=C1C(CCN(C)C)(C)OCC2 OZWMTVPSSFWHIM-UHFFFAOYSA-N 0.000 description 1
- ZTCKJGNZNKVHOJ-UHFFFAOYSA-N n,n-dimethyl-2-(1-phenylinden-1-yl)ethanamine;hydrochloride Chemical compound Cl.C1=CC2=CC=CC=C2C1(CCN(C)C)C1=CC=CC=C1 ZTCKJGNZNKVHOJ-UHFFFAOYSA-N 0.000 description 1
- WRHGGQFJPWBBTG-UHFFFAOYSA-N n,n-dimethyl-3-(6-phenylpyrido[2,3-b][1,4]benzodiazepin-11-yl)propan-1-amine Chemical compound N=1C2=CC=CN=C2N(CCCN(C)C)C2=CC=CC=C2C=1C1=CC=CC=C1 WRHGGQFJPWBBTG-UHFFFAOYSA-N 0.000 description 1
- JFTURWWGPMTABQ-UHFFFAOYSA-N n,n-dimethyl-3-naphthalen-1-yloxy-3-thiophen-2-ylpropan-1-amine Chemical compound C=1C=CC2=CC=CC=C2C=1OC(CCN(C)C)C1=CC=CS1 JFTURWWGPMTABQ-UHFFFAOYSA-N 0.000 description 1
- JZXRLKWWVNUZRB-UHFFFAOYSA-N n-(2-aminoethyl)-5-chloropyridine-2-carboxamide Chemical compound NCCNC(=O)C1=CC=C(Cl)C=N1 JZXRLKWWVNUZRB-UHFFFAOYSA-N 0.000 description 1
- IUZMSSDQGOBJTG-UHFFFAOYSA-N n-(2-fluorophenyl)-2-methoxy-n-[1-(2-phenylethyl)piperidin-4-yl]acetamide;hydrochloride Chemical compound Cl.C=1C=CC=C(F)C=1N(C(=O)COC)C(CC1)CCN1CCC1=CC=CC=C1 IUZMSSDQGOBJTG-UHFFFAOYSA-N 0.000 description 1
- IDHNGYVCZUQHFV-UHFFFAOYSA-N n-(3-chloropropyl)-1-phenylpropan-2-amine;hydron;chloride Chemical compound Cl.ClCCCNC(C)CC1=CC=CC=C1 IDHNGYVCZUQHFV-UHFFFAOYSA-N 0.000 description 1
- HWCORKBTTGTRDY-UHFFFAOYSA-N n-(4-chlorophenyl)-1,3-dioxo-4h-isoquinoline-4-carboxamide Chemical compound C1=CC(Cl)=CC=C1NC(=O)C1C2=CC=CC=C2C(=O)NC1=O HWCORKBTTGTRDY-UHFFFAOYSA-N 0.000 description 1
- FSFSWNBDCJVFGI-UHFFFAOYSA-N n-(4-chlorophenyl)-2-phenyl-n-(1-propan-2-ylpiperidin-4-yl)acetamide;hydron;chloride Chemical compound [Cl-].C1C[NH+](C(C)C)CCC1N(C=1C=CC(Cl)=CC=1)C(=O)CC1=CC=CC=C1 FSFSWNBDCJVFGI-UHFFFAOYSA-N 0.000 description 1
- VHXNDLUDRKRBCQ-KPVRICSOSA-N n-[(3s,4r)-1-[2-(4-ethyl-5-oxotetrazol-1-yl)ethyl]-3-methylpiperidin-4-yl]-n-(2-fluorophenyl)-2-methoxyacetamide;hydrochloride Chemical compound Cl.O=C1N(CC)N=NN1CCN1C[C@H](C)[C@H](N(C(=O)COC)C=2C(=CC=CC=2)F)CC1 VHXNDLUDRKRBCQ-KPVRICSOSA-N 0.000 description 1
- KVCOVXMNIYUKBS-UHFFFAOYSA-N n-[1-(2-phenylethyl)piperidin-4-yl]-n-pyrazin-2-ylfuran-2-carboxamide;hydrochloride Chemical compound Cl.C=1C=COC=1C(=O)N(C=1N=CC=NC=1)C(CC1)CCN1CCC1=CC=CC=C1 KVCOVXMNIYUKBS-UHFFFAOYSA-N 0.000 description 1
- YMRJQYDWCFOMRR-UHFFFAOYSA-N n-[1-[2-(4-ethyl-5-oxotetrazol-1-yl)ethyl]-4-phenylpiperidin-4-yl]-n-(2-fluorophenyl)propanamide;hydrochloride Chemical compound Cl.C1CN(CCN2C(N(CC)N=N2)=O)CCC1(C=1C=CC=CC=1)N(C(=O)CC)C1=CC=CC=C1F YMRJQYDWCFOMRR-UHFFFAOYSA-N 0.000 description 1
- ZWKFENYDXISLGK-UHFFFAOYSA-N n-[2-(3,4-dihydroxyphenyl)ethyl]adamantane-1-carboxamide Chemical compound C1=C(O)C(O)=CC=C1CCNC(=O)C1(C2)CC(C3)CC2CC3C1 ZWKFENYDXISLGK-UHFFFAOYSA-N 0.000 description 1
- NLRFFZRHTICQBO-UHFFFAOYSA-N n-[2-(diethylamino)-2-oxoethyl]-3,4,5-trimethoxybenzamide Chemical compound CCN(CC)C(=O)CNC(=O)C1=CC(OC)=C(OC)C(OC)=C1 NLRFFZRHTICQBO-UHFFFAOYSA-N 0.000 description 1
- NBHPRWLFLUBAIE-UHFFFAOYSA-N n-[2-[4-(5-chloro-2-oxo-3h-benzimidazol-1-yl)piperidin-1-yl]ethyl]-4-fluorobenzamide Chemical compound C1=CC(F)=CC=C1C(=O)NCCN1CCC(N2C(NC3=CC(Cl)=CC=C32)=O)CC1 NBHPRWLFLUBAIE-UHFFFAOYSA-N 0.000 description 1
- TXPUBJSOHAMNEI-BETUJISGSA-N n-[3-[(2s,6r)-2,6-dimethylpiperidin-1-yl]oxadiazol-3-ium-5-yl]-4-methoxybenzenecarboximidate Chemical compound C1=CC(OC)=CC=C1C(\[O-])=N\C1=C[N+](N2[C@@H](CCC[C@@H]2C)C)=NO1 TXPUBJSOHAMNEI-BETUJISGSA-N 0.000 description 1
- INSXAGGBFMXUIH-UHFFFAOYSA-N n-[3-[1-hydroxy-2-(methylamino)ethyl]phenyl]methanesulfonamide;methanesulfonic acid Chemical compound CS(O)(=O)=O.CNCC(O)C1=CC=CC(NS(C)(=O)=O)=C1 INSXAGGBFMXUIH-UHFFFAOYSA-N 0.000 description 1
- DTOKETCXTCHCDD-UHFFFAOYSA-N n-[4-(2,6-dimethylpiperidin-1-yl)butyl]-2-phenoxy-2-phenylacetamide Chemical compound CC1CCCC(C)N1CCCCNC(=O)C(C=1C=CC=CC=1)OC1=CC=CC=C1 DTOKETCXTCHCDD-UHFFFAOYSA-N 0.000 description 1
- HPZHFGBKCGWNGN-UHFFFAOYSA-N n-benzyl-2-methyl-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C=12C=CNC2=NC(C)=NC=1NCC1=CC=CC=C1 HPZHFGBKCGWNGN-UHFFFAOYSA-N 0.000 description 1
- WUECXCBONAGRSA-UHFFFAOYSA-N n-cyclohexyl-n-methyl-4-[(2-oxo-5,10-dihydro-3h-imidazo[2,1-b]quinazolin-7-yl)oxy]butanamide Chemical compound C=1C=C2NC3=NC(=O)CN3CC2=CC=1OCCCC(=O)N(C)C1CCCCC1 WUECXCBONAGRSA-UHFFFAOYSA-N 0.000 description 1
- IXIZLCOBHRPNNI-UHFFFAOYSA-N n-methyl-1-(3,4,5-trimethoxyphenyl)pent-4-en-2-amine;hydrochloride Chemical compound Cl.C=CCC(NC)CC1=CC(OC)=C(OC)C(OC)=C1 IXIZLCOBHRPNNI-UHFFFAOYSA-N 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- ZDFVWDHZXAGROF-UHFFFAOYSA-N n-propyl-n-pyridin-4-ylindol-1-amine;hydrochloride Chemical compound Cl.C1=CC2=CC=CC=C2N1N(CCC)C1=CC=NC=C1 ZDFVWDHZXAGROF-UHFFFAOYSA-N 0.000 description 1
- MCVPMHDADNVRKF-UHFFFAOYSA-N nabitan Chemical compound C=12C(CN(CC#C)CC3)=C3C(C)(C)OC2=CC(C(C)C(C)CCCCC)=CC=1OC(=O)CCCN1CCCCC1 MCVPMHDADNVRKF-UHFFFAOYSA-N 0.000 description 1
- 229950011562 nabitan Drugs 0.000 description 1
- UDQAWRWPAGUCRX-UHFFFAOYSA-N naboctate Chemical compound CC1(C)OC2=CC(C(C)CCCCCCC)=CC(OC(=O)CCCN(CC)CC)=C2C2=C1CCC(C)C2 UDQAWRWPAGUCRX-UHFFFAOYSA-N 0.000 description 1
- 229950007795 naboctate Drugs 0.000 description 1
- 229960004270 nabumetone Drugs 0.000 description 1
- 229950005486 naflocort Drugs 0.000 description 1
- 229940052683 nafronyloxalate Drugs 0.000 description 1
- 229950008948 namoxyrate Drugs 0.000 description 1
- 229960005016 naphazoline Drugs 0.000 description 1
- 229960004760 naphazoline hydrochloride Drugs 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- IBSSDTOGUGCBDB-UHFFFAOYSA-N naranol hcl Chemical compound Cl.C1=CC2=CC=CC=C2C2=C1OC1(O)C(C)CN(C)CC1C2 IBSSDTOGUGCBDB-UHFFFAOYSA-N 0.000 description 1
- 229960001851 narasin Drugs 0.000 description 1
- 239000003887 narcotic antagonist Substances 0.000 description 1
- 230000003533 narcotic effect Effects 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- NNEACMQMRLNNIL-CTHHTMFSSA-N naxagolide hydrochloride Chemical compound Cl.C1=C(O)C=C2[C@H]3OCCN(CCC)[C@@H]3CCC2=C1 NNEACMQMRLNNIL-CTHHTMFSSA-N 0.000 description 1
- 229960000619 nebivolol Drugs 0.000 description 1
- 229960001800 nefazodone Drugs 0.000 description 1
- VRBKIVRKKCLPHA-UHFFFAOYSA-N nefazodone Chemical compound O=C1N(CCOC=2C=CC=CC=2)C(CC)=NN1CCCN(CC1)CCN1C1=CC=CC(Cl)=C1 VRBKIVRKKCLPHA-UHFFFAOYSA-N 0.000 description 1
- DYCKFEBIOUQECE-UHFFFAOYSA-N nefazodone hydrochloride Chemical compound [H+].[Cl-].O=C1N(CCOC=2C=CC=CC=2)C(CC)=NN1CCCN(CC1)CCN1C1=CC=CC(Cl)=C1 DYCKFEBIOUQECE-UHFFFAOYSA-N 0.000 description 1
- 229960002441 nefazodone hydrochloride Drugs 0.000 description 1
- 229950009045 neflumozide Drugs 0.000 description 1
- 229960004925 nefopam hydrochloride Drugs 0.000 description 1
- PUUSSSIBPPTKTP-UHFFFAOYSA-N neridronic acid Chemical compound NCCCCCC(O)(P(O)(O)=O)P(O)(O)=O PUUSSSIBPPTKTP-UHFFFAOYSA-N 0.000 description 1
- 229950010733 neridronic acid Drugs 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229960003642 nicergoline Drugs 0.000 description 1
- 229960002497 nicorandil Drugs 0.000 description 1
- LBHIOVVIQHSOQN-UHFFFAOYSA-N nicorandil Chemical compound [O-][N+](=O)OCCNC(=O)C1=CC=CN=C1 LBHIOVVIQHSOQN-UHFFFAOYSA-N 0.000 description 1
- 229960004738 nicotinyl alcohol Drugs 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- 229950006046 nimazone Drugs 0.000 description 1
- 229960000715 nimodipine Drugs 0.000 description 1
- ITJNARMNRKSWTA-UHFFFAOYSA-N nisoxetine Chemical compound C=1C=CC=CC=1C(CCNC)OC1=CC=CC=C1OC ITJNARMNRKSWTA-UHFFFAOYSA-N 0.000 description 1
- 229950004211 nisoxetine Drugs 0.000 description 1
- 229950002230 nitrafudam Drugs 0.000 description 1
- 229960005425 nitrendipine Drugs 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229960002498 nomifensine maleate Drugs 0.000 description 1
- 239000002664 nootropic agent Substances 0.000 description 1
- 230000002474 noradrenergic effect Effects 0.000 description 1
- 229940053934 norethindrone Drugs 0.000 description 1
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 1
- 229960001858 norethynodrel Drugs 0.000 description 1
- 229960001158 nortriptyline Drugs 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 229950009597 nufenoxole Drugs 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 229960001136 obidoxime chloride Drugs 0.000 description 1
- 229950010634 ocaperidone Drugs 0.000 description 1
- OQJFBUOFGHPMSR-UHFFFAOYSA-N ocinaplon Chemical compound C=1C=CC=NC=1C(=O)C(=C1N=CC=2)C=NN1C=2C1=CC=NC=C1 OQJFBUOFGHPMSR-UHFFFAOYSA-N 0.000 description 1
- 229950010328 ocinaplon Drugs 0.000 description 1
- 229950005023 octazamide Drugs 0.000 description 1
- VZQRTFPDLVFLMB-UHFFFAOYSA-N octriptyline phosphate Chemical compound OP(O)(O)=O.CNCCC=C1C2=CC=CC=C2C2CC2C2=CC=CC=C12 VZQRTFPDLVFLMB-UHFFFAOYSA-N 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229950008283 ofornine Drugs 0.000 description 1
- OPZKBPQVWDSATI-UHFFFAOYSA-N oleoyl vanillylamide Natural products CCCCCCCCC=CCCCCCCCC(=O)NCC1=CC=C(O)C(OC)=C1 OPZKBPQVWDSATI-UHFFFAOYSA-N 0.000 description 1
- 229960004364 olsalazine sodium Drugs 0.000 description 1
- 229950010717 olvanil Drugs 0.000 description 1
- 229960000770 ondansetron hydrochloride Drugs 0.000 description 1
- 239000003402 opiate agonist Substances 0.000 description 1
- 239000003399 opiate peptide Substances 0.000 description 1
- 229960000543 opipramol hydrochloride Drugs 0.000 description 1
- 208000024196 oppositional defiant disease Diseases 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 108060005714 orexin Proteins 0.000 description 1
- 229960004534 orgotein Drugs 0.000 description 1
- 108010070915 orgotein Proteins 0.000 description 1
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 1
- 229960001243 orlistat Drugs 0.000 description 1
- 229950003655 orpanoxin Drugs 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- QEEJLLNYQOBRRM-KSHGRFHLSA-N ovine crf Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CO)[C@@H](C)CC)[C@@H](C)O)C(C)C)[C@@H](C)O)C1=CN=CN1 QEEJLLNYQOBRRM-KSHGRFHLSA-N 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229960002739 oxaprozin Drugs 0.000 description 1
- OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 description 1
- ADIMAYPTOBDMTL-UHFFFAOYSA-N oxazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1 ADIMAYPTOBDMTL-UHFFFAOYSA-N 0.000 description 1
- 229960004535 oxazepam Drugs 0.000 description 1
- 229960003544 oxetorone Drugs 0.000 description 1
- 229950010617 oxfenicine Drugs 0.000 description 1
- DIVDFFZHCJEHGG-UHFFFAOYSA-N oxidopamine Chemical compound NCCC1=CC(O)=C(O)C=C1O DIVDFFZHCJEHGG-UHFFFAOYSA-N 0.000 description 1
- 229950004943 oxidopamine Drugs 0.000 description 1
- 229950002487 oxiperomide Drugs 0.000 description 1
- 229950004080 oxiramide Drugs 0.000 description 1
- ZIFJVJZWVSPZLE-UHFFFAOYSA-N oxo-[[1-[[4-(oxoazaniumylmethylidene)pyridin-1-yl]methoxymethyl]pyridin-4-ylidene]methyl]azanium;dichloride Chemical compound [Cl-].[Cl-].C1=CC(=C[NH+]=O)C=CN1COCN1C=CC(=C[NH+]=O)C=C1 ZIFJVJZWVSPZLE-UHFFFAOYSA-N 0.000 description 1
- 229960001834 oxprenolol hydrochloride Drugs 0.000 description 1
- 229960003617 oxycodone hydrochloride Drugs 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229960005162 oxymetazoline hydrochloride Drugs 0.000 description 1
- BEEDODBODQVSIM-UHFFFAOYSA-N oxymetazoline hydrochloride Chemical compound Cl.CC1=CC(C(C)(C)C)=C(O)C(C)=C1CC1=NCCN1 BEEDODBODQVSIM-UHFFFAOYSA-N 0.000 description 1
- 229960005374 oxymorphone hydrochloride Drugs 0.000 description 1
- 229960002841 oxypertine Drugs 0.000 description 1
- 229960000649 oxyphenbutazone Drugs 0.000 description 1
- CNDQSXOVEQXJOE-UHFFFAOYSA-N oxyphenbutazone hydrate Chemical compound O.O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=C(O)C=C1 CNDQSXOVEQXJOE-UHFFFAOYSA-N 0.000 description 1
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 1
- 229960001723 oxytocin Drugs 0.000 description 1
- 108700043267 pGlu(5)-MePhe(8)-MeGly(9)- substance P (5-11) Proteins 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 229950007032 panadiplon Drugs 0.000 description 1
- 229950006391 pancopride Drugs 0.000 description 1
- XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 description 1
- 229960001789 papaverine Drugs 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229950011145 pareptide Drugs 0.000 description 1
- 108700037033 pareptide Proteins 0.000 description 1
- 229960001779 pargyline Drugs 0.000 description 1
- DPGKFACWOCLTCA-UHFFFAOYSA-N pazinaclone Chemical compound N=1C2=NC(Cl)=CC=C2C=CC=1N(C(C1=CC=CC=C11)=O)C1CC(=O)N(CC1)CCC21OCCO2 DPGKFACWOCLTCA-UHFFFAOYSA-N 0.000 description 1
- 229950003612 pazinaclone Drugs 0.000 description 1
- 229950001648 pazoxide Drugs 0.000 description 1
- 229950008034 pelrinone Drugs 0.000 description 1
- 229950005386 pemedolac Drugs 0.000 description 1
- 229960000761 pemoline Drugs 0.000 description 1
- NRNCYVBFPDDJNE-UHFFFAOYSA-N pemoline Chemical compound O1C(N)=NC(=O)C1C1=CC=CC=C1 NRNCYVBFPDDJNE-UHFFFAOYSA-N 0.000 description 1
- 229960004505 penfluridol Drugs 0.000 description 1
- NRPCWSUJMWEFOK-KDXIVRHGSA-N pentamorphone Chemical compound O([C@H]1C(=O)C=C[C@@]23NCCCCC)C4=C5[C@]31CCN(C)[C@@H]2CC5=CC=C4O NRPCWSUJMWEFOK-KDXIVRHGSA-N 0.000 description 1
- 229950011592 pentamorphone Drugs 0.000 description 1
- VOKSWYLNZZRQPF-GDIGMMSISA-N pentazocine Chemical compound C1C2=CC=C(O)C=C2[C@@]2(C)[C@@H](C)[C@@H]1N(CC=C(C)C)CC2 VOKSWYLNZZRQPF-GDIGMMSISA-N 0.000 description 1
- 229960005301 pentazocine Drugs 0.000 description 1
- OQGYMIIFOSJQSF-DTOXXUQYSA-N pentazocine hcl Chemical compound Cl.C1C2=CC=C(O)C=C2[C@@]2(C)[C@@H](C)[C@@H]1N(CC=C(C)C)CC2 OQGYMIIFOSJQSF-DTOXXUQYSA-N 0.000 description 1
- 229960003809 pentazocine hydrochloride Drugs 0.000 description 1
- QNLDTXPVZPRSAM-DTOXXUQYSA-N pentazocine lactate Chemical compound CC(O)C(O)=O.C1C2=CC=C(O)C=C2[C@@]2(C)[C@@H](C)[C@@H]1N(CC=C(C)C)CC2 QNLDTXPVZPRSAM-DTOXXUQYSA-N 0.000 description 1
- 229960001246 pentazocine lactate Drugs 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 229960001476 pentoxifylline Drugs 0.000 description 1
- BRBAEHHXGZRCBK-UHFFFAOYSA-N pentrinitrol Chemical compound [O-][N+](=O)OCC(CO)(CO[N+]([O-])=O)CO[N+]([O-])=O BRBAEHHXGZRCBK-UHFFFAOYSA-N 0.000 description 1
- 229950006286 pentrinitrol Drugs 0.000 description 1
- 125000001151 peptidyl group Chemical group 0.000 description 1
- 229960004803 perhexiline maleate Drugs 0.000 description 1
- IYNMDWMQHSMDDE-MHXJNQAMSA-N perindopril erbumine Chemical class CC(C)(C)N.C1CCC[C@@H]2N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H](C(O)=O)C[C@@H]21 IYNMDWMQHSMDDE-MHXJNQAMSA-N 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 229950009253 perlapine Drugs 0.000 description 1
- 208000022821 personality disease Diseases 0.000 description 1
- 229960000482 pethidine Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960005222 phenazone Drugs 0.000 description 1
- 229960003799 phenazopyridine hydrochloride Drugs 0.000 description 1
- 229960000436 phendimetrazine Drugs 0.000 description 1
- 229960000964 phenelzine Drugs 0.000 description 1
- 229950000688 phenothiazine Drugs 0.000 description 1
- 229960003006 phenoxybenzamine hydrochloride Drugs 0.000 description 1
- NCAIGTHBQTXTLR-UHFFFAOYSA-N phentermine hydrochloride Chemical compound [Cl-].CC(C)([NH3+])CC1=CC=CC=C1 NCAIGTHBQTXTLR-UHFFFAOYSA-N 0.000 description 1
- 229960001277 phentermine hydrochloride Drugs 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- AXNGJCOYCMDPQG-UHFFFAOYSA-N phenyl-[1-(2-phenylethyl)-4-piperidinyl]methanol Chemical compound C=1C=CC=CC=1C(O)C(CC1)CCN1CCC1=CC=CC=C1 AXNGJCOYCMDPQG-UHFFFAOYSA-N 0.000 description 1
- OCYSGIYOVXAGKQ-FVGYRXGTSA-N phenylephrine hydrochloride Chemical compound [H+].[Cl-].CNC[C@H](O)C1=CC=CC(O)=C1 OCYSGIYOVXAGKQ-FVGYRXGTSA-N 0.000 description 1
- 229960003733 phenylephrine hydrochloride Drugs 0.000 description 1
- 229960002036 phenytoin Drugs 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 229960001697 physostigmine Drugs 0.000 description 1
- HZOTZTANVBDFOF-PBCQUBLHSA-N physostigmine salicylate Chemical compound OC(=O)C1=CC=CC=C1O.C12=CC(OC(=O)NC)=CC=C2N(C)[C@@H]2[C@@]1(C)CCN2C HZOTZTANVBDFOF-PBCQUBLHSA-N 0.000 description 1
- 229960002516 physostigmine salicylate Drugs 0.000 description 1
- 229950007935 picenadol Drugs 0.000 description 1
- 229960001416 pilocarpine Drugs 0.000 description 1
- RNAICSBVACLLGM-GNAZCLTHSA-N pilocarpine hydrochloride Chemical compound Cl.C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C RNAICSBVACLLGM-GNAZCLTHSA-N 0.000 description 1
- 229960002139 pilocarpine hydrochloride Drugs 0.000 description 1
- 229960001963 pilocarpine nitrate Drugs 0.000 description 1
- 229960002164 pimobendan Drugs 0.000 description 1
- GLBJJMFZWDBELO-UHFFFAOYSA-N pimobendane Chemical compound C1=CC(OC)=CC=C1C1=NC2=CC=C(C=3C(CC(=O)NN=3)C)C=C2N1 GLBJJMFZWDBELO-UHFFFAOYSA-N 0.000 description 1
- 229960002310 pinacidil Drugs 0.000 description 1
- OUNSOXPSCMCFHX-UHFFFAOYSA-N pinadoline Chemical compound ClCCCCC(=O)NNC(=O)N1CC2=CC=CC=C2OC2=CC=C(Cl)C=C12 OUNSOXPSCMCFHX-UHFFFAOYSA-N 0.000 description 1
- 229950006680 pinadoline Drugs 0.000 description 1
- PHUTUTUABXHXLW-UHFFFAOYSA-N pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=NC=C[C]12 PHUTUTUABXHXLW-UHFFFAOYSA-N 0.000 description 1
- 229960002508 pindolol Drugs 0.000 description 1
- AXKPFOAXAHJUAG-UHFFFAOYSA-N pipamperone Chemical compound C1CC(C(=O)N)(N2CCCCC2)CCN1CCCC(=O)C1=CC=C(F)C=C1 AXKPFOAXAHJUAG-UHFFFAOYSA-N 0.000 description 1
- 229960002776 pipamperone Drugs 0.000 description 1
- 229960004265 piperacetazine Drugs 0.000 description 1
- YMODINPJYNHPTM-UHFFFAOYSA-N piperidin-1-yl-[2-(pyridin-4-ylamino)phenyl]methanone Chemical compound C=1C=CC=C(NC=2C=CN=CC=2)C=1C(=O)N1CCCCC1 YMODINPJYNHPTM-UHFFFAOYSA-N 0.000 description 1
- 150000003053 piperidines Chemical class 0.000 description 1
- KTOYYUONFQWSMW-UHFFFAOYSA-N pipotiazine palmitate Chemical compound C1CC(CCOC(=O)CCCCCCCCCCCCCCC)CCN1CCCN1C2=CC(S(=O)(=O)N(C)C)=CC=C2SC2=CC=CC=C21 KTOYYUONFQWSMW-UHFFFAOYSA-N 0.000 description 1
- 229960001485 pipotiazine palmitate Drugs 0.000 description 1
- 229960001408 piprozolin Drugs 0.000 description 1
- APUDBKTWDCXQJA-QIDMFYOTSA-N pirmenol Chemical compound C[C@H]1CCC[C@@H](C)N1CCCC(O)(C=1N=CC=CC=1)C1=CC=CC=C1 APUDBKTWDCXQJA-QIDMFYOTSA-N 0.000 description 1
- 229950008066 pirmenol Drugs 0.000 description 1
- SEINJQWGYXAADT-UHFFFAOYSA-N pirolazamide Chemical compound C1CN2CCCC2CN1CCC(C(=O)N)(C=1C=CC=CC=1)C1=CC=CC=C1 SEINJQWGYXAADT-UHFFFAOYSA-N 0.000 description 1
- 229950007366 pirolazamide Drugs 0.000 description 1
- 229960001369 piroxicam cinnamate Drugs 0.000 description 1
- 229950010078 piroximone Drugs 0.000 description 1
- 229960000851 pirprofen Drugs 0.000 description 1
- PIDSZXPFGCURGN-UHFFFAOYSA-N pirprofen Chemical compound ClC1=CC(C(C(O)=O)C)=CC=C1N1CC=CC1 PIDSZXPFGCURGN-UHFFFAOYSA-N 0.000 description 1
- 229950010229 pirsidomine Drugs 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 229950008688 pivopril Drugs 0.000 description 1
- FIADGNVRKBPQEU-UHFFFAOYSA-N pizotifen Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CCC2=C1C=CS2 FIADGNVRKBPQEU-UHFFFAOYSA-N 0.000 description 1
- 229960004572 pizotifen Drugs 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920001432 poly(L-lactide) Polymers 0.000 description 1
- 229960005483 polythiazide Drugs 0.000 description 1
- 229920000046 polythiazide Polymers 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000001242 postsynaptic effect Effects 0.000 description 1
- 229960000206 potassium canrenoate Drugs 0.000 description 1
- JTZQCHFUGHIPDF-RYVBEKKQSA-M potassium canrenoate Chemical compound [K+].O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)CCC([O-])=O)[C@@H]4[C@@H]3C=CC2=C1 JTZQCHFUGHIPDF-RYVBEKKQSA-M 0.000 description 1
- NLSAMWIBIQWHTK-CZKUEYQYSA-M potassium prorenoate Chemical compound [K+].C12=CC(=O)CC[C@]2(C)[C@H]2CC[C@](C)([C@](CC3)(O)CCC([O-])=O)[C@@H]3[C@@H]2[C@@H]2[C@H]1C2 NLSAMWIBIQWHTK-CZKUEYQYSA-M 0.000 description 1
- FYLPNLCXMZDAEE-CKPGHUGTSA-M potassium;3-[(7r,8r,9s,10r,13s,14s,17r)-17-hydroxy-7-methoxycarbonyl-10,13-dimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1h-cyclopenta[a]phenanthren-17-yl]propanoate Chemical compound [K+].C1C[C@]2(C)[C@@](CCC([O-])=O)(O)CC[C@H]2[C@@H]2[C@H](C(=O)OC)CC3=CC(=O)CC[C@]3(C)[C@H]21 FYLPNLCXMZDAEE-CKPGHUGTSA-M 0.000 description 1
- MZKKJVZIFIQOPP-UHFFFAOYSA-M potassium;4-aminobenzoate Chemical compound [K+].NC1=CC=C(C([O-])=O)C=C1 MZKKJVZIFIQOPP-UHFFFAOYSA-M 0.000 description 1
- IASZJGRIPLTJMA-UHFFFAOYSA-N potassium;[2-[3-bromo-5-[(5-carbamoyl-4-cyclopropyl-2-ethylimidazol-1-yl)methyl]-1-benzofuran-2-yl]phenyl]-(trifluoromethylsulfonyl)azanide Chemical compound [K+].NC(=O)C=1N(CC=2C=C3C(Br)=C(OC3=CC=2)C=2C(=CC=CC=2)[N-]S(=O)(=O)C(F)(F)F)C(CC)=NC=1C1CC1 IASZJGRIPLTJMA-UHFFFAOYSA-N 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229960003456 pralidoxime chloride Drugs 0.000 description 1
- HIGSLXSBYYMVKI-UHFFFAOYSA-N pralidoxime chloride Chemical compound [Cl-].C[N+]1=CC=CC=C1\C=N\O HIGSLXSBYYMVKI-UHFFFAOYSA-N 0.000 description 1
- 229960002095 pralidoxime iodide Drugs 0.000 description 1
- 229950007323 pranolium chloride Drugs 0.000 description 1
- 229960002847 prasterone Drugs 0.000 description 1
- MEUQWHZOUDZXHH-UHFFFAOYSA-N pravadoline Chemical compound C1=CC(OC)=CC=C1C(=O)C(C1=CC=CC=C11)=C(C)N1CCN1CCOCC1 MEUQWHZOUDZXHH-UHFFFAOYSA-N 0.000 description 1
- 229950002577 pravadoline Drugs 0.000 description 1
- WFXFYZULCQKPIP-UHFFFAOYSA-N prazosin hydrochloride Chemical compound [H+].[Cl-].N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 WFXFYZULCQKPIP-UHFFFAOYSA-N 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 229950008421 prednazate Drugs 0.000 description 1
- 229960001989 prenylamine Drugs 0.000 description 1
- 229950001511 pridefine Drugs 0.000 description 1
- WAAVMZLJRXYRMA-UHFFFAOYSA-N prifelone Chemical compound CC(C)(C)C1=C(O)C(C(C)(C)C)=CC(C(=O)C=2SC=CC=2)=C1 WAAVMZLJRXYRMA-UHFFFAOYSA-N 0.000 description 1
- 229950004465 prifelone Drugs 0.000 description 1
- 229950003568 primidolol Drugs 0.000 description 1
- 229950008936 prinoxodan Drugs 0.000 description 1
- REQCZEXYDRLIBE-UHFFFAOYSA-N procainamide Chemical compound CCN(CC)CCNC(=O)C1=CC=C(N)C=C1 REQCZEXYDRLIBE-UHFFFAOYSA-N 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- WIKYUJGCLQQFNW-UHFFFAOYSA-N prochlorperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 WIKYUJGCLQQFNW-UHFFFAOYSA-N 0.000 description 1
- 229960003111 prochlorperazine Drugs 0.000 description 1
- DSKIOWHQLUWFLG-SPIKMXEPSA-N prochlorperazine maleate Chemical compound [H+].[H+].[H+].[H+].[O-]C(=O)\C=C/C([O-])=O.[O-]C(=O)\C=C/C([O-])=O.C1CN(C)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 DSKIOWHQLUWFLG-SPIKMXEPSA-N 0.000 description 1
- 229960002153 prochlorperazine maleate Drugs 0.000 description 1
- 229950000504 procinonide Drugs 0.000 description 1
- 229960005360 procyclidine hydrochloride Drugs 0.000 description 1
- LUKSBMJXPCFBKO-UHFFFAOYSA-N prodilidine Chemical compound C=1C=CC=CC=1C1(OC(=O)CC)CCN(C)C1C LUKSBMJXPCFBKO-UHFFFAOYSA-N 0.000 description 1
- 229950006434 prodilidine Drugs 0.000 description 1
- 229950003795 prodolic acid Drugs 0.000 description 1
- 229960005284 prolintane hydrochloride Drugs 0.000 description 1
- JIVSXRLRGOICGA-UHFFFAOYSA-N promazine hydrochloride Chemical compound [H+].[Cl-].C1=CC=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 JIVSXRLRGOICGA-UHFFFAOYSA-N 0.000 description 1
- 229960001836 promazine hydrochloride Drugs 0.000 description 1
- XWIHRGFIPXWGEF-UHFFFAOYSA-N propafenone hydrochloride Chemical compound Cl.CCCNCC(O)COC1=CC=CC=C1C(=O)CCC1=CC=CC=C1 XWIHRGFIPXWGEF-UHFFFAOYSA-N 0.000 description 1
- 229960002443 propafenone hydrochloride Drugs 0.000 description 1
- 229960003402 propatylnitrate Drugs 0.000 description 1
- YZZCJYJBCUJISI-UHFFFAOYSA-N propatylnitrate Chemical compound [O-][N+](=O)OCC(CC)(CO[N+]([O-])=O)CO[N+]([O-])=O YZZCJYJBCUJISI-UHFFFAOYSA-N 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- JCRIVQIOJSSCQD-UHFFFAOYSA-N propylhexedrine Chemical compound CNC(C)CC1CCCCC1 JCRIVQIOJSSCQD-UHFFFAOYSA-N 0.000 description 1
- 229960000786 propylhexedrine Drugs 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 229960002662 propylthiouracil Drugs 0.000 description 1
- 229960002466 proquazone Drugs 0.000 description 1
- JTIGKVIOEQASGT-UHFFFAOYSA-N proquazone Chemical compound N=1C(=O)N(C(C)C)C2=CC(C)=CC=C2C=1C1=CC=CC=C1 JTIGKVIOEQASGT-UHFFFAOYSA-N 0.000 description 1
- 229950006475 prorenoate potassium Drugs 0.000 description 1
- 229930190098 proscillaridin Natural products 0.000 description 1
- 229960003584 proscillaridin Drugs 0.000 description 1
- MYEJFUXQJGHEQK-UHFFFAOYSA-N proscillaridin A Natural products OC1C(O)C(O)C(C)OC1OC1C=C2CCC3C4(O)CCC(C5=COC(=O)C=C5)C4(C)CCC3C2(C)CC1 MYEJFUXQJGHEQK-UHFFFAOYSA-N 0.000 description 1
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 229940121649 protein inhibitor Drugs 0.000 description 1
- 239000012268 protein inhibitor Substances 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 229960001509 protriptyline hydrochloride Drugs 0.000 description 1
- USEITRSTDJBLBU-UHOSZYNNSA-N proxorphan Chemical compound C([C@@]12C3=CC(O)=CC=C3C[C@@]3([C@@H]1CCOC2)[H])CN3CC1CC1 USEITRSTDJBLBU-UHOSZYNNSA-N 0.000 description 1
- 229950010636 proxorphan Drugs 0.000 description 1
- BALXUFOVQVENIU-KXNXZCPBSA-N pseudoephedrine hydrochloride Chemical compound [H+].[Cl-].CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 BALXUFOVQVENIU-KXNXZCPBSA-N 0.000 description 1
- 229960003447 pseudoephedrine hydrochloride Drugs 0.000 description 1
- 238000001671 psychotherapy Methods 0.000 description 1
- 150000003217 pyrazoles Chemical class 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 229960002151 pyridostigmine bromide Drugs 0.000 description 1
- NCZXKYCNHGRFHE-UHFFFAOYSA-N pyrinoline Chemical compound C=1C=CC=NC=1C(C=1N=CC=CC=1)(O)C(C=C1)=CC1=C(C=1N=CC=CC=1)C1=CC=CC=N1 NCZXKYCNHGRFHE-UHFFFAOYSA-N 0.000 description 1
- 229950006756 pyrinoline Drugs 0.000 description 1
- 229960001964 quazepam Drugs 0.000 description 1
- BHZFZYLBVSWUMT-ZCFIWIBFSA-N quazinone Chemical compound C1=CC=C2NC3=NC(=O)[C@@H](C)N3CC2=C1Cl BHZFZYLBVSWUMT-ZCFIWIBFSA-N 0.000 description 1
- 229950005340 quazinone Drugs 0.000 description 1
- IBBLRJGOOANPTQ-JKVLGAQCSA-N quinapril hydrochloride Chemical compound Cl.C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 IBBLRJGOOANPTQ-JKVLGAQCSA-N 0.000 description 1
- 229960003042 quinapril hydrochloride Drugs 0.000 description 1
- FLSLEGPOVLMJMN-YSSFQJQWSA-N quinaprilat Chemical compound C([C@H](N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)C(O)=O)CC1=CC=CC=C1 FLSLEGPOVLMJMN-YSSFQJQWSA-N 0.000 description 1
- 229960001007 quinaprilat Drugs 0.000 description 1
- 229950008842 quindonium bromide Drugs 0.000 description 1
- 229950003275 quinelorane Drugs 0.000 description 1
- XHKUDCCTVQUHJQ-LCYSNFERSA-N quinidine D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 XHKUDCCTVQUHJQ-LCYSNFERSA-N 0.000 description 1
- 229960002454 quinidine gluconate Drugs 0.000 description 1
- 229960004482 quinidine sulfate Drugs 0.000 description 1
- 108700040249 racecadotril Proteins 0.000 description 1
- YJQZYXCXBBCEAQ-UHFFFAOYSA-N ractopamine Chemical compound C=1C=C(O)C=CC=1C(O)CNC(C)CCC1=CC=C(O)C=C1 YJQZYXCXBBCEAQ-UHFFFAOYSA-N 0.000 description 1
- HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 description 1
- 229960003401 ramipril Drugs 0.000 description 1
- 229950005904 recainam Drugs 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- MQGIGGJUPITZSE-UHFFFAOYSA-N reclazepam Chemical compound C12=CC(Cl)=CC=C2N(C=2OCC(=O)N=2)CCN=C1C1=CC=CC=C1Cl MQGIGGJUPITZSE-UHFFFAOYSA-N 0.000 description 1
- 229950004797 reclazepam Drugs 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 108010056532 regramostim Proteins 0.000 description 1
- 229950006324 regramostim Drugs 0.000 description 1
- WFBMIPUMYUHANP-UHFFFAOYSA-N remifentanil hydrochloride Chemical compound [Cl-].C1C[NH+](CCC(=O)OC)CCC1(C(=O)OC)N(C(=O)CC)C1=CC=CC=C1 WFBMIPUMYUHANP-UHFFFAOYSA-N 0.000 description 1
- 229960003011 remifentanil hydrochloride Drugs 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 1
- 229960003147 reserpine Drugs 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229940116238 revex Drugs 0.000 description 1
- 229950006715 ribaminol Drugs 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229960001487 rimexolone Drugs 0.000 description 1
- QTTRZHGPGKRAFB-OOKHYKNYSA-N rimexolone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CC)(C)[C@@]1(C)C[C@@H]2O QTTRZHGPGKRAFB-OOKHYKNYSA-N 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- JUQLTPCYUFPYKE-UHFFFAOYSA-N ritanserin Chemical compound CC=1N=C2SC=CN2C(=O)C=1CCN(CC1)CCC1=C(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 JUQLTPCYUFPYKE-UHFFFAOYSA-N 0.000 description 1
- 229950009626 ritanserin Drugs 0.000 description 1
- 229960001634 ritodrine Drugs 0.000 description 1
- 229960000720 ritodrine hydrochloride Drugs 0.000 description 1
- 229950004692 roletamide Drugs 0.000 description 1
- 229950004252 rolicyprine Drugs 0.000 description 1
- 229950006945 rolodine Drugs 0.000 description 1
- 229950001166 romazarit Drugs 0.000 description 1
- 229960002349 ropinirole hydrochloride Drugs 0.000 description 1
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 1
- ANLWAEZHUOEOTI-GQKYHHCASA-N s-(chloromethyl) (6s,8s,9r,10s,11s,13s,14s,16r,17r)-6,9-difluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthrene-17-carbothioate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCCl)(O)[C@@]2(C)C[C@@H]1O ANLWAEZHUOEOTI-GQKYHHCASA-N 0.000 description 1
- MZWKCFGWAWRHDY-UHFFFAOYSA-N s-[2-(diethylamino)ethyl] 2,2-diphenylethanethioate;hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(C(=O)SCCN(CC)CC)C1=CC=CC=C1 MZWKCFGWAWRHDY-UHFFFAOYSA-N 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 229960000581 salicylamide Drugs 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 229950009768 salnacedin Drugs 0.000 description 1
- GIZKAXHWLRYMLE-UHFFFAOYSA-M sanguinarium chloride Chemical compound [Cl-].C1=C2OCOC2=CC2=C3[N+](C)=CC4=C(OCO5)C5=CC=C4C3=CC=C21 GIZKAXHWLRYMLE-UHFFFAOYSA-M 0.000 description 1
- 229950011197 sanguinarium chloride Drugs 0.000 description 1
- 229960001379 saralasin acetate Drugs 0.000 description 1
- 229960002530 sargramostim Drugs 0.000 description 1
- 108010038379 sargramostim Proteins 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229950008243 secbutabarbital Drugs 0.000 description 1
- 229950002093 seclazone Drugs 0.000 description 1
- KQPKPCNLIDLUMF-UHFFFAOYSA-N secobarbital Chemical compound CCCC(C)C1(CC=C)C(=O)NC(=O)NC1=O KQPKPCNLIDLUMF-UHFFFAOYSA-N 0.000 description 1
- 229960002060 secobarbital Drugs 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 229960003946 selegiline Drugs 0.000 description 1
- KHYPYQZQJSBPIX-UHFFFAOYSA-N sematilide Chemical compound CCN(CC)CCNC(=O)C1=CC=C(NS(C)(=O)=O)C=C1 KHYPYQZQJSBPIX-UHFFFAOYSA-N 0.000 description 1
- 229950008118 sematilide Drugs 0.000 description 1
- 229960004388 semduramicin Drugs 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- FHOCOBKCNJYXOP-OVLDLUHVSA-N seractide Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 FHOCOBKCNJYXOP-OVLDLUHVSA-N 0.000 description 1
- 229950001397 seractide Drugs 0.000 description 1
- YEITZTKANLXOTH-UHFFFAOYSA-N serazapine hcl Chemical compound Cl.C1N2C3=CC=CC=C3C(C(=O)OC)=C2C2CN(C)CCN2C2=CC=CC=C21 YEITZTKANLXOTH-UHFFFAOYSA-N 0.000 description 1
- 229950006250 sermetacin Drugs 0.000 description 1
- 230000000862 serotonergic effect Effects 0.000 description 1
- 229940126570 serotonin reuptake inhibitor Drugs 0.000 description 1
- GZKLJWGUPQBVJQ-UHFFFAOYSA-N sertindole Chemical compound C1=CC(F)=CC=C1N1C2=CC=C(Cl)C=C2C(C2CCN(CCN3C(NCC3)=O)CC2)=C1 GZKLJWGUPQBVJQ-UHFFFAOYSA-N 0.000 description 1
- 229960000652 sertindole Drugs 0.000 description 1
- 229960003660 sertraline hydrochloride Drugs 0.000 description 1
- RBGAHDDQSRBDOG-UHFFFAOYSA-N setoperone Chemical compound CC=1N=C2SCCN2C(=O)C=1CCN(CC1)CCC1C(=O)C1=CC=C(F)C=C1 RBGAHDDQSRBDOG-UHFFFAOYSA-N 0.000 description 1
- 229950009024 setoperone Drugs 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 229960002959 sincalide Drugs 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 201000002859 sleep apnea Diseases 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229940045640 sodium aminobenzoate Drugs 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940083618 sodium nitroprusside Drugs 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 229960004025 sodium salicylate Drugs 0.000 description 1
- 229940080313 sodium starch Drugs 0.000 description 1
- TVTJZMHAIQQZTL-WATAJHSMSA-M sodium;(2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylate Chemical compound [Na+].C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C([O-])=O)CCCC1=CC=CC=C1 TVTJZMHAIQQZTL-WATAJHSMSA-M 0.000 description 1
- HVBBVDWXAWJQSV-UHFFFAOYSA-N sodium;(3-benzoylphenyl)-(difluoromethylsulfonyl)azanide Chemical compound [Na+].FC(F)S(=O)(=O)[N-]C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 HVBBVDWXAWJQSV-UHFFFAOYSA-N 0.000 description 1
- PHJRJPWBPXLNAJ-FPUQOWELSA-M sodium;1-[(e)-[5-(4-bromophenyl)-1,3-oxazol-2-yl]methylideneamino]imidazolidin-3-ide-2,4-dione Chemical compound [Na+].C1=CC(Br)=CC=C1C(O1)=CN=C1\C=N\N1C(=O)[N-]C(=O)C1 PHJRJPWBPXLNAJ-FPUQOWELSA-M 0.000 description 1
- WFKJEZKHPGDCRK-UHFFFAOYSA-M sodium;2,2,2-trichloroethyl hydrogen phosphate Chemical compound [Na+].OP([O-])(=O)OCC(Cl)(Cl)Cl WFKJEZKHPGDCRK-UHFFFAOYSA-M 0.000 description 1
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 description 1
- JXRFTGPGWGUBQB-LHOUOPCDSA-M sodium;2-[(2r,3s,4s,5r,6s)-2,4-dihydroxy-6-[(1r)-1-[(2s,5r,7s,8r,9s)-7-hydroxy-2-[(2r,5s)-5-[(2r,3s,5r)-5-[(2s,3s,5r,6s)-6-hydroxy-3,5,6-trimethyloxan-2-yl]-3-[(2s,5s,6r)-5-methoxy-6-methyloxan-2-yl]oxyoxolan-2-yl]-5-methyloxolan-2-yl]-2,8-dimethyl-1,10-d Chemical compound [Na+].O1[C@H](C)[C@@H](OC)CC[C@@H]1O[C@@H]1[C@H]([C@@]2(C)O[C@H](CC2)[C@@]2(C)O[C@]3(O[C@@H]([C@H](C)[C@@H](O)C3)[C@@H](C)[C@H]3[C@@H]([C@@H](O)[C@H](C)[C@@](O)(CC([O-])=O)O3)OC)CC2)O[C@@H]([C@@H]2[C@H](C[C@@H](C)[C@@](C)(O)O2)C)C1 JXRFTGPGWGUBQB-LHOUOPCDSA-M 0.000 description 1
- JMHRGKDWGWORNU-UHFFFAOYSA-M sodium;2-[1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]acetate Chemical compound [Na+].CC1=C(CC([O-])=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 JMHRGKDWGWORNU-UHFFFAOYSA-M 0.000 description 1
- DCTVJZGYZTWBLO-UHFFFAOYSA-M sodium;2-[7-(4-methylsulfanylbenzoyl)-1-benzofuran-5-yl]acetate;hydrate Chemical compound O.[Na+].C1=CC(SC)=CC=C1C(=O)C1=CC(CC([O-])=O)=CC2=C1OC=C2 DCTVJZGYZTWBLO-UHFFFAOYSA-M 0.000 description 1
- AIJQWRAOMFRHTQ-UHFFFAOYSA-M sodium;2-aminoacetate;1,3-dimethyl-7h-purine-2,6-dione Chemical compound [Na+].NCC([O-])=O.O=C1N(C)C(=O)N(C)C2=C1NC=N2 AIJQWRAOMFRHTQ-UHFFFAOYSA-M 0.000 description 1
- XETSAYZRDCRPJY-UHFFFAOYSA-M sodium;4-aminobenzoate Chemical compound [Na+].NC1=CC=C(C([O-])=O)C=C1 XETSAYZRDCRPJY-UHFFFAOYSA-M 0.000 description 1
- TVGNJNYKOTWAJQ-UHFFFAOYSA-M sodium;4-butyl-5-oxo-1,2-diphenylpyrazol-3-olate;propane-1,2,3-triol Chemical compound [Na+].OCC(O)CO.C=1C=CC=CC=1N1C(=O)C(CCCC)=C([O-])N1C1=CC=CC=C1 TVGNJNYKOTWAJQ-UHFFFAOYSA-M 0.000 description 1
- XGUUCCVRACSUAD-UHFFFAOYSA-M sodium;5,5-bis(prop-2-enyl)pyrimidin-3-ide-2,4,6-trione Chemical compound [Na+].C=CCC1(CC=C)C(=O)NC(=O)[N-]C1=O XGUUCCVRACSUAD-UHFFFAOYSA-M 0.000 description 1
- XFOHHIYSRDUSCX-UHFFFAOYSA-M sodium;5-[[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]methyl]-1,3-thiazolidin-3-ide-2,4-dione Chemical compound [Na+].C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)[N-]C1=O XFOHHIYSRDUSCX-UHFFFAOYSA-M 0.000 description 1
- IIZQYKZCLMEPBU-UHFFFAOYSA-N sodium;6-chloro-1,2,4-benzothiadiazin-2-ide-7-sulfonamide Chemical compound S1N([Na])C=NC2=C1C=C(S(=O)(=O)N)C(Cl)=C2 IIZQYKZCLMEPBU-UHFFFAOYSA-N 0.000 description 1
- AVERBMQHYOZACV-UHFFFAOYSA-M sodium;7-chloro-4-[(3,4-dichlorophenyl)carbamoyl]-1,1-dioxo-2,3-dihydro-1$l^{6}-benzothiepin-5-olate;hydrate Chemical compound O.[Na+].C1CS(=O)(=O)C2=CC=C(Cl)C=C2C([O-])=C1C(=O)NC1=CC=C(Cl)C(Cl)=C1 AVERBMQHYOZACV-UHFFFAOYSA-M 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 229950002328 somalapor Drugs 0.000 description 1
- 208000016994 somatization disease Diseases 0.000 description 1
- 108700031632 somatrem Proteins 0.000 description 1
- 229960003259 somatrem Drugs 0.000 description 1
- 229950006833 somenopor Drugs 0.000 description 1
- 229950002069 somidobove Drugs 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- DKGZKTPJOSAWFA-UHFFFAOYSA-N spiperone Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCC2(C(NCN2C=2C=CC=CC=2)=O)CC1 DKGZKTPJOSAWFA-UHFFFAOYSA-N 0.000 description 1
- 229950001675 spiperone Drugs 0.000 description 1
- NYKCGQQJNVPOLU-ONTIZHBOSA-N spiradoline Chemical compound C([C@@H]([C@H](C1)N2CCCC2)N(C)C(=O)CC=2C=C(Cl)C(Cl)=CC=2)C[C@]21CCCO2 NYKCGQQJNVPOLU-ONTIZHBOSA-N 0.000 description 1
- 229950006495 spiradoline Drugs 0.000 description 1
- WZAIVXXKOAWTGQ-UHFFFAOYSA-N spiro[2,3-dihydronaphthalene-4,3'-piperidine]-1,2',6'-trione Chemical compound O=C1NC(=O)CCC11C2=CC=CC=C2C(=O)CC1 WZAIVXXKOAWTGQ-UHFFFAOYSA-N 0.000 description 1
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 1
- 229960002256 spironolactone Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 125000002730 succinyl group Chemical group C(CCC(=O)*)(=O)* 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229950005175 sudoxicam Drugs 0.000 description 1
- 229960004739 sufentanil Drugs 0.000 description 1
- GGCSSNBKKAUURC-UHFFFAOYSA-N sufentanil Chemical compound C1CN(CCC=2SC=CC=2)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 GGCSSNBKKAUURC-UHFFFAOYSA-N 0.000 description 1
- 229960001204 sufentanil citrate Drugs 0.000 description 1
- 238000009923 sugaring Methods 0.000 description 1
- YRALAIOMGQZKOW-UHFFFAOYSA-N sulfated caerulein Natural products C=1C=CC=CC=1CC(C(N)=O)NC(=O)C(CC(O)=O)NC(=O)C(CCSC)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(C(C)O)NC(=O)C(NC(=O)C(CC(O)=O)NC(=O)C(CCC(N)=O)NC(=O)C1NC(=O)CC1)CC1=CC=C(OS(O)(=O)=O)C=C1 YRALAIOMGQZKOW-UHFFFAOYSA-N 0.000 description 1
- PAQZZCOZHPGCFW-UHFFFAOYSA-N sulfinalol Chemical compound C1=CC(OC)=CC=C1CCC(C)NCC(O)C1=CC=C(O)C(S(C)=O)=C1 PAQZZCOZHPGCFW-UHFFFAOYSA-N 0.000 description 1
- 229950005165 sulfinalol Drugs 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 229960000894 sulindac Drugs 0.000 description 1
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
- 229960003967 suloctidil Drugs 0.000 description 1
- 229960004940 sulpiride Drugs 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- IBAUKGNDWVSETP-UHFFFAOYSA-N suproclone Chemical compound C1CN(C(=O)CC)CCN1C(=O)OC1C(SCCS2)=C2C(=O)N1C1=CC=C(C=CC(Cl)=N2)C2=N1 IBAUKGNDWVSETP-UHFFFAOYSA-N 0.000 description 1
- 229950003877 suproclone Drugs 0.000 description 1
- 229960004492 suprofen Drugs 0.000 description 1
- 229950002738 suritozole Drugs 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 229950001671 tametraline Drugs 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 229950000115 tampramine Drugs 0.000 description 1
- BRPOADLGOFPKKJ-UHFFFAOYSA-N tandamine Chemical compound C12=CC=CC=C2N(CC)C2=C1CCSC2(C)CCN(C)C BRPOADLGOFPKKJ-UHFFFAOYSA-N 0.000 description 1
- 229950006964 tandamine Drugs 0.000 description 1
- CEIJFEGBUDEYSX-FZDBZEDMSA-N tandospirone Chemical compound O=C([C@@H]1[C@H]2CC[C@H](C2)[C@@H]1C1=O)N1CCCCN(CC1)CCN1C1=NC=CC=N1 CEIJFEGBUDEYSX-FZDBZEDMSA-N 0.000 description 1
- 229950000505 tandospirone Drugs 0.000 description 1
- 229960000651 tasosartan Drugs 0.000 description 1
- ADXGNEYLLLSOAR-UHFFFAOYSA-N tasosartan Chemical compound C12=NC(C)=NC(C)=C2CCC(=O)N1CC(C=C1)=CC=C1C1=CC=CC=C1C=1N=NNN=1 ADXGNEYLLLSOAR-UHFFFAOYSA-N 0.000 description 1
- 229950007051 tazadolene Drugs 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 229960004084 temocapril Drugs 0.000 description 1
- FIQOFIRCTOWDOW-BJLQDIEVSA-N temocapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C[C@H](SC1)C=1SC=CC=1)=O)CC1=CC=CC=C1 FIQOFIRCTOWDOW-BJLQDIEVSA-N 0.000 description 1
- WZWYJBNHTWCXIM-UHFFFAOYSA-N tenoxicam Chemical compound O=C1C=2SC=CC=2S(=O)(=O)N(C)C1=C(O)NC1=CC=CC=N1 WZWYJBNHTWCXIM-UHFFFAOYSA-N 0.000 description 1
- 229960002871 tenoxicam Drugs 0.000 description 1
- VCKUSRYTPJJLNI-UHFFFAOYSA-N terazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1CCCO1 VCKUSRYTPJJLNI-UHFFFAOYSA-N 0.000 description 1
- 229960001909 terazosin hydrochloride Drugs 0.000 description 1
- 150000003504 terephthalic acids Chemical class 0.000 description 1
- UZQBKCWYZBHBOW-YIPNQBBMSA-N terlakiren Chemical compound C([C@@H](C(=O)N[C@@H](CSC)C(=O)N[C@@H](CC1CCCCC1)[C@@H](O)C(=O)OC(C)C)NC(=O)N1CCOCC1)C1=CC=CC=C1 UZQBKCWYZBHBOW-YIPNQBBMSA-N 0.000 description 1
- 108010069247 terlakiren Proteins 0.000 description 1
- 229950003204 terlakiren Drugs 0.000 description 1
- UISARWKNNNHPGI-UHFFFAOYSA-N terodiline Chemical compound C=1C=CC=CC=1C(CC(C)NC(C)(C)C)C1=CC=CC=C1 UISARWKNNNHPGI-UHFFFAOYSA-N 0.000 description 1
- SASWSEQJAITMKS-JJNNLWIXSA-N tert-butyl (2s)-2-[[(2s)-1-[[(2s)-1-[[(4s,5s,7s)-5-hydroxy-2,8-dimethyl-7-[[(2s,3s)-3-methyl-1-oxo-1-(pyridin-2-ylmethylamino)pentan-2-yl]carbamoyl]nonan-4-yl]amino]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]-methylamino]-1-oxo-3-phenylpropan-2-yl]carbamoyl]p Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)[C@@H](O)C[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC=1N=CC=CC=1)C(C)C)N(C)C(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H]1N(CCC1)C(=O)OC(C)(C)C)C1=CN=CN1 SASWSEQJAITMKS-JJNNLWIXSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 229950007324 tesicam Drugs 0.000 description 1
- 229950000997 tesimide Drugs 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 150000005621 tetraalkylammonium salts Chemical class 0.000 description 1
- TUGDLVFMIQZYPA-UHFFFAOYSA-N tetracopper;tetrazinc Chemical compound [Cu+2].[Cu+2].[Cu+2].[Cu+2].[Zn+2].[Zn+2].[Zn+2].[Zn+2] TUGDLVFMIQZYPA-UHFFFAOYSA-N 0.000 description 1
- 229960001423 tetracosactide Drugs 0.000 description 1
- 229940021790 tetrahydrozoline hydrochloride Drugs 0.000 description 1
- BJORNXNYWNIWEY-UHFFFAOYSA-N tetrahydrozoline hydrochloride Chemical compound Cl.N1CCN=C1C1C2=CC=CC=C2CCC1 BJORNXNYWNIWEY-UHFFFAOYSA-N 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- 229950006500 tetridamine Drugs 0.000 description 1
- 229960003433 thalidomide Drugs 0.000 description 1
- 229960004559 theobromine Drugs 0.000 description 1
- 229960005444 theophylline sodium glycinate Drugs 0.000 description 1
- 229960002178 thiamazole Drugs 0.000 description 1
- 125000002769 thiazolinyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 229960004098 thioridazine hydrochloride Drugs 0.000 description 1
- NZFNXWQNBYZDAQ-UHFFFAOYSA-N thioridazine hydrochloride Chemical compound Cl.C12=CC(SC)=CC=C2SC2=CC=CC=C2N1CCC1CCCCN1C NZFNXWQNBYZDAQ-UHFFFAOYSA-N 0.000 description 1
- JJSHYECKYLDYAR-UHFFFAOYSA-N thozalinone Chemical compound O1C(N(C)C)=NC(=O)C1C1=CC=CC=C1 JJSHYECKYLDYAR-UHFFFAOYSA-N 0.000 description 1
- 230000000929 thyromimetic effect Effects 0.000 description 1
- 229950007282 tiamizide Drugs 0.000 description 1
- QJJXOEFWXSQISU-UHFFFAOYSA-N tiazesim Chemical compound C1C(=O)N(CCN(C)C)C2=CC=CC=C2SC1C1=CC=CC=C1 QJJXOEFWXSQISU-UHFFFAOYSA-N 0.000 description 1
- 229950004626 tiazesim Drugs 0.000 description 1
- 229950009139 tifenamil Drugs 0.000 description 1
- 229960001502 tilidine hydrochloride Drugs 0.000 description 1
- NWJQIUPQBDVVLW-QZIXMDIESA-N timobesone acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)SC)(OC(C)=O)[C@@]1(C)C[C@@H]2O NWJQIUPQBDVVLW-QZIXMDIESA-N 0.000 description 1
- 229950004087 tinabinol Drugs 0.000 description 1
- 229950000282 tiodazosin Drugs 0.000 description 1
- 229950004554 tiospirone Drugs 0.000 description 1
- JWIXXNLOKOAAQT-UHFFFAOYSA-N tipepidine Chemical compound C1N(C)CCCC1=C(C=1SC=CC=1)C1=CC=CS1 JWIXXNLOKOAAQT-UHFFFAOYSA-N 0.000 description 1
- 229960000896 tipepidine Drugs 0.000 description 1
- BUJAGSGYPOAWEI-UHFFFAOYSA-N tocainide Chemical compound CC(N)C(=O)NC1=C(C)C=CC=C1C BUJAGSGYPOAWEI-UHFFFAOYSA-N 0.000 description 1
- 229960001792 tocamphyl Drugs 0.000 description 1
- OUDSBRTVNLOZBN-UHFFFAOYSA-N tolazamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1CCCCCC1 OUDSBRTVNLOZBN-UHFFFAOYSA-N 0.000 description 1
- 229960002277 tolazamide Drugs 0.000 description 1
- 229960002649 tolazoline hydrochloride Drugs 0.000 description 1
- 229960005371 tolbutamide Drugs 0.000 description 1
- MIQPIUSUKVNLNT-UHFFFAOYSA-N tolcapone Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC(O)=C(O)C([N+]([O-])=O)=C1 MIQPIUSUKVNLNT-UHFFFAOYSA-N 0.000 description 1
- 229960004603 tolcapone Drugs 0.000 description 1
- 229960001017 tolmetin Drugs 0.000 description 1
- UPSPUYADGBWSHF-UHFFFAOYSA-N tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 description 1
- 229960002044 tolmetin sodium Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- UDNUCVYCLQJJBY-YTFSRNRJSA-N tonazocine Chemical compound C1C2=CC=C(O)C=C2[C@]2(C)[C@@](CCC(=O)CCCCC)(C)[C@H]1N(C)CC2 UDNUCVYCLQJJBY-YTFSRNRJSA-N 0.000 description 1
- 229950005285 tonazocine Drugs 0.000 description 1
- 229950002859 tracazolate Drugs 0.000 description 1
- 229960003107 tramadol hydrochloride Drugs 0.000 description 1
- 229960001262 tramazoline Drugs 0.000 description 1
- 229940125725 tranquilizer Drugs 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 229950004724 transcainide Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 229960003741 tranylcypromine Drugs 0.000 description 1
- OHHDIOKRWWOXMT-UHFFFAOYSA-N trazodone hydrochloride Chemical compound [H+].[Cl-].ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 OHHDIOKRWWOXMT-UHFFFAOYSA-N 0.000 description 1
- 229960002301 trazodone hydrochloride Drugs 0.000 description 1
- 229950002905 trethinium tosilate Drugs 0.000 description 1
- 125000005270 trialkylamine group Chemical group 0.000 description 1
- 125000005208 trialkylammonium group Chemical group 0.000 description 1
- 125000005259 triarylamine group Chemical class 0.000 description 1
- 229960003386 triazolam Drugs 0.000 description 1
- JOFWLTCLBGQGBO-UHFFFAOYSA-N triazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1Cl JOFWLTCLBGQGBO-UHFFFAOYSA-N 0.000 description 1
- LMJSLTNSBFUCMU-UHFFFAOYSA-N trichlormethiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NC(C(Cl)Cl)NS2(=O)=O LMJSLTNSBFUCMU-UHFFFAOYSA-N 0.000 description 1
- 229960004813 trichlormethiazide Drugs 0.000 description 1
- 229960002741 triclofos sodium Drugs 0.000 description 1
- VSVSLEMVVAYTQW-VSXGLTOVSA-N triclonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(Cl)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CCl)[C@@]2(C)C[C@@H]1Cl VSVSLEMVVAYTQW-VSXGLTOVSA-N 0.000 description 1
- 229950008073 triclonide Drugs 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- 229950000451 triflumidate Drugs 0.000 description 1
- ZEWQUBUPAILYHI-UHFFFAOYSA-N trifluoperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 ZEWQUBUPAILYHI-UHFFFAOYSA-N 0.000 description 1
- 229960002324 trifluoperazine Drugs 0.000 description 1
- BXDAOUXDMHXPDI-UHFFFAOYSA-N trifluoperazine hydrochloride Chemical compound [H+].[H+].[Cl-].[Cl-].C1CN(C)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 BXDAOUXDMHXPDI-UHFFFAOYSA-N 0.000 description 1
- 229960000315 trifluoperazine hydrochloride Drugs 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- GPMXUUPHFNMNDH-UHFFFAOYSA-N trifluperidol Chemical compound C1CC(O)(C=2C=C(C=CC=2)C(F)(F)F)CCN1CCCC(=O)C1=CC=C(F)C=C1 GPMXUUPHFNMNDH-UHFFFAOYSA-N 0.000 description 1
- QDWJJTJNXAKQKD-UHFFFAOYSA-N trihexyphenidyl hydrochloride Chemical compound Cl.C1CCCCC1C(C=1C=CC=CC=1)(O)CCN1CCCCC1 QDWJJTJNXAKQKD-UHFFFAOYSA-N 0.000 description 1
- KVJXBPDAXMEYOA-CXANFOAXSA-N trilostane Chemical compound OC1=C(C#N)C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@@]32O[C@@H]31 KVJXBPDAXMEYOA-CXANFOAXSA-N 0.000 description 1
- 229960001670 trilostane Drugs 0.000 description 1
- 229960002906 trimazosin Drugs 0.000 description 1
- CHQOEHPMXSHGCL-UHFFFAOYSA-N trimethaphan Chemical compound C12C[S+]3CCCC3C2N(CC=2C=CC=CC=2)C(=O)N1CC1=CC=CC=C1 CHQOEHPMXSHGCL-UHFFFAOYSA-N 0.000 description 1
- 229940035742 trimethaphan Drugs 0.000 description 1
- 229950001577 trimetozine Drugs 0.000 description 1
- YDGHCKHAXOUQOS-BTJKTKAUSA-N trimipramine maleate Chemical group [O-]C(=O)\C=C/C([O-])=O.C1CC2=CC=CC=C2[NH+](CC(C[NH+](C)C)C)C2=CC=CC=C21 YDGHCKHAXOUQOS-BTJKTKAUSA-N 0.000 description 1
- UHLOVGKIEARANS-QZHINBJYSA-N tripamide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(=O)NN2C[C@@H]3[C@H]4CC[C@H](C4)[C@@H]3C2)=C1 UHLOVGKIEARANS-QZHINBJYSA-N 0.000 description 1
- 229950004678 tripamide Drugs 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- ZNRGQMMCGHDTEI-ITGUQSILSA-N tropisetron Chemical compound C1=CC=C2C(C(=O)O[C@H]3C[C@H]4CC[C@@H](C3)N4C)=CNC2=C1 ZNRGQMMCGHDTEI-ITGUQSILSA-N 0.000 description 1
- 229960003688 tropisetron Drugs 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- DTMPGSXFUXZBDK-UHFFFAOYSA-N uldazepam Chemical compound C12=CC(Cl)=CC=C2N=C(NOCC=C)CN=C1C1=CC=CC=C1Cl DTMPGSXFUXZBDK-UHFFFAOYSA-N 0.000 description 1
- 229950004526 uldazepam Drugs 0.000 description 1
- BDSYKGHYMJNPAB-LICBFIPMSA-N ulobetasol propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]2(C)C[C@@H]1O BDSYKGHYMJNPAB-LICBFIPMSA-N 0.000 description 1
- 229950008396 ulobetasol propionate Drugs 0.000 description 1
- 206010048828 underweight Diseases 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 229960004371 urofollitropin Drugs 0.000 description 1
- 229950002855 veradoline Drugs 0.000 description 1
- 229950008912 verilopam Drugs 0.000 description 1
- 229950005577 vesnarinone Drugs 0.000 description 1
- 229960001255 viloxazine Drugs 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- SVKVWRTVTPUQBY-MORSLUCNSA-N volazocine Chemical compound C([C@@]1(C)C2=CC=CC=C2C[C@@H]2[C@@H]1C)CN2CC1CC1 SVKVWRTVTPUQBY-MORSLUCNSA-N 0.000 description 1
- 229950001292 volazocine Drugs 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 229960004928 xamoterol Drugs 0.000 description 1
- 229950005523 xilobam Drugs 0.000 description 1
- 229960000537 xipamide Drugs 0.000 description 1
- MTZBBNMLMNBNJL-UHFFFAOYSA-N xipamide Chemical compound CC1=CC=CC(C)=C1NC(=O)C1=CC(S(N)(=O)=O)=C(Cl)C=C1O MTZBBNMLMNBNJL-UHFFFAOYSA-N 0.000 description 1
- AZJPPZHRNFQRRE-AZIXLERZSA-N xorphanol Chemical compound C([C@@]12CC(=C)C[C@@H]([C@H]2[C@H]2CC=3C1=CC(O)=CC=3)C)CN2CC1CCC1 AZJPPZHRNFQRRE-AZIXLERZSA-N 0.000 description 1
- 229950000214 xorphanol Drugs 0.000 description 1
- 229960004175 xylazine hydrochloride Drugs 0.000 description 1
- 229960001095 xylometazoline hydrochloride Drugs 0.000 description 1
- HUNXMJYCHXQEGX-UHFFFAOYSA-N zaleplon Chemical compound CCN(C(C)=O)C1=CC=CC(C=2N3N=CC(=C3N=CC=2)C#N)=C1 HUNXMJYCHXQEGX-UHFFFAOYSA-N 0.000 description 1
- 229960004010 zaleplon Drugs 0.000 description 1
- XQINQMZXDOSBBV-FDPNZRBCSA-N zalospirone hcl Chemical compound Cl.O=C([C@@H]1[C@@H]([C@@H]2C=C[C@H]1[C@H]1C=C[C@H]12)C1=O)N1CCCCN(CC1)CCN1C1=NC=CC=N1 XQINQMZXDOSBBV-FDPNZRBCSA-N 0.000 description 1
- JZFZEWWOIOYBTQ-VJBWXMMDSA-N zenazocine Chemical compound C1C2=CC=C(O)C=C2[C@@]2(C)[C@](CCC(=O)CCC(C)C)(C)[C@@H]1N(C)CC2 JZFZEWWOIOYBTQ-VJBWXMMDSA-N 0.000 description 1
- 229950007802 zidometacin Drugs 0.000 description 1
- 229960002791 zimeldine Drugs 0.000 description 1
- OYPPVKRFBIWMSX-SXGWCWSVSA-N zimeldine Chemical compound C=1C=CN=CC=1C(=C/CN(C)C)\C1=CC=C(Br)C=C1 OYPPVKRFBIWMSX-SXGWCWSVSA-N 0.000 description 1
- 229960000607 ziprasidone Drugs 0.000 description 1
- MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 description 1
- OSKWTWSFSUAPKP-KQUFBQNASA-N zofenoprilat arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N.C1[C@@H](C(O)=O)N(C(=O)[C@@H](CS)C)C[C@H]1SC1=CC=CC=C1 OSKWTWSFSUAPKP-KQUFBQNASA-N 0.000 description 1
- 229960005111 zolpidem tartrate Drugs 0.000 description 1
- YKPUWZUDDOIDPM-VURMDHGXSA-N zucapsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C/C(C)C)=CC=C1O YKPUWZUDDOIDPM-VURMDHGXSA-N 0.000 description 1
- 229960002860 zucapsaicin Drugs 0.000 description 1
- WFPIAZLQTJBIFN-DVZOWYKESA-N zuclopenthixol Chemical compound C1CN(CCO)CCN1CC\C=C\1C2=CC(Cl)=CC=C2SC2=CC=CC=C2/1 WFPIAZLQTJBIFN-DVZOWYKESA-N 0.000 description 1
- 108020001612 μ-opioid receptors Proteins 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明是通过将多种药物联合在一起来治疗成瘾失调。更具体地,本发明将多种药物的使用与行为干预结合起来,来治疗与酒精有关的疾病和失调以及治疗肥胖和调节体重。
Description
与有关的申请的交叉引用
本申请按照美国35U.S.C.§119(e)被授予优先权,是对于以下的临时专利申请,其号码是:60/875,668,2006年12月19日存档,60/898528,2007年1月31日存档,和60/931,031,2007年5月21日存档。
关于联邦资助的研究和发展的声明
本发明是部分在美国政府的国立卫生研究院AA01364号资金资助之下完成的。美国政府对这项专利拥有某一些的权利。
发明领域
本发明总体涉及使用联合疗法来治疗成瘾相关性疾病和病症,和冲动性控制病症特别是酒精相关性疾病和病症。
背景
酒精滥用和依赖是很广泛的,据估计有14万美国成年人在1992年滥用酒精或依赖于它,并且大约有10%的美国人将在他们人生的某个时候受到酒精依赖的影响。酒精依赖是一种遗传,社会心理和环境因素都会影响其发展和表现的慢性疾病,其特点是关注酒精的使用,耐受性和脱瘾。研究显示了阿片类(即Beta-内啡呔),多巴胺(DA),5-羟色胺(5-HT),γ-氨基丁酸(GABA),和谷氨酸对酒精依赖的开发和维持的意义。到目前为止,大多数药物治疗试验的重点放在单一的药理药物。然而,由于对这些药物疗法未能找到一致的结果,针对多个神经递质系统或多个基因的多个药物联合的疗效的调查也许是对于酒精依赖和其他成瘾失调和冲动控制障碍的药物治疗的未来发展更为重要。
各种药物和行为疗法已用于治疗酒精依赖。酒精在神经元的靶点包括许多神经递质系统和参与或调节这些系统的分子,包括GABA,DA,多巴胺,阿片类药物,阿片样肽和5-羟色胺(参照Johnson,2004,Expert Opin.Pharmacother.,5:9:1943-1955的评述)。
尽管在这个领域有一些数量的研究,在美国很少药物的治疗酒精依赖的药品得到批准。已经批准的药品有双硫醒,纳曲酮,(一种长效的纳曲酮制剂),并阿坎酸。双硫醒是一个不可逆转的乙醛脱氢酶抑制剂,会导致乙醛水平的升高,是一种酒精代谢中的有毒的中间物。使用双硫醒并且饮酒的患者会体会到动脉和毛细血管基调的扩张而产生的低血压,恶心,呕吐,面色发红,头痛,并可能在某些人来说,更糟糕的症状。因此,在使用双硫醒的背后的概念的是,酒精依赖的个体会把饮酒和不愉快的不良反应事件关联起来,因此,避免进一步的酒精消费。然而,最近的研究表明,双硫醒的用处有限,因为顺从服药的水平低,除非是由伴侣或配偶来执行服药。
纳曲酮的主要的作用点是在中脑缘通路的μ阿片类受体,推定是通过减少在伏隔核(NAc)的DA的释放来阻断酒精的强化效应。使用纳曲酮的研究报告说,阿片类拮抗与比安慰剂相比能更有效地减少嗜欲和重度饮酒,增加非饮酒天数的百分率,但不一定提高节欲。虽然这些研究支持纳曲酮的疗效,但其他有报告报道只有当个体高度顺从服药时此药才有有限的用处甚至根本没有用。
阿坎酸,GABA的结构类拟物,在近期解毒的个体中被批准可以促进节欲。虽然确切的作用机理还不清楚,这个药物被认为在NAc中可以恢复谷氨酸能介导的抑制和兴奋性神经传递。尽管这些药物在酒精治疗上有重要贡献,然而对许多人来说,节欲甚至减少重度饮酒水平仍然是难以捉摸的。这表明需要发现药物以提供更有效的治疗。
5-羟色胺(5-HT)功能失调可能会有助于酗酒的发展。5-羟色胺的受体在动物里有助于酒精的使用,因为酒精会增加那些能影响5-HT的受体的基底水平。在7个独特的5-HT受体的家庭中,三个已经知道对酒精依赖会有贡献:5-HT1A受体可能与酒精消费和耐受性发展有关联;5-HT2受体与奖赏和5-HT3受体与强化分别有关联。基于这些证据,一些5-羟色胺能的药物已被检验,但得到的是不一致的结果。目前,只有舍曲林与昂丹司琼(一个5-羟色胺-3(5-HT3)拮抗剂)被表明在饮酒过度的患者的某些亚型中似乎有希望,而氟西汀在对抑郁的酗酒者的治疗上有指望(见Kenna,2005,Drug Discovery Today:Therapeutic Strategies,2:1:71-78和Johnson,2000,Alcohol.Clin.Exp.Res.,24:1597-1601)。
5-HT3受体参与酒精奖赏效应的表达。行为药理学研究表明,许多酒精的奖赏效果是由在中脑和皮层的DA和5-HT受体之间的相互作用介导的。5-羟色胺受体在中脑-皮层-边缘含有DA的神经元的末梢里是密集分布的,在这些大脑区域里它们调节DA的释放。这些DA通路,尤其是那些在NAc的,都是在对那些包括酒精的被滥用的药物的奖赏效应的介导有重要的参与。5-HT3受体的阻断会降低DA活性,因此被滥用的药物(包括酒精)的奖赏效应,至少来自三个不同的动物模式。5-HT3受体拮抗剂:1)在大鼠中通过DA或酒精注射到伏隔核而诱导的过度运动得到衰减;2)对DiMe-C7(一种神经激肽)诱导的过度运动的抑制,这也是可通过DA受体拮抗剂氟奋乃静得到抑制;和3)在某些动物模型和不同的物种里减少酒精消费。
尽管在实验室的动物研究和在人的饮酒时段的研究里,主体服用选择性5-羟色胺再摄取抑制剂(SSRIs)之后会减少饮酒,然而在大多数的双盲法、安慰剂对照的使用SSRIs的研究里,饮酒或者其他任何对酒精依赖的测量都没有减少。但是最近的研究提示,由于疾病的异质性,或许酗酒的亚型之间对SSRIs有不同的反应。
动物实验表明,5-HT3受体有利于酒精通过中脑DA释放而产生的某些生化及行为效应。5-HT3拮抗剂在动物研究中一致地表现出对酒精偏好的抑制,并且最近的证据提示5-HT3A受体亚单位对于5-HT3拮抗剂诱导的酒精消费的减少是所必需的。
昂丹司琼,一个5-HT3受体拮抗剂,对SSRIs具有功能相反的效果,并且在5-HT3受体阻断5-羟色胺的激动性。昂丹司琼对早发性酗酒(EOA)而不是对晚发性酗酒(LOA)有效果,其中酗酒发病年龄(年龄低于与高于25岁)是确定酗酒亚型的基础(Johnson,2000,Alcohol.Clin.Exp.Res.,24:1597-1601)。在一项安慰剂对照试验里,271参加者通过分层到EOA和LOA亚型,然后每日两次服用1,4,和16微克/千克剂量的昂丹司琼并与安慰剂相比较(Johnson,2000,J.Am.Med.Assoc.,284:963-971)。EOA患者在服用昂丹司琼后(尤其是每日两次服用4微克/千克的)与LOA在所有的组里面相比饮酒明显减少。在另一项研究,结果表明,昂丹司琼治疗在EOA中与LOA相比更可能与饮酒结果有关联(Kranzler et al.,2003,Alcohol.Clin.Exp.Res.,27:1150-1155)。昂丹司琼在早发性酗酒的个体的检验仍在继续。
这些不同效应的原因仍是未知的;但是,一个假说提示,具有生物易感性的酗酒者所具有的5-羟色胺能的功能调节异常主要是与5-羟色胺转运体(SERT)功能相关联的(Johnson,2000,Alcohol.Clin.Exp.Res.24:1597-1601)。SERT的多态性变异(5′-HTTLPR)目前是被假设分别参与了对昂丹司琼和舍曲林在EOA和LOA酒精依赖个体的有效性上。鉴于流行病学研究表明酒精依赖有大约50-60%的遗传力,在某些有遗传易感性的酗酒者以药物治疗能取得积极成果的前景是有力的。最近的研究,因此,试图界定与酒精依赖相关联的遗传成分。这些发现突出了5-HT在酒精消费发挥的重要作用,尽管在使用5-羟色胺能类药的药物试验上有困难界定反应者与非反应者。
动物研究提示波动的DA水平有助于嗜欲,进而在节欲的酗酒者里导致复发。目标是上调在NAc里的在酗酒者里可能显著地被减少的D2受体(DRD2)的水平的策略,在继续节欲饮酒的期间可能是特别有益的。DA调控一般说来,而且尤其是DA的拮抗性,可能是药物发展的一个重要目标。与酒精信号有关联的奖赏通过中脑缘的通路来操作DA的释放并且精神分裂症的阳性症状似乎享有着类似的多巴胺能功能障碍。抗精神病药调节DA在DRD2的占位性,可能造成一个对DRD2的上调,可能与被减少的精神分裂症的阳性症状和被减少的药物使用是相关联的。
氟哌啶醇,泰必利,奥氮平,与氯氮平对降低嗜欲和酒精消费或增加节欲都表现出不同程度的疗效。虽然它们在理论上是有趣的药物用于研究的,使用DA拮抗剂来作为对酗酒的认真的治疗所带来的风险与典型或非典型精神抑制药的副作用已经超过了其所带来的益处。
阿立哌唑,非典型精神抑制药,很少具有与这些有关的药物相关联的使其受限制的副作用。阿立哌唑是一种部分多巴胺激动剂(PDA),具有混合HT1A/2A活性。如同其他的PDA那样,阿立哌唑在与DA受体的结合上具有高亲和性,但内在活性低,所以在高-或低多巴胺能有效度的条件下可以作为拮抗剂或激动剂。此外作为一种混合HT1A/2A受体药物,阿立哌唑在动物和人里独立显示出明显的减少酒精使用的效果。
中脑和皮层DA通路介导酒精的奖赏效应。酒精消费增加GABA受体活性,抑制中脑DA能神经元和促进DA神经传递。非-N-甲基-D-天冬氨酸(NMDA)谷氨酸拮抗剂阻扰GABA的活性,从而减少DA的释放。托吡酯(一个GABA/谷氨酸调制剂)和加巴喷丁是FDA批准的镇痫药。托吡酯的作为被认为是有多种机制的,包括加强GABA的抑制作用,从而在中脑减少DA的促长,通过对红藻氨酸的拮抗来激活红藻氨酸或AMPA型谷氨酸受体亚型,并抑制碳酸酐酶II型和IV型同工酶(Johnson,2004,Alcohol.Clin.Exp.Res.,28:1137-1144)。加巴喷丁在大脑中降低谷氨酸和增加GABA神经传递。从理论上讲,因此这些药物的独特的药理学正好适合对酒精依赖或脱瘾的治疗,并可以使大脑失调得到正常恢复,这在看到早期节欲期就可以看到。
在一项双盲法安慰剂对照的试验里,150名男性和女性在一个12周的期间里被滴定到每天最大剂量为300毫克托吡酯(Johnson etal.,2003,Lancet,361:1677-1685)。与安慰剂相比,托吡酯臂的参加者被报告在每天的饮酒数、饮酒天数和饮酒天每天的饮酒数上都显著的减少,而有显著多的节欲天数,并有显著低的嗜欲。因为节欲在开始这项研究时不是一个目标,药物在治疗的节欲起始阶段可能会更加有益。虽然加巴喷丁在酒精戒断综合症上作为苯并二氮杂的取代物越有来越多的使用,其为促进酗酒中的节欲作为纳曲酮的潜在的辅助剂也正在调查中。
将纳曲酮和阿坎酸联合在一起的基础是在于酒精依赖的积极和消极强化。纳曲酮可以影响受β-内啡肽阿片系统影响的酒精使用的积极强化,会调制多巴胺释放。消极强化,出现在一个人通过饮料以减少焦虑或减轻脱瘾,可能会受到阿坎酸的在节欲强化效应方面的帮助。虽然每个药物单独来说似乎看上去对于治疗和饮酒结果有中等而显著的影响,充分利用纳曲酮对复发率的减少和阿坎酸对饮酒频率的减少和对节欲的促进是COMBINE这项试验的基础,这项试验除了将这两种药物联合之外,还加上了治疗酒精依赖的行为策略。
在EOA中,纳曲酮曾经与昂丹司琼并服。在一项8周,双盲法,安慰剂对照的试验中,与安慰剂相比,两种药物联合显著地降低了每天的饮酒量和每个饮酒天的饮酒量,并对节欲天的百分比有积极的效果(Ait-Daoud et al.,2001,Psychopharmacology,154:23-27)。作者提示,在EOA病人亚型中将昂丹司琼与纳曲酮相加可以提供一个协同作用。
昂丹司琼和托吡酯已被证明对人的酒精依赖的治疗是有效的,大概是通过它们对皮质-中脑缘的多巴胺(CMDA)的作用。
神经科学的进步大大提高了对各种神经递质系统在对获得和维持酒精依赖的药物-行为效果的认识。药物的或直接或间接的与神经递质的相互作用以调制皮质-中脑缘的多巴胺(CMDA)神经元在过去的十年里是大多数药物学的中心(评述,见Wise and Bozarth,1987,Psychol.Rev.,94:469-492;Hyman and Malenka,2001,Nat.Rev.Neurosci.,2:695-703;Koob,2003,Alcohol Clin.Exp.Res.,27:232-243);和Weiss和Porrino,2002,J.Neurosci.,22:3332-3337)。直接DA拮抗剂未能一致性地表现出疗效,这可能是因为与在直接的突触后的阻断一起发生的高程度的神经适应减轻了对任何长期的治疗效果(Johnson and Ait-Daoud,2002,Psychopharmacology,149:327-344;Kreek et al.,2002,Nat.Rev.Drug Discov.,1:710-726)。
不同类型的联合疗法已用于试图来治疗和预防酒精依赖和狂饮。例如,Anton et al.(2006,J.Am.Med.Assoc.,295:2003-2017)将药物疗法(纳曲酮和阿坎酸)与行为治疗相联合。然而,对于联合药物治疗的有效性,目前的证据是缺乏的(Williams,2005,Am.Fam.Physician,72:9:1775-1780)。联合疗法也正在被检验来试图治疗其他与成瘾有关的疾病和失调。
长期以来,本领域需要组合物和方法用于治疗与成瘾有关的疾病和失调。本申请满足了这一需要。
发明概述
本发明包含一种把药物联合药物来治疗例如酒精依赖的成瘾疾病。由于大多数被滥用的药物的强化效应是由CMDA神经元介导,本发明提供了联合治疗药物,如托吡酯,昂丹司琼和纳曲酮作为有效的治疗成瘾疾病包括(但不限于)酗酒,饮食,可卡因,甲基苯丙胺,大麻,烟草滥用和成瘾,以及其他成瘾行为,包括但不限于,赌博和性。本领域普通技术人员将明白在本发明里用于组合药物治疗的化合物在某些情形下可以单独使用而不是作为一个组合的一部分来使用。本领域技术人员也明白化合物发明有用的组合药物疗法可在某些情况下用于任何组合。
在一个实施方案中,本发明提供了组合物和方法,以治疗或预防与酒精有关的疾病或失调,包括对患者给予具有有效治疗剂量的至少两种抗酒精剂或化合物,及任选的其他的治疗药物。本发明还进一步包含将社会心理管理技术作为辅助使用。一方面,本发明提供方法来治疗或预防在患者的与酒精有关的疾病或失调,包括给予的至少有两种化合物的有效剂量并类拟物,同系物,衍生物,修饰物,和药学上可接受的盐,选自5-羟色胺能制剂,5-羟色胺拮抗剂,选择性5-羟色胺再摄取抑制剂,5-羟色胺受体拮抗剂,阿片类拮抗剂,多巴胺能制剂,多巴胺释放抑制剂,多巴胺拮抗剂,去甲肾上腺素拮抗剂,GABA激动剂,GABA抑制剂,GABA受体拮抗剂,GABA通道拮抗剂,谷氨酸激动剂,谷氨酸拮抗剂,谷氨酰胺激动剂,谷氨酰胺拮抗剂,抗惊厥剂,NMDA阻断剂,钙通道拮抗剂,碳酸酐酶抑制剂,神经激肽,小分子,肽,维生素,协同因子,抗增食欲素剂,大麻素受体-1调节剂和皮质类固醇释放因子拮抗剂。一方面,神经激肽是NPY。本发明进一步包含给予其他的小分子和肽。
在一个实施方案,被治疗的与酒精有关的疾病或失调包括但不限于早发性酗酒,迟发性酗酒,酒精诱发的有错觉的精神障碍,酒精滥用,酒精中毒,酒精戒断性,酒精中毒谵妄,酒精戒断性谵妄,酒精诱发的持续性痴呆,酒精诱发的持续遗忘障碍,酒精依赖,酒精诱发的伴有幻觉的精神障碍,酒精诱发的情绪障碍,酒精诱发的或相关联的双相情感障碍,酒精诱发的或相关的创伤后压力心理障碍症,酒精诱发的焦虑症,酒精诱发的性功能障碍,酒精诱发的睡眠障碍,酒精诱发的或相关联的赌博障碍,酒精诱发的或相关联的性失调,没有另行指定的与酒精有关的失调,酒精中毒,和酒精戒断性。
在一个实施方案,本发明提供了组合物和方法,使与治疗前酒精消费频率相比,酒精消费频率降低。本领域普通技术人员将明白可以与患者先前的消费或一个没有接受治疗的对照患者的消费进行比较。一方面,该酒精消费的类型是酗酒。
在一个实施方案,本发明提供了组合物和方法,与在治疗前的酒精消费量进行比较或与一个没有接受治疗的对照患者的消费量进行比较,在一个患者里减少酒精消费量。
本发明的一个实施方案,本发明提供了组合物和方法,与一个没有接受治疗的对照患者进行比较,提高与酒精消费有关的身体或心理的后遗症。
在一个实施方案,本发明提供了组合物和方法,与一个没有接受治疗的对照患者进行比较,提高节欲率。
在一个实施方案,本发明提供了组合物和方法,与在治疗前的酒精消费水平进行比较或与一个没有接受治疗的对照患者的消费水平进行比较,在一个患者里减少酒精消费的平均水平。
在一个实施方案,本发明提供了组合物和方法,与在治疗前患者或与一个没有接受治疗的对照患者的酒精消费相比较,减少酒精消费和增加节欲。
在一个实施方案,本发明提供了组合物和方法来治疗一个有早发性酗酒倾向的患者。
在一个实施方案,本发明提供了组合物和方法来治疗有迟发性酗酒倾向的患者。
本领域普通技术人员将明白酒精消费具有多种参数或特征可被用来记述一个受与酒精有关的疾病或失调折磨的患者的特点。它也会意识到,联合疗法可有效治疗一个以上的参数,并有多种方法分析治疗效果。当测量酒精消费或酒精消费的频率,被分析的参数包括但不限于,重度饮酒天,重度饮酒天数,平均饮酒天数,每天饮酒的数量,节欲的天数,和嗜欲。主观和客观的测量都可用来分析治疗的有效性。例如,一个患者可以根据为报告而建立的准则和程序来自我报告。这些程序可以在治疗前、中、后不同的时间来执行。此外,用于测量酒精消费的测定法有现成可用的。这些测定法包括呼气酒精仪表读数,测定血清的CDT和GGT水平,和测定尿的5-HTOL水平。
本发明进一步提供与联合药物疗法同时使用的辅助疗法。本发明还提供进一步辅助的疗法或治疗,使患者顺从于一项社会心理管理计划。社会心理管理计划在本领域已知包括但不限于简短的行为顺从促进治疗,认知行为应对技巧疗法,动机强化疗法,动机增强疗法,十二步促长疗法(匿名的酗酒者),联合的行为干预,医疗管理,心理分析,心理动力治疗,和生物社会心理,报告,感情移入作用,需求,直接咨询和评估。本发明还包括使用另外的辅助疗法和治疗,包括催眠和针灸。
在一个实施方案,在服用的化合物里至少其中之一至少每天服用一次。在一方面,其服用至少每天两次。在另一个方面,其服用至少每周一次。在又一个方面,其服用至少每月一次。
在一个实施方案,化合物里至少其中之一是5-羟色胺受体拮抗剂。在一方面,5-羟色胺受体是5-羟色胺-3受体。在一方面,该化合物是昂丹司琼。
在一个实施方案,患者服用至少三种不同的化合物。
本领域普通技术人员将明白当两个或两个以上的化合物被服用时不一定要被同时服用或相同剂量。在一方面,当这些被作为药物联合疗法一部分的化合物也可被单独服用。在另一个方面,第一种化合物在第二种化合物被服用之前被服用。在又一个方面,第一种化合物和第二种化合物近乎同时被服用。在进一步的一个方面,第一种化合物在第二种化合物被服用之后被服用。
本发明进一步提供包含本发明化合物的药用组合物。药用组合物可能包括一个或多个本发明的化合物,并具有生物活性的类拟物,同系物,衍生物,修饰物,和药学上可接受的盐,和药学上可接受的载体。在一个实施方案,这些化合物被作为药用组合物被服用。
给药的途径可能依据所给的化合物的类型而变化。在一方面,该化合物通过如下的途径被给予,口服的,外用的,直肠的,肌肉内的,粘膜内的,鼻内的,吸入的,眼的,和静脉内的。
本发明进一步提供本发明中的化合物可以作为释控制剂来给予。
在一个实施方案,本发明提供了从一组包括托吡酯,昂丹司琼和纳曲酮的化合物里挑选出至少两种化合物来服用。在一方面,被服用的两种化合物是托吡酯和昂丹司琼。
在一个实施方案,本发明通过使用包括有效剂量的托吡酯和昂丹司琼的药用组合物而提供了对治疗与酒精有关的疾病和失调的组合物和方法。
被服用的具有活性的化合物的剂量将取决于正在接受治疗的条件,特定的化合物,和其他临床因子,如正在接受治疗的患者的年龄,性别,体重和健康,化合物的给药的途径,和被给予的组成类型(片剂,胶囊,溶液,悬浮液,吸入器,气溶胶,酏剂,锭剂,注射剂,贴片,油膏,乳膏等)。可以这样理解,本发明适用于人体和兽医学使用。
例如,在一个与在人体的口服有关的实施方案里,一个介于约0.1和300毫克/千克/天之间的剂量,或介于约0.5和50毫克/千克/天之间的剂量,或介于约1和10毫克/千克/天之间的剂量,通常是足够的,但将取决于以下的情况,正在被治疗的失调,治疗的时间,患者的年龄,性别,体重,和/或健康问题等。药物的组合可以以包含所有正在使用的药物的制剂来给予,或者药物可以分别给予。在某些情况下,期望给予多剂量/多次是有必要或者才起作用的。此外,在大多数的治疗方案上,至少有两种化合物将被使用。本发明还提供不同的治疗时间长度。
托吡酯在此是被作为一个在组合药物疗法中有用的药物。在一个实施方案,托吡酯是在剂量在约15毫克/天到约2500毫克/天的范围给予的。在一方面,托吡酯是在剂量在约25毫克/天到约1000毫克/天的范围给予的。在又一个方面,托吡酯是在剂量在约50毫克/天到约500毫克/天的范围给予的。在再一个方面,托吡酯是以约为300毫克/天的剂量来给予的。在又再一个方面,托吡酯是以约为275毫克/天的剂量来给予的。在一方面,托吡酯是以约为1毫克/天的剂量来给予的。
在一个实施方案,托吡酯是以约1毫克/千克的剂量来给予的。在一方面,托吡酯是以约10毫克/千克的剂量来给予的。在一方面,托吡酯是以约100毫克/千克的剂量来给予的。在一个实施方案,托吡酯是在剂量在约0.1毫克/千克/天到约100毫克/千克/天的范围来给予的。
托吡酯(C12H21NO8S;国际理论化学和应用化学联合会(IUPAC)名称:2,3:4,5-双-O-(1-甲基亚乙基)-β-D-吡喃果糖氨基磺酸酯;化学文摘(CAS)登录号97240-79-4)具有以下结构:
昂丹司琼是作为一个在本发明的在本文被披露的组合药物疗法中有用的药物。在昂丹司琼被用来作为一个联合疗法中的一种化合物时,其被给予的剂量和治疗方案可根据其他与其一同被给予的药物或若干种药物而变化,或基于其他标准,例如患者的年龄,性别,健康,和体重。本发明因此提供了使用不同剂量的昂丹司琼,例如约0.01微克/千克,约0.1微克/千克,约1.0微克/千克,约5.0微克/千克,约10.0微克/千克,约0.1毫克/千克,约1.0毫克/千克,约5.0毫克/千克,以及约10.0毫克/千克。在另一个实施方案,昂丹司琼在每次应用时是在剂量在约0.01微克/千克到约100微克/千克的范围来给予的。在一方面,昂丹司琼在每次应用时是在剂量在约0.1微克/千克到约10.0微克/千克的范围来给予的。在又一个方面,昂丹司琼在每次应用时是在剂量在约1.0微克/千克到约5.0微克/千克的范围来给予的。在再一个方面,昂丹司琼在每次应用时被给予约4.0微克/千克的剂量。在另一个方面,昂丹司琼在每次应用时被给予约3.0微克/千克的剂量。
昂丹司琼(C18H19N3O;化学文摘(CAS)登录号99614-02-5;国际理论化学和应用化学联合会(IUPAC)名称:9-甲基-3-[(2-甲基-1H-咪唑-1-基)甲基]-1,2,3,9-四氢咔唑-4-酮)具有以下结构:
本发明进一步提供使用其他药物如纳曲酮作为在这里被披露的药物联合疗法中的一部分。在一个实施方案,纳曲酮是以约为10毫克/天的剂量来给予的。在一方面,纳曲酮是以约为100毫克/天的剂量来给予的。在另一方面,纳曲酮在每次应用时是在剂量在约1毫克到约100毫克的范围来给予的。在本发明的再一个方面,每次使用时纳曲酮给予剂量为10毫克到50毫克。为了进一步方面的发明,昂丹司琼在每次应用时被给予约25毫克的剂量。
纳曲酮(C20H23NO4;17-(环丙基甲基)-4,5a-环氧-3,14-二羟基吗啡烷-6-酮盐酸盐;化学文摘(CAS)登录号16590-41-3)具有以下结构:
在一个实施方案,对一个患者用两个或更多个的化合物的联合治疗与使用任何单独的化合物的效果相比,结其果是加性的。在一个方面,使用两个或更多个的化合物的所看到的效果大于使用任何单独的化合物的效果。
在一个实施方案,对一个患者用两个或更多个的化合物的联合治疗与使用任何单独的化合物的效果相比,结其果是协同的。
在一个实施方案,其他化合物可用于与托吡酯和昂丹司琼相联合,例如,纳曲酮。
在本发明中附加的化合物可以被使用来对患者进行治疗。附加于以上所述的将至少两种药物联合来治疗,本发明还进一步提供了对本发明要治疗或预防疾病和失调可以给予至少一个额外的化合物来,包括但不限于双硫醒,阿坎酸,舍曲林,加兰他敏,纳美芬,纳洛酮,去氧骆驼蓬碱,苯并二氮杂,精神抑制药,利培酮,利莫那班,曲唑酮,氯苯氨丁酸,大麻素受体-1调节剂,食欲素调节剂,和阿立哌唑。在一方面,在托吡酯和昂丹司琼联合治疗药物上使用附加的化合物。本领域普通技术人员将明白,在某些情形下,在联合疗法中使用这些额外的化合物,将有加性效应和在某些情况下将有协同效应。在本领域中,对这些的联合来进行测试并且去分析其结果的方法是已经知道的。
除了在此处所描述的治疗或预防与成瘾有关的疾病和失调的联合药物疗法之外,如酒精有关的疾病和失调,其他类型的化合物可被给予来进一步治疗与成瘾有关的疾病和失调或者治疗其他疾病和失调。这些其他类型的化合物包括,但不限于肾上腺素能剂,肾上腺皮质类固醇激素,肾上腺皮质抑制剂,醛固酮拮抗剂,氨基酸,催醒剂,止痛剂,减食欲化合物,减食欲剂,抗焦虑剂,抗抑郁剂,抗高血压药,消炎药,止恶心药,抗中性白细胞减少药,抗强迫药,抗帕金森氏药,抗精神病药物,食欲抑制剂,血糖调节剂,碳酸酐酶抑制剂,强心剂,心血管药物,利胆剂,类胆碱(功)能药,胆碱能激动剂,胆碱酯酶去活化剂,认知佐剂,认知促进剂,激素,记忆佐剂,心理性能增强剂,情绪调节剂,精神抑制剂,神经保护剂,精神药物,松弛剂,镇静催眠药,兴奋剂,甲状腺激素,甲状腺抑制剂,拟甲状腺剂,脑缺血剂,血管收缩剂,和血管扩张剂。
在一个实施方案,本发明提供了减少中脑-皮层-边缘多巴胺活动性的方法和有用组合物。
在一个实施方案,本发明提供了调节中脑-皮层-边缘多巴胺活动性的方法和有用组合物。
在一个实施方案,本发明提供了抑制谷氨酸功能的方法和有用组合物。
在一个实施方案,本发明提供了促进γ-氨基丁酸的活动性的方法和有用组合物。
在一个实施方案,本发明提供了调节γ-氨基丁酸的活动性的方法和有用组合物。
本发明为此发明的药物的传送提供了多种方法。化合物可以例如以多种样式的药用组合物来提供也同样,包括,但不限于片剂,胶囊,丸剂,含片,糖浆,油膏,乳膏,酏剂,栓剂,悬浮液,吸入剂,注射剂(包括储库型制剂),和液体。
本发明还包含根据此发明的化合物的具有生物活性的类拟物,同系物,衍生物,和修饰物。在本领域中制备这些化合物的方法是已知的。在一方面,这些化合物是托吡酯,昂丹司琼和纳曲酮。
在这里所描述的治疗或预防与酒精相关的疾病和失调也对治疗或预防与成瘾有关的疾病和失调和冲动控制障碍。在一方面,这些组合物和方法引起了对CMDA神经元的间接的效应。这些可能会被引起的效应,例如,通过5-羟色胺能药物,阿片制剂,谷氨酸,或γ-氨基丁酸受体。在一方面,成瘾疾病和失调包括饮食失调,冲动控制障碍,与尼古丁相关的失调,与苯丙胺相关的失调,与大麻相关的失调,与可卡因相关的失调,致幻剂使用失调,与吸入剂有关的失调,与苯并二氮杂滥用或依赖相关的失调,和与阿片相关的失调。
本发明的组合物和方法也对多方面的联合治疗方法来治疗和调节体重下降,肥胖,和体重增加来说是有用的。本发明提供的不仅仅是单一的化合物,而所代替的是对于取食和饱腹感的通路上的多点都会有产生作用。进一步的,因为一些药物如托吡酯,昂丹司琼和纳曲酮有能力导致体重的减轻,可能是通过不同的机制(昂丹司琼对肠道蠕动和饱腹感的周边效应,纳曲酮通过降低暴饮暴食的冲动,以及托吡酯是通过对葡萄糖代谢的中央或代谢效应),这些效应也可能加在一起有协同性以至成为一种治疗剂,可用于在体重超重的个体中治疗肥胖症或协助诱导体重减轻,或可用于有利于减轻体重的任何情形下。真正的,这样的联合法来治疗肥胖症其吸引人之处在于其在诱导减肥的同时,也将诱导消费大量的食物的嗜欲和冲动性的减少(也是通过CMDA神经元介导的)。
因此,本发明用于治疗成瘾失调和相关联的冲动的联合疗法,包括肥胖,是一种新的和有用的治疗。基于数据和这里提供的描述,以及在本领域中已经知道的,本领域普通技术人员将知道如何把如托吡酯,昂丹司琼和纳曲酮这样的药物联成多种样式来优化本发明。这些药理学样式包括(但不限于)片剂,胶囊,可咀嚼的和在口腔里可吸收的材料(例如,舌下片剂),酏剂,悬浮液,吸入剂,喷雾剂,贴片,油膏和香膏,长效肌肉内注射(连同已被FDA批准的聚交酯胶囊或纳米技术),以及静脉内注射,皮下,粘膜内,或任何其他注射途径。
在一个实施方案,本发明为治疗肥胖提供了组合物和方法来对患者在有需要时给予至少有两种化合物的有效剂量,并类拟物,同系物,衍生物,修饰物,和药学上可接受的盐,选自5-羟色胺能制剂,5-羟色胺拮抗剂,选择性5-羟色胺再摄取抑制剂,5-羟色胺受体拮抗剂,阿片类拮抗剂,多巴胺能制剂,多巴胺释放抑制剂,多巴胺拮抗剂,γ-氨基丁酸激动剂,γ-氨基丁酸抑制剂,γ-氨基丁酸受体拮抗剂,γ-氨基丁酸通道拮抗剂,谷氨酸激动剂,谷氨酸拮抗剂,抗惊厥剂,和NMDA阻断剂,并且可选择性地与至少一种附加的有治疗活性的化合物相联合。
在一个治疗肥胖的实施方案,附加的有治疗活性的化合物是从包括抗糖尿病剂,抗高血脂剂,抗肥胖剂,抗高血压药和治疗与糖尿病相关联的并发症的药的组里挑选。
在一个治疗肥胖的实施方案,患者的身体质量指数约30.0或更高。
在一方面,被治疗肥胖的患者也接受了社会心理管理计划。
在对与酒精相关的疾病和失调和肥胖的治疗有用的组合物,联合疗法,对于调节体重增加和体重减轻也有作用。在一个实施方案,本发明为预防或抑制体重增加提供了有用的组合物和方法。在另一个方面,本发明为刺激体重减轻提供了有用的组合物和方法。例如,本发明的组合物和方法对于体重超重的患者的治疗是有用的,例如患者的身体质量指数在约25.0至约29.9之间。本领域普通技术人员将明白,与预防或减少体重增加相比较,相似的剂量和药物也是可用的,并且了解对于所给予的化合物的剂量和方案作出如何的调节。在一个实施方案,本发明使用托吡酯,昂丹司琼和纳曲酮这样的药物为调节体重控制提供了治疗。
在一个实施方案,其组合物和方法也有用于抑制食欲。
在一个实施方案,本发明的组合物和方法也有用于治疗或预防一个在与酒精有关的疾病和失调以外的与成瘾有关的疾病或失调以及体重控制的疾病和失调。其方法包括给予至少有两个本发明的化合物的有效剂量,并类拟物,衍生物,修饰物,和药学上可接受的盐。在一方面,这些化合物包括但不限于,5-羟色胺能制剂,5-羟色胺拮抗剂,选择性5-羟色胺再摄取抑制剂,5-羟色胺受体拮抗剂,阿片类拮抗剂,多巴胺能制剂,多巴胺释放抑制剂,多巴胺拮抗剂,去甲肾上腺素拮抗剂,γ-氨基丁酸激动剂,γ-氨基丁酸抑制剂,γ-氨基丁酸受体拮抗剂,γ-氨基丁酸通道拮抗剂,谷氨酸激动剂,谷氨酸拮抗剂,谷氨酰胺激动剂,谷氨酰胺拮抗剂,抗惊厥剂,N-甲基-D-天冬氨酸阻断剂,钙通道拮抗剂,碳酸酐酶抑制剂,神经激肽,和皮质类固醇释放因子拮抗剂。在一方面,这些化合物是托吡酯,昂丹司琼和纳曲酮。
该发明提供了在治疗成瘾疾病和失调的这些药物在使用上的一切可能的排列和组合,或者是单独或是任何的组合。在一个实施方案,成瘾失调包括,但不限于,饮食失调,冲动控制障碍,赌博障碍,性功能障碍,与尼古丁相关的失调,与苯丙胺有关的失调,与大麻有关的失调,与可卡因有关的失调,致幻剂使用失调,与吸入剂有关的失调,与苯并二氮杂滥用或依赖相关的失调,和与阿片相关的失调。食物和饮食失调包括,例如,暴饮暴食。在一方面,把联合药物疗法与行为调整疗法或干预一起提供。
本发明进一步提供给予本发明的化合物的试剂盒。
附图简述
图1,包含图1A,1B,1C,和1D,用图解法阐明了在酒精偏好(P)大鼠里托吡酯(10毫克/千克,IP)和昂丹司琼(0.001毫克/千克,IP)对酒精消费的联合效果。1A-单独的托吡酯;1B-单独的昂丹司琼;1C-昂丹司琼加托吡酯;1D-载体。纵坐标表示以克/千克表示的乙醇摄入量和横坐标表示时期数。
图2用图解法阐明了在两个星期节欲期之后的酒精偏好(P)大鼠里托吡酯(10毫克/千克,IP)和昂丹司琼(0.001毫克/千克,IP)对酒精消费的联合效果。纵坐标以基线变化百分比来表示酒精消费。横坐标表示载体,托吡酯,和昂丹司琼/托吡酯的联合。
图3用图解法阐明了在Wistar大鼠里低和高剂量的托吡酯(5和10毫克/千克,IP)和昂丹司琼(0.001和0.01毫克/千克,IP)对酒精消费的联合效果。纵坐标以基线变化百分比来表示酒精消费。横坐标表示载体,低昂丹司琼/低托吡酯,高昂丹司琼/低托吡酯,低昂丹司琼/高托吡酯,和高昂丹司琼/高托吡酯。
图4,包含图4A和4B,用图解法阐明了在P大鼠(4A)和Wistar大鼠(4B)里托吡酯(0,5,和10毫克/千克),昂丹司琼(0,0.001,和0.01毫克/千克),以及它们的联合(5和10毫克/千克托吡酯和0.001毫克/千克昂丹司琼)对酒精消费的效果。数据是跨过连续7个时期来绘制的,包括一个3天的基线期,测试期(注射当天)(0),和之后的3个时期。每只大鼠(N=18P大鼠;N=5Wistar大鼠)接受每个药物以及药物联合的每个剂量,而注射的顺序是随机的。每只大鼠在载体条件下进行了3次测试,其平均值被显示出。测试期被至少三个稳定期所分开。总体显著性首先在任何随后的比较之前得到。*与载体有显著差异;+与10毫克/千克单独的托吡酯有显著差异;#与10毫克/千克单独的托吡酯有显著差异的趋势(P=0.09)。为简单起见,所表示的数据是0.001毫克/千克剂量的托吡酯,因为它是剂量联合研究里的最完整的数据。图4A包括四个面板,图4B也包括四个面板。每个的左上角的面板显示单独的托吡酯。每个的右上角的面板显示单独的昂丹司琼。左下角的面板显示托吡酯和昂丹司琼的联合。在每个条件下与基线相比的百分比变化在右下角面板显示(是指在测试期)。
图5,包含图5A和5B,用图解法表示在P大鼠(A)和Wistar大鼠(B)里载体,托吡酯(10毫克/千克),昂丹司琼(0.001毫克/千克,只是P大鼠)并托吡酯和昂丹司琼的组合(分别为10/0.001毫克/千克)对酒精剥夺效应(ADE)的影响。数据是跨过连续7个时期来绘制的,包括一个3天的基线期,乙醇被恢复的测试期(1),和测试期之后的3个时期。对每个状态与基线相比的百分比变化进行了表示(在测试当天,1)。每只大鼠(N=18P大鼠;N=5Wistar大鼠)在每个条件下进行了测试,而条件之间的顺序在时期之间是均衡的。在每一轮的ADE测试之前大鼠在至少三周被维持于乙醇上。*与载体有显著差异;+与10毫克/千克单独的托吡酯有显著差异。图5A和5B每一个包括一个表示乙醇摄入的左面板和一个表示基线变化的右面板。
图6,包含图6A和6B,用图解法阐明了在P大鼠里(图6A)和在Wistar大鼠里(图6B)在急性测试期里载体,托吡酯(5和10毫克/千克),和托吡酯与昂丹司琼的联合(分别是5和10毫克/千克以及0.001毫克/千克)对水消费的效果。数据是把每个测试期观察到的平均值和在每个测试期之前的基线平均值来绘制的。每个数据点表示的是N=18(P大鼠)或N=5(Wistar大鼠)。
图7用图解法阐明了在人体用托吡酯和昂丹司琼的联合来治疗酒精依赖。纵坐标表示饮酒数/天,并且横坐标表示时间(以周为单位)。
详细描述
缩写名,通用名,和首字母缩略词
5-HT-5-羟色胺
5-HT3-5-羟色胺受体的亚型,5-羟色胺-3受体
5-HTOL-5-羟基色醇
ADE-酒精剥夺效应
BBCET-简短的行为顺从促进治疗
BED-暴饮暴食症
b.i.d.-一日两次
BRENDA-生物社会心理,报告,感情移入,需求,直接咨询和评估
CBI-联合行为干预
CBT-认知行为应对技巧疗法,也被指作认知行为疗法
CDT-碳水化合物缺乏转铁蛋白
CMDA-皮质中脑缘的多巴胺
DA-多巴胺
EOA-早发性酗酒
GABA-γ-氨基丁酸(也被指作γ-氨基丁酸)
GGT-γ-谷氨酰转移酶
ICD-冲动控制障碍
IP-腹膜内
LOA-迟发性酗酒
MET-动机增强疗法
MM-医疗管理
NAc-伏隔核
纳曲酮-一种μ阿片受体拮抗剂
NMDA-N-甲基-D-天门冬氨酸
NOS-没有另行指定
P-酒精偏好大鼠
SSRI-选择性5-羟色胺再摄取抑制剂
TSF-十二步促长疗法(匿名的酗酒者)
VTA-腹侧被盖区
定义
在描述和声明本发明时,以下的专有名词将根据在以下所给的定义来使用。除非另有规定,在这里所用到的所有技术和科学词汇与在本发明所属领域里的普通技术人员的通常的理解是具有相同的涵义。虽然任何与在这里所描述的相类似和相等同的方法和材料也可以用于本发明的实践或测试,在这里我们只描述首选的方法和材料。在本节中,在这里所使用的每一个下列的术语都有与其相关联的含义。在下面所列的基团,取代基,以及范围的特定的和首选的值只是用于说明的目的,它们并不排除基团和取代基界定范围之内其他定义的值或其他的值。
在这里所使用的,本文中的冠词“一”是指一个或一个以上,即至少有一个在文章的语法里的对象。通过举例来说,“一个成份”是指一个成份或一个以上的成份。
术语“约”,在这里所使用,意味着大约,在其区域,粗略地,在其附近。当术语“约”与一个数值范围结合使用时,它通过把所设的数值的上下边界扩展来加以修改。一般来说,术语“约”,在这里所使用,是指在所述数值的上下各加20%的方差来修改这个数值。
“成瘾失调”包括,但不限于,饮食失调,冲动控制障碍,与酒精有关的失调,与尼古丁有关的失调,与苯丙胺有关的失调,与大麻有关的失调,与可卡因相关的失调,赌博,性功能障碍,致幻剂使用失调,与吸入剂有关的失调,与苯并二氮杂滥用或依赖相关的失调,和与阿片相关的失调。
术语“附加的有治疗活性的化合物”,在本发明的上下文里,是指一种化合物在使用或者给予时不仅是对于所要治疗的失调而言而是指其附加的治疗用途。这种化合物,例如,可包括一种是被用来治疗一个无关的疾病或失调,或者一个对于成瘾疾病或失调的主要治疗可能无法作出反应的疾病或失调。被附加的有治疗活性的化合物所进行治疗的疾病和失调包括,例如,高血压和糖尿病。
在这里所使用,术语“气雾剂”,是指在空气中的悬浮体。特别的,气雾剂是指本发明的颗粒化或雾化的制剂和它在空气中的悬浮体。
在这里所使用,“受影响的细胞”,是指一个患有一个疾病或失调的患者的一个细胞,从而受影响的细胞与一个没有患有疾病,不具有状况,没有失调的患者相比有被改变的表型。
细胞或组织“被影响”因于一个疾病或者失调是指细胞或组织与一个没有患有疾病,不具有状况,没有失调的患者的相同的细胞或组织相比有被改变的表型。
在这里所使用,“激动剂”是指物质成分,当被给予哺乳动物例如人的时候,增强或扩展了一个所感兴趣的生物活性。这种效应可能是直接的或间接的。
“与酒精有关的疾病”在这里所使用是指与酒精消费有关的疾病和失调,包括,但不限于,酒精诱发的有错觉的精神障碍;酒精滥用;酒精中毒;酒精戒断性;酒精中毒谵妄;酒精戒断性谵妄;酒精诱发的持续性痴呆;酒精诱发的持续遗忘障碍;酒精依赖;酒精诱发的伴有幻觉的精神障碍;酒精诱发的情绪障碍;酒精诱发的或相关联的双相情感障碍;酒精诱发的或相关的创伤后压力心理障碍症;酒精诱发的焦虑症;酒精诱发的性功能障碍;酒精诱发的睡眠障碍没有另有规定(NOS)的与酒精有关的疾病。
在这里所使用,“氨基酸”是由全称来表示,由与其相对应的三个字母代码来表示,或由与其相对应的一个字母代码来表示,如下表所示:
全称 三个字母代码 一个字母代码
天冬氨酸 Asp D
谷氨酸 Glu E
赖氨酸 Lys K
精氨酸 Arg R
组氨酸 His H
酪氨酸 Tyr Y
半胱氨酸 Cys C
天冬酰胺 Asn N
谷氨酰胺 Gln Q
丝氨酸 Ser S
苏氨酸 Thr T
甘氨酸 Gly G
丙氨酸 Ala A
缬氨酸 Val V
亮氨酸 Leu L
异亮氨酸 Ile I
蛋氨酸 Met M
脯氨酸 Pro P
苯丙氨酸 Phe F
色氨酸 Trp W
表达语“氨基酸”在这里所使用是指包括天然氨基酸和合成氨基酸都在内的,并包括D和L氨基酸。“标准氨基酸”是指任何在常见的自然出现的肽里的二十个标准L-氨基酸。“非标准氨基酸残基”是指在标准氨基酸以外的其他的任何氨基酸,无论是合成制备的或是来自于天然来源的。在这里所使用的“合成氨基酸”也包含经过化学修饰的氨基酸,包括但不限于盐,氨基酸衍生物(如酰胺),和取代物。在本发明的肽所包含的氨基酸里,特别是在羧基端或氨基端,可以通过甲基化,酰胺化,乙酰化来修饰或被其他的化学基团所取代以致能改变肽的循环的半衰期,不会对它们的活性有不利的影响。此外,在本发明的肽里二硫键可能存在或不存在。
术语“氨基酸”在这里与“氨基酸残基”在使用上可以互换,并可以指游离的氨基酸和肽上的氨基酸残基。是否指的是游离的氨基酸或肽上的氨基酸残基通过上下文将是明显的。
氨基酸有以下的通用结构:
氨基酸根据侧链R可分为七组:(1)脂肪族侧链;(2)含有羟基(OH)的侧链;(3)含有硫原子的侧链;(4)含有酸性或酰胺基团的侧链;(5)含有碱性基团的侧链;(6)含有芳香环的侧链;和(7)脯氨酸,是一个亚氨基酸而其侧链与其氨基是稠合的。
在这里所使用的“氨基酸置换”是指在以下五个组里的互换:
I.小的脂肪族的,非极性或略有极性的残基:
丙氨酸(Ala),丝氨酸(Ser),苏氨酸(Thr),脯氨酸(Pro),甘氨酸(Gly);
II.极性的,带负电荷的残基及其酰胺:
天冬氨酸(Asp),天冬酰胺(Asn),谷氨酸(Glu),谷氨酰胺(Gln);
III.极性的,带正电荷的残基:
组氨酸(His),精氨酸(Arg),赖氨酸(Lys);
IV.大的,脂肪族的,非极性的残基:
蛋氨酸(Met),亮氨酸(Leu),异亮氨酸(Ile),缬氨酸(Val),半胱氨酸(Cys)
V.大的,芳香族的残基:
苯丙氨酸(Phe),酪氨酸(Tyr),色氨酸(Trp)
本发明用来描述肽化合物的命名法,沿用了常规的做法,也就是把每个氨基酸残基的氨基放在左边和把羧基放在右边。用来表示本发明被选择出来的实施方案的表达式里,氨基端和羧基端基团,尽管没有被特别地提示,将会被理解为它们在生理pH值的形式,除非另有说明。
术语“碱性的”或“带正电荷的”氨基酸,在这里所使用,是指那些R基团在pH 7.0带净正电荷的氨基酸,并包括,但不限于,标准氨基酸的赖氨酸,精氨酸和组氨酸。
在这里所使用的,化学化合物的“类拟物”是化合物,通过举例来说,与另一个在结构上类似但不一定是其异构体(例如,5-氟尿嘧啶是胸腺嘧啶类拟物)。
“拮抗剂”是指物质成分,当给予一个哺乳动物比如人的时候,抑制或妨碍在哺乳动物里的可归因于一个内源性化合物的水平或者存在的生物活性。这种影响可能是直接的或间接的。
在这里所使用的,术语“抗酒精剂”是指任何有活性的药物,制剂,或方法,表现出对治疗和预防疗酒精成瘾,酒精滥用,酒精中毒,和/或酒精戒断性的一个或一个以上症状的活性,包括在哺乳动物的患者里显著地减少,限制,或预防酒精消费的药物,制剂和方法。
术语“食欲抑制”,在这里所使用,是指减少,降低,或在过量的食物消费的情形下,对食欲的改良。这种抑制减少了对食物的渴望或者嗜欲。食欲抑制可导致体重减轻或所渴望得到的体重控制。
术语“平均饮用量”在这里所使用,是指在一个星期期间里所消费的饮料数。术语“平均饮用量”在这里与术语“平均水平饮用量”在使用上可以互相交换。
“化合物”,在这里所使用,是指任何类型的物质或者制剂普遍认为这是药物,或候选药物,以及以上物质的组合和混合物。
“对照”患者是一个与测试患者具有相同特征的患者,例如一个类似的依赖类型等。对照患者可以,例如,在与测试患者正在接受治疗或被检验的确切的或者几乎相同的时间被检验。对照患者也可以,例如,在与测试患者被检验的时间远距离的时间被检验,而且对照患者的检验结果与从测试患者检验得到的结果可以进行比较。
“测试”患者是指一个正在被治疗的患者。
在这里所使用,化合物的“衍生物”是指化学上的化合物可以从另一个有类似结构的化合物通过一个或更多个步骤生产出来,如把氢原子(H)取代为烷基,酰基,或氨基基团。
“疾病”是指患者处于这样的健康状态,患者不能保持内环境稳定,并且如果疾病得不到改良那么患者的健康继续恶化。与此相反,一个在患者里“失调”是指患者处于一个这样的健康状态那就是患者能够保持内环境稳定,但是患者的健康状态与没有这个失调相比不利。然而,以上所描述的“疾病”和“失调”的定义并不意味着会取代那些与特指的成瘾疾病或失调有关的定义或者普遍用法。
疾病,病症,或失调得到“缓解”是指疾病或失调的症状的严重性,病人所经历的这一症状的频率,或者这两者,都得到了减少。
在这里所使用,“有效剂量”意味着能够产生要选择的效应的足够的剂量,例如缓解疾病或失调的症状。在给予两个或更多种化合物的情景里,每种化合物的剂量,当与另一个(些)化合物组合在一起给予的时候,可能不同于当这种化合物被单独给予的时候。
术语“酏剂”,在这里所使用,一般是指透明的,加糖的,通常含有酒精的含有香味物质的水醇液体,有时含有有活性的药剂。
在这里所使用,有“功能”的分子是指处在呈现出其所具有的特征的性质或者活性的那一个状态的分子。有功能的酶,举例来说,是呈现出其所具有的特征的特征催化活性的一个。
“重度饮酒天,”在这里所使用的,是指男人或女人在每一个饮酒天所消费的标准饮料分别多于约5个或4个。
在这里所使用,术语“吸入器”是指将如溶液,粉末和相类似的药物通过鼻腔和肺来给予的装置。举例而言,术语“吸入器”的目的是包括由推进器驱动的吸入器,这样如被用于对急性哮喘发作来给予抗组胺药,和塑料的喷雾瓶,如用来给予解充血药。
术语“抑制”,在这里所使用的,是指化合物或任何制剂的能力,以减少或阻碍被描述的功能,水平,活性,合成,释放,结合等,并以术语“抑制”所使用的情景为基础。较合宜的,抑制了至少10%,更合宜的至少25%,甚至更合宜的的至少50%,而且最合宜的,是功能被抑制了至少75%。术语“抑制”与术语“减少”和“阻断”是被互换使用的。
术语“抑制复合体”,在这里所使用的,是指抑制复合体的形成或与两个或更多蛋白质的相互作用,和抑制此复合体的功能或活性。这一术语还包含分裂已形成的复合体。然而,这个术语并隐含着这个复合体的所有的每一个功能必须同时被抑制。
术语“抑制蛋白质”,在这里所使用的,是指任何方法或技术以抑制蛋白质的合成,水平,活性,或功能,以及抑制所感兴趣的蛋白质的合成,水平,活性,或功能的诱导或刺激的方法。这个术语也指任何代谢或调节的通路,可以调节感兴趣的蛋白质的合成,水平,活性,或功能。这一术语包括与其他分子的结合和复合体的形成。因此,术语“蛋白抑制剂”是指任何的制剂或化合物,其应用时会导致蛋白质功能或蛋白质通路功能的抑制。然而,这个术语并隐含着这个复合体的所有的每一个功能必须同时被抑制。
由于此处使用的一个“说明材料”,包括出版物,录制,图,或任何其他表达的媒介,可以被用来沟通在用来减轻在这里书面陈述的各种疾病或失调的试剂盒里的本发明的化合物的有用性。可选择地,或替换性地,说明材料可以描述在一个患者里减轻疾病或失调的一个或多个方法。本发明的试剂盒的说明材料可以,比如说,粘贴在一个里面包含被识别的化合物发明的容器里或者被与里面包含被识别的化合物的容器一同运输。或者,说明材料可与容器分开运输但其目的是接受者把说明材料和化合物合作使用。
在这里所使用的,“配体”是与靶化合物或分子特异地结合的化合物。配体与化合物有“特异的结合与”或“特异的反应”,是指当这个配体在结合反应里执行功能时能够决定在异质的化合物的一个样本中这种化合物的存在。
“受体”是特异结合配体的化合物或分子。
在这里所使用的,术语“连接”是指两个基团之间的联系。这个联系可以是共价或非共价键,包括但不限于离子键,氢键和疏水/亲水相互作用。
在这里所使用的,术语“连接体”是指把其他两个分子要么共价或非共价连接的分子,例如,通过离子键或氢键或范德华相互作用。
术语“鼻腔给予”在所有的语法形式是指对本发明的至少一种化合物通过鼻腔粘膜到达血液的给予来使得本发明的至少一种化合物全身性输送。鼻腔给予来输送的优势是它不需要用注射器和注射针来注射,它避免坏死,并且可以伴随肌肉内给药,药物的跨粘膜给予是非常接纳自身给药的。
在这里所使用的,术语“核酸”包括核糖核酸(RNA)以及单链和双链脱氧核糖核酸(DNA)和互补脱氧核糖核酸(cDNA)。进一步的,术语“核酸”,“DNA”,“RNA”和相似的术语还包括核酸类拟物,即有磷酸二酯骨干之外的类拟物。例如,所谓的“肽-核酸”,在本领域中已知的把骨干的磷酸二酯键代替为肽键,在本发明的范围内会被考虑。由“核酸”还意味着任何核酸,无论是否由脱氧核苷或核苷组成,以及是否由磷酸二酯连接或修改的连接,如磷酸三酯,氨基磷酸酯,硅氧烷,碳酸盐,羧甲基酯,acetamidate,氨基甲酸酯类,硫醚,桥接氨基磷酸酯,桥接亚甲基膦酸酯,桥接磷酰胺酯,桥接磷酰胺酯,桥接亚甲基膦酸酯,硫代磷酸酯,甲基膦酸酯,硫代磷酸酯,桥接硫代磷酸酯或桥接砜的连接,和这些连接的组合。术语核酸也特异性地包括在由五个生物学上出现的碱基(腺嘌呤,鸟嘌呤,胸腺嘧啶,胞嘧啶和尿嘧啶)之外的其他的碱基所组成的核酸。在这里使用常规标记法来描述多聚核苷酸的序列:一个单链多聚核苷酸序列的左手端是其5′-端;一个双链多聚核苷酸序列的左手方向被称为其5′-方向。对新生成的RNA转录本的5′到3′加成的方向被称为转录方向。与一个信使RNA(mRNA)具有相同的序列的DNA链被称为“编码链”;位于一个参照点的5′的DNA链的序列被称为“上游序列”;位于一个参照点的3′的DNA链的序列被称为“下游序列。”
除非另有规定,“编码氨基酸序列的核苷酸序列”包括编码相同的氨基酸序列的互为简并版本的所有的核苷酸序列。编码蛋白质和RNA的核苷酸序列可以包括内含子。
“肥胖”通常是指由于脂肪过量而体重增加的病症。治疗肥胖的药物通常分为三组:(1)那些减少食物摄入的,如干扰单胺受体的药物,如去甲肾上腺素能受体,5-羟色胺受体,多巴胺受体,和组胺受体;(2)那些增加代谢的;和(3)那些通过抑制胰脂肪酶来增加产热或减少脂肪的吸收(Bray,2000,Nutrition,16:953-960 and Leonhardt et al.,1999,Eur.J.Nutr.,38:1-13)。肥胖是用身体质量指数(BMI)来定义的。BMI的计算是体重(千克)/[身高(米)]2。根据美国疾病控制和预防中心(CDC)和世界卫生组织(WHO)的准则(World Health Organization.Physical status:The use and interpretation of anthropometry.Geneva,Switzerland:World Health Organization 1995.WHO Technical ReportSeries),对于20岁以上的成人,BMI分为以下四个类型:低于18.5被认为体重不足,18.5-24.9被认为正常,25.0-29.9被认为体重超重,30.0及以上被认为肥胖。
术语“寡聚核苷酸”有代表性地是指短的多聚核苷酸,通常不大于50个核苷酸。将是这样理解的,当一个核苷酸序列是由DNA序列来表示(即,A,T,G,C),这也包括一个RNA序列(即,A,U,G,C)在其中的“U”代替了“T”。
术语“肽”有代表性地是指短的多肽。
“多肽”是指由氨基酸残基,其相关的自然发生的结构变异体,合成的非天然存在的有联系通过肽键连接的类拟物,其相关的自然发生的结构变异体,并合成的非自然发生的类拟物所组成的聚合物。合成的多肽可以使用一个使用一个自动多肽合成仪来合成。
术语“蛋白质”有代表性地是指大的多肽。
“重组多肽”是重组的多聚核苷酸在表达时产生的。
肽包含2个或更多氨基酸的序列,其中氨基酸是自然发生的或合成的(非自然发生的)氨基酸。肽类似物是包括一个或更多以下修饰的多肽:
1.肽,其中的一个或更多肽基--C(O)NR--连接(键)被一个非肽的连接所取代,例如一个--CH2-甲基氨基甲酸酯(--CH2OC(O)NR--)连接,一个膦酸酯连接,一个-CH2-磺酰胺(-CH 2--S(O)2NR--)连接,一个尿素(--NHC(O)NH--)连接,一个--CH2-仲胺连接,或与一个烷基化肽基连接(--C(O)NR--),其中R是C1-C4烷基;
2.肽,其中N-端是被衍生成为了一个--NRR1基团,成为了一个--NRC(O)R基团,成为了一个--NRC(O)OR基团,成为了一个NRS(O)2R基团,成为了一个--NHC(O)NHR基团,其中的R和R1是氢原子或C1-C4烷基;
3.肽,其中C-端是被衍生成为了一个--C(O)R2,其中的--R2是从以下的选组里来选的,C1-C4烷氧基,和--NR3R4其中的R3和R4是独立的从包括氢原子和C1-C4烷基。
术语“每次应用”在这里所使用的是指对患者给予药物或化合物。
在这里所使用的,术语“药学上可接受的载体”包括任何标准的制药载体,如磷酸盐缓冲盐溶液,水,乳剂如油/水或水/油乳剂,以及各种类型的润湿剂。这一术语也包括任何被美国联邦政府管理机构批准的或列入美国药典的用于动物,包括人类的制剂。
在这里所使用的,术语“生理上可接受的”酯或盐意味着活性成分的酯或盐的形式与药用组合物里的其他任何成分是相容的,并且对把这个组合物所给予的患者来说不是有害的。
术语“预防”,在这里所使用的,意味着手段来使一些情况亭止,或采取提前措施来阻止一些情况的可能或大概的发生。在医药的情景里“预防”通常是指为减少获得一个疾病或病症的机会所采取的行动。
在这里所使用的,对末端的氨基基团而言的“保护基团”是指肽的末端的氨基基团,就是在传统的肽合成上所使用的使得末端的氨基基团与任何的各种氨基末端保护基团相偶联。这样的保护基团包括,例如,酰基保护基团,如甲酰基,乙酰基,苯甲酰基,三氟乙酰基,琥珀酰基,并甲氧琥珀酰基;芳香族氨酯保护基团,如苄氧羰基;和脂肪族氨酯保护基团,例如,叔-丁氧羰基或adamantyloxycarbonyl。适合的保护基团,见Gross and Mienhofer,eds.,The Peptides,vol.3,pp.3-88(Academic Press,New York,1981)。
在这里所使用的,对一个末端的羧基基团而言的“保护基团”是指一个肽的末端的羧基基团,就是使得末端的羧基基团与任何的各种羧基末端保护基团相偶联。这种保护基团包括,例如,对叔-丁基,苄基,或其他通过酯键或醚键与末端羧基连接的可接受的基团。
术语“社会心理管理计划”,在这里所使用的,与被用于对成瘾和与酒精有关的疾病和失调所进行的联合药物疗法治疗来进行补充的各种类型的咨询和管理技术有关。
在这里所使用的,术语“被纯化的”,和相类似的术语是有关于相对在自然环境里与这个分子或者化合物正常相关联的其他的组成组合物而言这个分子或者化合物的富集。术语“被纯化的”不一定表明在过程中已经取得了特定分子的完全纯度。一个“被高度纯化的”在这里所使用是指一个大于90%纯度的化合物。
“减少”-见“抑制”。
术语“调节”是指对所任何兴趣的功能或活动的刺激或抑制。
“样品”,在这里所使用的,指的是从患者里而来的生物样品,包括,但不限于,正常的组织样品,活组织检查,血液,唾液,粪便,精液,眼泪,和尿液。一个样品也可以是从患者里而来的任何材料来源,其中包含所感兴趣的细胞,组织,或液体。
由“小干扰RNAs(siRNAs)”是指,尤其地,被分离的双链RNA分子是由正义链和反义链所组成的。在一方面,它是有大于10个核苷酸的长度。siRNA也指单个的转录本包括靶基因的正义的和反义的序列,例如,一个发夹。siRNA进一步包括任何形式的双链RNA(由蛋白质分解而分裂的较大的双链RNA的产物,部分被纯化的RNA,本质上是纯的RNA,合成的RNA,重组产生的RNA)以及不同于在自然出现的RNA而通过加成,删除,取代,和/或改变一个或多个核苷酸的被改变的RNA。
由术语“特异地结合”,在这里所使用的,意味着分子在识别和结合特定的分子,但不在大体上识别或结合样品里的其他的分子,或者它意味着作为细胞调节过程的一个部分的两个或更多分子之间的结合,而所述的分子不在大体上识别或结合样品里的其他的分子。
术语“标准”,在这里所使用的,是指用于比较的某种事物。例如,在当加到测试的化合物时是为了比较结果而给予或加给和使用的已知的标准的制剂或化合物,它也可以是当测量制剂或化合物对参数或功能的效应时,一个被测量的标准的参数或功能以获得一个对照值。标准也可指“内标准”,例如是一个制剂或者化合物按已知的剂量加入到样品里,是有用于决定这样的事情,就是当样品在所感兴趣的标记被测量之前被处理或者接受纯化或提取的程序的纯化或回收率。内标准经常是一个感兴趣和被纯化的标记,通常被标记上,如用放射性同位素,使其可以与内源性的标记相比能被识别出来。
诊断或治疗的“患者”是哺乳动物,包括人。
术语“包含对早发性酗酒倾向性的患者,”在这里所使用的,是指具有,或其特征是对早发性酗酒有倾向性。
术语“症状”在这里所使用的,是指任何病态的现象或在结构,功能,或感觉的正常的偏离,被病人所体验并指示出疾病。形成对比的,一个迹象是疾病的客观证据。例如,一个流血的鼻子是一个迹象。对于病人,医生,护士和其他观察者来说是明显的。
在这里所使用的,术语“治疗”包括对特异的疾病,失调,或病症的预防法,或与对一个特异的疾病,失调,或病症的症状的减轻和/或所说症状的预防或消除。一个“预防性的”治疗是对一个没有呈现出疾病的迹象或者仅呈现出疾病的早期迹象的患者所给予的治疗其目的是降低与疾病相关联的病状发展的风险。“正在治疗”在这里使用时与“治疗”是可以互相交换的。
“治疗性的”治疗是对呈现出病状迹象的患者所给予的治疗其目的是缩小或消除这些迹象。
化合物的“治疗上的有效剂量”是化合物的剂量对于这种化合物被给予的患者来说足够以产生有益的效果。
化学定义
在这里所使用的,术语“卤素”或“卤代”包括溴,氯,氟和碘。
术语“卤代烷基”在这里所使用的是指烷基基团带有至少一个卤素取代基,例如,氯甲基,氟乙基或三氟甲基等。
术语“C1-Cn烷基”其中n是整数,在这里所使用的,表示支链或直链烷基基团具有从一到所指定的数目的碳原子。通常C1-C6烷基基团包括,但不限于,甲基,乙基,正丙基,异丙基,丁基,异丁基,仲丁基,叔丁基,戊基,己基等。
术语“C2-Cn烯基”其中n是整数,在这里所使用的,表示烯烃不饱和的支链或直链基团具有从二到所指定的数目的碳原子和至少一个双键。这样的基团的例子包括,但不限于,1-丙烯基,2-丙烯基,1,3-丁二烯基,1-丁烯基,己烯基,戊烯基等。
术语“C2-Cn炔基”其中n是整数指的是不饱和的支链或直链基团具有从二到所指定的数目的碳原子和至少一个三键。这样的基团的例子包括,但不限于,1-丙炔基,2-丙炔基,1-丁炔基,2-丁炔基,1-戊炔基等。
术语“C3-Cn环烷基”其中n=8,表示环丙基,环丁基,环戊基,环己基,环庚基,和环辛基。
在这里所使用的,术语“可任选被取代的”是指从零个到四个取代基,其中的每一个取代基是被独立地选择的。每一个被独立地选定的取代基与其他的取代基相比可能是相同或不同的。
在这里所使用的术语“芳基”是指可任选被取代的单环或双环碳环环状系统具有一个或两个芳香环包括,但不限于苄基,苯基,萘基,四氢萘基,茚满基,茚基等。可任选被取代的芳基包括具有从零到四个取代基的芳基化合物,被取代的芳基包括具有一个或更多的取代基的芳基化合物。术语(C5-C8烷基)芳基是指通过烷基基团与母体部分相连接的任何芳基基团。
术语“杂环基团”是指可任选被取代的单环或双环的碳环环状系统具有一到三个杂原子其中的杂原子是从包括氧,硫,和氮的这个组里来选择的。在这里所使用的术语“杂芳基”是指可任选被取代的单环或双环的碳环环状系统具有一个或两个芳香环含有从一到三个杂原子并包括,但不限于,呋喃基,噻吩基,吡啶基等。
术语“二环的”表示不饱和或饱和的稳定的7-至12-元的桥接或稠合的二环的碳环。二环的环可被连接到任何一个碳原子而提供一个稳定的结构。这一术语包括,但不限于,萘基,二环己基,二环己烯基等。
本发明的化合物包含在分子里的一个或多个非对称中心。根据本发明,没有指定立体化学的结构是被理解为包含其所有的各种光学异构体,以及外消旋混合物。
本发明的化合物中可能以互变异构的形式存在包括混合物以及其单独个体的互变异构体。例如下面的结构:
术语“药学上可接受的盐”指的是保留生物学的有效性和本发明化合物的性质而没有生物学或其他不良的性质的盐。在许多情况下,本发明的化合物能够凭借着氨基和/或羧基基团或类似的基团形成酸和/或碱盐。
实施方案
本发明包括使用药物或化合物的组合使用来治疗成瘾和强迫性疾病和失调,尤其是与酒精相关的疾病和失调。本发明进一步包括辅助治疗的使用和疗法例如社会心理管理模式,催眠和针灸。
在一些实施方案里,第一个和第二种化合物于接近同时被给予。在其他的实施方案里,第一种化合物在第二化合物之前被给予。在还有其他的实施方案里,第一种化合物在第二种化合物之后被给予。如果三个或更多的化合物被给予时,本领域普通技术人员将明白三个或更多的化合物可以同时或根据不同的次序而被给予。
在这里所披露的某些实施方案,个体被给予包含两个或更多的化合物的组合的药用组合物来治疗或预防与成瘾有关的疾病或失调或与冲动控制有关的疾病或失调。在这些其中的一些实施方案里,每种化合物是单独化学实体。但是,在其他的实施方案里,至少有两种化合物可以通过化学键相连在一起,例如共价键,这样至少两个不同的化合物形成同一个分子里单独的部分。在一方面,化学键是这样被选择的例如在进入体内之后,这个键被破坏,例如通过酶的作用,酸水解,碱水解等,并且形成了这两个单独的化合物。
在本领域以前的结构-活性关系(SAR)研究的数据可被用来作为指导确定使用哪些化合物以及在分子上的最佳的某个或多个位置上来附着系链将保持这样化合物的高的药效和选择性。该系链或连接部分是从对于将生物活性分子连接在一起表现出用处的那些里面来选择。这里披露的是可以以不同组合被连接在一起来形成异二价的治疗性分子的有代表性的化合物。
在科学文献中被报告的连接体的例子包括亚甲基(CH2)n连接体(Hussey et al.,J.Am.Chem.Soc.,2003,125:3692-3693;Tamiz et al.,J.Med.Chem.,2001,44:1615-1622),寡乙烯氧基O(-CH2CH2O-)n单位被用于把纳曲酮与其他阿片类的连接,具有化学式-NH-(COCH2NH)nCOCH2CH2CO--(NHCH2CO)nNH--用来把阿片类拮抗剂和激动剂连接在一起的甘氨酸寡聚物((a)Portoghese et al.,Life Sci.,1982,31:1283-1286.(b)Portoghese et al.,J.Med.Chem.,1986,29:1855-1861),用于把阿片类肽连接在一起的亲水的二胺(Stepinski et al.,Internat.J.of Peptide & Protein Res.,1991,38:588-92),刚性的双链DNA间隔物(Paar et al.,J.Immunol.,2002,169:856-864)和可生物降解的连接物聚(L-乳酸)(Klok et al.,Macromolecules,2002,35:746-759)。把一个系链附着于一种化合物可导致这种化合物达到一个更良好的结合定位。连接物本身可能是也可能不是可生物降解的。连接物可以采取一个药物前体的形式和可调的形式使所连接的药物有最佳的释放动力学。这个连接物可以在其整个长度上在构象上是灵活的或否则这个系链的一个片段可被设计为在构象上是受限制的(Portoghese et al.,J.Med.Chem.,1986,29:1650-1653)。
关于与酒精有关的失调,包括但不限于酒精滥用和酒精依赖,至少有两种化合物选自包括托吡酯,昂丹司琼,和纳曲酮和类拟物,衍生物,和修饰物,和药学上可接受的盐的组里,可以被用于减少与这种与酒精有关的疾病相关联的酒精消费。在一方面,托吡酯和昂丹司琼被使用。由此,本发明提供了在酒精消费的基础上的方法来治疗或预防与酒精相关的失调,包含给予需要这样的治疗或预防的患者至少有两种化合物的有效剂量从包括托吡酯,昂丹司琼,和纳曲酮和类拟物,衍生物,和修饰物,和药学上可接受的盐的组里选出。在再一方面,组合药物疗法是与行为调整疗法相结合被使用的。
本发明包括本发明的化合物的具有生物活性的类拟物,同系物,衍生物,和修饰物。制备这些化合物的方法在本领域中是已知的。在一方面,这些化合物是托吡酯,昂丹司琼,和纳曲酮。
托吡酯(C12H21NO8S;国际理论化学和应用化学联合会(IUPAC)名称:2,3:4,5-双-O-(1-甲基亚乙基)-β-D-吡喃果糖氨基磺酸酯;化学文摘(CAS)登录号97240-79-4)具有以下结构:
昂丹司琼(C18H19N3O;化学文摘(CAS)登录号99614-02-5;国际理论化学和应用化学联合会(IUPAC)名称:9-甲基-3-[(2-甲基-1H-咪唑-1-基)甲基]-1,2,3,9-四氢咔唑-4-酮)具有以下结构:
纳曲酮(C20H23NO4;17-(环丙基甲基)-4,5a-环氧-3,14-二羟基吗啡烷-6-酮盐酸盐;化学文摘(CAS)登录号16590-41-3)具有以下结构:
对与酒精相关的疾病和失调的治疗和预防的有效性可以通过几种途径来探测和测量。例如,患者可以根据为报告而建立的准则和程序来自我报告。对酒精消费的客观测量包括使用呼气酒精仪表读数,测定血清的CDT水平,和测定血清的γ-谷氨酰转移酶(GGT)的水平。尿的5-HTOL也可被测量并且为近期的酒精消费的一个指标。5-HTOL是5-HT的一个次要的代谢产物。多于一种的这些类型的测定需要被执行以确保准确性。其他的主观和客观的测量也是已知的。这些测量可以在治疗前,治疗中和治疗后的各种时间被采取或执行。
在这里所描述的给药途径,剂量数额,和剂型可被用于对于本发明的化合物的给予或者药学上可接受的盐来预防或治疗酒精消费。在本发明里所使用的化合物在生物学上的组合物和方法上的合适的形式包括药学上可接受的盐,晶型,溶剂合物,水合物,和药物前体。
本发明里的至少两种化合物,或药学上可接受的盐的有效剂量,不论是单独的或者是与一个第二治疗剂相联合,被给予受试者将在这个受试者里可检测地治疗或预防酒精消费。在作为示例性实施方案里,本发明里的至少两种化合物,或药学上可接受的盐,不论是单独的或者是与一个附加的治疗剂相联合的给予,将产生使酒精消费的减少为至少约10%,20%,30%,50%或更大,可达到约75-90%,或约95%或更大。
本组合物可以任选包含药学上可接受的盐的合适的剂量,使得以这个形式对病人进行适当的给予。
本组合物可以在被给予受试者时与行为疗法或者结合或相互配合。
被包括于本发明的范围内的是各种单个的端基异构体,对映异构体和非对映异构体及其混合物。此外,本发明的化合物也包括任何药学上可接受的盐,例如:碱金属盐,如钠和钾;铵盐;单烷基铵盐;二烷基铵盐;三烷基铵盐;四烷基铵盐;和氨丁三醇盐。这些化合物的水合物和其他溶剂合物是被包括在本发明的范围之内的。
被给予作为联合疗法来治疗与酒精有关的病症的附加的治疗剂可以包括传统上的抗酒精剂和/或其他制剂。本发明的有用的抗酒精剂通过组合制剂和协同治疗的方法包括,但不限于:双硫醒(Litten etal.,Expert Opin Emerg.Drugs 10(2):323-43,2005);纳曲酮(Volpicelli etal.,Arch.Gen.Psychiatry 49:876-880,1992;O′Malley et al.,Arch.Gen.Psychiatry 49(11):881-887,1992);阿坎酸(Swift,N.Engl.J.Med.340(19):1482-1490,1999);昂丹司琼(Pettinati et al.,Alcohol Clin.Exp.Res.24(7):1041-1049,2000;Stoltenberg,Scott,Clinical &Experimental Research 27(12):1853-1859,2003);舍曲林(Pettinati et al.,Alcohol Clin.Exp.Res.24(7):1041-1049,2000);泰必利(Shaw et al.,Br.J.Psychiatry 150:164-8,1987);γ羟基丁酸酯(Poldrugo F.and Addolorato G.,Alcohol Alcoholism 34(1),15-24,1999);加兰他敏(Novel pharmacotherapies and patents for alcohol abuseand alcoholism 1998-2001,Expert Opinion on Therapeutic Patents,Vol.11,No.10,pages 1497-1521(2001);U.S.Pat.No.5,932,238);纳美芬(Revex)(Drobes et al.,Alcohol Clin Exp Res.,28(9):1362-70(2004);纳洛酮(Julius,D.,and Renault,P.,eds.,Narcotic Antagonists:NaltrexoneProgress Report,NIDA Research Monograph Series,Number 9.DHEWPublication No.(ADM)76-387,Bethesda,Md.:National Institute onDrug Abuse,1976;Jenab and Inturrisi,Molecular Brain Research 27:95-102,1994);desoxypeganine(Doetkotte et al.,Alcoholism:Clinical &Experimental Research,International Society for Biomedical Research onAlcoholism 12th World Congress on Biomedical Alcohol Research,Sep.29-Oct.2,2004,Heidelburg/Mannheim,Germany,28(8)Supplement:25A,2004);苯二氮类(Ntais et al.,Benzodiazepines for alcohol withdrawal,Cochrane Database Syst.Rev.(3):CD005063,2005;Mueller T I et al.,Alcohol Clin.Exp.Res.29(8):1411-8,2005);精神抑制剂例如左旋美普卡因和甲硫达嗪;吡乙酰胺;可乐定;酰胺咪嗪;氯美噻唑左乙拉西坦;奎硫平(Monnelly et al.,J.Clin.Psychopharmacol.24(5):532-5,2004);利培酮;利莫那班;曲唑酮(Janiri et al.,Alcohol 33(4):362-5,1998);托吡酯(Johnson B A et al.,Lancet 361:1677-1685,2003);阿立哌唑(Beresford et al.,J.Clin.Psychopharmacol.25(4):363-6,2005);和莫达非尼(Saletu et al.,Prog.Neuropsychopharmacol.Biol.Psychiatry 14(2):195-214,1990);安哌齐特,和莫达非尼。
托吡酯的氨基磺酸盐衍生物,或任何本发明的其他化合物及它们的衍生物,类拟物或修饰物,可以在使用时根据本发明的方法与一个或更多其他药物化合物结合使用,只要这个制药剂有某种的用处而且在治疗与酒精相关的病症上也是有效果的。本领域普通技术人员将能够容易地识别那些在本发明里有用的制药剂。本领域普通技术人员也将认识到许多其他的化合物属于这些类型并且根据本发明对于治疗与酒精有关的病症是有用的。在一方面,本发明的抗酒精化合物是与对于其他状况有用的药物联合使用的。
其他的治疗剂可以是抗尼古丁剂。有用的抗尼古丁剂包括,但不限于,可乐定和安非他酮。
其他的治疗剂可以是抗鸦片剂。有用的抗鸦片剂包括,但不限于,美沙酮,可乐定,洛非西定,盐酸左旋乙酰美沙酮,纳曲酮,和丁丙诺啡。
其他的治疗剂可以是抗可卡因剂。有用的抗可卡因剂包括,但不限于,地昔帕明,金刚烷胺,fluoxidine,和丁丙诺啡。
其他的治疗剂可以一个食欲抑制剂。有用的食欲抑制剂包括,但不限于,芬氟拉明,苯丙醇胺,和马吲哚。
其他的治疗剂可以是麦角酸二乙基酰胺(“抗-LSD”)剂。有用的抗-LSD剂包括,但不限于,地西泮。
其他的治疗剂可以是抗苯环己哌啶(“抗-苯环利定”)剂。有用的抗-苯环利定剂包括,但不限于,氟哌啶醇。
其他的治疗剂可以是抗帕金森氏病剂。有用的抗帕金森氏病剂包括,但不限于,多巴胺前体,如左旋多巴,L-苯丙氨酸和L-酪氨酸;神经保护剂;多巴胺激动剂;多巴胺再摄取抑制剂;抗胆碱能剂如金刚烷胺和美金刚;和1,3,5-三取代金刚烷,如1-氨基-3,5-二甲基金刚烷(U.S.Pat.No.4,122,193 to Sherm et al.)。
其他的治疗剂可以是抗抑郁剂。有用的抗抑郁剂包括,但不限于,阿米替林,氯丙咪嗪,多塞平,丙咪嗪,三甲丙咪嗪,阿莫沙平,地昔帕明,马普替林,去甲替林,protripylinc,氟西汀,氟伏沙明,帕罗西汀,舍曲林,文拉法辛,安非他酮,奈法唑酮,曲唑酮,苯乙肼,强内心百乐明,司来吉兰,可乐定,加巴喷丁,和2-吡啶基[7-(吡啶-4-基)吡唑[1,5-a]嘧啶-3-基]甲酮化合物在2-和4-吡啶环上都至少有一个取代基。抗抑郁剂包括但不限于单胺氧化酶抑制剂,选择性5-羟色胺再摄取抑制剂,三环类抗抑郁药,四环类抗抑郁药,去甲肾上腺素摄取抑制剂,选择性去甲肾上腺素再摄取抑制剂,和5-羟色胺和去甲肾上腺素摄取抑制剂。
其他的治疗剂可以是抗焦虑剂。有用的抗焦虑剂包括,但不限于,苯二氮类,如阿普唑仑,利眠宁,氯硝西泮,氯氮,地西泮,哈拉西泮,劳拉西泮,奥沙西泮,和普拉西泮;非苯二氮类的制剂,如丁螺环酮;和镇静剂,如巴比妥类药物。
其他的治疗剂可以是抗精神病药。有用的抗精神病药包括,但不限于,吩噻嗪,如氯丙嗪,苯磺酸美索达嗪,硫利达嗪,马来酸乙酰奋乃静,氟奋乃静,奋乃静和三氟拉嗪;噻吨,如氯普噻吨,和氨砜噻吨;和其他杂环化合物,如氯氮平,氟哌啶醇,洛沙平,吗啉吲酮,匹莫齐特,与利培酮。作为示例性抗精神病药物包括盐酸氯丙嗪,盐酸硫利达嗪,盐酸氟奋乃静,盐酸氨砜噻吨,和盐酸吗啉吲酮。
其他的治疗剂可以是减肥药。有用的减肥的药物包括,但不限于,β-肾上腺素受体激动剂,例如,β-3受体激动剂如,但不限于,芬氟拉明;右芬氟拉明;西布曲明;安非他酮;氟西汀;芬特明;苯丙胺;甲基苯丙胺;右旋苯丙胺;苄非他明;苯二甲吗啉;二乙胺苯丙酮;马吲哚;苯丙醇胺;去甲肾上腺素;5-羟色胺再摄取抑制剂,如西布曲明;和胰脂肪酶抑制剂,如奥利司他。
一个本发明之内包含的药物的类型的清单,和这些类别内的特定药物如以下所提供。
肾上腺素能剂:肾上腺酮;甲磺酸阿米福林;盐酸安普乐定;酒石酸溴莫尼定;盐酸达哌拉唑;盐酸地特诺;地匹福林;盐酸多巴胺;麻黄素硫酸盐;肾上腺素,重酒石酸肾上腺素;环硼肾上腺素;盐酸乙硫酰丙喹;盐酸乙非他明;氢溴酸羟苯丙胺;可巴君;硫酸美芬丁胺;重酒石酸间羟胺;盐酸美替唑啉;盐酸萘唑啉;酒石酸去甲肾上腺素;羟多巴胺;盐酸羟甲唑啉;盐酸去氧肾上腺素;盐酸苯丙醇胺;苯丙醇胺缓释胶囊;盐酸普瑞特罗;丙己君;盐酸伪麻黄碱;盐酸四氢唑啉;盐酸曲马唑啉;盐酸赛洛唑啉。
肾上腺皮质类固醇:环丙奈德;醋酸脱氧皮质酮;新戊酸去氧皮质酮;醋酸地塞米松;醋酸氟氢可的松;氟莫奈德;氢化可的松半琥珀酸酯;甲泼尼龙半琥珀酸酯;萘非可特;普西奈德;醋酸替莫贝松;替培啶。
肾上腺皮质抑制剂:氨鲁米特;曲洛司坦。
酒精抑制剂:双硫醒。
醛固酮拮抗剂:坎利酸钾;坎利酮;地西利酮;孕甲酯丙酸钾;丙利酸钾;螺内酯。
氨基酸:丙氨酸;天门冬氨酸;盐酸半胱氨酸;胱氨酸;组氨酸;异亮氨酸;亮氨酸;赖氨酸;醋酸赖氨酸;盐酸赖氨酸;蛋氨酸;苯丙氨酸;脯氨酸;丝氨酸;苏氨酸;色氨酸;酪氨酸;缬氨酸。
催醒剂:莫达非尼。
止痛剂:对乙酰氨基酚;盐酸阿芬太尼;氨基苯甲酸钾;氨基苯甲酸钠;胺苯肟胺;阿尼利定;盐酸阿尼利定;盐酸阿尼帕米;阿尼洛泮;安替比林;阿司匹林;苯恶洛芬;盐酸炎痛静;盐酸比西发定;盐酸布芬太尼;马来酸溴法罗明;溴芬酸钠;盐酸丁丙诺啡;布他西丁;布替西雷;布托啡诺;酒石酸布托啡诺;卡马西平;卡巴匹林钙;盐酸卡比芬;柠檬酸卡芬太尼;琥珀酸环丙法朵;西拉马朵;盐酸西拉马朵;氯尼塞利;氯尼辛;可待因;磷酸可待因;硫酸可待因;盐酸Conorphone;环佐辛;盐酸右奥沙屈;Dexpemedolac;地佐辛;二氟尼柳;酒石酸双氢可待因;二甲法登;诺瓦经;盐酸多匹可明;氨甲茚酮;盐酸依那朵林;依匹唑;酒石酸麦角胺;盐酸乙氧偶氮苯;依托芬那酯;丁香酚;非诺洛芬;非诺洛芬钙;枸橼酸芬太尼;氟喹氨苯酯;氟苯柳;氟尼辛;氟尼辛葡甲胺;马来酸氟吡啶;氟丙喹宗;盐酸氟朵林;氟比洛芬;盐酸氢吗啡酮;异丁芬酸;吲哚洛芬;酮佐辛;酮啡诺;酮咯酸氨丁三醇;盐酸来替米特;左旋乙酰美沙酮;盐酸左旋乙酰美沙酮;盐酸左南曲朵;酒石酸左啡诺;盐酸洛非咪唑;草酸洛芬太尼;洛西那朵;氯诺昔康;水杨酸镁;甲芬那酸;盐酸美大麻坦;盐酸哌替啶;盐酸美他齐诺;盐酸美沙酮;醋美沙朵;甲氧夫啉;左美丙嗪;乙酸美克法胺;盐酸米姆本;盐酸米芬太尼;吗林那宗;硫酸吗啡;莫沙佐辛;盐酸大麻坦;盐酸纳布啡;盐酸纳美酮;纳莫雷特;盐酸南曲多;萘普生;萘普生钠;萘普索;盐酸奈福泮;盐酸奈西利定;盐酸诺美沙朵;盐酸奥芬太尼;奥他酰胺;奥伐尼;延胡索酸奥昔托隆;羟考酮,盐酸羟考酮;对苯二酸羟考酮;盐酸羟吗啡酮;培美酸;戊吗酮;喷他佐辛;盐酸喷他佐辛;乳酸喷他佐辛;盐酸非那吡啶;盐酸非尼拉朵;盐酸哌西那朵;匹那朵林;吡非尼酮,吡罗昔康乙醇胺;马来酸普拉朵林;盐酸普地利定;盐酸普罗法朵;延胡索酸Propirarn;盐酸右布洛芬;萘磺酸右布洛芬;普罗沙唑;柠檬酸普罗沙唑;酒石酸普罗啡烷;盐酸吡咯利芬;盐酸瑞芬太尼;柳胆来司;马来酸二乙氨乙柳胺;水杨酰胺;水杨酸葡甲胺;双水杨酯;水杨酸钠;甲磺酸螺朵林;舒芬太尼,枸橼酸舒芬太尼;他美辛;他尼氟酯;他洛柳酯;琥珀酸他扎朵林;特丁非隆;四氢甲吲胺;替呋酸钠;盐酸替利定;硫平酸;甲磺酸托那佐辛;盐酸曲马多;盐酸曲芬太尼;三乙醇胺;盐酸维拉朵林;盐酸维立洛泮;伏拉佐辛;甲磺酸佐尔啡诺;盐酸甲苯噻嗪;甲磺酸Zenazocine;佐美酸钠;珠卡赛辛。
食欲减退剂 包括右芬氟拉明在内的化合物。
食欲抑制剂:阿米雷司;苯异丙胺缩氯醛;盐酸对氯苯丁胺;氯氨雷司;盐酸Clortennine;盐酸二乙胺苯丙酮;盐酸芬氟拉明;非尼雷司;氟多雷司;氟氨雷司;琥珀酸左旋苯丙胺;马吲哚;盐酸美芬雷司;盐酸苯甲吗啉;芬特明;盐酸西布曲明。
抗焦虑剂:盐酸阿达色林;阿吡坦;甲磺酸比螺酮;溴他西尼;格来色林;盐酸伊沙匹隆;马来酸米立司琼;奥西普隆;盐酸昂丹司琼;帕那普隆;泮考必利;帕秦克隆;盐酸舍氮平;柠檬酸坦度螺酮;盐酸扎螺酮。
抗大麻剂:利莫那班和其它有用的药物,包括调节大麻类受体的药物。
抗抑郁剂:盐酸阿达色林;阿地唑仑;甲磺酸阿地唑仑;阿拉丙酯;盐酸烯丙他明;盐酸氨甲达林;盐酸阿密替林;阿莫沙平;甲磺酸阿普氮平;延索胡酸阿扎克生;氮卓吲哚;盐酸阿齐帕明;Bipenarnol Hydrochloride;盐酸安非他酮;布他西丁;盐酸布替林;卡罗沙酮;卡他唑酯;Ciclazindol;盐酸西多塞平;甲磺酸西洛巴明);盐酸氯达酮;盐酸氯米帕明;延索胡酸可替宁;胺氢咔唑;盐酸苯环戊胺;盐酸环丙利多;环丙米特;托西酸达来达林;盐酸达泊西汀;马来酸苯唑吡醇;盐酸氮卓尼尔;盐酸地普帕明;右旋咪唑;右伊马芬;盐酸二苯西平;盐酸地奥沙曲;盐酸度硫平;盐酸多塞平;盐酸度洛西汀;马来酸依氯那明;恩环丙酯;盐酸依托哌酮;盐酸泛曲酮;Fehmetozole Hydrochloride;苯甲吗酮;延胡索酸非唑拉明;盐酸氯曲辛;氟西汀;盐酸氟西汀;盐酸氟洛克生;更非辛;硫酸胍诺西芬;盐酸伊马芬;盐酸咪洛克生;盐酸丙咪嗪;盐酸茚洛秦;盐酸英曲替林;伊普吲哚;异卡波肼;延胡索酸凯替帕明;盐酸洛非帕明;氯他拉明;马普替林;盐酸马普替林;盐酸美利曲辛;盐酸米拉醋胺;盐酸米纳普林;米氮平;吗氯贝胺;硫酸莫达林;盐酸萘帕他定;盐酸奈帕咪唑;盐酸奈法唑酮;尼索西汀;盐酸硝呋坦;马来酸诺米芬辛;盐酸去甲替林;磷酸奥克替林;盐酸奥匹哌醇;盐酸羟丙替林;奥昔哌汀;帕罗西汀;硫酸苯乙肼;盐酸吡喃达明;苯噻啶;盐酸普立地芬;盐酸普罗林坦;盐酸普罗替林;马来酸喹哌嗪;罗利普林;盐酸赛罗西汀;盐酸舍曲林;盐酸西布曲明;舒必利;舒立托唑;盐酸他美曲林;延索胡酸坦帕明;盐酸坦达明;盐酸硫西新;托扎啉酮;盐酸托莫西汀;盐酸曲唑酮;盐酸曲苯佐明;三甲丙咪嗪;马来酸三甲丙咪嗪;盐酸文拉法辛;盐酸维洛沙秦;盐酸齐美定;氯苯吡。
抗高血压药:Aflyzosin Hydrochloride;阿立帕米;阿尔噻嗪;盐酸氨喹新;苯磺酸氨氯地平;马来酸氨氯地平;醋酸阿那立肽;马来酸阿替丙嗪;贝磷地尔;贝米曲啶;甲磺酸苯达洛尔;苄氟噻嗪;苯噻嗪;盐酸倍他洛尔;硫酸苄甲胍;盐酸贝凡洛尔;盐酸二氯地尔;比索洛尔;延胡索酸比索洛尔;盐酸布新洛尔;丁吡考胺;布噻嗪:坎沙曲;坎沙曲拉;卡托普利;卡维地洛;西罗普利;氯噻嗪钠;西氯他宁;西拉普利;可乐定;盐酸可乐定;氯帕胺;环戊甲噻嗪;环噻嗪;达罗地平;硫酸异喹胍;盐酸地拉普利;硫米齐特;二氮嗪;盐酸地来洛尔;苹果酸地尔硫卓;地替吉仑;甲磺酸多沙唑嗪;依卡曲尔;马来酸依那普利;依那普利拉;依那吉仑;甲磺酸恩屈嗪;依匹噻嗪;依普罗沙坦;甲磺酸依普罗沙坦;甲磺酸非诺多泮;马来酸黄酮地洛;氟地平;氟司喹南;福辛普利钠;福辛普利拉;胍那苄;醋酸胍那苄;硫酸胍那克林;硫酸胍那决尔;胍西定;一硫酸胍乙啶;硫酸胍乙啶;盐酸胍法新;硫酸胍尼索喹;硫酸胍氯酚;盐酸胍诺克丁;胍诺沙苄;硫酸胍生;硫酸胍诺西芬;盐酸肼苯哒嗪;肼屈嗪缓释胶囊;氢氟甲噻;茚达立酮;吲达帕胺;Indolaprif Hydrochloride;吲哚拉明;盐酸吲哚拉明;盐酸吲哚瑞酯;拉西地平;来尼喹新;左旋克罗卡林;赖诺普利;盐酸洛非西定;氯沙坦钾;盐酸洛硫嗪;美布氨酯;盐酸美加明;美沙洛尔;盐酸美沙洛尔;美沙噻嗪;甲氯噻嗪;甲基多巴;盐酸甲基多巴乙酯;美替洛尔;美托拉宗;延胡索酸美托洛尔;琥珀酸美托洛尔;甲酪氨酸;米诺地尔;马来酸莫那匹尔;莫唑胺;奈比洛尔;尼群地平;奥福宁;盐酸巴吉林;帕佐昔特;盐酸培兰色林;培哚普利叔丁胺盐;苯氧苄胺盐酸盐;吡那地尔;匹伏普利;泊利噻嗪;盐酸哌唑嗪;普米洛尔;盐酸普齐地洛;盐酸喹那普利;喹普利拉;盐酸喹唑嗪;盐酸喹洛雷;盐酸喹吡罗;奎纽溴胺;雷米普利;萝芙木;利血平;沙普立沙坦钾;醋酸沙拉新;硝普钠;盐酸硫氧洛尔;他索沙坦;盐酸替鲁地平;盐酸替莫普利;盐酸特拉唑嗪;特拉吉仑;噻美尼定;盐酸噻美尼定;帖克纳芬;替大麻酚;硫达唑嗪;盐酸噻戊托辛;三氯噻嗪;盐酸曲马唑嗪;樟脑磺酸咪噻吩;盐酸曲莫沙明;曲帕胺;希帕胺;盐酸占吉仑;精氨酸佐芬普利拉。
抗炎药:阿氯芬酸;二丙酸阿氯米松;阿孕奈德;阿尔法淀粉酶;安西法尔;安西非特;氨芬酸钠;盐酸氨普立糖;阿那白滞素;阿尼罗酸;阿尼扎芬;阿扎丙宗;巴柳氮二钠;苄达酸;苯恶洛芬;盐酸苄达明;菠萝蛋白酶;溴哌莫;布地奈德;卡洛芬;环洛芬;辛喷他宗;克利洛芬;丙酸氯倍他索;丁酸氯倍他松;氯吡酸;丙酸氯硫卡松;醋酸三氟米松;可托多松;地夫可特;地索奈德;去羟米松;二丙酸地塞米松;双氯芬酸钾;双氯芬酸钠;双醋酸双氟拉松;二氟米酮钠;二氟尼柳;二氟泼尼酯;地弗他酮;二甲亚砜;羟西缩松;恩甲羟松;恩莫单抗;依诺利康钠;依匹唑;依托度酸;依托芬那酯;联苯乙酸;非那莫;芬布芬;芬氯酸;苯克洛酸;芬度柳;夫拉扎酮;芬替酸;夫拉扎酮;氟扎可特;氟灭酸;氟咪唑;醋酸氟尼缩松;氟尼辛;氟尼辛葡甲胺;氟可丁丁酯;醋酸氟米龙;氟喹宗;氟比洛芬;氟瑞托芬;丙酸氟替卡松;呋喃洛芬;呋罗布芬;哈西奈德;卤倍他索丙酸酯;醋酸卤泼尼松;异丁芬酸;布洛芬;布洛芬铝;布洛芬吡甲酯;伊洛达普;吲哚美辛;吲哚美辛钠;吲哚洛芬;吲哚克索;吲四唑;醋酸异氟泼尼松;伊索克酸;伊索昔康;酮洛芬;盐酸洛非咪唑;氯诺昔康;氯替泼诺;甲氯芬那酸钠;甲氯芬那酸;甲氯松二丁酸酯;甲芬那酸;美沙拉明;美西拉宗;磺庚甲泼尼龙;Momiflumate;萘丁美酮;甲氧萘丙酸;甲氧萘丙酸钠;萘普索;尼马宗;奥沙拉秦钠;奥古蛋白;奥帕诺辛;奥沙普秦;羟保泰松;盐酸瑞尼托林;戊聚硫钠;甘油保泰松钠;吡非尼酮;吡罗昔康;肉桂酸吡罗昔康酯;吡氧噻嗪乙醇胺;吡咯洛;泼那扎特;普立非酮;普罗度酸;普罗喹宗;普罗沙唑;柠檬酸普罗沙唑;利美索龙;氯马扎利;柳胆来司;沙那西定;双水杨酯;血根氯铵;司克拉宗;丝美辛;舒多昔康;舒林酸;舒洛芬;他美辛;他尼氟酯;他洛柳酯;特丁非隆;替尼达普;替尼达普钠;替诺昔康;替昔康;苄叉异喹酮;四氢达明;硫平酸;托美丁;托美丁钠;三氯氟松;三氟米酯;齐多美辛;佐美酸钠。
止恶心药:盐酸布可利嗪;乳酸苯甲嗪;盐酸大麻克酯。
抗中性白细胞减少药:非格司亭;来格司亭;莫拉司亭;瑞拉司亭;沙格司亭。
抗强迫剂:马来酸氟伏沙明。
抗帕金森氏药:甲磺酸苯扎托品;比哌立登;盐酸比哌立登;乳酸比哌立登;卡金刚酸;盐酸西拉多巴;多巴金刚;盐酸爱普耙嗪;拉扎贝胺;左旋多巴;盐酸洛美曲林;酸莫非吉兰;盐酸那高利特;硫酸帕立太特;盐酸普环啶;Quinetorane Hydrochloride;盐酸罗匹尼罗;盐酸司立吉林;托卡朋;盐酸三己芬迪.减蠕动药:盐酸氰苯哌酰胺;地芬诺辛;盐酸地芬诺酯;氟哌醇胺;盐酸利达脒;盐酸洛哌丁胺;马来他姆;奴芬克索;止痛药。
抗精神病药:马来酸醋奋乃静;氢溴酸阿仑替莫;阿尔哌汀;阿扎哌隆;马来酸巴氮平;苯哌利多;盐酸苄吲吡林;Brofbxine;溴哌利多;溴哌利多癸酸酯;盐酸布他拉莫;布他哌嗪;马来酸布他哌嗪;马来酸丙酰奋乃静;盐酸卡伏曲林;氯普马嗪;盐酸氯普马嗪;氯普噻吨;桂哌林;辛曲胺;磷酸氯马克仑;氯哌噻吨;氯哌莫齐;甲磺酸氯哌帕生;盐酸氯哌隆;氯噻平;马来酸氯噻吨胺;氯氮平;盐酸环丙奋乃静;达哌啶醇;盐酸依他唑酯;非尼米特;氟西吲哚;氟甲氮平;氟非那嗪癸酸酯;氟奋乃静庚酸酯;盐酸氟奋乃静;氟司哌隆;氟司必林;氟曲林;盐酸吉伏曲林;卤培米特;氟哌啶醇;氟哌啶醇癸酸酯;伊潘立酮;盐酸咪多林;仑哌隆;琥珀酸马扎哌汀;美索达嗪;美索达嗪苯磺酸酯;甲硫平;咪仑哌隆;米利哌汀;盐酸吗啉吲酮;盐酸萘拉诺;盐酸奈氟齐特;奥卡哌酮;奥氮平;奥哌咪酮;五氟利多;马来酸喷硫平;奋乃静;匹莫齐特;盐酸哌氧平;匹泮哌隆;哌西他嗪;哌泊噻嗪棕榈酸酯;盐酸匹喹酮;乙二磺酸丙氯拉嗪;马来酸丙氯拉嗪;盐酸丙嗪;瑞莫必利;盐酸瑞莫必利;盐酸林卡唑;盐酸氯氟哌醇;舍吲哚;司托哌隆;螺旋哌丁苯;甲硫哒嗪;盐酸甲硫哒嗪;氨砜噻吨;盐酸氨砜噻吨;盐酸硫哌立酮;盐酸替螺酮;盐酸三氟拉嗪;三氟哌啶醇;三氟普马嗪;盐酸三氟普马嗪;盐酸齐拉西酮。
食欲抑制剂:盐酸右旋芬氟拉明;酒石酸苯甲曲嗪;盐酸苯丁胺。
血糖调节剂:人胰岛素;胰高血糖素;妥拉磺脲;甲苯磺丁脲;氯磺丙脲;醋酸己脲和格列吡嗪。
碳酸酐酶抑制剂:乙酰唑胺;乙酰唑胺钠,双氯非那胺;盐酸多佐胺;醋甲唑胺;Sezolarmide Hydrochloride。
心脏抑制剂:盐酸乙酰卡尼;氯化乙酰胆碱;阿克索胺;腺苷;胺碘酮;阿普林定;盐酸阿普林定;富马酸阿替利特;盐酸阿齐利特;比地索胺;己哌丁苄胺马来酸盐;布色酮;盐酸丁丙吲嗪;克冠酸钠;卡泊酸;西苯唑啉;琥珀酸西苯唑啉;磷酸氯非铵;地索布胺;丙吡胺;磷酸丙吡胺;磷酸双异丙吡胺;多非利特;羟布林;醋酸依地福龙;依米铵托西酸盐;盐酸恩卡尼;醋酸氟卡尼;富马酸伊布利特;盐酸英地卡尼;富马酸伊帕利特;盐酸劳拉义明;盐酸劳卡尼;硫酸甲氧苯汀;盐酸美西律;莫地卡尼;莫雷西嗪;奥昔拉米;盐酸吡美诺;吡拉酰胺;普拉氯铵;盐酸普鲁卡因胺;盐酸普罗帕酮;吡诺林;喹度溴铵;葡萄糖酸奎尼丁;硫酸奎尼丁;盐酸瑞卡南;甲苯磺酸瑞卡南;盐酸利索利特;盐酸罗匹妥英;盐酸司美利特;马来酸舒立卡尼;妥卡尼;盐酸妥卡尼;群司卡尼。
强心剂:阿托地近;氨力农;贝莫拉旦;布托巴胺;卡巴折伦;琥珀酸卡沙群;去乙酰毛花苷;洋地黄;洋地黄毒苷;地高辛;多巴酚丁胺;盐酸多巴酚丁胺;乳酸生物酸多巴酚丁胺;酒石酸多巴酚丁胺;依诺昔酮;盐酸伊马唑旦;吲哚利旦;盐酸伊索马唑;乳糖醛酸左多巴酚丁胺;硫酸利沙齐农;美多力农;米力农;盐酸培力农;匹克苯丹;匹罗昔酮;普啉索旦;海葱次苷;喹齐酮;盐酸他佐洛尔;维司力农。
心血管制剂:多培沙明;盐酸多培沙明。
利胆药:去氢胆酸;芬西布醇;羟甲香豆素;哌普唑林;辛卡利特;托莰非。
胆碱能剂:醋克利定;氯贝胆碱;卡巴胆碱;地美溴铵;右泛醇;腆依可酯;异氟磷;氯醋甲胆碱;溴化新斯的明;甲硫酸新斯的明;毒扁豆碱;水杨酸毒扁豆碱;硫酸毒扁豆碱;毛果芸香碱;盐酸毛果芸香碱;硝酸毛果芸香碱;溴吡斯的明。
胆碱能激动剂:呫诺美林;酒石酸呫诺美林。
胆碱酯酶失活剂:双复磷;氯解磷定;碘解磷定;甲磺磷定。
抗球虫剂:阿普西特;甲基盐霉素;生度米星;生度米星钠。
认知辅助剂:甲磺酸二氢麦角碱;吡拉西坦;盐酸普拉西坦;硫酸普拉西坦;盐酸他克林。
认知增强药:盐酸贝西吡啶;利诺吡啶;西波吡啶。
激素:己烯雌酚;黄体酮;17-羟基黄体酮;甲羟孕酮;炔诺孕酮;异炔诺酮;雌二醇;甲地孕酮;炔诺酮;左炔诺孕酮;Ethyndiol;炔雌醇;美雌醇;雌酮;马烯雌酮;17-alpha-二氢马烯雌酮;马烯雌酮;17-alpha-二氢马萘雌酮;17-alpha-雌二醇;17-beta-雌二醇;醋酸亮丙瑞林;胰高血糖素;睾内酯酮;克罗米芬;人更年期促性腺激素;人绒毛膜促性腺激素;尿促卵泡素;溴麦角环肽;戈那瑞林;促黄体生成激素释放激素和类拟物;促性腺激素;达那唑;睾酮;脱氢表雄酮;雄烯二酮;二氢睾酮;松弛激素;催产素;加压素;卵泡抑制素;卵泡调节蛋白质;Gonadoctrinins;卵母细胞成熟抑制剂;胰岛素生长因子;促卵泡激素;促黄体生成激素;他莫昔芬;Corticorelin Ovine Triftutate;替可克肽;美托孕素;垂体,后叶;醋酸司拉克肽;猪丙氨生长素;人蛋氨生长素;生长激素;猪诺生长素;牛度生长素。
记忆辅助剂:Dimoxamine Hydrochloride;利巴米诺。
心理性能增强剂:茴拉西坦。
情绪调节剂:酚加宾。
精神抑制剂:富马酸度奥哌隆;利培酮。
神经保护剂:地卓西平马来酸盐。
精神调节药:米那普林。
弛缓剂:盐酸阿地芬宁;阿库氯铵;氨茶碱;阿珠莫林钠;巴氯芬;盐酸苯佐他明;异丙基甲丁双脲;氯苯甘油氨酯;氯唑沙宗;环桂氟胺;桂美君;Clodanolene;盐酸环苯扎林;丹曲林;丹曲林钠;Fenalanide;盐酸非尼啶醇;盐酸非托西酯;盐酸黄酮哌酯;氟立安定;氟美吗酮;盐酸氟西泮;己芴溴铵;盐酸异戊拉明;劳氨酯;盐酸美贝维林;麦秀卜宁;美他沙酮;美索巴莫;盐酸美三嗪酮;苹果酸萘甲唑林;马来酸奈立膦酸;盐酸罂粟碱;盐酸哌泊索仑;Quinctolate;利托君;盐酸利托君;罗咯定;甘氨酸茶碱钠;盐酸双苯乙硫酯;希洛班。
镇静催眠药:阿洛巴比妥;阿洛米酮;阿普唑仑;阿洛巴比妥钠;苯他西泮;溴替唑仑;仲丁比妥;仲丁比妥钠;布他比妥;卡普脲;卡波氯醛;氯醛甜菜碱;水合氯醛;盐酸氯氮卓;盐酸氯哌喹酮;氯乙双酯;环丙西泮;盐酸环庚吡喹醇;地西泮;氯醛比林;艾司唑仑;乙氯维诺;依托咪酯;非诺班;氟硝西泮;膦西泮;格鲁米特;哈拉西泮;氯甲西泮;甲氯喹酮;甲丙氨酯;甲喹酮;咪达氟;三聚乙醛;戊巴比妥;戊巴比妥钠;哌拉平;普拉西泮;夸西泮;瑞氯西泮;咯来米特;司可巴比妥;司可巴比妥钠;舒普罗酮;萨立多胺;曲卡唑酯;马来酸曲匹泮;三唑仑;三甲氧苯醋酰胺;磷酸三氯乙酯钠;曲美托嗪;乌达西泮;扎来普隆;盐酸唑拉西泮;酒石酸唑吡坦。
5-羟色胺拮抗剂:阿坦色林酒石酸盐;安麦角;酮色林;利坦色林。
5-羟色胺抑制剂:盐酸辛那色林;芬克洛宁;甲磺酸二甲替嗪;托西曲喹铵。
5-羟色胺受体拮抗剂:盐酸托烷司琼。
兴奋剂:安福萘酸;苯丙胺磺酸盐;二甲胺嗪磺酸盐;盐酸阿布他明;阿扎苯胺;咖啡因;蓝肽;蓝肽二乙胺;西沙比利;富马酸达佐必利;右旋苯丙胺;硫酸右旋苯丙胺;盐酸二氟嗪;盐酸二甲弗林;盐酸多沙普仑;醋酸乙色胺;香草酰二乙胺;盐酸芬乙茶碱;盐酸氟巴尼酯;氟替尔;磷酸组胺;盐酸茚屈林;美非沙胺;盐酸甲基苯丙胺;盐酸哌甲酯;匹莫林;盐酸吡咯戊酮;扎莫特罗;富马酸扎莫特罗。
增效剂:盐酸丙基解痉素。
甲状腺激素:左旋甲状腺素钠;碘甲腺氨酸钠;Liotrix。
甲状腺抑制剂:甲巯咪唑;丙硫氧嘧啶。
拟甲状腺素药:盐酸甲状米登。
脑缺血制剂:盐酸右啡烷。
血管收缩剂:血管紧张素胺;苯赖加压素;美西麦角;马来酸美西麦角。
血管扩张剂:前列地尔;盐酸氮氯嗪;硫酸巴美生;盐酸苄普地尔;布替利嗪;柠檬酸西替地尔;盐酸卡波罗孟;氯硝甘油;盐酸地尔硫卓;双嘧达莫;氢普拉明;丁四硝酯;非洛地平;盐酸氟桂利嗪;福司地尔;海索苯定;肌醇烟酸酯;盐酸异丙沙明;硝酸异山梨醇酯;单硝酸异山梨酯;盐酸苯氧丙酚胺;利多福心;甲苯地尔;富马酸甲苯地尔;双盐酸米贝拉地尔;盐酸米氟嗪;米克昔定;萘呋胺酯草酸盐;盐酸尼卡地平;尼麦角林;尼可地尔;烟醇;硝苯地平;尼莫地平;尼索地平;羟苯甘氨酸;盐酸氧烯洛尔;硝酸戊四醇酯;己酮可可碱;戊硝醇;马来酸哌克昔林;吲哚洛尔;哌多明;普尼拉明;丙帕硝酯;舒洛地尔;盐酸特罗地林;盐酸替普地尔;盐酸妥拉唑林;烟胺羟丙茶碱。
对本发明的化合物来进行测定的检测和方法在这里被描述或在本领域是已知的。例如,见Lippa et al.,U.S.Pat.Pub.No.2006/0173-64,2006年8月3日出版。
本发明进一步包括治疗和预防肥胖,即影响体重减少和防止体重增加。肥胖是一个以过多的脂肪在体内的积累为特征的病症。肥胖已被确认为是疾病的主要原因之一并且正在成为一个全球性问题。增加的并发症的例子如高血压,非胰岛素依赖型糖尿病,动脉硬化,血脂异常,某些类型的癌症,睡眠呼吸暂停,以及骨关节炎已经被联系于在一般人群里的增加的的肥胖的例子。在一个方面,本发明包括对受试者给予所需要的一个联合疗法来引起体重减少。例如,具有BMI大于约25(25.0-29.9被认为是体重超重)的受试者被识别来用于治疗。在一方面,个体具有BMI大于30(30和以上被认为是肥胖)。在另一个方面,受试者可以被作为治疗的目标来预防体重增加。在一个实施方案,一个人是被指导来至少每天一次使用本发明的至少一种化合物并且至少每天一次使用本发明的一个第二种化合物。化合物可能所在的形式是,例如,片剂,锭剂,液体等。在一个方面,第三种化合物每天也被使用。在一个实施方案,化合物可能超过每天一次被使用。在另一个实施方案,化合物少于每天一次被使用。剂量可以根据在本领域所已经知道的或根据受试者的年龄,性别,健康,体重等来确定什么是最佳的来确定。根据本发明的方法对治疗肥胖有用的化合物,包括,但不限于,托吡酯,纳曲酮和昂丹司琼。见Weber(U.S.Pat.Pub.No.20070275970)和McElroy(U.S.Pat.No.6,323,236)对治疗肥胖,成瘾疾病,和冲动控制障碍有用的药物的给予以及对确定剂量的规划上获得附加的信息和技术。
正在接受治疗以导致体重减少的受试者可能会在一个数个月的期间里被监测。在一方面,建议剂量被调整使得每个个体失去体重是在一个每6个月为初始体重的10%的。但是,每一个个体体重减少的速率可以被进行治疗医生根据个人的特别的需要来被调整。
如果初始的剂量没有效果,那么在联合疗法里的一个或更多的化合物的剂量可以被提高。如果初始的剂量导致比上面的速率一个更快的体重减少,在至少两种化合物里的一个或更多的剂量可以被减少。
药学上可接受的碱加成盐可能从无机碱和有机碱来制备。从无机碱衍生的盐,包括只是通过举例来说,钠,钾,锂,铵,钙,和镁盐。从有机碱导出的盐包括,但不限于,一级,二级和三级胺的盐,如烷基胺,二烷基胺,三烷基胺,取代烷基胺,二(取代烷基)胺,三(取代烷基)胺,烯基胺,二烯基胺,三烯基胺,取代烯基胺,二(取代烯基)胺,三(取代烯基)胺,环烷基胺,二(环烷基)胺,三(环烷基)胺,取代环烷基胺,二取代环烷基胺,三取代环烷基胺,环烯基胺,二(环烯基)胺,三(环烯基)胺,取代环烯基胺,二取代环烯基胺,三取代环烯基胺,芳基胺,二芳基胺,三芳基胺,杂芳基胺,二杂芳基胺,三杂芳基胺,杂环胺,二杂环胺,三杂环胺,混合的二胺和三胺其中胺上的至少两个取代基是不同的,并且选自烷基,取代烷基,烯基,取代烯基,环烷基,取代环烷基,环烯基,取代环烯基,芳基,杂芳基,杂环,和类似的。还被包括的是这样的胺,其中的两个或三个取代基,与氨基上的氮在一起,形成一个杂环的或杂芳基的基团。适合的胺的例子包括,只是通过举例来说,异丙胺,三甲基胺,二乙胺,三(异丙基)胺,三(正丙基)胺,乙醇胺,2-二甲基氨基乙醇,氨基丁三醇,赖氨酸,精氨酸,组氨酸,咖啡因,普鲁卡因,海巴胺,胆碱,甜菜碱,乙二胺,氨基葡萄糖,N-烷基还原葡糖胺,可可碱,嘌呤,哌嗪,哌啶,吗啉,N-乙基哌啶等。还应该明白就是其他羧酸衍生物在本发明的实践里也会是有用的,例如,羧酸酰胺,包括甲酰胺,低级烷基甲酰胺,二烷基甲酰胺,和类似的。
药学上可接受的酸加成盐可能从无机和有机的酸来制备。盐是从这样的无机酸衍生的,包括盐酸,氢溴酸,硫酸,硝酸,磷酸,和类似的。盐是从这样的有机酸衍生的包括乙酸,丙酸,乙醇酸,丙酮酸,草酸,苹果酸,丙二酸,琥珀酸,马来酸,延胡索酸,酒石酸,柠檬酸,苯甲酸,肉桂酸,扁桃酸,甲基磺酸,乙烷磺酸,对甲苯磺酸,水杨酸,和类似的。
社会心理干预和管理
本发明的药物联合治疗可以进一步被补充来对受试者提供社会心理干预和/或管理的形式,例如简短的行为顺从促进治疗(BBCET)。BBCET,一个标准化的,手册-指导的,简短的(即,在约15分钟送交),社会心理顺从增强程序,强调药物的顺从是对改变参与者的饮酒行为来说是起决定性的(Johnson et al.,BriefBehavioral Compliance Enhancement Treatment(BBCET)manual.In:Johnson BA,Ruiz P,Galanter M,eds.Handbook of clinical alcoholismtreatment.Baltimore,MD:Lippincott Williams & Wilkins;2003,282-301)。简短的干预(Edwards et al.,J.Stud.Alcohol.1977,38:1004-1031)例如BBCET,被显示有利于酒精依赖的治疗。BBCET是以国家精神健康研究所(the National Institute of Mental Health)的合作抑郁症试验的临床管理状况为原形的,对那个研究来说它被用做一个对药物状况的辅助(Fawcett et al.Psychopharmacol Bull.1987,23:309-324)。BBCET已成功地在托吡酯治疗酒精依赖的单地点和多地点效能的试验里作为社会心理治疗的平台被成功地使用了(Johnson et al.,Lancet.2003,361:1677-1685;Johnson et al.,JAMA,2007,298:1641-1651)。它是由受过训练的临床医师,包括护理师和其他非专业人士来送交的。BBCET送交的一律性和一致性是通过持续性的培训和监督来确保的。BBCET是受版权保护的材料(Johnson et al.,Brief BehavioralCompliance Enhancement Treatment(BBCET)manual.In:Johnson BA,Ruiz P,Galanter M,eds.Handbook of clinical alcoholism treatment.Baltimore,MD:Lippincott Williams & Wilkins;2003,282-301)。
本发明还包括使用社会心理管理计划以外的其他BBCET,包括但不限于:认知行为应对技巧疗法(CBT)(Project MATCH ResearchGroup.Matching Alcoholism Treatments to Client Heterogeneity:Project MATCH posttreatment drinking outcomes.J Stud Alcohol.1997;58:7-29),动机增强疗法(MET)(Project MATCH Research Group.Matching Alcoholism Treatments to Client Heterogeneity:ProjectMATCH posttreatment drinking outcomes.J.Stud.Alcohol.1997,58:7-29),十二步促长疗法(TSF)(Project MATCH Research Group.Matching Alcoholism Treatments to Client Heterogeneity:ProjectMATCH posttreatment drinking outcomes.J.Stud.Alcohol.1997,58:7-29),联合行为干预(CBI),(Anton et al.,JAMA,2006,295:2003-2017)医疗管理(MM)(Anton et al.,JAMA,2006,295:2003-2017),或生物社会心理,报告,感情移入,需求,直接咨询和评估(BRENDA)模式(Garbutt et al.,JAMA,2005,293:1617-1625)。本发明还包括使用替换性的干预措施,例如催眠或针灸来协助治疗一个成瘾疾病或病症。
社会心理管理计划都可以在对受试者使用本发明的联合药物疗法来治疗之前,期间和治疗之后被使用。
本领域普通技术人员将认识到,社会心理管理计划,以及替换性的干预措施如催眠或针灸,可以与药物联合疗法相结合来治疗在酒精有关的疾病和病症以外的成瘾和冲动有关的病症。
本发明进一步包括联合药物疗法和行为(社会心理)干预或培训的使用来治疗其他的成瘾和/或冲动控制障碍。
例如,暴饮暴食症(BED)是以离散的暴饮暴食的时期为特征的也就是在一个离散的时间期里大量的粮食被消费并且没有对饮食控制的意识。有神经性贪食症的人被报告有脑电图的异常,并且对抗癫痫药物苯妥英的反应显示出暴饮暴食的减少。此外,在癫痫病人里的有对照的试验里,托吡酯与和暴饮暴食无关的食欲的抑制和体重的减少相关联的。昂丹司琼也被显示减少了暴饮暴食。
BED是精神病症上一个以进行有害的行为来作为对不可抗拒冲动的反应为特征的宽广地被定义为冲动控制障碍(ICDs)的一个更大分类的一个亚类。ICDs被提示可能与强迫症有关或相似,可能是强迫症的形式。已经有这样的假设就是ICDs可能与情绪障碍有关或可能是情感系列病症(affective spectrum disorder)的形式,一个被假设的病症的家族与抑郁症分享至少一个共同的生理学的异常。在精神病症诊断和统计手册(DSM-IV),ICD的本质特征是无法抗拒一个冲动,驱动,或诱惑来进行一项对本人或其他人有害的行为。对大多数的ICDs,个人在做这个行为之前感觉到一个持续增加的紧张或觉醒,并且在做这个行为的时候体验到高兴,满意,或释放。在行为被进行之后,可能有也可能没有后悔或内疚。ICDs被列在一个剩余的类别,ICDs在其他地方未能分类(Not Elsewhere Classified),其中包括间歇性爆发性障碍(IED),盗窃癖,病态赌博,纵火癖,拔发癖,和没有另行指定(NOS)的ICDs。没有另行指定(NOS)的ICDs的例子是强迫性的购买或购物,重复性的自残,非性旁态的性成瘾,严重的咬指甲,强迫性的皮肤搔抓,有冲动的特点的人格障碍,注意缺损多动障碍,以暴饮暴食为特征的饮食病症,和药物使用障碍。
许多药物可造成身体和/或心理的成瘾。那些最熟知的药品包括阿片类药物,如海洛因,鸦片和吗啡;拟交感神经药,包括可卡因和苯丙胺,镇静催眠药,包括酒精,苯二氮类,和巴比士类;和尼古丁,具有与阿片类药物和拟交感神经药类似的效果。药物成瘾是以对使用药物的嗜欲或强迫为特征的并且没有能力来限制对它的摄入。此外,药物依赖与药物的耐受性,在反复给药后药物效果的丧失,以及脱瘾,当药物没有被消费时身体上的和行为上的症状的出现相关联的。当一个药物在反复被给予导致对每个剂量的一个增加的反应时敏化作用就发生了。耐受性,敏化,和脱瘾是证明中枢神经系统由于药物的继续使用而导致的一个变化的现象。这种变化激励成瘾的个体来继续消费这个药物尽管有严重的社会的,法律的,身体的,和/或职业的后果。
注意缺损障碍包括,但不限于,注意缺损多动障碍,以注意缺失为主的类型;注意缺损多动障碍,以多动-冲动为主的类型;注意缺损多动障碍,组合的类型;没有另行指定(NOS)的注意缺损多动障碍;品行障碍;对立违抗性障碍;和没有另行指定(NOS)的破坏性行为障碍。
抑郁障碍包括,但不限于,抑郁症,复发性的;低落性情感病症;没有另行指定(NOS)的抑郁症;和抑郁症,单次发作。
帕金森氏病包括,但不限于,抗精神病药诱发的帕金森氏病。
成瘾病症包括,但不限于,饮食障碍,冲动控制障碍,与酒精有关的病症,与尼古丁有关的病症,与苯丙胺有关的病症,与大麻有关的病症,与可卡因有关的病症,赌博,性功能障碍,致幻剂使用病症,与吸入剂有关的病症,和与阿片类有关的病症,所有这些被分成亚类如下所列。
饮食障碍包括,但不限于,神经性贪食症,非清除型;暴食症厌食症,清除型;和没有另行指定(NOS)的饮食障碍。
冲动控制障碍包括,但不限于,间歇性爆发性障碍,盗窃癖,纵火癖,病态赌博,拔发癖和没有另行指定(NOS)的冲动控制障碍。
与尼古丁有关的病症包括,但不限于,尼古丁依赖,尼古丁脱瘾,和没有另行指定(NOS)的与尼古丁有关的病症。
与苯丙胺有关的病症包括,但不限于,苯丙胺依赖,苯丙胺滥用,苯丙胺中毒,苯丙胺脱瘾,苯丙胺中毒谵妄,苯丙胺诱发的有错觉的精神障碍,苯丙胺诱发的伴有幻觉的精神障碍,苯丙胺诱发的情绪障碍,苯丙胺诱发的焦虑症,苯丙胺诱发的性功能障碍,苯丙胺诱发的睡眠障碍,没有另行指定(NOS)的与苯丙胺有关的病症,苯丙胺中毒,和苯丙胺脱瘾。
与大麻有关的病症包括,但不限于,大麻依赖;大麻滥用;大麻中毒;大麻中毒谵妄;大麻诱发的有错觉的精神障碍;大麻诱发的伴有幻觉的精神障碍;大麻诱发的焦虑症;没有另行指定(NOS)的与大麻有关的病症;和大麻中毒。
与可卡因有关的病症包括,但不限于,可卡因依赖,可卡因滥用,可卡因中毒,可卡因脱瘾,可卡因中毒谵妄,可卡因诱发的有错觉的精神障碍,可卡因诱发的伴有幻觉的精神障碍,可卡因诱发的情绪障碍,可卡因诱发的焦虑症,可卡因诱发的性功能障碍,可卡因诱发的睡眠障碍,没有另行指定(NOS)的与可卡因相关的病症,可卡因中毒,和可卡因脱瘾。
致幻剂使用障碍包括,但不限于,致幻剂依赖,致幻剂滥用,致幻剂中毒,致幻剂脱瘾,致幻剂中毒谵妄,致幻剂诱发的有错觉的精神障碍,致幻剂诱发的伴有幻觉的精神障碍,致幻剂诱发的情绪障碍,致幻剂诱发的焦虑症,致幻剂诱发的性功能障碍,致幻剂诱发的睡眠障碍,没有另行指定(NOS)的与致幻剂有关的病症,致幻剂中毒,和致幻剂的持续性的知觉病症(回闪)。
与吸入剂有关的病症包括,但不限于,吸入剂依赖;吸入剂滥用;吸入剂中毒;吸入剂中毒谵妄;吸入剂诱发的有错觉的精神障碍;吸入剂诱发的伴有幻觉的精神障碍;吸入剂诱发的焦虑症;没有另行指定(NOS)的与吸入剂有关的病症;和吸入剂中毒。
与阿片类有关的病症包括,但不限于,阿片类依赖,阿片类滥用,阿片类中毒,阿片类中毒谵妄,阿片类诱发的有错觉的精神障碍,阿片类诱发的伴有幻觉的精神障碍,阿片类诱发的焦虑症,阿片类,没有另行指定(NOS)的与阿片类有关的病症,阿片类中毒,和阿片类脱瘾。
抽动障碍包括,但不限于,杜瑞氏症(Tourette’s Disorder),慢性运动或发声的抽动障碍,短暂性的抽动障碍,没有另行指定(NOS)的抽动障碍,口吃,自闭症,和躯体化障碍。
本发明还包含同时至少两个成瘾疾病或病症或冲动控制障碍的治疗。例如,本发明提供了同时治疗与酒精相关的疾病和体重控制(见例子)。
本发明也包括对由本发明的化合物所组成的药用组合物的使用化合物来实践本发明的方法,其组成包含至少一个合适的化合物和一个在药学上可接受的载体。
其他对本发明的实践有用的方法可在以下被找到,例如在U.S.Pat.Pub.No.2006/0173064(Lippa et al.),U.S.Pat.No.6,323,236(McElroy),和U.S.Pat.Pub.No.2007/0275970。
在一个实施方案,本发明的一个组合物可能包含本发明的一种化合物。在另一项实施方案,本发明的一个组合物可能包含多于一个的本发明的化合物。在一个实施方案,对于治疗其他病症有用的附加的药物或化合物可以是组合物里的部分。在一个实施方案,包含本发明里的仅一种化合物的一个组合物可以同时与包含本发明的至少一个其他化合物的另一个组合物同时被给予。在一个实施方案,不同的组合物可能在彼此之间不同的时间被给予。当本发明的一个组合物包含本发明的仅一种化合物时,一个附加的成分包含至少一个附加的化合物也必须被使用。
对于本发明的实践有用的药用组合物可能,例如,以输送一个在1纳克/千克/天和100毫克/千克/天之间的一个剂量被给予。
对于本发明的方法有用的药用组合物可能这样被给予,例如,系统性的口腔的固体制剂,或如眼的,栓剂的,气溶胶的,外用的或其他类似的制剂。除了适合的化合物以外,这种药用组合物可能包含药学上可接受的载体和已知的用于加强和促进药物给予的其他成分。其他可能的制剂,如纳米颗粒,脂质体,重新封闭的红细胞,和基于免疫的系统也可能被用于对一个适合的化合物的给予,或一个类拟物,修饰物,或衍生物,根据本发明的方法。
使用任何在这里所描述的方法被识别的化合物可能被配制成和被给予受试者来治疗在这里所披露的疾病。本领域普通技术人员将认识到这些方法对其他的疾病,病症和状况也将是有用的。
一个“前体药物”是指一个在体内转化成为其母体药物的药物。前体药物经常是有用的因为,在某些情况下,它们可能会比母体药物更容易地被给予。它们可能,例如,通过口腔给药是有生物学上可利用性的而其母体药物不是。这个前体药物可能也在制药的组合物里具有与其母体药物相比改善了的溶解度,或可能表现出增加的适口性或更容易来配制。一个例子,但不受其限制,一个前体药物将是本发明一的种化合物将以一个酯(“前体药物”)来给予以便利跨过一个细胞膜来传输而其在水里的溶解度会不利于流动性但后来通过代谢被水解为羧酸,就是活性的实体,一旦进入细胞里在那里在水里的溶解度是有益处的。前体药物的一个进一步的例子可能是一个短肽(多聚氨基酸)与一个酸基团成键而肽被代谢以来提供有活性的一部分。
本发明包含药用组合物的制备和使用,药用组合物中包括一个在这里作为一个活性成分的对于在这里所披露的疾病的治疗有用的一种化合物。这样一种药物组合物可能仅包括活性成分,以适合于对受试者给药的一个形式,或药用组合物可能包含活性成分和一个或更多在药学上可接受的载体,一个或更多附加的成分,或这些的某种组合。活性成分可能在药用组合物里以一个生理学上可接受的酯或盐的形式存在,如与一个生理学上可接受的阳离子或阴离子,这在本领域是众所周知的。
在这里所描述的药用组合物的制剂可能通过在药理学的本领域上任何已知的或此后发展的任何的方法来制备。一般地,这种制备方法包括把活性成分与一个载体或一个或更多的辅助成分相结合的步骤,以及之后,如果有必要或合乎需要的,把产品取形或包装成一个所想达到的单一的或多剂量的单位。
尽管在这里所提供的对药用组合物的描述主要被针对适合对人类伦理给药的药用组合物,熟练的技工将会理解,这样的组合物通常适用于给予各种的动物。对适合给予人类的药用组合物修饰为了使其组合物成为适合给予各种动物是被完全理解的,普通熟练的兽医学药理学家通常可以设计和进行这样的修饰,如果有任何需要的话,所要的仅是普通的试验。本发明的药用组合物所给予的受试者被设想包括,但不限于,人类和其他灵长类动物,哺乳动物包括商业上有关的哺乳动物如牛类,猪类,马类,绵羊类,猫类,狗类,以及鸟类包括商业上有关的鸟类如鸡,鸭,鹅和火鸡。
本发明的方法所包含的一种给药类型是肠胃外的给药,其中包括,但不限于,通过对一个组合物的注射来对一个药用组合物给药,通过一个手术切口来使用一个药用组合物,通过一个穿透组织的非手术伤口来使用一个药用组合物,和相类似的。特别的,肠胃外的给药被设想包括,但不限于,皮下的,腹腔内的,肌肉内的,和胸骨内的注射,和肾脏透析注入技术。
对本发明的方法有用的药用组合物可能以适合于口腔的,直肠的,阴道的,肠胃外的,外用的,肺的,鼻腔内的,吸入的,颊腔的,眼的,鞘内的或一个其他的给药的途径的制剂被制备,包装,或出售。其他被设想的制剂包括预定的纳米颗粒,脂质体的制备,重新封闭的含有活性成分的红细胞,以及基于免疫的制剂。
本发明的药用组合物可能以一个适合通过颊腔的肺的给药的制剂被制备,包装,或出售。
本发明的方法的药用组合物可能以散装,作为一个单位剂量,或作为一个复数性的单位剂量,被制备,包装,或出售。在这里所使用的,一个“单位剂量”是一个离散数额的药用组合物包含一个被预先确定数额的活性成分。活性成分的数额,一般等于对一个个体所给予的活性成分的剂量,或这样一个剂量的一个便利的一部分,例如,这个剂量的一半或三分之一。
活性成分的相对数额,药学上可接受的载体,和在本发明的药用组合物其他成分的药物的任何附加的成分将会变化,这取决于被治疗的受试者的本身,大小和状况的问题和进一步取决于组合物被给予的途径。只是通过举例来说,组合物可能包含在0.1%和100%(w/w)之间的活性成分。
在活性成分以外,本发明的药用组合物可能进一步包含一个或更多的附加的制药上的活性剂。特别被设想的其他制剂包括止呕剂和清除剂如氰化物和氰酸清除剂。
本发明的药用组合物的控释或缓释制剂可能使用常规的技术制成。
本发明的药用组合物的适合于口腔服用的制剂可能以一个离散的固体剂量单位的形式被制备,包装,或出售包括,但不限于,片剂,硬的或软的胶囊,扁囊剂,含片,或锭剂,每一个包含被预先确定数额的活性成分。其他的适合于口腔服用的制剂包括,但不限于,成为粉末状或颗粒状的制剂,水性的或油性的悬浮液,水性的或油性的溶液,或乳化液。
在这里所使用的,“油性的”液体是包含含碳的液体分子,并且与水相比呈现出较少的极性特征。
包含活性成分的片剂可能,例如,通过把活性成分压缩或模制来制成,可选择地与一个或更多的成分在一起。被压缩的片剂可能通过压缩被制备,在合适的装置里,以自由流动的形式的活性成分例如粉末或颗粒制备,可选择地与一个或更多的结合剂,润滑剂,赋形剂,表面活性剂,和分散剂混合起来。被制模的片剂可以通过模制来制成,在合适的装置里,活性成分的混合物,药学上可接受的载体,和至少足够的液体来润湿这个混合物。被使用于片剂制造的药学上可接受的赋形剂包括,但不限于,惰性稀释剂,造粒和崩解剂,结合剂,和润滑剂。已知的分散剂包括,但不限于,马铃薯淀粉和羟基乙酸淀粉钠。已知的表面活性剂包括但不限于,十二烷基硫酸钠。已知的稀释剂包括,但不限于,碳酸钙,碳酸钠,乳糖,微晶纤维素,磷酸钙,磷酸氢钙,和磷酸钠。已知的造粒和崩解剂包括但不限于,玉米淀粉和海藻酸。已知的结合剂包括,但不限于,明胶,阿拉伯胶,预糊化玉米淀粉,聚乙烯吡咯烷酮,和羟丙基甲基纤维素。已知的润滑剂包括,但不限于,硬脂酸镁,硬脂酸,硅石,和滑石粉。
片剂可以是非涂层的或涂层的通过使用已知的方法来实现在受试者的胃肠道的延迟崩解,从而提供持续的释放和对活性成分的吸收。通过例子来说,如甘油单硬脂酸酯或甘油二硬脂酸酯的材料可被用于大衣片剂。进一步通过例子来说,片剂可能使用在美国专利4,256,108;4,160,452;和4,265,874所描述的方法来涂层以形成渗透性控释片。片剂可进一步包含甜味剂,调味剂,着色剂,防腐剂,或这些的一些的组合为了提供制药上优雅的和美味的制备。
包含活性成分的硬的胶囊可能使用生理学上可降解的成分被制成,如明胶。这样的硬的胶囊包含活性成分,并可能进一步包含附加的成分,例如,惰性固体稀释剂如碳酸钙,磷酸钙,或高岭土。
包含活性成分的软的胶囊可能使用生理学上可降解的成分被制成,如明胶。这样的软的胶囊包含活性成分,可能与水或油介质相混合,如花生油,液体石蜡,或橄榄油。
乳果糖也可以作为一个自由和易受浸蚀的填充料被使用并且在本发明的化合物以胶囊的形式被制备时是有用的。
本发明的适合于口腔服用的药用组合物的液体制剂可能或以液态形式或以干产品形式被制备,包装,或出售意图是为与水或另一个适合的载体在使用前重新构建。
液体悬浮液可能使用常规的方法来制备以达到在水性的或油性的载体里活性成分的悬浮。水性的载体包括,例如,水和等渗盐水。油性的载体,包括,例如杏仁油,油酯,乙醇,植物油如花生,橄榄,芝麻,或椰子油,分级的植物油,和矿物油如液体石蜡。液体悬浮液可能进一步包含一个或更多的附加的成分包括,但不限于,悬浮剂,分散或润湿剂,乳化剂,缓和剂,防腐剂,缓冲液,盐,调味料,着色剂,和甜味剂。油性的悬浮液可能进一步包括一个增稠剂。已知的悬浮制剂包括,但不限于,山梨醇糖浆,氢化可食用脂肪,海藻酸钠,聚乙烯吡咯烷酮,黄蓍树胶,阿拉伯胶和纤维素衍生物如羧甲基纤维素钠,甲基纤维素,和羟丙基甲基纤维素。已知的分散或润湿剂包括,但不限于,自然发生的磷脂,如卵磷脂,以下的缩合产物由烯化氧与脂肪酸,与长链脂肪醇,与长链脂肪醇,源自于脂肪酸和己六醇的偏酯,或源自于脂肪酸和己六醇和己六醇酸酐(如聚氧乙烯硬脂酸,十七氧乙烯十六醇,聚氧乙烯山梨醇单油酸酯,和聚氧乙烯山梨醇酐单油酸酯,分别的)。称为乳化剂包括,但不限于,卵磷脂和阿拉伯胶。已知的防腐剂包括,但不限于,甲基,乙基,或正丙基对羟基苯甲酸,抗坏血酸和山梨酸。已知的甜味剂包括,例如,甘油,丙二醇,山梨醇,蔗糖,和糖精。已知的用于油性悬浮液的增稠剂包括,例如,蜂蜡,硬的石蜡,和十六醇。
在一方面,以糖浆或酏剂的形式的制剂或以液滴的方式为了给予可能包含活性成分和甜味剂在一起,尽可能是没有热量的,而且也可能进一步包含尼泊金甲酯或丙对苯作为防腐剂,调味品和合适的颜色。
活性成分的液体溶液在水性或油性的溶剂可能以在相当大的程度上与液体悬浮液相同的方式来制备,主要的不同是,活性成分在溶剂里被溶解,而不是被悬浮。本发明的药用组合物的液体溶液包含关于液体悬浮液的描述的每一个成分,也被理解就是用于悬浮的制剂将不一定会辅助活性成分在溶剂里的溶解。水性的溶剂包括,例如,水和等渗盐水。油性的溶剂包括,例如,杏仁油,油酯,乙醇,植物油如花生,橄榄,芝麻,或椰子油,分级的植物油,和矿物油如液体石蜡。
本发明的制药上的制备成为粉末状或颗粒状的制剂可能使用已知的方法来制备。这种制备可能被直接给予受试者,被使用,例如,来形成片剂,来填充胶囊,或制备水性的或油性的悬浮液或溶液通过向其加入水性的或油性的载体。这些制剂的每一个可能进一步包含一个或更多的分散或润湿剂,悬浮剂,和防腐剂。附加的赋形剂,如填充料和甜味剂,调味剂,或着色剂,也可能被包括在这些制剂里。
本发明的药用组合物可能也以水包油或油包水的乳剂的形式被制备,包装,或出售。油相可能是植物油,如橄榄油或花生油,矿物油,如液体石蜡,或这些的组合。这样的组合物可能进一步包含一个或更多的乳化剂包括自然发生的树胶如阿拉伯胶或黄蓍树胶,自然发生的磷脂如大豆磷脂或卵磷脂,源自于脂肪酸和己六醇酸酐组合的酯或偏酯如山梨醇酐单油酸酯,和这样的偏酯与氧乙烯的缩合产物如聚氧乙烯山梨醇酐单油酸酯。这些乳液可能也包括附加的成分包括,例如,甜味剂或调味剂。
本发明的药用组合物可能以适合直肠给药的制剂被制备,包装,或出售。这样的组合物可能是这样的形式,例如,栓剂,保留灌肠制剂,和用来直肠或结肠灌洗的溶液。
栓剂制剂可通过把活性成分与非灌洗的药学上可接受的在普通的室温(即约20℃)是固体的赋形剂相结合并且在受试者的直肠温度是液体(即在一个健康的人约37℃)。适合的药学上可接受的赋形剂包括,但不限于,可可脂,聚乙二醇,和各种的甘油酯。栓剂制剂可能进一步包含各种附加的成分包括,但不限于,抗氧化剂和防腐剂。
用于直肠或结肠灌洗的保留灌肠的制备或溶液可通过把活性成分与药学上可接受的液体载体相结合来制成。就如在本领域熟知的,灌肠制备可能被给予通过使用,并可能被包装在其内,适应受试者的直肠解剖学的输送装置。灌肠制备可能进一步包含各种的附加组合物,包括,但不限于,抗氧化剂和防腐剂。
本发明的药用组合物可能以适合阴道给药的制剂被制备,包装,或出售。这样的组合物可能是这样的形式,例如,栓剂,浸渍的或涂层的可插入阴道的材料如止血栓,灌洗制剂,或胶体或乳膏或用于阴道灌洗的溶液。
使用化学组合物来对材料浸渍或涂层在本领域是已知的,并且包括,但不限于把化学组合物沉积或结合与表面的方法,把化学组合物在材料的合成之中合并到材料的结构里(即如生理学上的可降解的材料),和吸收水性的或油性的溶液或悬浮液成为吸收性的材料的方法,有或没有随后的烘干。
用于阴道灌洗的灌洗的制备或溶液可能通过把活性成分与制药上可接收的液体载体相结合来制成。如在本领域是熟知的,灌洗的制备可能被给予通过使用,并可能被包装在其内,适应受试者的阴道解剖学的输送装置。灌洗的制备可能进一步包含各种的附加组合物,包括,但不限于,抗氧化剂,抗生素,抗真菌剂,和防腐剂。
在这里所使用的,药用组合物的“肠胃外的给药”包括任何的给药途径是通过是以通过受试者的组织的身体上的裂口来通过这个裂口进入组织来给予药用组合物为特征的。肠胃外的给药从而包括,但不限于,通过组合物的注射来给予药用组合物,通过手术切口来使用此组合物,通过穿透组织的非手术伤口来使用药用组合物,和相类似的。特别地,肠胃外的给药被设想包括,但不限于,皮下的,腹腔内的,肌肉内的,和胸骨内的注射,和肾脏透析注入技术。
适合肠胃外的给药的药用组合物的制剂包含与药学上可接受的载体,如无菌水或无菌等渗盐水结合的活性成分。这种制剂可能以适合丸剂给药或持续给药的形式被制备,包装,或出售。可注射的制剂可能以一个单位剂量如安瓿或以多剂量的含有防腐剂的容器的形式被制备,包装,或出售。肠胃外的给药的制剂包括,但不限于,悬浮液,溶液,在油性的或水性的载体的乳液,糊剂,和可植入的缓释或可生物降解的制剂。这样的制剂可能进一步包含一个或更多的附加的成分包括,但不限于,悬浮,稳定,或分散剂。在肠胃外的给药的制剂的一个实施方案,活性成分被提供是以干的(即,粉末或颗粒)的形式为了与一个合适的载体(例如,无菌的无热原的水)来重新构成在对重新构成的肠胃外的给药之前。
本发明的药用组合物可能以无菌的可注射的水性的或油性的悬浮液或溶液的形式被制备,包装,或出售。这样的悬浮液或溶液可能根据本领域已知的被制备,并可能包含,除了活性成分之外,附加的成分如在这里所描述的分散剂,润湿剂,或悬浮剂。这样的无菌的可注射的制剂可能被制备使用无毒性的肠胃外的可接受的稀释剂或溶剂,例如水或1,3-丁烷二醇,举例来说。其他可接受的稀释剂和溶剂包括,但不限于,林格氏溶液,等渗氯化钠溶液,并固定油如合成的单或双甘油酯。其他肠胃外的可给予的并且是有用的制剂包括那些包含的活性成分是以微晶的形式,在脂质体的制剂里,或作为可生物降解的聚合物体系的组成部分。用于缓释或植入的组合物可能包含药学上可接受的聚合的或疏水性的材料如乳液,离子交换树脂,难溶性聚合物,或难溶盐。
适合外用给药的制剂包括,但不限于,液体或半液体制备,如搽剂,洗剂,水包油或水油乳剂如面乳膏,油膏或糊剂,和溶液或悬浮液。可外用给药的制剂可能,例如,包含从约1%至约10%(w/w)活性成分,尽管活性成分的浓度可能会高达活性成分在溶剂里的溶解度的限度。外用给药的制剂可能进一步包含一个或更多在这里所描述的附加的成分。
本发明的药用组合物可能以适合通过颊腔的肺的给药的制剂被制备,包装,或出售。这样的制剂可能包括干的颗粒其中包含活性成分,并且直径在约0.5到约7纳米的范围里,尽可能地是从约1到约6纳米。这样的组合物可能被便利地以干粉末的形式来给药使用装置包括干粉末储存器并有抛射剂流,可被指导来分散粉末或使用自我推进的溶剂/粉末扩散容器例如装置其中包含在密封的容器里的低沸点抛射剂里被溶解或悬浮的活性成分。尽可能地,这样的粉末包括这样的颗粒,也就是在其中按重量来说至少98%的颗粒直径大于0.5纳米和按数量来说至少95%的颗粒直径小于7纳米。更尽可能地,按重量来说至少95%的颗粒直径大于1微米和按数量来说至少90%的颗粒直径小于6纳米。干粉末的组合物尽可能地包括固体精细粉末稀释剂如糖,并便利地以单位剂量的形式被提供。
低沸点抛射剂一般包括了具有在大气压下沸点低于65°F的液体抛射剂。一般地,抛射剂可能构成组合物的约50%至约99.9%(w/w),并且活性成分可能构成组合物的约0.1%至约20%(w/w)。抛射剂可能进一步包括附加的成分如液体非离子或固体阴离子表面活性剂或固体稀释剂(尽可能地具有颗粒大小与包含活性成分的颗粒大小是相同的数量级)。
为肺部给药所制备的本发明的药用组合物也可能以溶液或悬浮液的液滴的形式来提供其活性成分。这种制剂可能以水性的或稀释的酒精性溶液或悬浮液被制备,包装,或出售,可选择性的是无菌的,包括活性成分,并且可能被便利地通过使用任何的雾化的或粉化的装置来给予。这样的制剂可能进一步包含一个或更多的附加的成分,包括,但不限于,如糖精钠的增味剂,挥发油,缓冲制剂,表面活性剂或防腐剂,如羟基苯甲酸甲酯。通过这种给药途径所提供的滴液尽可能地具有平均直径在从约0.1到约200纳米的范围里。
在这里所描述的有用于肺部的输送的制剂对于本发明的药用组合物的鼻腔内的输送也是有用的。
另一个适合鼻腔内给药的制剂是包含活性成分的粗的粉末并且其平均颗粒是从约0.2到约500微米之间。这样的制剂是以鼻吸药的方式来给予的,即,从被置于靠近鼻孔的一个盛有粉末的容器里通过鼻腔通道来快速吸入。
适合鼻腔给药的制剂可能,例如,包括从大约仅仅约0.1%(w/w)到几乎约100%(w/w)的活性成分,并可能进一步包括一个或更多的在这里所描述的附加的成分。
本发明的药用组合物可能以适合颊腔的给药的制剂被制备,包装,或出售。这种制剂可能,例如,是以使用常规的方法制成的片剂或锭剂的形式,而且可能,例如,包含约0.1%至约20%(w/w)的活性成分,这个平衡包含口腔内可分解或可降解的成分以及,可选择的,一个或更多的在这里所描述的附加的成分。替换性地,适合于颊腔的给药的制剂可能包含粉末或气溶胶化或雾化的包含活性成分的溶液或悬浮液。这种粉末化的,气溶胶化的,或雾化的制剂,当被分散后,尽可能地有平均的颗粒或液滴大小在从约0.1至约200纳米的范围里,并可能进一步包括一个或更多的在这里所描述的附加的成分。
本发明的药用组合物可能以适合眼的给药的制剂被制备,包装,或出售。这种制剂可能,例如,是滴眼液的形式,例如,在水性的或油性的液体载体里的0.1%至1.0%(w/w)的活性成分的溶液或悬浮液。这样的滴液可能进一步包括缓冲剂,盐,或一个或更多在这里所描述的附加组合物。其他有用的可以通过眼的给药的制剂包括那些在其中包含以微晶的形式或在脂质体的制剂里的活性成分。
本发明的药用组合物可能以适合粘膜内给药的制剂被制备,包装,或出售。本发明提供了粘膜内的化合物的给药来允许跨粘膜的化合物的通过或吸收。这种给药的类型对口腔的(牙龈的,舌下的,颊腔的),直肠的,阴道的,肺的,鼻腔等的吸收是有用的。
本发明的药用组合物舌下给药对活性成分来说有一个优势就是在一些情形下,当通过口腔给予,会通过肝脏受到一个大幅度的首次通过的代谢及酶促降解,导致快速代谢和治疗活性的一个丧失是与肝脏酶把这个分子转化成没有活性的代谢产物的活性有关的,或由于这个生物转化被减少的活性。
在一些情况下,给药的一个舌下途径能够产生在作用上的一个迅速的开始,由于颊粘膜的相当大的通透性和血管化。此外,舌下给药也可允许对这样的有效组合物的给予,即在口腔给药之后在胃粘膜的或者消化粘膜的水平上不是在正常情形下被吸收的,或替换性的在食入之后在酸性介质里被部分或完全降解的,例如片剂。
在现有技术已知的舌下片剂制备技术通常是把包含活性成分和如稀释剂,结合剂,崩解剂和辅助剂的压缩赋形剂的粉末的混合物通过直接压缩来制备的。在一个替换性的制备方法,活性成分和压缩赋形剂可预先成为干的或湿的颗粒。在一方面,活性成分是分布于整个片剂的质量。WO 00/16750描述了舌下使用的迅速崩解的片剂并包含有序的混合物其中的活性成分是以微颗粒的形式粘附于在大小上来说大幅度更大的可溶于水的颗粒的表面,构成了对活性微颗粒的负载,其组合物也包括粘膜粘附剂。WO 00/57858描述了舌下使用的片剂,包括活性成分与泡腾系统相联合意图是为促进吸收,并且也是pH值调节剂。
本发明的化合物可以被制备成适合给药的制剂或药用组合物,允许或提高跨粘膜的吸收。粘膜吸收增强剂包括,但不限于,胆汁盐,脂肪酸,表面活性剂,或酒精。在特定的实施方案,渗透增强剂可以是胆酸钠,十二烷基硫酸钠,脱氧胆酸钠,甘牛胆酸盐,甘胆酸钠,二甲基亚砜或乙醇。在进一步的实施方案,本发明的化合物可以与粘膜透入增强剂在一起制备以促进化合物的输送。这个制剂也可以与使溶解度,药物稳定性,和通过如鼻粘膜,口腔粘膜,阴道粘膜,呼吸的,和肠粘膜的粘膜吸收达到最佳的pH值来制备。
为了进一步加强在本发明里的药物制剂的粘膜输送,包含活性制剂的制剂也可能包括亲水的低分子量的化合物作为一个基或赋形剂。这种亲水的低分子量的化合物为可溶于水的活性制剂提供了使其通过的通道媒介,如生理学上有活性的肽或蛋白质,可能通过此基扩散到体表在那里活性制剂被吸收。亲水的低分子量的化合物可选择地吸收从粘膜或给药氛围的水分并且溶解可溶于水的活性肽。亲水的低分子量的化合物的分子量一般不超过10000,并且尽可能地不超过3000。示例性亲水的低分子化合物包括多元醇化合物,如低聚糖,二糖和单糖如蔗糖,甘露醇,乳糖,L-阿拉伯糖,D-赤藓糖,D-核糖,D-木糖,D-甘露糖,D-半乳糖,乳果糖,纤维二糖,龙胆二糖,甘油和聚乙二醇。在本发明里可以作为载体的亲水的低分子量的化合物的其他例子包括N-甲基吡咯烷酮,和醇类(例如,寡聚乙烯醇,乙醇,乙二醇,丙二醇等)。这些亲水的低分子量的化合物可被单独或相互之间联合或与鼻腔内制剂的其他活性或非活性成分联合。
当本发明的控释制药制备进一步包含一个亲水基,许多选项是可有效可包含的。亲水性的聚合物,例如聚乙二醇和聚乙烯吡咯烷酮,糖醇,例如D-山梨醇和木糖醇,糖类,如蔗糖,麦芽糖,乳果糖,D-果糖,葡聚糖,和葡萄糖,表面活性剂例如聚氧乙烯-氢化蓖麻油,聚氧乙烯聚氧丙烯二醇,聚氧乙烯山梨糖醇酐高阶脂肪酸酯,盐,如氯化钠和氯化镁,有机酸如柠檬酸和酒石酸,氨基酸如如甘氨酸,beta-丙氨酸,和赖氨酸盐酸盐,并氨基糖,如葡甲胺被给出作为亲水基的例子。聚乙二醇,蔗糖,和聚乙烯吡咯烷酮的首选和聚乙二醇进一步首选。一个或一组两个或两个以上的亲水基地可用于本发明。
本发明设想通过吸入器来通过肺,鼻腔,或口腔给药。在一个实施方案,吸入器的输送可以是计量的剂量。
吸入器是对本发明的至少一种化合物病人自我给药的装置包含喷雾吸入器(例如,鼻腔的,口腔的,或肺的喷雾吸入器)包含气溶胶喷雾制剂是由至少本发明的化合物和药物上可接受的分散剂组成的。在一方面,此装置是计量的为了分散气溶胶制剂的一个数额通过形成一个喷雾包含本发明的至少一种化合物的有效地治疗本发明所涵盖的一个疾病或病症的剂量。分散剂可能是表面活性剂,例如,但不限于,聚氧乙烯脂肪酸酯,聚氧乙烯脂肪酸醇,聚氧乙烯山梨糖醇酐脂肪酸酯。基于磷脂的表面活性剂也可被使用。
在其他的实施方案,气溶胶制剂是以干粉末喷雾剂制剂来提供的并且在其中本发明的化合物是以精细分开的粉末出现的。干粉末制剂可进一步包括膨胀剂,例如,但不限于,乳糖,山梨醇,蔗糖,和甘露醇。
在另一个特定的实施方案,气溶胶制剂是液体气溶胶制剂进一步包括药学上可接受的稀释剂,例如,但不限于,无菌水,生理盐水,缓冲盐水和葡萄糖溶液。
在进一步的实施方案,气溶胶制剂进一步包括本发明的至少一个附加的化合物在这样的浓度就是被装置分散的气溶胶制剂的计量的数额包含在这里所披露的附加的化合物的一个剂量是一个这样的计量的数额就是当与本发明的至少第一个或第二种化合物联合使用时能有效地改善疾病或病症的症状。
因此,本发明为对与成瘾有关的疾病或病症例如一个与酒精有关的疾病或病症的门诊病人的治疗提供了一个自我给药的方法。这种给药可用于在医院里,在医疗办公室里,或在医院或医疗办公室之外被非医务人员进行自我给药。
本发明的化合物将被制备为适合鼻腔给予的一个制剂或药用组合物。在一个进一步的实施方案,本发明的化合物可以被配制成粘膜渗透增强剂来便利药物的输送。这个制剂也可以在使溶解度,药物稳定性,和鼻粘膜的吸收达到最佳的pH值被制备,和其他所考虑的。
为在吸入器或吹药器使用的胶囊,水泡,并药液筒可被配制成包含在这里所提供的药用组合物的粉末混合物;合适的粉末垫,例如乳糖或淀粉;和性能调节剂,例如L-亮氨酸,甘露醇,或硬脂酸镁。乳糖可以是无水的或以一水合物的形式。其他合适的赋形剂包括右旋糖酐,葡萄糖,麦芽糖,山梨醇,木糖醇,果糖,蔗糖和海藻糖。这里提供的为吸入/鼻腔内给药的药用组合物可能进一步包括合适的味道,如薄荷脑和左薄荷脑,或甜味剂,如糖精或糖精钠。
通过吸入来给药,根据本发明的方法来使用的化合物是以从一个加压的包装或喷雾器以便于输送的气溶胶喷雾剂的呈现的形式,并使用合适的抛射剂,例如,二氯二氟甲烷,三氯氟甲烷,二氯四氟乙烷,二氧化碳或其他合适的气体。在加压气溶胶的情形下,剂量单位可通过提供从一个阀门到传送一个计量的数额来确定。为在吸入器或吹药器使用的例如明胶的胶囊和药液筒可以被配制成包含药物的粉末混合物和合适的粉末垫,例如乳糖或淀粉。
在这里所使用的,“附加的组分”包括,但不限于,一个或更多如下的:赋形剂;表面活性剂;分散剂;惰性稀释剂;造粒和崩解剂;结合剂;润滑剂;甜味剂;调味剂;染色剂;防腐剂;生理学上可降解的成分例如明胶;水性的载体和溶剂;油性的载体和溶剂;悬浮剂;分散或湿润剂;乳化剂;镇痛剂;缓冲液;盐;增稠剂;填料;乳化剂;抗氧化剂;抗生素;抗真菌剂;稳定剂;和药学上可接受的聚合的或疏水的材料。其他的“附加的组分”可能被包括在本发明的药用组合物里的是在本领域已知的并且被描述,例如在Genaro,ed.,1985,Remingtoh′s Pharmaceutical Sciences,MackPublishing Co.,Easton,PA,在这里被编入在参考文献里。
有代表性地,本发明的化合物的剂量可以被给予动物,尽可能地是人,剂量的范围是每千克动物的体重从1.0微克至约100克。所给予的精确剂量将会根据任何数量的因素而变化,包括但不限于,正在被治疗的动物类型和疾病状态的类型,动物的年龄和给药的途径。尽可能地,化合物的剂量将是在每千克动物的体重从约1毫克到约10克来变化。更加尽可能地,化合物的剂量将是在每千克动物的体重从约10毫克到约1克来变化。
化合物可以被给予受试者经常到每日数次,或者它也可以不这么经常地被给予,例如一天一次,一周一次,两周一次,一个月一次,或者甚至更不这么经常,例如数月一次,或者甚至一年一次或更少。剂量的频率将对将本领域技术人员来说是明显的并且将依靠任何数量的因子,例如,但不限于,正在被治疗的疾病的类型和严重程度,动物的类型和年龄,等。
发明也包括试剂盒包含本发明的化合物和说明材料来描述化合物的给药。在另一项实施方案,这个试剂盒包含(尽可能是消毒的)溶剂适合在把化合物给予哺乳动物时把本发明的组成部分溶解或悬浮。
在这里所使用的,“说明材料”,包括出版物,录制,图,或任何其他表达的媒介,可以被用来沟通在用来减轻在这里书面陈述的各种疾病或病症的试剂盒里的本发明的化合物的有用性。可选择地,或替换性地,说明材料可以描述在受试者里减轻疾病或病症的一个或更多方法。本发明的试剂盒的说明材料可以,比如说,粘贴在一个里面包含被识别的化合物发明的容器里或者被与里面包含被识别的化合物的容器一同运输。替换性地,说明材料可与容器分开运输但其目的是接受者把说明材料和化合物合作使用。
不用进一步的描述,相信本领域普通技术人员可以,用前面的描述和下述的说明性的例子,制造和使用本发明的化合物和本发明和实践被声明的方法。下述的工作的例子,因此,特异地指出本发明尽可能的实施方案,而不是以任何方式被解释为对披露的剩余部分的限制。
实施例
昂丹司琼和托吡酯的联合用药作为对酒精依赖,体重控制,和成瘾病症潜在的治疗的检测
在这里所描述的实验检测了昂丹司琼和托吡酯的联合效果来确定是否这些药物当联合的时候可能会产生加性的和/或协同的效应。实验检测了联合治疗对调制与成瘾有关的疾病和病症的能力,例如酒精滥用的两个重要方面:总消费量和复发,以及体重控制。
不希望被任何特别的理论所约束,既有直接的又有间接的神经机制来特异地把昂丹司琼和托吡酯的效果联合起来。支持直接机制的,基础研究表明通过增强在伏隔核的DA的释放的酒精的奖赏效果的表达是通过激活5-HT3受体来介导的。5HT3受体拮抗剂,昂丹司琼,调制在中脑-皮层-边缘系统的上基部的但不是基部的DA神经元活动性。进入伏隔核的DA输入对从伏隔核投射到皮质结构的GABA神经元是抑制的。因此,5HT3拮抗性的净功能效应也促进对海马和皮质的GABA能输出。所以,可以合理地预期,托吡酯促进在海马和皮层的GABA能传输的的能力将对昂丹司琼的能力来说至少是加性的。
支持间接的机制的,5-HT3拮抗性将被预期会加强回到VTA的GABA输入。这样,DA在VTA的发射将被抑制。托吡酯对回到VTA的GABA的输出的促进作用将被预期增强昂丹司琼诱导的DA在VTA发射的抑制。此外,托吡酯被预期通过AMPA/卡因酸谷氨酸受体来减少从VTA和伏隔核的DA兴奋性输入,从而进一步增强GABA能的功能和抑制中脑DA神经细胞的发射。合在一起,这个机制上的建议为把昂丹司琼和托吡酯联合来治疗酗酒和其他成瘾和与冲动控制有关的疾病提供了一个健全的和强有力的原理。当然,联合的治疗效果被预期将在EOA中最为深远,其中昂丹司琼也可以改善5-羟色胺能异常。
联合的另一个令人惊讶的潜在的益处是昂丹司琼的某些效果可以减少托吡酯的不良事件。例如,由于昂丹司琼可增强认知精神运动性能,它有这样的潜力来抵消从使用托吡酯而来的认知精神运动性能的降低。此外,当托吡酯单独时,感觉异常是一个非常频繁(在个体中发生超过50%)和麻烦的不良事件显著减少了顺从。所以,有兴趣的是昂丹司琼,当单独给予时是与感觉异常不相关的,似乎通过一个还是未知的机制减少了从托吡酯的感觉异常率;但不希望被任何特别的理论所约束,在这里提议可能是因为昂丹司琼有抗焦虑的特性。因此,这个联合与简单的加性的或协同的对饮酒结果的改善相比可能会有一个甚至更大的治疗效果,而且也因为顺从使用昂丹司琼和托吡酯的联合的顺从将得到增强(尤其是超过并在托吡酯之上)通过减少不良事件型面(见下面)。
令人惊讶的是,以下所描述的数据提示托吡酯/昂丹司琼组合,与每个药物单独相比,有加性的有益效果。
实施例1
在酒精偏好(P)大鼠里托吡酯(10毫克/千克,IP)和昂丹司琼(0.001毫克/千克,IP)对酒精消费的联合效果。虽然单独的托吡酯产生了酒精消费的中等的减少(图1A,左上角的面板;例如,从基线的13%±5%的下降),当与一个在它自己不影响酒精消费的昂丹司琼的剂量相联合时(图1B,右上角的面板;例如,从基线的1%±7%下降),从被观察到的基线的酒精消费有一个强大的和持续的下降(图1C,左下角的面板;例如,从基线的23%±5%的下降)。在载体注射之后没有显着的差异被观察到(图1D,右下角的面板)或在其他托吡酯/昂丹司琼的联合之后(数据没有显示)。数据是跨过连续7个时期来绘制的,包括一个3天的基线期,昂丹司琼和/或托吡酯注射被给予的测试期,和测试期之后的3个时期。每一个数据点表示17只大鼠的平均值(±标准误差)。
用图解法阐明了在酒精偏好(P)大鼠里托吡酯(10毫克/千克,IP)和昂丹司琼(0.001毫克/千克,IP)对酒精消费的联合效果。1A-单独的托吡酯;1B-单独的昂丹司琼;1C-昂丹司琼加托吡酯;1D-载体。纵坐标表示以克/千克表示的乙醇摄入量和横坐标表示时期数。
实施例2
在两个星期戒酒期之后的酒精偏好(P)大鼠里托吡酯(10毫克/千克,IP)和昂丹司琼(0.001毫克/千克,IP)对酒精消费的联合效果。大鼠在戒酒前的至少三个月里在一个24-小时-使用的二瓶选择程序之下对酒精溶液(10%)和水可以无限制地使用以来诱发酒精依赖。在一个两周的戒酒期间里大鼠对食物和水有完全的使用权限。随后,酒精溶液被再引进并且托吡酯(10毫克/千克)单独的和与昂丹司琼(0.001毫克/千克)联合的效果被检验。如所预期的,被载体治疗的大鼠在戒酒之后呈现出在酒精消费上的一个显著的增加(图2)。托吡酯在它自己时衰减了酒精剥夺效应。当托吡酯与一个在它自己时没有对酒精消费没有影响的低水平的昂丹司琼联合时,不仅酒精剥夺效应被完全阻断了,而且这个联合从在基线观察的水平上降低了消费。数据是以酒精消费的基线水平的变化来表示的,并且每一个数据点表示在2至3只大鼠之间的平均值。
实施例3
在Wistar大鼠里低和高剂量的托吡酯(5和10毫克/千克,IP)和昂丹司琼(0.001和0.01毫克/千克,IP)对酒精消费的联合效果。
与从P大鼠得到的结果相反,从Wistar大鼠得到的结果表明昂丹司琼的两个剂量(0.001毫克/千克,低Ond;和0.01毫克/千克,高Ond),当与高剂量的托吡酯相联合时(10毫克/千克,高Top)会减少酒精消费(图3)。这样的效果是令人惊讶的,因为初步的发现似乎表明当每一个药物单独被给予后会缺乏调制(数据没有显示)。在每个条件下,实验里用到了四到五只大鼠。数据是通过与酒精消费的基线水平相比的变化来表示的。
实施例4
通过使用动物模型对恩丹西和托吡酯的联合用药作为对酒精依赖的潜在的治疗的检测的进一步的研究
昂丹司琼和托吡酯的效果被检验的是它们对酒精滥用的两个重要方面的调制能力:总消费量和复发。总消费量是在一个24-小时-使用的二瓶选择程序之下被检验,其中大鼠对酒精溶液(10%)和水可以无限制地使用。酒精复发是通过对在酒精依赖的大鼠在一个延长的戒酒期之后的酒精消费的检测来评估的。特别地说,在酒精依赖的大鼠里,当酒精在一个延长的戒酒期之后被重新引入,大鼠的消费水平与戒酒之前相比会有显著的增加。从两个不同的品系的大鼠里得到的结果-一个是酒精偏好品系的大鼠对酒精滥用有遗传易感性和一个是Wistar品系的大鼠没有对酒精滥用的遗传易感性。我们的数据提示与每一个药物在单独时相比,托吡酯/昂丹司琼的联合的加性的有益的效果,特别是在P大鼠里。
1)托吡酯与昂丹司琼的联合在大鼠里降低了酒精消费:消费量是在一个24-小时-使用的二瓶选择程序(10%乙醇与水相比较)之下被检验。为了诱发饮酒,Wistar大鼠和P大鼠都通过一个标准蔗糖衰减程序来被训练。在P大鼠里,托吡酯单独时在10-毫克/千克剂量下产生了与基线酒精消费相比的一个显著的减少,并且这种效果持续了数天(图4)。虽然昂丹司琼在自己时没有影响酒精消费,当与高剂量的托吡酯相联合时,酒精消费被明显降低,并且,与托吡酯单独的效果相似,这个效果是持久的。值得注意的是,昂丹司琼和高剂量的托吡酯的联合与托吡酯单独时相比产生了在消费上的更大的降低。类似的效果在与水比较对乙醇的偏好上也观察到了。在基线,平均偏好是0.6±0.2,在托吡酯单独时,昂丹司琼单独时,托吡酯和昂丹司琼相联合,以及载体在测试期间所观察到的平均值分别是0.51±0.2(-9±4%基线的变化),0.58±0.0(1±2%),0.51±0.03(-11±4%),和0.59±0.03(1%±0)。在Wistar大鼠里,尽管每个药在单独被给予时没有观察到对消费的影响,当两者相联合时,一个显著的降低被观察到了。相似地,在Wistar大鼠里与水比较对乙醇的偏好没有观察到显著的变化。在基线,平均偏好率为0.30±0.03并且在托吡酯单独时,昂丹司琼单独时,托吡酯和昂丹司琼相联合,以及载体在测试期间所观察到的平均值分别是0.25±0.03(-6±7%基线的变化),0.26±0.04(2±2%),0.31±0.02(1±3%;P<0.05),and 0.3±0.03(6%±4)。
托吡酯单独时在P大鼠里但不是在Wistar大鼠里影响酒精消费的发现仅在P大鼠但Wistar大鼠引起了托吡酯的疗效可能取决于遗传品系的可能性。也可能与P大鼠相比在Wistar大鼠里降低消费高剂量是必要的。但是,重要地要指出的是在Wistar大鼠里的发现是初步的(n=5)。然而,这些数据显示,在P大鼠和Wistar大鼠里托吡酯和昂丹司琼的联合有效地减少了酒精消费。
2)托吡酯与昂丹司琼的联合在P大鼠里阻断了酒精剥夺效应 (ADE):对复发来说已被用作一个啮齿动物模型的一个模式是酒精剥夺模型。该模型是基于一致的发现(在人和动物里),经过一个剥夺时期之后与基线相比酒精消费有一个增加(称为酒精剥夺效应,或ADE)。为了这一程序,在至少为六个月的维持酒精消费期之后托吡酯,昂丹司琼,和它们的联合的慢性给药的效果被检验了。在一个稳定的三天的基线之后,乙醇被撤出一共是15天。在进入撤出期八天,单独的托吡酯,单独的昂丹司琼(仅在P大鼠里),它们的联合,或载体的慢性的每天的治疗开始了。在第16天,在一个30分钟的预处理之后乙醇被恢复。消费在1小时后(数据没有显示)和在24小时后(图5)被测量。对P大鼠来说,托吡酯和昂丹司琼在单独时都阻断了ADE(P值<0.05),而且,当联合时,不仅是ADE被阻断了(P<0.05),而且消费被抑制到一个低于剥夺之前的基线的水平(P<0.05)。与此成对比的,在Wistar大鼠里,在慢性治疗之后没有显著效果被观察到,这可能是因为所测试的剂量可能太低或因为迄今只有少数动物已被测试(n=5)。也可能是这些药物的效果在P大鼠和Wistar大鼠里是不同的,也许是因为遗传上的差异。
3)托吡酯和昂丹司琼的联合的效果似乎在P大鼠里对酒精消费 是有选择性的:鉴于以往与托吡酯有关的工作,我们关注的是它将非选择性地影响饮酒行为。然而,正如图6所示,托吡酯,在这些低剂量,在或者P大鼠或者Wistar大鼠里在急性测试期间不影响水的消费(P>0.05)。在慢性治疗阶段也没有影响水的消费(与基准水平相比;P值>0.05;被载体处理过的大鼠和接受低剂量的托吡酯的大鼠在乙醇恢复当天确实显示水的消费量减少了,大概因为乙醇摄入的大量增加)或在急性或慢性阶段与昂丹司琼联合时(P值>0.05)。我们还检测了托吡酯单独时和与昂丹司琼联合时对总体液体摄入量和食物消费在其治疗阶段期间的影响,并且发现没有显著的效果(数据没有显示;P值>0.05)。在昂丹司琼治疗之后,没有对水或总体液体消费或食物摄入被观察到(数据没有显示;P值>0.05)。
实施例5
昂丹司琼和托吡酯的联合用于在人里治疗酒精依赖,体重控制,和其他成瘾病症
一个六周的开放标记的试验性的研究被开展来决定昂丹司琼(4微克/千克,每天两次)和托吡酯(可达到300毫克/天)的联合在10个酒精依赖的个体里的安全性(American Psychiatric Association.Diagnostic and Statistical Manual of Mental Disorders,4th edition.Washington,D.C.:American Psychiatric Association;1994)。尽管缺乏安慰剂对照组,饮酒数据(图7)显示了与基线相比在跨越研究的星期里一个明显和深化的减少表明是有前途的。平均基线饮酒是8.90±1.20饮料数/天。此外,戒酒天数的百分率从4.22±1.96提高到78.57±7.14(数据没有被绘图)。这个昂丹司琼和托吡酯的联合的不良事件率一般来说低于那些在托吡酯单独时所得到的,例如,头晕-17%对28%;感觉异常-17%对54%;和精神运动性能的减慢-17%对27%。所有这些昂丹司琼和托吡酯的联合的不良事件被报告是温和的,并且没有伴随的药物或医疗的干预是必要的。昂丹司琼和托吡酯的联合与任何严重的不良事件或受试者题从研究里撤出没有关联。所有的症状是轻度的,并且没有任何医疗干预的需要得到了解决。只有两个参与者退出。这些数据提示与托吡酯单独时相比更少的不良事件似乎与昂丹司琼和托吡酯的联合有关联。尽管有此告诫没有牢固的疗效的结论可以得出因为没有安慰剂组,而且不同的研究可能不能直接比较,值得注意的是,跨越这项联合的试验每天的饮料数的平均减少是-7.95然而它只是-3.28当在早发性酗酒者里昂丹司琼被单独测试时(Johnson et al.,2000,J.Am.Med.Assoc.,284:963-971)。这些数据,因此,这些数据与昂丹司琼的和托吡酯的治疗效果将是相加性的提议是一致的(表1)。
表1。治疗酒精依赖的药物的Cohen的效果大小
在早发性酗酒者里的昂丹司琼 | 托吡酯 | 昂丹司琼+托吡酯 | |
每天的饮料数 | -0.55 | -0.80 | -1.0 |
每个饮酒天的饮料数 | -0.48 | -0.63 | -0.7 |
戒酒天的百分率 | +0.27 | +0.73 | +0.85 |
不同的研究有不同的群体大小和实验模式。Cohen的效果大小测量这两个变量之间的关系的强度。效应大小为0.2,0.5,和0.8(在或者正的或者负的方向)分别是小的,中的,和大的(Cohen J.Statistical Power Analysis for the Behavioral Sciences.2nd ed.Hillsdale,NJ:L.Erlbaum Associates;1988)。
在酒精依赖研究的被治疗的受试者对体重减轻也被监测作为托吡酯和昂丹司琼相联合与托吡酯或昂丹司琼单独治疗相比的一个潜在的效果。
值得注意地,在托吡酯和昂丹司琼相联合的研究里,33%的个体报告了体重减轻,而在托吡酯单独时,只有19.7%报告了体重减轻,在服用昂丹司琼单独时的个体里也没有体重减轻的明显的报告。因此,昂丹司琼和托吡酯相联合对体重减轻的效果是令人惊讶的,因为它超过了由个别药物单独时的体重减轻的聚集的简单累加所预期的和支持不同的神经化学过程来在一起提供一个协同的反应的事实。真正地,这在本文以前已经被阐述了,即托吡酯的主要作用是影响与葡萄糖和脂的控制相关的代谢过程,而昂丹司琼可能作用于减少周围肠道运动以及与中枢神经系统相关的狂饮的冲动。因此,昂丹司琼和托吡酯的联合被提议通过一个对中枢神经系统,代谢,和周围效应的联合对减少肥胖有一个出乎意料的强有力的和令人惊讶的效果。
总之,这些临床数据提示昂丹司琼和托吡酯的联合将是安全的,如果作用机理的药理学上累加作用的机理可以推广,类似的发现在可卡因治疗上可以被看到。然而,关键的是领悟到,对酗酒显示疗效的昂丹司琼的剂量是显著的和令人惊讶的不同于-真正地,对于一个70千克的个体,几乎30倍小于-被提议来治疗可卡因依赖(即4微克/千克对4毫克,每天两次)。此外,作为对可卡因依赖的治疗的被提议的托吡酯天花板剂量(即200毫克/天)是对酒精中毒治疗来的小大约1/3。因此,总体的数据表明昂丹司琼和托吡酯的联合将作为酒精依赖的治疗有用,而且对可卡因依赖的治疗也很可能是有效的,或对于酒精和可卡因的双重依赖。
所披露的每一个专利,专利申请,并在这里引用的出版物在此通过引用把它们的全部都合在一起了。
标题在这里被包括为了参考和帮助找到某些部分的位置。这些标题的意图并不是要限制在其之下所描述的概念的范围,并且这些概念在其他部分和贯穿于整个的说明中可能有适用性。
被披露的实施方案的以前的描述被提供以使任何在本领域有技能的人可以制作或使用本发明。这些实施方案的各种修改对于那些在本领域那些技术熟练的人来说将是显而易见的,而且在这里所定义的通用的原则在没有离开本发明的范围的精神下可应用于其他的实施方案。相应地,本发明的意图并不是只限于在这里所显示的实施方案而是符合与在这里被披露的原则和新的特征相一致的最广的范围。
Claims (107)
1.在有需要的受试者中用来治疗或预防与酒精有关的疾病或失调的方法,所说的方法包括对所说的受试者给予有效剂量的至少两个选自以下的化合物,或其类似物,衍生物,修饰物,或药学上可接受的盐:5-羟色胺能药,5-羟色胺拮抗剂,选择性5-羟色胺再摄取抑制剂,5-羟色胺受体拮抗剂,阿片类拮抗剂,多巴胺能药,多巴胺释放抑制剂,多巴胺拮抗剂,去甲肾上腺素拮抗剂,γ-氨基丁酸激动剂,γ-氨基丁酸抑制剂,γ-氨基丁酸受体拮抗剂,γ-氨基丁酸通道拮抗剂,谷氨酸激动剂,谷氨酸拮抗剂,谷氨酰胺激动剂,谷氨酰胺拮抗剂,抗惊厥剂,N-甲基-D-天冬氨酸阻断剂,钙通道拮抗剂,碳酸酐酶抑制剂,神经激肽,小分子,肽,维生素,协同因子,和皮质类固醇释放因子拮抗剂,从而在受试者中治疗或预防与酒精有关的疾病或失调。
2.权利要求1的方法,其中所说的受试者是人。
3.权利要求1的方法,其中所说的与酒精有关的疾病或失调选自早发性酗酒,迟发性酗酒,酒精诱发的伴有错觉的精神障碍,酒精滥用,酒精中毒,酒精脱瘾,酒精中毒谵妄,酒精脱瘾谵妄,酒精诱发的持续性痴呆,酒精诱发的持续遗忘障碍,酒精依赖,酒精诱发的伴有幻觉的精神障碍,酒精诱发的情绪障碍,酒精诱发的或相关联的双相情感障碍,酒精诱发的或相关的创伤后压力心理障碍,酒精诱发的焦虑症,酒精诱发的性功能障碍,酒精诱发的睡眠障碍,酒精诱发的或相关联的赌博障碍,酒精诱发的或相关联的性失调,没有另行指定的与酒精有关的失调,酒精中毒,和酒精脱瘾。
4.权利要求3的方法,其中所说的治疗与所说的治疗之前的酒精消费频率相比或与没有得到所说的治疗的对照受试者相比,减少了酒精消费的频率。
5.权利要求4的方法,其中所说的酒精消费包含重度饮酒。
6.权利要求3的方法,其中所说的治疗与在所说治疗之前的被消费的酒精量相比或与没有得到所说的治疗的对照受试者相比,减少了被消费的酒精量。
7.权利要求6的方法,其中所说的酒精消费包含重度饮酒。
8.权利要求3的方法,其中所说的治疗与没有得到所说的治疗的对照受试者相比,改善了与酒精消费有关的身体或心理的后遗症。
9.权利要求3的方法,其中所说的治疗与没有接受所说的治疗的对照受试者相比增加了所说的受试者的节欲率。
10.权利要求3的方法,其中所说的治疗与所说的治疗之前的水平或与没有接受所说的治疗的对照受试者相比减少了酒精消费的平均水平。
11.权利要求3的方法,其中所说的治疗与所说的治疗之前的酒精消费和节欲或与没有接受所说的治疗的对照受试者相比减少了酒精消费和增加了节欲。
12.权利要求3的方法,其中所说的受试者包含对早发性酗酒或迟发性酗酒的倾向性。
13.权利要求3的方法,其中所说的受试者还被顺从于一个社会心理管理计划。
14.权利要求13的方法,其中所说的社会心理管理计划选自简短的行为顺从促进治疗,认知行为应对技巧疗法,动机增强疗法,十二步促长疗法,联合的行为干预,医疗管理,心理分析,心理动力治疗,和生物社会心理,报告,感情移入作用,需求,直接咨询和评估。
15.权利要求1的方法,其中所说的受试者进一步接受催眠或针灸。
16.权利要求1的方法,其中所说的至少两种化合物的至少一种是一周至少一次被给予的。
17.权利要求16的方法,其中所说的至少两种化合物的至少一种是一天至少一次被给予的。
18.权利要求1的方法,其中所说的至少两种化合物的至少一种是5-羟色胺受体拮抗剂。
19.权利要求18的方法,其中所说的5-羟色胺受体是5-羟色胺-3受体。
20.权利要求1的方法,其中至少三种化合物被给予所说的受试者。
21.权利要求1的方法,其中所说的至少两种化合物是分别被给予的。
22.权利要求21的方法,其中所说的至少两种化合物的第一种化合物在给予所说的至少两种化合物的第二种化合物之前被给予。
23.权利要求1的方法,其中所说的至少两种化合物的第一种化合物与第二种化合物几乎同时被给予。
24.权利要求1的方法,其中所说的至少两种化合物的第一种化合物在所说的至少两种化合物的第二种化合物被给予之后被给予。
25.权利要求1的方法,其中所说的至少两种化合物作为一种药物组合物被给予。
26.权利要求1的方法,其中所说的至少两种化合物是通过选自口服的,外用的,直肠的,肌肉内的,粘膜内的和静脉内的途径被给予的。
27.权利要求26的方法,其中所说的至少两种化合物是通过口服的途径被给予的。
28.一种药用组合物,所述组合物包含权利要求1的至少两种化合物,及其生物活性的类拟物,同系物,衍生物,修饰物,和药学上可接受的盐,和药学上可接受的载体。
29.权利要求28的药用组合物,所说的组合物包含有效剂量的托吡酯和昂丹司琼,及其生物活性的类拟物,同系物,衍生物,修饰物,和药学上可接受的盐。
30.权利要求1的方法,其中所说的至少两种化合物的至少一种是作为释控制剂来给予的。
31.权利要求1的方法,其中所说的至少两种化合物选自托吡酯,昂丹司琼和纳曲酮,及其生物活性的类拟物,同系物,衍生物和修饰物。
32.权利要求1的方法,其中所说的至少两种化合物中的两个是托吡酯和昂丹司琼,及其生物活性的类拟物,同系物,衍生物,和修饰物。
33.权利要求32的方法,其中所说的至少两种化合物是托吡酯和昂丹司琼,及其生物活性的类拟物,同系物,衍生物和修饰物。
34.权利要求32的方法,其中的托吡酯是以从约15毫克/天至约2500毫克/天的范围的剂量被给予的。
35.权利要求34的方法,其中的托吡酯是以从约25毫克/天至约1000毫克/天的范围的剂量被给予的。
36.权利要求35的方法,其中的托吡酯是以从约50毫克/天至约500毫克/天的范围的剂量被给予的。
37.权利要求36的方法,其中的托吡酯是以约300毫克/天或约275毫克/天的范围的剂量被给予的。
38.权利要求32的方法,其中的托吡酯是以从约0.1毫克/千克/天至约100毫克/千克/天的范围的剂量被给予的。
39.权利要求32的方法,其中的托吡酯是一周至少一次被给予的。
40.权利要求39的方法,其中的托吡酯是一天至少一次被给予的。
41.权利要求32的方法,其中的昂丹司琼每次应用是以从约0.01微克/千克至约100微克/千克的范围的剂量被给予的。
42.权利要求41的方法,其中的昂丹司琼每次应用是以从约0.1微克/千克至约10.0微克/千克的范围的剂量被给予的。
43.权利要求42的方法,其中的昂丹司琼每次应用是以从约1.0微克/千克至约5.0微克/千克的范围的剂量被给予的。
44.权利要求43的方法,其中的昂丹司琼每次应用是以约4.0微克/千克或每次应用约3.0微克/千克的剂量被给予的。
45.权利要求32的方法,其中的昂丹司琼是一周至少一次被给予的。
46.权利要求32的方法,其中的昂丹司琼是一天至少一次被给予的。
47.权利要求32的方法,其中所说的至少两种化合物是托吡酯和昂丹司琼。
48.权利要求47的方法,其中的托吡酯是以约300毫克/天的剂量被给予,而昂丹司琼在每次应用时是以约4.0微克/千克的剂量被给予。
49.权利要求32的方法,其中纳曲酮每次应用是以从约1毫克至约100毫克的范围的剂量被给予的。
50.权利要求49的方法,其中纳曲酮每次应用是以从约10毫克至约50毫克的范围的剂量被给予的。
51.权利要求50的方法,其中纳曲酮每次应用是以约25毫克的剂量被给予的。
52.权利要求51的方法,其中纳曲酮是一天至少二次被给予的。
53.权利要求52的方法,其中纳曲酮是一天二次被给予的。
54.权利要求2的方法,其中给予所说的受试者的至少一种化合物还选自双硫醒,阿坎酸,舍曲林,加兰他敏,纳美芬,纳洛酮,去氧骆驼蓬碱(desoxypeganine),苯并二氮杂,抗精神病药,利培酮,利莫那班,曲唑酮和阿立哌唑。
56.权利要求1的方法,其中选自肾上腺素能剂,肾上腺皮质类固醇,肾上腺皮质抑制剂,醛固酮拮抗剂,氨基酸,兴奋剂,止痛剂,减食欲化合物,减食欲剂,抗焦虑剂,抗抑郁剂,抗高血压药,消炎药,止恶心药,抗中性白细胞减少药,抗强迫药,抗帕金森氏病药,抗精神病药物,食欲抑制剂,血糖调节剂,碳酸酐酶抑制剂,强心剂,心血管药物,利胆剂,类胆碱能药,胆碱能激动剂,胆碱酯酶去活化剂,认知佐剂,认知促进剂,激素,记忆佐剂,心理性能增强剂,情绪调节剂,精神抑制剂,神经保护剂,精神药物,松弛剂,镇静催眠药,兴奋剂,甲状腺激素,甲状腺抑制剂,拟甲状腺剂,脑缺血剂,血管收缩剂,和血管扩张剂的至少一种化合物还被给予所述受试者。
57.权利要求1的方法,其中所说至少两种化合物的效果是相加的。
58.权利要求1的方法,其中所说至少两种化合物的效果是协同的。
59.权利要求1的方法,其中所说的治疗降低中脑-皮层-边缘的多巴胺活性。
60.权利要求1的方法,其中所说的治疗抑制谷氨酸功能。
61.权利要求1的方法,其中所说的治疗促进γ-氨基丁酸的活性。
62.在有需要的受试者中治疗糖尿病的方法,所说的方法包括给予受试者有效量的至少一个选自以下的化合物,及其类似物、同系物,衍生物,修饰物,和药学上可接受的盐:5-羟色胺能药,5-羟色胺拮抗剂,选择性5-羟色胺再摄取抑制剂,5-羟色胺受体拮抗剂,阿片类拮抗剂,多巴胺能药,多巴胺释放抑制剂,多巴胺拮抗剂,γ-氨基丁酸激动剂,γ-氨基丁酸抑制剂,γ-氨基丁酸受体拮抗剂,γ-氨基丁酸通道拮抗剂,谷氨酸激动剂,谷氨酸拮抗剂,抗惊厥剂和NMDA-阻断剂,从而任选与至少一种其它的治疗有效的化合物联合治疗或预防糖尿病。
63.权利要求62的方法,其中所述至少一种其它的治疗有效的化合物选自抗糖尿病药、抗高脂血症药、抗肥胖药、抗高血压药和用于治疗因糖尿病引起的或与糖尿病有关的并发症的药物。
64.权利要求62的方法,其中所述受试者具有约30.0或以上的体重指标。
65.治疗或抑制患有体重增加或变成体重超重的受试者的方法,所说的方法包括给予所述受试者有效量的至少一个选自以下的化合物,及其类似物、同系物,衍生物,修饰物,和药学上可接受的盐:5-羟色胺能药,5-羟色胺拮抗剂,选择性5-羟色胺再摄取抑制剂,5-羟色胺受体拮抗剂,阿片类拮抗剂,多巴胺能药,多巴胺释放抑制剂,多巴胺拮抗剂,γ-氨基丁酸激动剂,γ-氨基丁酸抑制剂,γ-氨基丁酸受体拮抗剂,γ-氨基丁酸通道拮抗剂,谷氨酸激动剂,谷氨酸拮抗剂,抗惊厥剂和N-甲基-D-天冬氨酸阻断剂,从而任选与至少一种其它的治疗有效的化合物联合治疗或预防患有体重增加或变成体重超重的受试者。
66.权利要求65的方法,其中所述至少一种其它的治疗有效的化合物选自抗糖尿病药、抗高脂血症药、抗肥胖药、抗高血压药和用于治疗因糖尿病引起的或与糖尿病有关的并发症的药物。
67.在有需要的受试者中减少体重损失的方法,所说的方法包括给予所述受试者有效量的至少二种选自以下的化合物,或其类似物、衍生物,修饰物,和药学上可接受的盐:5-羟色胺能药,5-羟色胺拮抗剂,选择性5-羟色胺再摄取抑制剂,5-羟色胺受体拮抗剂,阿片类拮抗剂,多巴胺能药,多巴胺释放抑制剂,多巴胺拮抗剂,γ-氨基丁酸激动剂,γ-氨基丁酸抑制剂,γ-氨基丁酸受体拮抗剂,γ-氨基丁酸通道拮抗剂,谷氨酸激动剂,谷氨酸拮抗剂,抗惊厥剂和N-甲基-D-天冬氨酸阻断剂,任选与至少一种其它的治疗有效的化合物组合,从而在有需要的受试者中减少体重损失。
68.权利要求67的方法,其中所述至少一种其它的治疗有效的化合物选自抗糖尿病药、抗高脂血症药、抗肥胖药、抗高血压药和用于治疗因糖尿病引起的或与糖尿病有关的并发症的药物。
69.权利要求67的方法,其中所述受试者具有约25.0-29.9的体重指标。
70.权利要求67的方法,其中所述受试者还被顺从于一个社会心理管理计划。
71.权利要求70的方法,其中所说的社会心理管理计划选自简短的行为顺从促进治疗,认知行为应对技巧疗法,动机增强疗法,十二步促长疗法,联合的行为干预,医疗管理,心理分析,心理动力治疗,和生物社会心理,报告,感情移入作用,需求,直接咨询和评估。
72.权利要求67的方法,其中所说的受试者进一步接受催眠或针灸。
73.权利要求67的方法,其中所说的至少两种化合物的至少一种是一周至少一次被给予的。
74.权利要求73的方法,其中所说的至少两种化合物的至少一种是一天至少一次被给予的。
75.权利要求67的方法,其中所说的至少两种化合物的至少一种是5-羟色胺受体拮抗剂。
76.权利要求75的方法,其中所说的5-羟色胺受体是5-羟色胺-3受体。
77.权利要求67的方法,其中至少三种化合物被给予所说的受试者。
78.权利要求67的方法,其中所说的至少两种化合物是分别被给予的。
79.权利要求78的方法,其中所说的至少两种化合物的第一种化合物在给予所说的至少两种化合物的第二种化合物之前被给予。
80.权利要求67的方法,其中所说的至少两种化合物的第一种化合物与第二种化合物几乎同时被给予。
81.权利要求67的方法,其中所说的至少两种化合物的第一种化合物在给予所说的至少两种化合物的第二种化合物之后被给予。
82.权利要求67的方法,其中所说的至少两种化合物作为一种药物组合物被给予。
83.权利要求67的方法,其中所说的至少两种化合物是通过选自口服的,外用的,直肠的,肌肉内的,粘膜内的、鼻内的、吸入的、眼内的和静脉内的途径被给予的。
84.权利要求83的方法,其中所说的至少两种化合物是通过口服的途径被给予的。
85.一种药用组合物,所述组合物包含权利要求67的至少两种化合物,及其生物活性的类拟物,同系物,衍生物,修饰物,和药学上可接受的盐,和药学上可接受的载体。
86.权利要求85的药用组合物,所说的组合物包含有效量的托吡酯和昂丹司琼,及其生物活性的类拟物,同系物,衍生物和修饰物。
87.权利要求67的方法,其中所说的至少两种化合物的至少一种是作为释控制剂来给予的。
88.权利要求67的方法,其中所说的至少两种化合物选自托吡酯,昂丹司琼和纳曲酮,及其生物活性的类拟物,同系物,衍生物和修饰物。
89.权利要求67的方法,其中所说的至少两种化合物中的两个是托吡酯和昂丹司琼,及其生物活性的类拟物,同系物,衍生物和修饰物。
90.权利要求88的方法,其中的托吡酯是以从约15毫克/天至约2500毫克/天的范围的剂量被给予的。
91.权利要求90的方法,其中的托吡酯是以从约25毫克/天至约1000毫克/天的范围的剂量被给予的。
92.权利要求91的方法,其中的托吡酯是以从约50毫克/天至约500毫克/天的范围的剂量被给予的。
93.权利要求92的方法,其中的托吡酯是以约300毫克/天或约275毫克/天的范围的剂量被给予的。
94.权利要求88的方法,其中的托吡酯是以从约0.1毫克/千克/天至约100毫克/千克/天的范围的剂量被给予的。
95.权利要求88的方法,其中的托吡酯是一周至少一次被给予的。
96.权利要求95的方法,其中的托吡酯是一天至少一次被给予的。
97.权利要求88的方法,其中的昂丹司琼每次应用是以从约0.01微克/千克至约100微克/千克的范围的剂量被给予的。
98.权利要求97的方法,其中的昂丹司琼每次应用是以从约0.1微克/千克至约10.0微克/千克的范围的剂量被给予的。
99.权利要求98的方法,其中的昂丹司琼每次应用是以从约1.0微克/千克至约5.0微克/千克的范围的剂量被给予的。
100.权利要求99的方法,其中的昂丹司琼每次应用是以约4.0微克/千克或每次应用约3.0微克/千克的剂量被给予的。
101.权利要求88的方法,其中的昂丹司琼是一周至少一次被给予的。
102.权利要求88的方法,其中的昂丹司琼是一天至少一次被给予的。
103.权利要求88的方法,其中所说的至少两种化合物是托吡酯和昂丹司琼。
104.权利要求103的方法,其中的托吡酯是以约300毫克/天的剂量被给予,而昂丹司琼在每次应用时是以约4.0微克/千克的剂量被给予的。
105.一种在有需要的受试者中调节食欲的方法,该方法包括给予所述受试者有效剂量的至少二种选自以下的化合物,或其类似物、衍生物,修饰物,或药学上可接受的盐:5-羟色胺能药、5-羟色胺拮抗剂,选择性5-羟色胺再摄取抑制剂,5-羟色胺受体拮抗剂,阿片类拮抗剂,多巴胺能药,多巴胺释放抑制剂,多巴胺拮抗剂,γ-氨基丁酸激动剂,γ-氨基丁酸抑制剂,γ-氨基丁酸受体拮抗剂,γ-氨基丁酸通道拮抗剂,谷氨酸激动剂,谷氨酸拮抗剂,抗惊厥剂和N-甲基-D-天冬氨酸阻断剂,从而任选与至少一种其它的治疗有效的化合物进行联合治疗或预防。
106.一种治疗或预防成瘾性疾病或失调的方法,所述成瘾性疾病或失调选自饮食失调,冲动控制障碍,与尼古丁相关的失调,与苯丙胺相关的失调,与大麻相关的失调,与可卡因相关的失调,致幻剂使用失调,与吸入剂有关的失调,与苯并二氮杂滥用或依赖苯并二氮杂相关的失调,和与阿片相关的失调,所述方法包括给予所述受试者有效量的至少二种选自以下的化合物,或其类似物、衍生物,修饰物,或药学上可接受的盐:5-羟色胺能药、5-羟色胺拮抗剂,选择性5-羟色胺再摄取抑制剂,5-羟色胺受体拮抗剂,阿片类拮抗剂,多巴胺能药,多巴胺释放抑制剂,多巴胺拮抗剂,去甲肾上腺素拮抗剂,γ-氨基丁酸激动剂,γ-氨基丁酸抑制剂,γ-氨基丁酸受体拮抗剂,γ-氨基丁酸通道拮抗剂,谷氨酸激动剂,谷氨酸拮抗剂,谷氨酰胺激动剂,谷氨酰胺拮抗剂,抗惊厥剂、N-甲基-D-天冬氨酸阻断剂,钙通道拮抗剂,碳酸酐酶抑制剂,神经激肽和皮质类固醇释放因子拮抗剂,从而在受试者中治疗或预防成瘾性疾病或失调。
107.一种用于给予本发明化合物的药剂盒,所说的药剂盒包括至少两个本发明的化合物,施药器,和为了使用的说明材料。
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US87566806P | 2006-12-19 | 2006-12-19 | |
US60/875,668 | 2006-12-19 | ||
US60/898,528 | 2007-01-31 | ||
US60/931,031 | 2007-05-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN101663028A true CN101663028A (zh) | 2010-03-03 |
Family
ID=41790588
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200780051498A Pending CN101663028A (zh) | 2006-12-19 | 2007-12-19 | 托吡酯和昂丹司琼对酒精消费的联合效果 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101663028A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109870583A (zh) * | 2019-04-15 | 2019-06-11 | 德阳市人民医院 | 急性胰腺炎相关的代谢物及其应用 |
-
2007
- 2007-12-19 CN CN200780051498A patent/CN101663028A/zh active Pending
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109870583A (zh) * | 2019-04-15 | 2019-06-11 | 德阳市人民医院 | 急性胰腺炎相关的代谢物及其应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11905562B2 (en) | Serotonin transporter gene and treatment of opioid-related disorders | |
US20110065628A1 (en) | Medication Combinations for the Treatment of Alcoholism and Drug Addiction | |
US20100041689A1 (en) | Combined Effects of Topiramate and Ondansetron on Alcohol Consumption | |
US20100076006A1 (en) | Topiramate Plus Naltrexone for the Treatment of Addictive Disorders | |
EP1158973A2 (en) | Use of sulfamate derivatives for treating impulse control disorders | |
US20180098970A1 (en) | Use of isoindoles for the treatment of neurobehavioral disorders | |
AU2010242062A1 (en) | Serotonin transporter gene and treatment of alcoholism | |
CN101663028A (zh) | 托吡酯和昂丹司琼对酒精消费的联合效果 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
AD01 | Patent right deemed abandoned |
Effective date of abandoning: 20100303 |
|
C20 | Patent right or utility model deemed to be abandoned or is abandoned |